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Abstract
Chlamydia trachomatis is the most common bacterial sexually transmitted disease worldwide. 
Not only does Chlamydia target urogenital tissue that can lead to host infertility, it is also 
responsible for a high occurence of blinding trachoma in the developing world.
Complete sequencing analysis of the C. trachomatis genome revealed a unique family of 
Polymorphic membrane proteins (Pmps) that had previously remained undiscovered. Nine to 
twenty-one pmp genes were found across the varied Chlamdia species, encoding for large 
proteins all phylogetically related to one of six basic subtypes. C. tractomatis encodes nine of 
these proteins termed PmpA -  Pmpl. At present, information about the Pmps is limited with the 
vast majority of data derived from genomic analysis. Such studies have suggested that the 
Pmps act as virulence factors possibly offering antigenic variation to evade the host defenses. 
Although this has been displayed genotypically it is yet to be confirmed phenotypically. One of 
the major problems for studying such proteins in this bacterium, is that Chlamydia reside within 
a host cell and differentiate between two very different morphological forms during infection 
and the Pmps appear to be expressed at different stages within this biphasic life cycle. 
Additional theories have suggested that the Pmps act as adhesions, possibly displaying tissue 
specific tropism in attachment to host cells, an essential step in Chlamydial growth and 
survival. This has previously been shown for specific regions of Pmp D and Pmp G 
homologues belonging to C.pneumoniae but has not been repeated with other Pmps. 
Furthermore, bioinformatic data has proposed that the Pmp proteins are autotransporter 
proteins, a secretory protein that forms a beta-barrel pore within the outer membrane to allow 
translocation of the functional protein to the bacterial outer surface.
The aim of this study was to gain a better understanding of the Pmps proteins. Specifically to 
clone, express and purify full length or truncated recombinant Pmps (rPmp) for secondary 
structural and functional analysis to test the theory that Pmps are putative adhesins. 
Expressing membrane proteins in a heterologous system poses many obstacles and the 
expression of rPmp proteins was hindered by the formation of insoluble aggregates and low 
yields. Several rPmps were produced and three truncated rPmps were expressed as soluble 
proteins with the use of nanodiscs to mimic the lipid bilayer. Purification of these domains 
resulted in a substantial loss of protein and subsequently secondary structural analysis could 
not be carried out on these proteins. However protein interactions were tested with urogenital 
cell lines using chemical cross-linking, immunocytochemistry, surface plasmon resonance and 
ellipsometry. Truncated rPmp domains of Pmp D, Pmp G and Pmp I were shown to interact 
with endometrial cells, supporting the theory that Pmps are involved in attachment. Also, 
putative proteolytic cleavage was observed, possibly indicating Pmpl is cleaved and released 
from the Chlamydial surface.
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1.1 M em brane  p ro te ins
Membrane proteins are essential components of the most basic cellular processes. 
Despite the extraordinary differences amongst organisms nearly a third of all gene 
products in both prokaryotes and eukaryotes encode proteins destined to be inserted 
into a lipid membrane (W agner et al., 2006). These proteins often form self­
assembled complexes, providing a diverse range of essential functions necessary for 
the uptake of nutrients, waste removal, energy generation, cell division and cell- 
signalling. A large proportion of membrane proteins are therefore transporters 
enabling the movement of ions, small molecules and macromolecules across the 
membrane and thus have key roles in many diseases. Consequently they are of 
immense economical importance as many current pharmaceuticals and emerging 
drug candidates target membrane proteins therefore studies to determine the 
structure and function of such proteins are vital for drug discovery. Despite this, there 
are very few membrane proteins with known three-dimensional structural information. 
As of December 2012, 376 unique structures in the Protein Data Bank (PDB) are of 
independent integral membrane proteins, these account for only -0 .4%  of the total 
entries. This representation is extremely low due to the tremendous challenges 
associated with studying membrane proteins.
1.2 The C h lam yd ia les
The order of Chlamydiales consists of a large group of non-motile, coccoid, Gram- 
negative bacteria characterised by their obligatory growth in host animal cells 
(Cevenini et al., 2002). This order holds one family, the Chlamydiaceae that can be 
further subdivided into two genera, although Chlamydia and Chlamydophila taxonomy 
at present remains controversial due to the rapid advances in this field of research 
(AbdelRahman and Belland 2006). Chlamydia trachomatis is a species belonging to 
the genus Chlamydia as are Chlamydia pneumoniae, Chlamydia psittica  and 
Chlamydia pecorum  (Cevenini et al., 2002). Collectively this family are the etiological 
mediators of many important human and animal diseases with C. trachomatis, C. 
pneumoniae and C. psittica  all being pathogenic to humans. However C. psittaci is 
primarily a threat for animals, mainly birds, only infecting humans accidentally. In 
contrast, C. pneumoniae  is a widespread human pathogen causing chronic respiratory 
diseases accounting for 10-15% of community-acquired pneumonia, bronchitis and 
sinusitis. More recently this organism has been closely associated with a heightened 
risk of developing atherosclerotic and cerebrovascular problems amongst sufferers 
(AbdelRahman and Belland 2006). Some strains of non-human origin have also been
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isolated from marsupials, frogs and horses (Cevenini et al., 2002), indicating that C. 
pneumoniae  could be adapting to new environments. Also advantageous to this strain 
is the ability to infect and replicate within a diverse range of cells including epithelial, 
endothelial, smooth muscle cells and monocytes/macrophages that would all add to 
the pathogenesis of this species (Kuo et al., 1995).
1.2.1 Chlamydia trachomatis
C. trachomatis is strictly a human pathogen that primarily infects columnar epithelial 
cells of the genital and conjunctival regions and thus has a smaller host range than 
that of C.pneumoniae (Cevenini et al., 2002). To date this species has been shown 
responsible for the most common bacterial sexually transmitted disease (STD) in both 
the UK (Health Protection Agency, 2012) and worldwide, (Jotblad et al., 2012, Katz et 
al., 2012) particularly in young adults. Genital infections with this species also carry 
other identified risks; these include a higher chance of the transmission of HIV and an 
increased likelihood of developing human papilloma virus-induced cervical neoplasia 
(Crane et al., 2006). However there is a vast spectrum of other complications 
associated with a Chlamydia STD that are far more common. Amongst these are 
pelvic inflammatory disease (PID) leading to possible ectopic pregnancy and/or 
infertility, epididimitis, urethritis, cervicitis and infant pneumonitis that can be passed 
from mother to child during birth (Nunes et al., 2007). Infant pneumonitis often occurs 
because the infection is frequently asymptomatic and therefore remains untreated 
usually being detected during other routine tests. Alternatively when C. trachomatis 
infects the ocular regions it causes trachoma, a chronic follicular conjunctivitis (Crane 
et al., 2006) that when left untreated results in scarring of the conjunctiva tissues, 
visual impairment and eventually complete loss of sight. The World Health 
Organisation (2012) estimates that 300-500 million people are afflicted by trachoma 
worldwide making it the most prevalent form of infectious preventable blindness. The 
majority of cases are found in the developing world, where good hygiene and 
medication are scarce and the disease can easily be transmitted by flies carrying the 
C. trachomatis organsism. The type of disease inflicted by C. trachomatis  is 
dependent upon the serovar of the organism that causes the infection, as certain 
serovars display tropism for specific tissues (Jeffrey et al., 2010).
1.2.1.1 S erovars
Within C.trachomatis there are 2 subcategories arranged by pathobiotypes, the 
trachoma biovar and the lymphogranuloma venereum (LGV) biovar (Brunelle and
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Sensabaugh 2006). Collectively these are made up of at least 15 serologically distinct 
serovars grouped according to their disease type, severity and tissue tropism (Carlson 
et al., 2005). The trachoma biovariants A,B,Ba,C,D,E,F,G,H,l,J and K are responsible 
for infecting the columnar epithelial cells of genital and ocular tissues. Specifically, 
serovars A-C are associated with blinding trachoma, while D-K are involved in STDs. 
LGV biovariants consist of serovars L|, L2 and L3 that penetrate the submucosa of the 
urogenital epithelial surfaces infecting the primary lymph nodes (Brunelle and 
Sensabaugh 2006) and subsequently cause more invasive urogenital diseases often 
involving genital ulceration, lymphadentitis and proctitis (Nunes et al., 2007). Although 
Chlamydiae prove to be a diverse group of bacteria in terms of disease, tissue tropism 
and pathogenesis they share one common unifying feature, their biphasic life cycle 
that bears much resemblance to that of the viral life cycle (AbdelRahman and Belland 
2006).
1.3 The C h lam yd ia l Life C ycle
In order to reproduce, all Chlamydia alternate between 2 morphological states, the 
elementary body and the reticulate body with an intermediate inclusion body phase 
(Nunes et al., 2007). A full replication cycle takes between 40-72 hours (Cevenini et 
al., 2002) and is finalised by the release of numerous elementary bodies to further 
spread infection.
1.3.1 E lem en tary  body
Chlamydiae in the form of the elementary body (EB) are in an infectious but 
metabolically inert state adapted for survival in an extracellular environment (Nunes et 
al., 2007). At approximately 0.3 pm, the nucleoid is highly compact due to 
chromosomal condensation by the bacterial histone-like proteins HctA and HctB 
(AbdelRahman and Belland 2006). Their cell wall is rigid (section 1.5), ensuring 
osmotic stability by the cross-linking of the cysteine rich outer membrane proteins 
major outer membrane protein (MOMP), OmcB and OmcA, collectively forming the 
Chlamydial outer membrane complex (COMC). Also thought to contribute is a 
hexagonal arrayed protein layer made predominantly of OmcB situated on the inner 
surface of the COMC.
The EB initiates the primary stage of replication by attachment and subsequent entry 
to the host cell shown in Figure 1.1 (Cevenini et al., 2002). The ability of Chlamydia  to 
efficiently infect a diverse range of non-phagocytic cell types indicates that the 
bacterial adhesin mechanism involved must recognise a conserved cellular receptor
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amongst the hosts (AbdelRahman and Belland 2006). So far neither of these 
adhesins or receptors has been positively identified. Some suggestions for adhesions 
point towards the bacterial OmpA, OmcB and Hsp70 proteins, but the more recent 
discovery of the polymorphic membrane proteins (Pmps) has led to the proposal that 
these large outer membrane proteins could play an important role in attachment.
The interaction between the EBs and the host cell surface is thought to be a two-step 
process with initial attachment being reversible. This occurs through electrostatic 
interactions of the bacteria via Chlamydial OmpA, OmcB and/or Pmps possibly with 
host cell heparan-sulfate containing glycosaminoglycans (GAGs). The second 
interaction is irreversible and the receptor involved is yet to be identified. Clifton et al. 
(2004) found that immediately following the irreversible binding step, a Type III 
Secretion Sytem (T3S) exported protein is transported into the host cell. This protein 
is rapidly phosphoylated at the tyrosine residues with actin recruitment likely to act as 
a signalling molecule, subsequently getting its name TARP (Translocated actin- 
recruiting phosphoprotein). TARP is likely to be involved in triggering the uptake of 
Chlamydia by phagocytosis or as an early effector molecule involved in the primary 
differentiation of EBs into RBs. Once internalised the EB sits protected from the host’s 
defences in a non-acidified phagolysosome/inclusion where differentiation into the RB 
begins (Cevenini et al., 2002).
1.3.2 Inc lus ion  m em b ran e  and en erg y  acq u is itio n
Replication within a unique non-acidified membrane bound vacuole, termed the 
inclusion, occupies the next stage in the life cycle. Very little is known about the 
biogenesis and composition of this membrane and how it functions. As the chlamydial 
micro-colony grows and chlamydiae advance through their developmental cycle, the 
enveloping inclusion membrane must enlarge to accompany this (Figure 1.1). Acting 
as a barrier, impermeable to molecules as small as 520 Daltons it allows the passage 
of very low molecular weight compounds to diffuse freely across it (Grieshaber et al., 
2002). Moreover this barrier must also be crossed by chlamydial proteins delivered 
into the host cell cytosol therefore it is likely to contain proteins that serve this purpose 
(Zhong et al., 2001). One group of proteins that have been discovered in the inclusion 
membrane are termed the Inc proteins (Rockey et al., 2002). They share minimal 
sequence identity and are considered to provide a diverse range of functions acting as 
effector molecules involved in host cell signalling pathways and interacting with the 
host microtubule network and centrosomes (Mital et al., 2010) possibly secreted via
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Type III secretion (section 1.4.4), yet largely the function of these proteins remain 
uncharacterised.
Unable to synthesise ATP for replication and intracellular survival, Chlamydia acquire 
nutrients and energy from host cell membrane lipids, such as sterols, sphingolipids, 
glycerophospholipids and neutral lipids from as early as two hours post infection 
(Scidmore et al., 2003, Valdivia 2008). This process is characterised by an increased 
metabolic function of the mitochondria and an enhanced uptake of long-chain fatty 
acids using both vesicle-dependent and vesicle-independent methods (Cocchiaro et 
al., 2008, Valdivia 2008).
Vesicle dependent uptake is achieved when the inclusion interrupts the passage of 
Golgi-derived exocytic vacuoles and multi-vesicular bodies which move from the Golgi 
to the plasma membrane. Via inclusion-vacuole fusion the chlamydiae seize the 
vesicle contents (Valdivia 2008). Vesicle-independent uptake involves interactions of 
the inclusion with endoplasmic-derived lipid droplets. These organelles are filled with 
energy rich substrates (sterol esters and triaglycerides) encapsulated by a 
phospholipid monolayer and utilised as an energy source during replication 
(Cocchiaro et al., 2008).
1.3.3 R eticu la te  body
The reticulate body (RB) is the metabolically active non-infectious form more 
specialised for replication and is subsequently found after infection upon entry into the 
host cell (AbdelRahman and Belland 2006) (Figure 1.1). Structurally it has a more 
flexible, thus fragile cell wall adapted for intracellular survival where it resides in the 
inclusion protected from the host’s immune defences. Its size ranges from 0.5-1.0 pm 
making them much larger than EBs with less dense nuclear material and more 
ribosomes. The RBs surface is covered with T3S needle-like projections that extend 
and penetrate the inner surface of the inclusion membrane (Matsumoto 1982, Peters 
et al., 2007).
The exact triggering mechanism of primary differentiation from EB to RB has not been 
clearly identified. However, the process can be blocked by transcription and 
translation inhibiting antibiotics suggesting de novo protein expression is necessary to 
begin intracellular growth (Scidmore et al., 1996). Carry over mRNA from the EBs is 
rapidly degraded as transcription of new mRNA needed for growth begins 
(AbdelRahman and Belland 2006). These genes encode proteins involved in the 
translocation of host-derived metabolites into the bacterial cell such as ADP/ATP
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translocase, nucleotide phospate transporters and oligopeptide permease (Shaw et 
al., 2002). All these proteins are essential for the parasitic growth mechanism of the 
RB, which feeds from the host’s energy supply to undergo binary fission. Following 
the period of rapid cell division, 10-12 hours post-infection, the RBs begin to re- 
differentiate back into EBs (AbdelRahman and Belland 2006). Again the signal for this 
remains unclear. Possibilities include quorum sensing, although genomic analyses do 
not support this. Other proposals involve the dissociation of RBs from the inclusion 
membrane via the removal of the T3S needle apparatus from the inclusion’s inner 
membrane surface (Bavoil et al., 2000). However no definitive conclusions have been 
made.
Secondary differentiation involves the expression of numerous late-cycle genes 
encoding components of the COMC (OmcA and OmcB) and proteins involved in 
condensation of the chromosome (HctA and HctB) (AbdelRahman and Belland 2006). 
Also at this stage it is thought that some of the early proteins associated with the EB 
infection are expressed, such as T3S needle like projection proteins (section 1.4.4) 
for entry and Pmps for possible attachment. This stage is quickly followed by host cell 
lysis with the release of newly formed EBs back into the extracellular environment to 
start the process over again. Given the marked differences in the outer membrane 
organisation between the EBs and the RBs, knowledge of the composition of the outer 
membrane is important for understanding the life cycle.
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1.4 The G ram -n eg ative  E nvelope
In contrast to Gram-positive bacteria, which only possess one biological membrane, 
the cell envelope of Gram-negative bacteria is composed of two asymmetrical 
membranes (Figure 1.2) (Desvaux et al., 2004a). An inner and outer membrane 
system sandwiches the periplasmic space and the thin peptidoglycan layer 
characteristic of Gram-negative organisms (Beveridge 1999). In the context of 
protein transport, Gram-negative organisms can also be referred to a ‘d iderm ’ 
bacteria (two lipid bilayers) as oppose to Gram-positive which are ‘monoderm ’ due 
to the single bilayer (Desvaux et al., 2009). This double bilayer structure produces a 
robust cell envelope, which can endure extreme pH and temperature changes whilst 
being elastic in order to expand under atmospheric pressure changes. The outer 
membrane comprises phospholipids, proteins and a complex lipopolysaccharide 
(LPS). The lipid region of the LPS acts as an endotoxin causing illness upon 
entering the circulatory system. Although the cell envelope of Gram-negative 
bacteria is a more complex structure it is still capable of transporting essential 
substances both in and out of the cell. This takes place via membrane spanning 
proteins that form pores or via more complicated transport systems. To date, five 
major secretion systems have been described among Gram-negative bacteria 
(types I to V sections 1.4.2 to 1.4.6), (Desvaux et al., 2004a), some of these 
mechanisms are shown to be important in Chlamydia.
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Figure 1.2 - Schematic diagram depicts the typical structure of the Gram-negative cell 
wall. Shown is the outer membrane linked by lipoproteins to a single-layered peptidoglycan. 
The peptidoglycan is situated within the periplasmic space sandwiched between the outer 
and inner membranes. The outer membrane includes porins, which allow the passage of 
small hydrophilic molecules across the membrane, and lipopolysaccharide molecules that 
extend into extracellular space. The Chlamydial cell envelope differs by the loss of the 
peptidoglycan layer, instead a highly cysteine enriched protein network is in place in the 
outer membrane (described in section 1.5). Adapted from Cabeen and Jacobs-Wagner 
(2005).
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1.4.1 The  Sec T ran slo co n
Protein secretion and protein insertion into the membranes is essential in outer 
membrane protein biogenesis and relies on specific transportation systems within 
the cell. For this there exists a ubiquitous membrane protein complex positioned in 
the plasma membrane of bacteria and archaea (SecY), and in the ER of eukaryotic 
cells (Sec61) (Gold et al., 2007). The bacterial core translocase consists of the
integral inner membrane proteins SecY, SecE, and SecG, which make up an
oligomeric complex (Sijbrandi et al., 2003) (Figure 1.3). Two modes of 
translocation, co- and post-translational are carried out at the Sec complex. Some of 
the proteins synthesised in the cytosol carry N-terminal signal sequences, which are 
recognised for Sec targeting. In the event of co-translational translocation, the 
ribosome-nascent chain complex is targeted to the membrane via the signal 
recognition particle (SRP) and its receptor. In principle, the SRP-targeting pathway 
in E. coli is homologous to the SRP-targeting pathway that targets both secretory 
and membrane proteins to the endoplasmic reticulum (ER) membrane in
eukaryotes. The eukaryotic SRP binds to the N-terminal signal sequence of
secretory and membrane proteins as soon as it is exposed outside the ribosome 
(De Gier and Luirink 2001). Further translation is inhibited until the SRP contacts its 
receptor at the ER membrane and then dissociates from the nascent chain, 
occurring in close proximity to the Sec complex, enabling protein translocation to be 
driven by the associated chain elongation (Gold et al., 2007). During post- 
translational translocation, bacteria have a mechanism that pushes proteins across 
the channel by use of a motor protein ATPase SecA. In addition, the reaction 
requires a cytosolic component SecB to aid targeting to the membrane and to 
prevent premature protein folding and aggregation of the pre-protein. Upon 
translocation the protein is delivered into the periplasm and the signal peptide is 
cleaved.
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Figure 1.3 - Diagram of the SRP mediated pathway for Sec co-translationanal 
pathway. The ribosome-nascent chain complex is targeted to the membrane via the signal 
recognition particle (SRP) and its receptor. Translation is inhibited until the SRP contacts its 
receptor at the membrane. Protein translocation is driven by the associated chain elongation 
into the periplasm. During post-translational translocation, bacteria have a mechanism that 
pushes proteins across the channel by use of a motor protein ATPase SecA. The cytosolic 
component SecB aids targeting to the membrane and to prevent premature protein folding 
and aggregation of the pre-protein in the cytoplasm. Upon translocation the protein is 
delivered into the periplasm and the signal peptide is cleaved.
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1.4.2 Type  I S ecre tion
T1S is associated with an oligomeric complex consisting of three functional 
subunits: the pore-forming outer membrane protein, a membrane fusion protein 
(MFP), and within the inner membrane sits the ATP binding cassette (ABC) protein 
(Binet et al., 1997). It is largely believed that secretion is Sec independent and is a 
continuous procedure through both membranes. Continuous secretion is initiated 
when an effector molecule binds to the inner membrane ATP binding cassette. The 
effector molecule itself contains a secretion signal located within its C-terminal 
region, this signal sequence is thought to be specific, only interacting with its 
dedicated ABC transporter protein (Jarchau et al., 1994). Therefore the molecules 
secreted by T1S are not processed during secretion and do not form distinct 
periplasmic intermediates (Henderson et al., 2004). The binding of the effector 
molecule to the ABC protein causes an interaction between the MFP and the outer 
membrane protein allowing secretion. One example of this is the secretion of alpha 
hemolysin (HlyA) a large exotoxin from E.coli, believed to interact with host cells 
leading to insertion in to the plasma membrane to of eukaryotic cells (Gentschev et 
al., 2002). This T1S is made up of TolC (outer membrane pore protein), HlyD (MFP) 
and HlyB (ABC protein). Binding of the effector molecule triggers the interaction 
between HlyD and TolC to allow passage of the effector molecule. However, there 
are various suggestions for the mechanisms of the complex detailing small 
disparities between different species of bacteria. To date, TS1 has not been 
identified amongst the Chlamydia species.
1.4.3 Type II S ecre tion
All proteins secreted via the T2S have an N-terminal signal peptide (Henderson et 
al., 2004). Secretion via this pathway is a two step Sec-dependent process in which 
the protein or molecule is first exported across the inner membrane under the 
direction of SecB, into the periplasmic space (Desvaux et al., 2004b). Sec B is a 
cytoplasmic chaperone that recognises the mature part of the unfolded protein 
targeted for secretion and subsequently directs it to the Sec translocon (section  
1.4.1). Upon transportation into the periplasm, studies have shown that the protein 
adopts a quasi-native state which is aided by certain chaperones such as disulfide 
bond isomerise, DsbA (Thanassi 2002). These steps are necessary for further 
transportation across the outer membrane complex termed the secreton. The 
secreton is a multimer of up to 16 protein subunits (Desvaux et al., 2004b, Desvaux 
et al., 2004c) that form a channel to allow translocation to the external milieu. The
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best studied T2S is for the pullulanase enzyme PulA from Klebsiella oxytoca. This 
starch hydrolysing lipoprotein forms micelles once secreted from the bacteria 
(Takizawa and Murooka 1985). This pathway has been identified in a variety of 
other bacterial secretory proteins including cholera toxin of Vibrio cholera, exotoxin 
A of Pseudomonas aeruginosa and several other cell-wall degrading enzymes 
(Sandkvist 2001).
It is also proposed that this process uses the Tat (twin-arginine translocation) 
pathway (Desvaux et al., 2004b). In contrast to the Sec pathway (which transports 
proteins in an unfolded manner), the Tat pathway serves to actively translocate 
folded proteins across the lipid bilayer. Like TS1, this secretion system has also not 
yet been identified as a method of protein secretion amid the Chlamydia species.
1.4 .4  Type III S ecretion
The type III secretion system was first identified in pathogenic Yersinia spp. for the 
secretion of Yop proteins (Henderson et al., 2004). Since then more T3S proteins 
have been found in several plant and mammalian pathogens including Salmonella 
enterica, Shigella flexeri, E.coli and C.trachomatis. Type III secretion systems are 
largely associated with virulence amongst Gram-negative pathogens so their 
presence in C. trachomatis has raised much interest.
T3S translocate their effector molecule across both the inner and outer membranes 
in a sec-independent manner (Henderson et al., 2004). The mechanism in which the 
effector molecule itself is targeted to, or recognises the T3S apparatus remains 
unclear. However, once the effector molecule reaches the cytoplasmic side of the 
T3S, secretion proceeds through the needle-like structure of the apparatus (Figure 
1.4)
The T3S apparatus is composed of a complex array of about 20 different proteins,
conserved among T3S systems that span both the inner and outer membranes
(Stephens and Lammel 2001). The needle-like structure (CopN) protrudes from the
surface of the bacterium and is able to penetrate eukaryotic host cells to inject
effector molecules (CopD/CopB) (Peters et al., 2007). The components of the
chlamydial T3S are clustered in three operons. In terms of protein structure and
content the core apparatus bears a strong resemblance to a Gram-negative flagellar
basal body. The secretin proteins in the outer membrane oligomerise to form the
outer membrane pore CdsC at the distal portion of the complex (Fields et al., 2006).
Among the T3S systems this region generally has surface-exposed domains,
normally these do not directly interact with host components, however, this is
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different in C. trachomatis where they are thought to be host-interactive. The distal 
portion is linked to the inner membrane components by the CdsJ region that spans 
the periplasm (Figure 1.4). The anchored region in the inner membrane is made up 
of integral proteins CdsQ-V and CdsD. Portions of CdsD are also surface-exposed 
and may also be host-interactive (Tanzer and Hatch 2001a). These T3S systems 
are energy dependent, possessing an ATPase thought to be the CdsN protein in 
Chlamydia (Hueck 1998).
To date there has been no definitive mechanism identified as to what triggers the 
T3S function in chlamydiae (Fields et al., 2006). Evidence suggests that they are 
polarised and are induced upon contact with host cell membranes (Hueck 1998). 
T3S needle-like protrusions can be seen on the surface of RBs and may be involved 
in the differentiation of RBs into EBs as well as having some role in the attachment 
and entry into host cells (section 1.3).
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Figure 1.4 - Diagrammatical representation of the chlamydial T3S apparatus. The
secretin-like protein CdsC sits exposed in the outer membrane and is linked by the 
periplasmic lipoprotein CdsJ to the multiple inner membrane proteins. CopN signifies the 
surface exposed needle-like projection. Adapted from Peters et al., ( 2007).
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1.4.5 Type IV S ecretion
The least characterised of the secretion systems, T4S is mainly associated with the 
transfer of DNA by conjugation (Desvaux et al., 2004b). As with other pathways, the 
effector molecules also have a wide variety of other functions and thus secretion 
includes multi-subunit toxins, monomeric proteins as well as nucleoprotein DNA 
conjugation intermediates (Henderson et al., 2004). One well studied mechanism is 
of secretion of the pertussis toxin from Bordetella pertussis, the causative agent of 
whooping cough. This toxin belongs to the A-B5 family of toxins (Tamura et al., 
1982). Unlike other T4S, this multi-subunit protein is secreted to the extracellular 
milieu rather than directly into the host cell. Subunits S2-S5, also known as the B 
domain, interact with host cell glycoprotein receptors mediating translocation of the 
A domain (subunit S1) into the host cytosol to interfere with signalling pathways 
(Malaisse et al., 1984). In contrast, the Agrobacterium tumefaciens T-DNA transfer 
system involves the secretion of several effectors, VirD2, VirE2 and VirF directly into 
the host cell cytosol (Citovsky et al., 1992, Howard et al., 1992). VirD2 is secreted 
as a nucleoprotein complex, covalently associated with a single-stranded copy of T- 
DNA for transfer. Delivery of the T-DNA into the host cell is mediated upon 
interaction of the complex with VirE2 resulting in crown gall tumour formation. The 
role of VirF is not yet fully understood. The T2S system can be either Sec 
dependent or Sec independent (Desvaux et al., 2004b). The transfer of T-DNA by 
A.tumefaciens takes place as a single continuous step whereas the export of 
pertussis toxin resembles that of the T2S pathway where secretion occurs in two 
steps. First the toxin subunits are translocated across the inner membrane via Sec 
machinery and then are subsequently targeted for export across the outer 
membrane (Henderson et al., 2004).
1.4.6  Type V  S ecre tion  S ystem
Autotransporters are a distinct family of secreted proteins employing the type V 
secretion pathway (Va or AT-1 system) in which all the necessary elements for 
transportation of the protein are contained within the polypeptide sequence itself 
(Veiga et al., 2004). Other proteins categorised under the type V secretion umbrella 
are those secreted via the the two-partner secretion pathway (type Vb), and the type 
Vc system (also termed AT-2) (Henderson et al., 2004). Proteins secreted via these 
pathways have similarities in their primary structures as well as prominent 
similarities in their modes of biogenesis. Members of this protein fam ily include
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virulence factors such as the lgA1 proteases from Neisseria gonorrhoeae and 
Haemophilus influenzae.
1.4.6.1 V a  pathw ay - A u to tran sp o rters
Generally autotransporters are large secretory proteins made up of three distinct 
domains shown in Figure 1.5a. The N-terminal region contains the signal peptide 
leader sequence that targets the protein to the Sec apparatus in the inner 
membrane (Desvaux et al., 2004a) and this region itself is composed of three 
domains, a positively charged amino terminus (n-domain), a hydrophobic core 
region (/7-domain) and a consensus signal peptidase recognition site, SPasel (c- 
domain) that is cleaved by components of the Sec machinery to release the pro­
protein into the periplasm. Adjacent to the signal domain is the functional passenger 
domain. This region offers the most sequence diversity among the proteins as this 
performs the extracellular function. To date this function has always been linked to a 
role in bacterial virulence, either by exhibiting enzymatic activity (protease, 
peptidase or lipase) or by acting as an adhesin, toxin or cytotoxin. Finally a 25-30 
kDa C-terminal region builds the translocation unit needed to export the passenger 
domain. This can be further divided into two subunits, a short linker region with a a- 
helical structure and a (3-domain which folds into a p-barrel secondary structure 
forming a pore embedded in the outer membrane (Figure 1.5b) (Maurer et al., 
1999). The mechanism which triggers the folding of the C-terminal domain is still not 
recognised. Periplasmic chaperones could be involved or the process may just be 
spontaneous yet the p-domains of all autotransporters are thought to have some 
homology. Importantly there are several proposals regarding the translocation 
mechanism of the passenger domain, including a monomeric form (Figure 1.6a) 
and an oligomeric form whereby autotranslocator p-domains form oligomeric rings in 
the membrane to produce a large pore for translocation of several passenger 
domains concomitantly shown in Figure 1.6b (Henderson et al., 2004). 
Furthermore, these passenger domains may sometimes be cleaved to produce a 
mature active protein.
It is proposed that autotransporters have and continue to evolve by domain shuffling 
such that novel members arise by the linking a new passenger domain to a generic 
P-barrel domain (Henderson et al., 2004). Phylogenetic analysis has shown that 
horizontal transfer of autotranslocator P-domain encoding regions between distant 
organisms is a rare event yet functional passenger domains have spread by 
horizontal transfer (Henderson and Nataro 2001b) suggesting that most
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autotransporters have arisen through fusion events between passenger domains 
and (3-domains.
1.4 .6 .2  V b  pathw ay
The bacterial two-partner Vb secretion pathway shares many similarities to the 
conventional autotansporter Va secretion pathway whereby the passenger domain 
possesses a signal sequence that directs translocation across the inner membrane 
and following its export into the periplasm, the passenger domain inserts into an 
outer membrane pore formed by a (3-barrel (Henderson et al., 2000). Once 
translocation to the surface of the bacterium has occurred, the passenger domain 
may also undergo further proteolytic processing however, in contrast to the 
autotransporter pathway, the passenger domain and the pore-forming (3-domain (the 
transporter domain) are translated as two separate proteins referred to as TpsA and 
TpsB. In addition compared to the Va autotransporter, the (3-barrel topology appears 
different, by containing more amphipathic (3-strands compared to the (3-domain of 
type Va autotransporters (Yen et al., 2002).
1.4 .6 .3  V c  pathw ay
Members of the Oca (Oligomeric Coiled-coil Adhesins) family have been described 
as a subfamily of oligomeric autotransporters. Y. pestis YadA possesses six 
different domains: an N-terminal signal sequence, head, neck, stalk, linker, and a C- 
terminal region consisting of only four (3-strands (Hoiczyk et al., 2000). This type of 
trimeric conformation and mode of secretion has been proposed as an alternative 
model for autotransporter secretion system and has been designated the type Vc or 
AT-2 pathway (Figure 1.6c).
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Figure 1.5 - Schematic representation of the three functional domains and folding of 
monomeric autotransporter protein, (a) A short N- terminal leader is necessary for 
localisation to the inner membrane of Gram-negative bacteria, adjacent to the functional 
passenger domain (red) linked to the C-terminal autotranslocator p-barrel pore (yellow) 
adapted from (Henderson and Lam 2001a). (b) Crystal structure of a typical p-barrel 
autotanslocator membrane domain, the functional passenger/linker domain (red) traverses 
the translocating unit (yellow). Typically the barrel interior is highly hydrophilic due to the 
presence of charged amino acids. Taken from Henderson et al., (2004).
Figure 1.6 - Diagram of the various proposed strategies for the translocation of the 
passenger domain to the external surface of the Gram-negative outer membrane, (a)
The autotransporter domain (green) exports the passenger domain (star) outside the cell in 
typical Va autotransporter pathway, passenger domain may be cleaved from the linker 
region (red) to release the functional domain or may remain intact with the membrane, (b) 
The autotansporters form oligomers at the membrane to produce large pores for 
translocation of the passenger domains, (c) An oligomeric coiled passenger domain forms 
as tetramers exposed to the external milieu.
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1.5 The C h lam yd ia l E nvelope
During all the stages of the developmental cycle (section 1.3), Chlamydia cells 
appear to be surrounded by the double membrane system characteristic of Gram- 
negative cells (Figure 1.2) (Bavoil et al., 1984). However, their cell envelope differs 
by the lack of a peptidoglycan layer within the periplasm (Kosma 1999). This 
anomaly remains unclear as genomic analyses have shown a complete set of 
genes that would enable its synthesis. Instead the chlamydial envelope contains a 
considerable amount of disulfide bond crosslinked proteins in the outer membrane 
and periplasm, a feature which is thought to stabilize the cell envelope (Hatch 1996) 
and so the peptidoglycan layer could have been lost by evolution where the 
requirement for a rigid cell wall in the RBs form was lost due to its intracellular 
location (Kosma 1999). Like other gram-negative bacteria, Chlamydiae have a vast 
array of proteins spanning the outer membrane. Many of these are unique to this 
organism, thus raising much interest in their function. There are difficulties in 
studying these proteins due to the intracellular residence of the Chlamydiae 
species, so the majority of data to date is derived from genomic analysis.
Typically the Chlamydial outer membrane proteins (OMPs) boast several functions: 
firstly they are involved in specific nutrient and metabolite attainment (Rzomp et al., 
2006), secondly, they act as adhesions to, or invaders of, the host cells and tissues 
(Wehrl et al., 2004, Fadel and Eley 2008), thirdly, some are thought to be type III 
secretion proteins in place to deliver pathogen effector kinases or phosphotases 
(i.e. TARP) (Jewett et al., 2008); and finally others act as host immune evaders by 
employing antigenic shift variations (Stephens and Lammel 2001). The main 
Chlamydial OMPs are crucial components in the attachment and entry of EBs 
during the life cycle and include OmpA (MOMP), T3S and the Pmps.
1.5.1 The M ajo r O u te r M em brane  P rote in
The Major Outer Membrane Protein is a major constituent of the Chlamydial outer 
membrane with a similar structure and molecular mass of 40kDa among species 
(Kosma 1999). It functions as a porin bearing structural similarities to porins found in 
other Gram-negative organisms (Bavoil et al., 1984). This cysteine-rich protein 
comprises of four domains with seven cysteine residues (Caldwell et al., 1981) that 
are essential in the formation of the disulfide-linked COMC of the EB (McCafferty et 
al., 1995). MOMPs are surface exposed, closely associated with LPS and have 
species-specific epitopes (Batteiger et al., 1993). Su et al, (1996) , found strong 
evidence to suggest that MOMP functions as a chlamydial cytoadhesin to
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glycosaminoglycans (GAGs) of host cells. This protein has therefore been the main 
focus for an anti-chlamydia vaccine. Partial protection against infection has been 
observed in animals immunised with preparations of MOMP although protection 
against re-infection appears to be serovar-specific (Batteiger et al., 1993).
1.5.2 The P o lym o rp h ic  M em brane  P ro te in s  (P m p)
The polymorphic membrane proteins remained largely undiscovered until complete 
sequence analysis of the C .trachomatis genome by Stephens et al, (1998). A 
super-family of genes were revealed with a nine-member family termed pmpA - 
pmp! present in C. trachomatis (Stothard et al., 2003), which has expanded to 21 
homologs in C. pneumoniae  (Mygind et al., 2004). Importantly, these coding regions 
represent 13.6% and 17.5% of the Chlamydia-spectf\c coding regions within these 
two genomes (Kalman et al., 1999, Read et al., 2000), since Chlamydia only retain 
genomic material critical for survival, these proteins are considered to have a key 
function in Chlamydia biology (Hatch 1998).
1.5.2.1 P h ylo g en y  and c lass ifica tio n
The Pmp proteins are all phylogenetically related to one of 6 basic subtypes, PmpA, 
B, D, E, G and H (Grimwood et al., 2001). Pmp C is adapted from Pmp B, Pmp F is 
derived from Pmp E and Pmp I is a variation of Pmp G. The pmp  genes vary in size, 
ranging from approximately 2,600 to 5,300 base pairs, thus encode large proteins 
between 90 -187kD a in mass (Stothard et al., 2003). They are unique to Chlamydia 
and account for 3.15% of the organism’s genetic coding capacity (Gomes et al., 
2006). The genes are diverse in nucleotide sequence, sharing between 9-42% 
sequence homology, however the sequence diversity of individual pmps  between 
different serovars has not been explored extensively. Diversification and expansion 
is most prominent with pmpG  of C. pneumoniae, C. caviae and C. abortus where 
four subtypes have evolved suggesting this Pmp is under selective pressure 
possibly responding to specific host traits or defences requiring a higher level of 
antigenic variation (Tan, et al. 2006). Interestingly, some of the C. trachomatis pmp  
genes are located in clusters suggesting that they regulate or may work as one 
entity, pmp A, B and C are in close association with each other, as are E/F  and G/H  
although on opposing DNA strands with pmp I in close proximity (F igure  1.7) 
(Gomes et al., 2007). However there is no evidence to suggest they are 
polycistronic. Instead this may allow for a high mutation rate to provide antigenic 
variation among species. Conversely pmp D sits alone on the chromosome 
suggesting some important preserved function for this protein.
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1.5 .2 .2  C h aracteris tics  o f Pm p prote ins
The pmp family encode several carboxy tryptophan residues and a carboxy terminal 
phenylalanine typical of proteins that localise to the outer membrane (Stephens et al., 
1998). In addition an amino terminal leader peptide sequence consistent with 
localisation to the inner membrane is also present on most of the Pmp proteins with 
the exception of Pmp A that differs in this respect (Skipp et al., 2005). Protein 
sequence analysis has indicated that these Pmp carboxy terminal domains are 
predicted to form a p-barrel pore structure embedded within the outer membrane and 
are likely to function as an autotransport secretory protein (type V secretion), 
transferring the adjacent functional passenger domain through the pore to the 
extracellular surface as described in section 1.4.6 (Henderson and Lam 2001a, 
Henderson and Nataro 2001b). Additionally P-loop motifs associated with pore 
regulatory gating mechanisms via GTP/ATP binding have been identified within the 
Pmp I autotanslocator domain and Pmp G passenger domain of C. trachomatis 
(Henderson and Lam 2001a) supporting the formation of a p-barrel pore although a P- 
loop motif in the passenger domain of Pmp G may not be consistent with regulatory 
closing of a pore region. In contrast, generally Pmps have relatively high levels of 
cysteine residues (Tanzer and Hatch 2001a, Tanzer et al., 2001b) inconsistent with 
the ability to secrete proteins via the autotransporter pathway as studies have shown 
intra-peptide disulfide bonds inhibit translocation of the passenger domains (Jose et 
al., 1996). However, studies have since emerged showing that limited disulfide bond 
formation within the passenger domain of Shigella protein IcsA does not prevent 
translocation of this domain through the p-barrel pore (Brandon and Goldberg 2001). 
The folding mechanisms of Pmps prior to translocation are unclear. W hether or not 
these cysteine residues form extensive disulfide bonds such that translocation via an 
autotransporter p-barrel is impractical has yet to be determined. Alternatively these 
cysteines may form inter-peptide disulfide bonds with other cysteine-rich proteins such 
as MOMP, OmcA and OmcB maybe offering added structure and rigidity associated 
with the EB COMO (Hatch 1996, Henderson and Lam 2001a).
The autotransporter theory is further supported where proteolytic processing of Pmps 
into amino passenger domain and carboxy p-barrel domains has been positively 
identified in vitro (Grimwood et al., 2001, Vandahl et al., 2002, Wehrl et al., 2004, 
Vandahl et al., 2005) however these studies have not extended beyond investigations 
with Pmp D or Pmp D homologues. Also consistent with autotransport is that the 
putative passenger domains of some of the Pmps are most immunogenic suggesting
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this domain is more accessible to the host’s immune mechanisms, playing a key role 
in Chlamydia pathogenesis (Crane et al., 2006, Byrne 2010).
The most common features shared by all the Pmps is the repeated tetrapeptide motifs 
GGAI and FXXN (where X represents any amino acid) found in the putative 
passenger domains of the proteins (Stephens et al., 1998). These motifs have been 
associated with attachment to host cells in many other organisms (Grimwood and 
Stephens 1999). Another feature that indicates a role as an adhesin is the presence of 
RGD motifs (within the Pmp D and Pmp F passenger domains) of the type implicated 
in cell-cell adhesion, although such motifs are not recognised in the other C. 
trachomatis Pmps. Furthermore, studies have demonstrated that for some of the 
Pmps, the passenger domains associates with host cell surfaces including Pmp D of 
C. trachomatis and Pmp D and Pmp G homologues of C. pneumoniae  (Wehrl et al., 
2004, Molleken et al., 2010a). Speculation that Pmps function as adhesins in 
Chlamydial attachment is prevalent yet rationally, studies to support this are still 
limited and lacking in published data. Furthermore, studies have not investigated the 
other Pmp proteins to determine if they display the same functionality. Additionally 
there are no repeated studies focussed on the expression and processing of all the 
Pmps to determine if they all carry the autotransport mechanism.
1.5 .2 .3  E xpression , lo ca lisa tio n  and the role o f Pm ps
Studies have shown that all nine C.trachomatis Pmps are transcribed in EBs, but 
stable translation and presence in the outer membrane has not been demonstrated for 
them all. Pmp E, Pmp G and Pmp H have been identified as major constituents of this 
C. trachomatis LGV serovar L2 outer membrane late in the developmental cycle 
whereas none of the seven other predicted Pmp proteins were detected (Tanzer and 
Hatch 2001a, Mygind et al., 2006). More recently Pmp B, Pmp C, Pmp D, Pmp E, 
Pmp F, Pmp G, and Pmp H were found in the COMC of the same serovar (Liu et al., 
2010). Pmp A has not been detected in the EB throughout the studies but had 
previously been detected in the RB (Skipp et al., 2005b) so it is speculated that Pmp 
A does not reside in the outer membrane of EBs, also supported by bioinformatic 
analysis that shows a lack of signal peptide in this Pmp (Stephens et al., 1998). 
However, the Pmps are not abundant proteins in the chlamydial membranes therefore 
expression levels of certain Pmps not identified in these studies may have been below 
the limits of detection or expressed in a tissue tropism manner by some serovars but 
not others.
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Evidence shows that Pmps stimulate the expression of cytokines (Johnson 2004, 
Wang et al., 2005) and serum samples from C. trachomatis-infected patients have 
also shown anti-Pmp antibodies to all nine rPmps (Tan et al., 2009b) indicating Pmps 
are possibly targeted by the host immune response. Pmp D has already been shown 
to act as an immune decoy mechanism (Crane et al., 2006). However, there is still no 
clear picture of how the immune system fully responds to Chlamydia infections except 
that the organism has a dynamic ability to evade the hosts system in the cell inclusion.
1.6 The ch a llen g es  o f s tudy ing  m em b ran e  prote ins
In order to obtain structural and functional data it is often necessary to produce tens, 
sometimes hundreds, of milligrams of highly purified material (Bill et al., 2011). 
However, the majority of membrane proteins are endogenously expressed at levels 
too low to purify and it is rare that a single protein species is a major component of the 
membrane. Where this is the case it has been exploited. Bacteriorhodopsin, is the 
only protein constituent of the purple membrane of the bacterium Halobacteria  
salinaria where straightforward preparation of the membrane was sufficient to obtain 
high yields of pure protein (Belrhali et al., 1999). The requirement for large amounts of 
protein has therefore resulted in a bias of structure determination efforts towards 
membrane proteins which are naturally abundant, such as photosynthetic reaction 
centres and aquaporins. This is not possible for studies that aim to investigate the 
structure and function of Pmps as these proteins are not endogenously expressed in 
high abundance (Tan et al., 2009a). However, membrane proteins can often be over­
expressed in an ectopic expression system as recombinant proteins. Although 
recombinant expression of membrane proteins is technically challenging it is not 
impossible whilst the inability to perform basic genetic manipulations with Chlamydia  
is well acknowledged and subsequently studies lag behind those of other infective 
organisms. Since the C. trachomatis genome was published less than two decades 
ago leading to the discovery of the pmp  gene family, the majority of information with 
reference to the Pmps is derived from genomic analyses. Studies that have explored 
the Pmps at the protein level have employed recombinant Pmps in the form of 
misfolded inclusion bodies and have yet to investigate the structure and function of 
each of these proteins. An advantage with using recombinant expressed protein is 
that the facility to manipulate or modify the protein to improve stability, solubility, 
enable detection and purification is possible (W agner et al., 2006).
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1.7 A im s o f the S tudy
The overall aim of this study is to gain an understanding of the role of Chlamydia 
trachomatis Polymorphic Membrane Proteins as potential autotransporters that act as 
adhesins to initiate infection of host cells. Specifically the aims are to clone, express 
and purify recombinant Pmps or the predicted Pmp functional domains for structural 
and functional analyses. Purified recombinant Pmps and recombinant Pmp functional 
domains can be used in secondary structure analysis to verify that the predicted Pmp 
C-terminal autotranslocator domains are consistent with the p-barrel structure of 
autotransporters as bioinformatic analyses predicts. Binding interactions with female 
urogenital cells may show that Pmps specifically interact with cells as putative 
adhesins. Currently there are no effective vaccines to tackle Chlamydia infections due 
to the lack of immunogenic target proteins. Treatment relies upon the administration of 
antibiotics, which can often be problematic due to the bacteria's ability to evolve and 
acquire resistance. Data generated from these studies will hopefully contribute to the 
understanding of the role Pmps play in the attachment to and invasion of host cells. 
As a crucial step in the chlamydial infective cycle, these proteins could become a 
suitable target for future vaccine developments in an effort to prevent the spread of 
chlamydial infections. This is of both fundamental and topical importance given that C. 
trachomatis is the most prevalent STD worldwide.
Specific objectives of this study:
• To produce recombinant expression constructs containing full length pm pA- 
pm pl genes and/or the smaller predicted pmp passenger or autotranslocator 
domain sequences. This is to be achieved by the amplification of each gene 
and/or domain sequence from genomic DNA using custom designed primers 
with PCR. Each construct will be designed to incorporate a hexahistidine tag 
on the C-terminus of the recombinant Pmp for detection with an anti-His 
antibody during expression trials.
• To attempt the overexpression of recombinant full length Pmps and/or 
recombinant truncated Pmp domains using E. coli as an experimentally 
amenable system. The expression of recombinant Pmps as inclusion bodies 
will be avoided since the requirement for protein suitable for structural and 
functional analyses is of importance. Instead efforts will focus on targeting
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expression to the membranes or to a membrane-like environment. This is 
expected to involve several different expression screening trials and where 
expression is observed, focus will begin to optimise these methods.
• Purification of the recombinant Pmp proteins using immobilised metal ion 
affinity chromatography facilitated by the hexahistidine tag on the C-terminus 
coupled with other conventional purification techniques such ion exchange 
chromatography will be employed where necessary. The secondary structure 
of the purified recombinant Pmps will then be examined by circular dichroism.
• Recombinant Pmps expressed and targeted to E. coli or artificial membranes 
(to mimic a native membrane protein environment) will be used in functional 
adherence assays to investigate Pmps as putative adhesins to female 
urogenital cells. Several methods will be explored, including methods to exploit 
the C-terminal poly-histidine tag where generic anti-His antibodies can be used 
to detect and/or immobilise recombinant Pmps for interaction studies. 
Specifically, recombinant Pmps will be incubated with whole cells followed by 
chemical cross-linking to permanently fix recombinant Pmp interactions. 
Putative interactions will be detected using Western blotting and 
Immunocytochemical staining techniques.
• Optical biosensor techniques will be employed where appropriate to also 
investigate putative interactions between the recombinant Pmps and 
urogenital cells. Methods including Surface Plasmon Resonance and 
Ellipsometry will be explored, whereby interactions are monitored in real time 
by changes in reflected light from an experimental surface.
A summary for each the aims and outcomes is displayed in Figure 6.2, Figure 6.3 
and Figure 6.4.
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Chapter 2 - Recombinant Cloning Strategies for 
C.trachomatisPmp Expression Constructs
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2.1 In troduction
This chapter describes the preliminary work undertaken to lay the groundwork 
necessary for studying the structure and function of C. trachomatis Polymorphic 
Membrane Proteins (Pmps). It describes the development of cloning strategies to 
produce suitable E. coli expression constructs for the production of both full length 
and truncated recombinant Pmps.
Cloning strategies were developed using the published genome of C. trachomatis, 
serovar D (std.gen.northwestern.edu) for primer design, sequencing alignment and 
verification. It was thought feasible to use serovar D for this purpose as the genome of 
serovar E was not yet published and a high sequence homology between some pmps 
amongst the serovars of C. trachomatis was reported (Stothard et al., 2003). Using 
restriction fragment length polymorphism (RFLP), little variation among the 15 
serovars for pmpA  and pmpD  was shown as both were found to be highly conserved. 
Interestingly a significant variation in sequences between serovars was evident for 
some of the other genes, in particular pmp F, pmpH, pm pl and pmpE. These Pmps 
are thought to have a role in tissue specific targeting. However serovars D and E are 
of the same tissue specific tropism both infecting urogenital epithelial cells so any 
variation within the gene sequence was expected to be modest. Because of repeated 
similarities, it was expected that pmpA  and pmpD  would be the least challenging to 
clone and interestingly most of the published information that exists to date is based 
on data obtained from studies of Pmp D where function as an adhesion and as an 
immune decoy protein has been suggested (Wehrl et al., 2004, Crane et al., 2006). 
Pmp A also stimulates interest being the only Pmp that does not appear to have a 
recognised signal leader peptide sequence, suggesting an alternative functional role 
or localisation (Gomes et al., 2005). Highly variable Pmp F, Pmp H, Pmp I and Pmp E 
predicted to have a role in tissue specific targeting, are of particular interest as 
microbial virulence factors (Stothard et al., 2003).
It is widely accepted that expression of recombinant membrane proteins can be a 
difficult process due to the high attrition rate associated with the stages involved 
during cloning, expression and purification. Therefore, few recombinant proteins are 
expressed in native, full-length. One approach to reduce the high attrition is to begin 
with a larger number of clones using a high-throughput approach (Cowieson et al., 
2005). The method used by the Northeast Structural Genomics Consortium Project 
examines certain characteristics within protein sequences to determine possible 
structural domain boundaries and subsequently produce nested sets of constructs for
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full-length proteins, multi-domain and single domain constructs. These alternative 
constructs often led to better expression and increased the likelihood for success in 
further investigations (Graslund et al., 2008). A similar approach was used to begin 
this project as it was difficult to determine which particular Pmps would be expressed.
Therefore, as the starting point for this research, one particular Pmp was not singled 
out for analysis; instead attempts were made to construct expression plasmids for 
each of the pmps. Consequently the targets for cloning were all nine of the full length 
pmps, and truncated pmps based on the predicted autotansporter domains by 
creating expression constructs containing the N-terminal passenger domain predicted 
to exhibit the functional part of the protein, and the C-terminal autotranslocator region 
that forms the pore within the membrane (section 1.4.6).
The full length sequences were termed pmpx-FL, N-terminal passenger domain 
sequences are termed pmpx-N  and the C-terminal autotranslocator domains termed 
pmpx-C  where x represents the particular pmpA  - pmpl. All putative pmp  constructs 
underwent expression screening, optim isation and ultimately purification for 
subsequent functional studies (chapters 3, 4 and 5). This was deemed the most 
favourable approach to begin this project in an effort to increase the outcome of 
successful expression targets.
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2.2 M ateria ls /M eth o d s
2.2.1 S upp lie rs  used in th is  ch ap ter
Analytical grade chemicals were used throughout this study with all solutions being 
prepared using sterile water. Materials were obtained from the following suppliers.
Bio-Rad Laboratories Ltd., Hemel Hemsted, Hertfordshire; GE Healthcare Ltd., 
Amersham, Buckinghamshire; Invitrogen Life Technologies., Paisley; Merck 
Chemicals Ltd., Beeston, Nottingham; New England Biolabs (UK) Ltd., Hitchin, 
Hertfordshire; NovagenI Merck Chemicals Ltd., Beeston, Nottingham; Sigma 
Aldrich Company Ltd., Gillingham, Dorset; Starlab UK., Blakelands, Milton Keynes; 
Stratagene Ltd., Cambridge; Thermo-Fisher Scientific UK., Loughborough, 
Leicestershire; Qiagen Ltd., Crawley, W est Sussex.
Molecular biology methods used were essentially those described in Sambrook et al. 
(2001), with some modifications. Glassware and media were sterilised by autoclaving 
at 121°C, 15 p.s.i. for 20 minutes. Solutions were made from molecular biology grade 
reagents and sterilised by filtration or autoclaving before use. Custom DNA primers 
were synthesised by Sigma Aldrich.
2.2 .2  P rim er D esign
Commercial primers were not available for the amplification of pmp  genes therefore 
primers incorporating restriction sites were designed to flank the C. trachomatis pmp 
genes and/or the sequences of predicted functional domains. As previously described 
the nucleotide sequence of the pmps of serovar E was not available, therefore serovar 
D pmp sequences were used as a reference source, obtained from the STD sequence 
database of Los Alamos National Laboratory (std.gen.northwestern.edu). The primer 
sequences are given in Table 2.1.
To allow directional cloning into the multiple cloning site (MCS) of the desired pET 
vector (section 3.2.2) the restriction sites chosen to be incorporated into the primers, 
were those that did not appear to be present within the gene so each pmp  sequence 
was examined using NEBcutter V2.0 (New England Biolabs) to identify restrictions 
sites within the sequence. In addition the cloning procedure was designed to 
incorporate a poly-histidine tag at the C-terminus. The restriction sequences were 
manually aligned with the 5 ’ and 3 ’ regions of the reference gene sequence. This led 
to some mismatching and minor changes to the N and C terminal sequences as the 
restriction sequence and gene sequence were not complementary. Adjacent
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complementary nucleotide bases were extended either side of the restriction 
sequence to produce a primer of between 15-30 bases in length with approximately 
40-60% GC content. The primer pairs were checked for compatible melting 
temperature Tm using the DNA calculator (Sigmaaldrich.com). Regions within primers 
that could result in primer dimers or primer hairpin loops were avoided.
To ensure the resultant protein coding sequence was in the correct open reading 
frame and bearing the polyhistidine tag, the recombinant theoretical sequence was 
translated using the Expasy Translate Tool (Expasy http://web.expasy.org/translate/). 
Bases were added or subtracted accordingly in a way to minimise alteration to the 
amino acid composition at the N and C terminals. Primers were manufactured by 
Sigma Aldrich Ltd and are displayed in Table 2.1.
2 .2 .3  PC R  A m p lifica tio n  o f T a rg e t D N A  fro m  G en o m ic  D N A
A PCR mixture was made up of the primers shown in Table 2.1 with the components 
listed in Table 2.2 according to the KOD Hotstart kit instructions (Novagen). The 
tested cycle conditions are displayed in Table 2.3 and the equipment used was MWG 
Biotech Primus 96 plus thermal cycler. The genomic DNA from a serovar E clinical 
strain C.trachomatis was provided by Dr Adrian Eley, (University of Sheffield). Each of 
the target DNAs optimal set up and cycle conditions were optimised and are displayed 
in Table 2.4. The PCR products were examined by agarose gel electrophoresis 
(section 2.2.4). Initial positive identification was made by comparison of the size of 
the PCR product in relation to serovar D predicted pmp  gene size. PCR products were 
purified and digested with appropriate enzymes before ligation into pET vectors.
35
Ge
ne
/Re
gio
n 
Pri
me
rs 
Re
str
ict
ion
 
Ve
cto
r 
Fu
sio
n 
Tag
 
Se
lec
tiv
e
site
s 
Ma
rke
r
Ko.£<
CO
XCOXCD
o
JOCOCMI—LUCl
LO
<
cdo
”  §8 8
I  8
<  5CD< <  CD<  OP- gI—
cd<CDOI—
3OCD<
~ui—03
<<o<
<CDOO
O O O  CD CD O  I-  <  
LO CO(1)CO1_
CD>CDX
*£Q.
Xc .
COX
X) 
00 C\l I— LU Cl
O O O JZZ  X
LO
I— O I—cd CD <CDCD <O <  § 2 
8 §CD I—O CD CD I—<<CD CD
§ SO <<  CD
LO CO
CDOCD<CDO<OoCD
0CO1—0>0X
CQQ.£0.
xc0X
JO 
00 CM 1— LU Cl
O O O JOz  X
co LOO CD h -CDU H-<  O
O <s § s iCD 5
5  O t << oCD <  CD O <  o  oCD
LO CO
0COl_
0>0X
u.I0  Q.1
Xc0X
JO 
00 CM 
I—  LLJ Cl
CO
O  LO
3  <<  CD
<  °  ^  CD
<CD <CD b<<
I— oCD CD CD O  CD <  I-  <  <  I-  O o
CD <  h - CD
LO CO
"D 0CO
% 0 £ > o 0)
LL X
QQ.
I
Xc
0X
O
JO 
00 
CM I— LU Cl
O 5= O O
CO LO
CD CDO  oh - CD
t  °K O O  CD
»- 9i-  <j~  CDt <& 8  CD ^  CD <<  h-<  I-<  h-<  O<  oCD O  CD O
CD CD I—
LO CO
CD<
0CO1_
0>0
IX
U.
LUa£o.
JO 
CM 
CM I— LU Cl
0 O T3 JOz  X
CO LO
o  Jrr
<  oh - CDo  <I -  CD0  <h- <  I— <;
<  §  
n  °  
<  <
1  <  
t  8<  i— CD O  h - O<  I -  H  O<  O 
CD H-<  CD O  CD
LO COTO 0CO|  0 £ > 
O  <1) LL X
lu
Q.£o.
xCL£<
eg0Cl
£ £S— L.a> a>i iz  o
JO 
CM 
CM I— LUCL
CO
oO
3I-
b  f
CD h
o  g
g  8h - CD I-  O CD O CD CD<  CD CD CD
3  *O<<
o
LO co  
•a
0
o
0CO 1 
0>0X
U.■CDa  T- £ *  a. co
eg0CL
£ £i— u£  £i iz  o
JO 
CM CM I— LUQ_
CO LO
CD O <  O
e i
<  tCD 5
CD °<  °
8  8  P OI-  OCD Oo  <
LO co  "O
0
0  co 1 0 > 0 tX
u.I0a
I
CM
0
CO
DCCL£<
JO 
CM 
CM I— 
LU  C l
O
X
CD <
<  8  a  o<  (i)CD
O
O O
o  <
i ; h
<o
o  <  <  CD <  O
LO coTO 0 CO|  0 £ > o 0LL X
LL.
3CQ.£0.
T303£‘-Pco
CO£o
‘5>o
0£0O)
75£O'•£O£3s-
T3
0
■o0
~o£0
(A0£0O)a
Ea
LU
L .0>oi_00
4-o
£O'■P0o
a
E0
o 'oQ.
0£
CM
0
A
0
CDCO
XCL
E<
C/3
X
03
X0)sz
Ei_0
IO
JC
CO
CMI— LUCL
<13 3 =-C o
CO
O  LO 
<
O  5
<  °  O  O  u  CD 
O  
O<  CD
£  -  §  3
<CD O  
O
CD
h-<<O  CD
<  t“  H  CD O  CDCD • -O  O
LO CO
0 3  CD C/3i_
03 >  03IX
Q.I
xCLE<
_Q
CO
CMI— LU 
Q.
<  <  o
CD os so CD
O
<<  oCD <
o  1=
g 8
LO co
03 03
m S'5 |  03C. > o  <13LL X
1
£
Q.
xc
CO
X
-C lco
CM I— LU
CL
LO
CO
COif)
:>I
Q
a
£
Q.
XCLE<
-Q 
CM 
CM I— LU 
CL
X
co
O
o  o  
t  °^  o
^  I -CD o
t  CD
I— ^O  CD h - <  
I -  O
t  <  o
I— <■o  §  O  p  CD O
CD o
<  °
LO co
03  03J= C/3i ®c  >o 03 LL X
£
ac
a
£
a
o
-Q 
CO 
CM I— LUCL
0  03x= o
LO
CD
<  O< < p  s
CDCDCDO  CD O  CD<CD
8  5
CD <
O  CD<I—
<  CD I— CD CD CD 
LO co
-D 003i_ 0  >  0 X
xc0X
_Q 
CO 
CM I— LUCL
0  03c  o
<  CD O  CD CD O  CD CD CD <
CD <  CD CD
E -<  o
CO
<CD <  CD h -
<  CD O  o  O  <  <D <  CD H-CDO<CD CD
LO CO
03 0C/3|  0 c. > o 0 
LL X
QQ.£Q.
xCLE<
CD
0CL
Es—
0
C/3
X0x0_c
EL_0
io
-Q 
CM CM I— LU 
CL
=  o0 -Cif) X
CO
CDI -<\—
<  LO
<  O9  o<f -<<
s  °<  h -o9  CD
P  CD
5  ^CD p  CD O  I— I—H- O  CD CD
9  <<  H<  <  CD O
LO CO
0COL_
0>0o :
CDa
£Q.
03
0X
0
CLC/303
CO
0303C
'•*->Coo
LLICD
£
Cl
£
CLE0
0
030
03C0
CO0c0O)
aEa.
LU
L_0>o
aE0
o 'oQ.
0
CM
0
-Q0I -
0 =c<
I
Q.
03c
0
3:a
0 30  CD
£  . i
.2  Q. O) v *_0 o
0c0
0 3Toco'5Oc3s—
03
0
0SC
CDa
o.£a
Q
Ia
I
Q.
COc'0Eo
0 3
0c
0
0 3C
00 3
0 o
a  g
*5  -2co
D.0oX0
0
JC
oc34 —
co"CL£CL
0 3
00OC30C0
0 3
0 3C0
0SZ
ClE0
0
0 3L_0  
c
1CL
_Ca00
0 30*4—».c
0 3
SZ
0 3x :
0i_0
CO0
CO0i—
0 300i—oCLi_ooc
JC
0 30-#—*SZ
0 3
IE
0 3
x:
CO
0 3c0
0 30i tc0;o
i_0jo
co0
o =
CLE0
0 30C
0 3
CO0
0 3
0
.C
0i_0
03
0>4
_0
CLCO
03
O_co
0
0l_
0
CO
0 3
0
Co
CO34 —
0 30
0 3C
0
Q
£
CL
0
0Oc
03cr
0co
l_0E
0 3C0
0-X
0Eco
L-» O 0  
0 CO
co"!_oo0>
■0o1—
0EEoo
0sz
co
Reagent Set-up 1 Set-up 2
KOD x10 Buffer 5.0 pi 5.0 pi
MgS04 1.0 mM 1.5 mM
dNTPs 0.2 mM 0.2 mM
Forward primer 0.2 pM 0.3 pM
Reverse primer 0.2 pM 0.3 pM
Template DNA ~1 ng ~1 ng
KOD polymerase 1.5 pi 1.5 pi
Total volume 50 pi 50 pi
Table 2.2 - The two optimised PCR component set-up conditions used to amplify full-length 
and truncated pmp genes. The set up condition used to amplify each particular gene is displayed 
in Table 2.4 denoted by 1 or 2
Thermocycler Conditions
a b c
Initial Denaturation 94°C - 2 min 94°C -2  min 94°C - 2 min
Denaturation 94°C -15 sec 94°C -15 sec 94°C -15 sec
Annealing 57°C - 30 sec 54°C - 30 sec 50°C - 30 sec 30 cycles
Extension 72°C - 4 min 72°C - 4 min 72°C -  2.5 min
Final Extension 72°C -10 min 72°C -10 min 72°C -10 min
4°C -  hold 4°C -  hold 4°C -  hold
Table 2.3 - The three optimised PCR thermocycler conditions used to amplify full-length and 
truncated pmp genes. The set-up condition used to amplify each particular gene is displayed in 
Table 2.4 denoted by a or b or c using an MWG Biotech Primus 96 plus thermal cycler.
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pmpA 1 a
pmpB 2 a
pmpC 2 a
pmpD 1 or 2 a
pmpE 2 c
pmpF 1 a
pmpH 1 a
pmpl 1 a
pmpA-N 1 b
pmpD-N 1 or 2 b
pmpH-N 2 b
pmpl-N 1 b
pmpD-C 2 a
pmpG-C 1 b
Table 2.4 - Shows optimum PCR reaction set-up conditions and PCR cycle conditions 
for the amplification of each target DNA. See Table 2.2 and Table 2.3 for individual 
parameters.
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2 .2 .4  A g aro se  gel e lec tro p h o res is
DNA samples were prepared with 6X DNA sample buffer (40% (w/v) sucrose in 
sterile water containing 0.1% bromophenol blue) and separated in a 1% agarose 
slab gel with TAE buffer (40 mM Tris-acetate, pH 8.0, 1 mM EDTA) and ethidium 
bromide (0.5 pg/ml). The molecular size and quantification of DNA was carried out 
by visual comparison of the bands under UV illumination (images captured using a 
UVP epi II dark room with Labworks software version 4.0) to DNA markers (2-log 
DNA ladder, 1 kb DNA ladder or 100 bp DNA ladder, New England Biolabs) which 
were separated alongside the samples.
2.2 .5  P urifica tion  o f PC R  products
PCR reactions were purified using the QIAGEN gel extraction purification kit, where 
specific amplification of pmps was observed. This was done according to the 
manufacturer’s instructions with the exception of the gel excision steps 1-4 which 
were omitted (Qiagen).
2.2 .6  R estric tion  d igestion  o f P C R  products  and p lasm id  D N A
Purified PCR products and commercial pET plasmid DNA (100 -  500 ng) were 
digested with the appropriate restriction endonuclease (shown in Table 2.1). The 
reactions were made with (0.5 -  2 U) endonuclease in the manufacturer’s buffer 
according to their instructions, supplied by New England Biolabs. Endonuclease 
digestion of plasmid DNA was confirmed by agarose gel electrophoresis.
2.2 .7  P urifica tion  o f restric tion  d ig ested  D N A  frag m en ts
Digested DNA was mixed with DNA sample buffer and separated by agarose gel 
electrophoresis. DNA fragments were excised using a sterile scalpel and weighed. 
The DNA was purified using the QIAGEN gel extraction purification kit according to 
the manufacturer’s instructions (Qiagen). The absorbance of 1 pi of purified DNA 
product was measured using Thermo Scientific NanoDrop® ND-1000 
Spectrophotometer to quantify the DNA.
2.2 .8  D ep h o sp h o ry la tio n  o f lin earised  p lasm id  D N A
To minimise self ligation, linearised vector DNA was routinely dephosphorylated 
with calf intestine alkaline phosphatase (CIP) before the protein coding sequence 
was inserted. CIP (1 U) was added to approximately 5 pg DNA in CIP reaction 
buffer (CIP and CIP reaction buffer supplied by New England Biolabs, and diluted 
as directed). The mixture was incubated at 37° C for 30 minutes, before arresting
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the action of the enzyme by heating to 75° C for 10 minutes or immediately 
purifying the DNA (section 2.2.5).
2 .2 .9  L igation  o f D N A  frag m en ts
Vector and insert DNA were ligated using T4 DNA ligase which catalyses the 
formation of a phosphodiester bond between the 5 ’ phosphate and the 3 ’ hydroxyl 
termini. To 30 ng dephosphorylated vector DNA, a 1 to 3-fold molar excess of insert 
DNA was mixed with 1 U T4 DNA ligase (New England Biolabs) in the 
corresponding T4 DNA ligase buffer. Dependent upon the size of the insert DNA the 
reaction was incubated between 1 and 16 hours at room temperature, 16° C or 8° 
C. Ligation was assessed by agarose gel electrophoresis. The ligated DNA was 
transformed into highly efficient NEB 10-beta competent E.coli host cells (New 
England Biolabs) as described section 2.2.10.
2 .2 .10  T ran sfo rm atio n  o f cells
A 20 pi aliquot of competent NEB 10-beta E.coli cells (section 2.2.11) was thawed 
on ice, and 20 -  200 ng plasmid DNA added and gently stirred. The cells were 
incubated for 30 minutes on the ice and then heat shocked at 42° C for 45 seconds. 
500 pi SOC outgrowth media (2 % Vegetable Peptone, 0.5 % Yeast Extract, 
lO m M N aC I, 2.5 mM KCI, 10m M M gC I2, 10m M M gS O 4, 20 mM Glucose), was 
added to the cells and the suspension incubated at 37° C for 1 hour with agitation. 
All of the cell suspension was spread onto a pre-warmed LB agar plate (Tryptone 
10g/L, Yeast extract 5g/L, NaCI 5g/L, agar 15 g/L containing the appropriate 
antibiotic (ampicillin 100 pg/ml or kanamycin 34 pg/ml)). The plate was incubated 
overnight at 37° C for colony propagation.
2.2.11 G en otype  o f c o m p eten t E .coli
NEB 10-beta: araD 139 A(ara-leu)7697 fhuA lacX74 galK($80 A(lacZ)M15) mcrA 
galU recA1 endA1 nupG rpsL (StrR) A(mrr-hsdRMS-mcrBC) (New England Biolabs)
2.2 .12  S elective  co lony  propagation
Single bacterial colonies were selected and used to inoculate 5 ml Luria-Bertani 
broth (LB, 1% (w/v) NaCI, 1% (w/v) tryptone, 0.5% (w/v) yeast extract, pH 7) 
containing the appropriate antibiotic in a 50 ml Falcon tube, and incubated overnight 
at 37° C in an orbital incubator at 200 rpm. The culture was subsequently 
centrifuged at 5000 g for 10 minutes, and plasmid extracted as in section 2.2.13.
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2.2 .13  Iso la tion  o f p lasm id  D N A
The plasmid was transformed into competent E.coli as described section 2.2.10. 
The cell pellet was lysed and the plasmid DNA was extracted using QIAGEN mini- 
prep kit according to the manufacturer's instructions (Qiagen). For extracting high 
concentrations of plasmid DNA <500 pg/ml, the Purelink™ HiPure plasmid 
maxiprep kit was used according to manufacturer’s instructions (Invitrogen).
2 .2 .14  R estric tion  M apping
Restriction sites predicted to be present within the recombinant plasmids were 
mapped using restriction endonuclease digestion as in section 2.2.6, Both single 
and double restriction digests were carried out. Using the sizes of the DNA 
fragments after digestion, the positions of these sites could be confirmed. 
Restriction mapping was used to determine the orientation and size of the insert in 
the cloning vector. Putative clones identified by mapping were sent for DNA 
sequencing as in section 2.2.15 to confirm the insert was correct and in frame.
2.2 .15  A u to m ated  D N A  seq u en c in g
DNA sequence analysis was carried out by Eurofins MWG based on Taq 
dyedeoxy™ terminator cycle sequencing with the use of T7 promoter and terminator 
region primers flanking both 3'-5' and 5-3 ' sequences (Eurofins MWG Operon).
2 .2 .16  S ite D irected  M u tag en esis
Site-directed mutagenesis was performed using PCR and the Quikchange™ Site- 
Directed Mutagenesis Kit (Stratagene) according to the manufacturer instructions. 
Primers specific for the desired mutation were individually designed (Table 2.5). 
The QuikChange site-directed mutagenesis method used the high fidelity 
PfuTurbo™ DNA polymerase, the PCR conditions were adapted for each 
mutagenesis based upon the length of the DNA sequence as in Table 2.6.
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pPmpA23b-N Forward - GTGGTGGTGGTGGTGCTACGAGGTTCTATTTGC 
Reverse - GCAAATAGAACCTCGATGCACCACCACCACCAC
pPmpl23b-N Forward -  ACAGCGGCCGCAACTCGAGCACCAC 
Reverse -  GT GGT GCT CGAGTT GCGGCCGCT GT
pPmpG22b-C Forward -  CCGT CG ACCCT AAT ACAGCAAAT AAT GGT CCTT AT ACT C 
Reverse - G AGT AT AAGGACCATT ATTT GCT GT ATT AGGGT CGACGG
Table 2.5 - Primers for site-directed mutagenesis. The primers designed to correct the reading 
frame for each of the truncated pmps were used with the thermocycler conditions in Table 2.6.
pPmpA23b-N pPmpG22b-C pPmpl23b-N
Initial Denaturation 95°C -1 min 95°C -1 min 95°C -1 min
Denaturation 95°C - 50 sec 95°C - 50 sec 95°C - 50 sec 18 cycles
Annealing 60°C - 50 sec 60°C - 50 sec 60°C - 50 sec
Extension (1 min/ kb) 68°C -  5.5 mini 68°C - 7 min 68°C - 5 min
Final Extension 68°C - 7 min 68°C - 7 min 68°C - 7 min
4°C -  hold 4°C -  hold 4°C -  hold
Table 2.6 - PCR conditions for Site-Directed Mutagenesis. Shows the cycle conditions for each 
of the truncated pmp constructs (pmpA-N, pmpG-C and pmpl-N) that required site-directed 
mutagenesis using the primers in Table 2.5 to correct the reading frame of the expression 
construct.
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2.3 R esults
2.3.1 PC R  o f fu ll length pm p genes (p m p-FL)
Numerous trials altering the components and/or the thermocycler conditions were 
carried out to obtain optimal amplification for all nine pmp genes and truncated pmp 
genes. Changes in annealing temperature based on the Tm of the primers were 
essential to obtain amplification of certain pmps. Variations in the primer 
concentration and M gS 04 aided the amplification of specific pmps and truncated 
pmps. These variables resulted in two different component set-up conditions and 
three different cycle conditions as shown in Table 2.2 and Table 2.3. PCR 
amplifications of the pmp gene were achieved for 8 of the 9 full length DNA targets. 
The exception was pmpG-FL where specific PCR products of the expected size 
could not be amplified (data not shown) with either of the two primers sets in 
combination with several alterations to the PCR conditions and components.
The agarose gel image in Figure 2.1 shows the amplification of putative pmpB-FL 
and pmpC-FL. The predicted size of serovar D pmpB is -5250  bp and pmp C is 
-5300  bp. The obtained sizes of amplified pmpB-FL and pmpC-FL were 
approximately 5300 bp indicated by red arrows. Additionally non-specific 
amplifications were observed with pmpB-FL, pmpC-FL visible at approximately 1600 
bp, 2500 bp and 3000 bp To minimise the possibility of these being incorporated 
into the vector the PCR products of the desired size were isolated from the gel prior 
to purification.
Figure 2.2 shows the amplification of pmpD-FL, the predicted size of serovar D 
pmpD is -4592  bp. The obtained size of pmpD-FL was approximately 4600 bp 
indicated by red arrow. The non-specific amplification product visible at 
approximately 3500 bp was omitted from ligation into a vector by excising pmpD-FL 
from the gel for purification.
Finally the remainder of the amplified full length pmps are displayed in Figure 2.3. 
The predicted sizes of serovar D pmps are: pmpA -2920  bp, pmp E -2980  bp, pmp 
F -3100, pmp H -  3000 and pmp I -  2630 bp. The obtained sizes of pmpA-FL, 
pmpE-FL, pmpF-FL and pmphl-FL were all approximately 3000 bp and pmpl-FL was 
approximately 2600 bp indicated by the red arrows.
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Figure 2.1 - Agarose gel showing the amplification of pmpB-FL and pmpC-FL obtained 
by PCR. The gel shows the full length pmpB and pmpC (red arrows) amplified from 
genomic DNA using primers shown in Table 2.1. Lanes 2 and 3 contained 10pl of the PCR 
products pmpB-FL and pmpC-FL respectively, obtained using optimised reaction set-up 
conditions and thermocycler conditions as shown in Table 2.4. Lane 1 contains 2-log DNA 
marker (New England Biolabs) with sizes indicated on the left in base pairs.
b p
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Figure 2.2 - Agarose gel showing the amplification of pmpD-FL obtained by PCR. The
gel shows the full length pmpD amplified from genomic DNA using primers shown in Table 
2.1 and cycle conditions displayed in Table 2.3. Lanes 2 and 3 contained 10pil of the PCR 
products obtained using both reaction set-up conditions 1 and 2 respectively, shown in Table 
2.2. Lane 1 contains 2-log DNA marker (New England Biolabs) with sizes indicated on the 
left in base pairs. The cut in the gel is to remove blank lanes.
69
bp
6000
4000
3000
2000
Figure 2.3 - Agarose gel showing the amplification of pmpA-FL, pmpE-FL, pmpF-FL 
and pmp I obtained by PCR. The gel shows the full length pmpA, pmpE, pmpF and pmp! 
amplified from genomic DNA using primers shown in Table 2.1 and cycle conditions 
displayed in Table 2.3. All lanes contained 1 OjliI of PCR product obtained using reaction set­
up conditions shown in Table 2.2. Lane 2 shows pmpA-FL, lane 3 shows pmpE-FL, lane 4 
pmpF-FL, lane 5 pmpH-FL and lane 6 contained pmpl-FL Lane 1 contains 2-log DNA marker 
(New England Biolabs) with sizes indicated on the left in base pairs.
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2.3 .2  C o n stru ctio n  o f fu ll length pm ps exp ress io n  vecto rs  w ith  pET  
vecto rs  pE T23b(+), pE T 22b (+ ) and pE T28b(+)
Purified, digested vectors and amplified PCR products were ligated and transformed 
into E.coli strain NEB 10-beta (New England Biolabs) for plasmid propagation as 
described in section 2.2.12. The restriction sites and pET vector for each construct 
are listed in Table 2.1.
Transformant colonies were propagated and plasmid DNA isolated. These plasmids 
were analysed by gel electrophoresis alongside empty pET vector controls. Putative 
clones that were of a size expectant upon uptake of the pmp insert were subjected 
to both single and double restriction digestion mapping at specific recognised site, 
these restriction sites were determed from serovar D genomic sequences as close 
similarity was expected, to produce a map of fragments that were distinct to confirm 
the orientation and presence of the pmp insert DNA. The restriction maps of 
putative clones containing pmpB-FL, pmpC-FL, pmpE-FL, pmpF-FL  and pmpH-FL 
did not produce the expected insert size or fragment sizes. The fragments produced 
using restriction digestion were indicative of a truncated insert, an incorrect insert or 
an insert that was inserted in the wrong direction, sequencing of these inserts 
confirmed the coding sequences were unsuitable for expression (data not shown). 
Figure 2.4a, Figure 2.5a and Figure 2.6a show the putative recombinant clones 
containing pmpA, pmpD  and pm pl respectively. The fragment sizes obtained from 
restriction mapping of each of these putative clones suggested the coding sequence 
inserted in each plasmid was correct (Figure 2.4b, Figure 2.5b and Figure 2.6b). 
These constructs were named pPmpA23b-FL, pPmpD28b-FL and pPmpl23b-FL, to 
indicate the pmp insert and the pET vector.
Automated DNA sequencing verified that the coding regions for full length PmpA, 
PmpD and Pmpl were present, correct and in-frame with a C-terminal hexahistidine 
tag. The protein encoded by the DNA sequence within the N- and C- terminal 
regions showed differences to the published serovar D as a consequence of cloning 
procedure is displayed in Table 2.7. The remainder of the serovar E Pmp 
sequences within these regions were the same as published serovar D sequences 
as far as the sequencing reaction was performed. The automated sequencing 
reaction determines the sequence up to 1000 nucleic acids before it is exhausted, 
therefore only the N and C terminal regions of these inserts were determined for the 
purposes of verifying the insert was correct.
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Restriction Expected
Sites Fragments (bp)
Nhel/Notl -3600, -3000
Notl -6600
Xbal -5300,-1300
Xbal/Xhol -3600, -1700, -1300
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Figure 2.4 - Agarose gel showing recombinant plasmid pPmpA23b-FL miniprep 
preparation and restriction mapping characterisation, (a) The gel shows isolated 
plasmids from E.coli clones transformed with ligated pET23b and pmpA-FL extracted as in 
section 2.2.13. Lane 6 contains undigested empty control plasmid pET23b. Lanes 2, 3 and 5 
show putative supercoiled non-recombinant vector, indicated by green arrow. Lane 4 shows 
putative supercoiled recombinant vector, indicated by the blue arrow. Lane 1 contains a 2- 
log DNA marker (New England Biolabs) with sizes indicated on the left in base pairs. 
Comparison of lanes and empty vector gives indication of successful ligation, (b) The single 
clone from lane 4, panel (a) was subjected to single and double digestion with the restriction 
enzymes Nhel/Notl (lane 1), Notl (lane 2), Xbal (lane 3) and Xbal/Xhol (lane 4). Lane 5 
contained linear pET23b at 3666 bp, digested with Xhol while lane 6 contained DNA ladder.
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Figure 2.5 - Agarose gel showing recombinant plasmid pPmpD28b-FL miniprep 
preparations and restriction mapping characterisation, (a). The gel shows isolated 
plasmids from E.coli transformed with ligated pET28b and pmpD-FL extracted as in section 
2.2.13. Lane 5 contains undigested empty control plasmid pET28b. Lanes 1 and 4 show 
supercoiled non-recombinant vectors, indicated by green arrow. Lanes 2 and 3 show 
putative supercoiled recombinant vector, indicated in line with the blue arrow. Comparison of 
lanes and empty vector gives indication of successful ligation, (b) The two clones from lanes 
2 and 3 in gel (a), were subjected to single and double digestion with the restriction enzymes 
Ncol/Notl (lanes 2 and 5) or Ncol (lanes 3 and 6) or BamHI (lanes 4 and 7). Lanes 1 and 8 
contained 2-log DNA ladder.
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Xhol -4900,-1400
Nhel/Notl -3600, -2600
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Figure 2.6 - Agarose gels showing recombinant plasmid pPmpl23b-FL miniprep 
preparation and restriction mapping characterisation, (a) The gel shows isolated 
plasmids from E.coli transformed with ligated pET23b and pmpl. Lane 5 contains undigested 
empty control plasmid pET23b at -3500 bp. Lane 3 shows supercoiled non-recombinant 
vector at -3500 bp, indicated by green arrow. Lanes 1, 2 and 4 show putative supercoiled 
recombinant vectors, indicated by the blue arrow. Comparison of lanes and empty vector 
gives indication of successful ligation, (b) The three clones from lanes 1, 2 and 4 in gel (a) 
above were subjected to single and double digestion with the restriction enzymes Xhol 
(lanes 3-5) or Nhel/Notl (lanes 6-8) or Notl/Xbal (lanes 9-11). Lane 2 contained linear 
pET23b digested with Xhol at 3666pb. Lane 1 contained Quick-load 100 bp DNA ladder 
(New England Biolabs).
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recombinant N-terminus; MAS NRVIEIHAHYDQRQLS-
published N-terminus; M- - NRVIEIHAHYDQRQLS-
*  _ '■k-k-k-k-k-kic-kit-k-k-k-k-k-k-k
recombinant C-terminus; - SNSLSCGGYVGLAAALEHHHHHHH
published C-terminus; - SNSLSCGGYVGE
•kii-k-k-k-kic-k-k'k-k'k
recombinant N-terminus; M GSEKDIKSTCSKFSL-
published N-terminus; M SSEKDIKSTCSKFSL-
recombinant C-terminus; - KLGYEANAGLRLIFAAALEHHHHHH
published C-terminus; -KLG Y E A N TG LR LIF
recombinant N-terminus; MASRPDHMNFCCLCAA-
published N-terminus; M--RPDHMNFCCLCAA-
recombinant C-terminus; - SYSLDLGTTYRLAAALEHHHHHH
published C-terminus; - SYSLDLGTTYRF
Table 2.7 - Sequence variation of the C and N terminals of the serovar E clinical 
recombinant full length Pmps compared to the published serovar D sequences.
Sequnce matches are highlighted by ( * )  and recombinant changes as a result of the 
cloning procedure are highlighted by (. ) .
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2.3 .3  P C R  o f tru n ca ted  pm p genes
The predicted functional domains of some of the Pmp protein sequences (Pmp A, 
Pmp D, Pmp G, Pmp H and Pmp I) were determined using the protein BLAST 
analysis tool (http://blast.ncbi.nlm.nih.gov), based upon this the primers were 
designed to flank each end of the domain as in section 2.2.2. The agarose gel 
images in Figure 2.7 show the amplification of putative truncated pmpA-N  (Pmp A 
passenger domain), PmpH-N  (Pmp H passenger domain) and Pmpl-N  (Pmp I 
passenger domain). The predicted approximate sizes of these passenger domain 
sequences are -1450  bp for pmp A, -1500  bp for pmp H  and -1220  bp for pmp I. 
The fragments obtained were of the expected sizes. Figure 2.8 shows the 
amplification of putative PmpD-N  (Pmp D passenger domain) and pmpG-C  (Pmp G 
autotranslocator domain). The predicted approximate size of these coding regions 
are -3500  bp and -1100  bp respectively, the obtained size for pmpD-N  was 
between 3000 and 4000 bp as indicated by the red arrow and the obtained product 
for pmpG-C  was -1100  bp, indicated by the purple arrow. Finally, Figure 2.9 shows 
amplification of PmpD-C  (Pmp D autotranslocator domain) the predicted size of the 
autotranslocator region of pmpD  is -1000  bp. The fragment obtained for pmpD-C  is 
approximately 1000 bp indicated by red arrow
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Figure 2.7 - Agarose gel showing the amplification of pmpA-N, PmpH-N and Pmpl-N 
obtained by PCR. The gel shows truncated N-terminal predicted passenger regions of 
pmpA, pmpH and pmpl amplified from genomic DNA using primers shown in Table 2.1 and 
cycle conditions displayed in Table 2.3. All lanes contained 10pl of PCR product obtained 
using reaction set up conditions shown in Table 2.2. Lane 2 shows pmpA-N, lane 3 shows 
pmpH-N, and lane 4 shows pmpl-N. Lane 1 contains a 2-log DNA marker.
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Figure 2.8 - Agarose gel showing the amplification of PmpD-N and PmpG-C obtained 
by PCR. The gel shows the truncated N-terminal predicted passenger region of pmp D and 
predicted C-terminal autotransporter coding region of pmp G amplified from genomic DNA 
using primers shown in Table 2.1 and cycle conditions displayed in Table 2.3. All lanes 
contained 10pl of PCR product obtained using reaction set up conditions shown in Table 
2.2. Lanes 2 and 3 show N-term pmpD amplified using set up conditions 1 and 2 
respectively. Lanes 4 and 5 were empty. Lane 6 shows C-term pmpG indicated by the 
purple arrow. Lane 1 contains 2-log DNA marker with sizes indicated on the left in base 
pairs.
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Figure 2.9 - Agarose gel showing the amplification of pmpD-C obtained by PCR. The
gel shows the predicted C-terminal autotransporter region of pmpD (red arrow) amplified 
from genomic DNA using primers shown in Table 2.1 and cycle conditions displayed in 
Table 2.3. Lane 2 contained 10pil of the PCR product obtained using reaction set up 
conditions 2, shown in Table 2.2. Lane 1 contains 2-log DNA marker with sizes indicated on 
the left in base pairs.
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2 .3 .4  C o n stru c tio n  o f tru n cated  pm p exp ress io n  vecto rs  w ith  pET  
vectors  pE T23b(+), pE T 22b (+) and pE T28b(+)
Purified, digested vectors and amplified PCR products were ligated and transformed 
into E.coli strain NEB 10-beta (New England Biolabs) for plasmid propagation as 
described earlier for full length pmp  expression constructs. Transformant colonies 
were propagated and the plasmid DNA isolated was analysed by gel 
electrophoresis alongside empty pET vector controls. Putative clones were 
subjected to both single and double restriction digestions at specific recognised 
sites derived from serovar D genomic sequences as close similarity was expected. 
The map of fragments (Figure 2.10, Figure 2.11, Figure 2.12 and Figure 2.13) 
confirmed the orientation and presence of the truncated pmp insert DNA for PmpA- 
N, PmpD-C, PmpG-C and Pmpl-N these constructs were named pPmpA23b-N, 
pPmpD28b-C, pPmpG22b-C and pPmpl23b-N to indicate the truncated pmp  insert 
and the pET vector. However the sequencing of three of these inserts (pm pA-N , 
pmpG-C  and Pm pl-N ) were not in the correct open reading frame and required 
further manipulation using site-directed mutagenesis to correct the frameshifts. The 
sequencing of the PmpD autotranslocator domain was identical to serovar D 
autotranslocator domain (Figure 2.16).
The restriction maps of putative clones containing the pmp passenger domain 
sequences pmpD-N  and pmp/-/-/V did not produce the expected insert size or 
fragment sizes. Restriction mapping analysis showed some of the expected 
restriction sites were not present within the construct containing the passenger 
domain sequence of pmpD, in particular some sites that were expected to be 
located within the last 600 - 700 bases of sequence were absent. Sequencing 
analysis revealed this region to be missing from the construct (data not shown) 
resulting in the loss of approximately 200 amino acids from the Pmp D passenger 
domain. The cloning procedure was repeated a further five times with new 
amplifications of pmpD-N  and newly digested pET vector however the outcome 
remained the same. Numerous efforts were made to ligate the passenger domain 
sequence of pm pH  (pmpH-N) into digested pET22b but only a small percentage of 
clones appeared to contain the vector with an insert. Restriction mapping analysis 
showed the expected restriction sites were not present within the construct (data not 
shown) therefore the insert was unlikely to contain pmpH-N.
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Nhel/Xhol -3600, -1500
Figure 2.10 - Agarose gel showing putative recombinant plasmid pPmpA23b-N 
miniprep preparation and restriction mapping characterisation, (a) The gel shows 
isolated plasmids from E.coli transformed with ligated pET23b and pmpA-N extracted as in 
section 2.2.13. Lane 14 contains undigested empty control plasmid pET23b. Lanes 3, 4, 6, 
7, 8, 9 and 13 show supercoiled non-recombinant vector, indicated by blue arrow. Lanes 2, 
5, 10, 11 and 12 show putative supercoiled recombinant vector, indicated by the green 
arrow. Lane 1 contains 2-log DNA marker with sizes indicated on the left in base pairs. 
Comparison of lanes and empty vector gives indication of successful ligation, (b) The 5 
clones from lanes 2, 5, 10, 11 and 12 were subjected to a double digestion with the 
restriction enzymes Nhel/Xhol to check the size of the inserts. All fragments were of 
expected size. The clone in lane 6 was sent for DNA sequencing for verification.
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Figure 2.11 - Agarose gel showing recombinant plasmid pPmpD28b-C miniprep 
preparations and restriction mapping characterisation, (a). The gel shows isolated 
plasmids from E.coli transformed with ligated pET28b and pmp D autotranslocator domain 
sequence, extracted as in section 2.2.13. Lanes 2-13 show putative successful supercoiled 
recombinant plasmids. The expected size is approximately 6500 bp. Lane 1 contains 2-log 
DNA ladder, (b) Two clones, lanes 2 and 8 from gel (a) were subjected to single and double 
digestion with the restriction enzymes Xhol (lanes 2 and 5), BamHI/EcoRV (lanes 3 and 6) 
and Ncol (lanes 4 and 7). Lane 8 contained 2-log DNA ladder.
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Figure 2.12 - Agarose gel showing recombinant plasmid pPmpG22b-C miniprep 
preparations and restriction mapping characterisation, (a) The gel shows isolated 
plasmids from E.coli transformed with ligated pET22b and pmp G autotranslocator domain 
extracted as in section 2.2.13. Lanes 2-6 show putative successful supercoiled recombinant 
vector. Lane 7 contains supercoiled pET22b. Lane 1 contains 2-log DNA ladder, (b) All 
clones from gel (a) were subjected to double digestion with the restriction enzymes Xhol and 
Sail to examine the size of the inserts. The fragments of the clone in lane 3 were of 
expected size with an insert of approximately 1100 bp (green arrow) and linearised pET22b 
at -5700 bp (blue arrow), this clone was sent for sequencing. Lane 1 contained 2-log DNA 
ladder.
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Figure 2.13 - Agarose gel showing recombinant plasmid pPmpl23b-N miniprep 
preparations and restriction mapping characterisation, (a) The gel shows isolated 
plasmids from E.coli transformed with ligated pET23b and the pmp I passenger domain 
sequence (pmpl-N), extracted as in section 2.2.13. Lane 3 shows putative successful 
supercoiled recombinant vector. Lanes 2, 4, 5 and 6 show supercoiled non-recombinant 
vector. Lane 7 contains supercoiled pET23b. Comparison of lanes and empty vector gives 
indication of successful ligation. Lane 1 contains 100bp DNA ladder (New England Biolabs), 
(b) The putative clone in lane 3 from gel (a) was subjected to a double digestion with the 
restriction enzymes Nhel and Not! to cut either side of the size of the insert. The fragments 
were of expected size with an insert of approximately 1100 bp (green arrow) linearised 
pET23b (blue arrow). Lane 1 contained 2-log DNA ladder.
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M E F D Y S T N V W G F A F G G F R T L S A E N L V A I D G Y K G
M E F D Y S T N V W G F A F G G F R T L S A E N L V A I D G Y K G
A Y G G A S A G V D I Q L M E D F V L G V S G A A F L G K M D S Q
A Y G G A S A G V D I Q L M E D F V L G V S G A A F L G K M D S Q
K F D A E V S R K G V V G S V Y T G F L A G S W F F K G Q Y S L G
K F D A E V S R K G V V G S V Y T G F L A G S W F F K G Q Y S L G
E T Q N D M K T R Y G V L G E S S A S W T S R G V L A D A L V E Y
E T Q N D M K T R Y G V L G E s S A S W T S R G V L A D A L V E Y
R S L V G P V R P T F Y A L H F N P Y V E V S Y A S M K F P G F T
R S L V G P V R P T F Y A L H F N P Y V E V S Y A S M K F P G F T
E Q G R E A R S F E D A S L T N I T I P L G M K F E L A F I K G Q
E Q G R E A R S F E D A S L T N I T I P L G M K F E L A F I K G Q
F s E V N S L G I S Y A W E A Y R K V E G G A V Q L L E A G F D w
F s E V N S L G I S Y A W E A Y R K V E G G A V Q L L E A G F D w
E G A P M D L P R Q E L R V A L E N N T E W S s Y F S T V L G L T
E G A P M D L P R Q E L R V A L E N N T E W S s Y F S T V L G L T
A F C G G F T S T D S K L G Y E A N A G L R L I F A A A L E H H H
A F C G G F T S T D S K L G Y E A N T G L R L I F S t o p
H  H  H  S t o p
Figure 2.14 - Sequence of C.trachomatis serovar E recombinant C-terminal Pmp D 
autotranslocator domain compared to published serovar D. Recombinant Pmp D 
autotranslocator sequence is shown in black, published serovar D Pmp D sequence is 
aligned in red with the recombinant changes underlined.
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2.3.4.1  S ite-D irec ted  m u tag en es is  o f pP m pA 23b-N , p P m p G 22b -C  and  
pP m pl23b -N  exp ress io n  vecto rs
The Expasy translated sequencing results for the passenger domain of construct 
(pPmpA23b-N) showed the C-terminal region of this domain was incorrect (Expasy 
Translate Tools). The translated sequence of the pmpA-N  insert within pPmpA23b- 
N was found to be consistent with serovar D sequence up to the penultimate serine, 
after which an isoleucine and glutamatic acid were replaced by a single serine 
resulting in a frameshift and the loss of the Histidine affinity tag and the stop codon, 
underlined in Figure 2.15. Primers were designed for site-directed mutagenesis to 
correct the frameshift shown in Table 2.5, the addition of one nucleic acid upstream 
of the affinity tag sequence produced a penta-his tag at the C-terminus in addition to 
five amino acids preceding the stop codon as shown in Figure 2.16.
DNA sequencing and Expasy translation of the insert within pPmpG22b-C (Pmp G 
autodomain) showed the construct was out of frame within its N-terminus region 
Figure 2.17. The pelB sequence of pPmpG22b-C was correct up to the highlighted 
valine, this was the region where the pmpG-C  was inserted into the vector, a 
frameshift within this region resulted in the incorrect Pmp G autotranslocator protein 
sequence and multiple stop codons. Primers were designed and used for site- 
directed mutagenesis to correct the frameshift, the addition of one nucleic acid 
modified the N-terminus resulting in reinstatement of the predicted Pmp G 
autotranslocator sequence as determined by the published genomic sequence of 
serovar D, Figure 2.18.
Finally Expasy translation of the passenger domain of the pmp I construct 
(pPmpl23b-N) showed the C-terminal region was incorrect (Expasy Translate 
Tools). The expected pET23b hexahistidine tag sequence and the stop codon were 
not present as shown in Figure 2.19. The sequence of the insert in pPmpl23b-N 
was found to be correct up to the highlighted serine where primers were 
subsequently designed for site-directed mutagenesis to correct the frameshift, the 
addition of one nucleic acid upstream of the affinity tag sequence regained the 
hexa-histidine tag at the C-terminus in addition to the stop codon Figure 2.20.
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G V I Q L Q G D M K G S V S F V D Q R G A I I F T N N Q A V T S
■G V I Q L Q G D M K G s V S F V D Q R G A I I F T N N Q A V T S
s S M K H S G R G G A I s G D F A G s R I L F L N N Q Q I T F E G
s S M K H S G R G G A I s G D F A G S R I L F L N N Q Q I T F E G
N S A V H G G A I Y N K N G L V E F L G N A G P L A F K E N T T I
N S A V H G G A I Y N K N G L V E F L G N A G P L A F K E N T T I
A N G G A I Y T S N F K A N Q Q T S P I L F S Q N H A N K K G G A
A N G G A I Y T s N F K A N Q Q T S P I L F S Q N H A N K K G G A
I Y A Q Y V N L E Q N Q D T I R F E K N T A K E G G G A I T S S Q
I Y A Q Y V N L E Q N Q D T I R F E K N T A K E G G G A I T S S Q
C S I T A H N T I I F S D N A A G D L G G G A I L L E G K K P S L
c S I T A H N T I T F s D N A A G D L G G G A I L L E G K K P S L
T L I A H S G N I A F s G N T M L H I T K K A S L D R H N S I L I
T L I A H S G N I A F s G N T M L H I T K K A S L D R H N S I L I
K E A P Y K I Q L A A N K N H S I H F F D P V M A L S A S S S P I
K E A P Y K I Q L A A N K N H S I H F F D P V M A L S A S S s P I
Q I N A P E Y E T P F F S P K G M I V F S G A N L L D D A R E D V
Q I N A P E Y E T P F F S P K G M I V F s G A N L L D D A R E D V
A N R T S I E H H H H H H S t o p
A N R T s - S T T T T T E I R L L T K p E R
Figure 2.15 - Depicts the frame shift mutations caused by the loss of nucleic acids in 
putative pPmpA23b-N. The expected C-terminal sequence of the recombinant pmp A 
passenger domain following ligation of digested pmpA-N into digested pET23b is shown in 
black. The actual sequence after ligation is aligned in blue. The translational changes 
caused by the frameshift are underlined. The frameshift occurred following the highlighted 
serine residue. The hexahistine tag is replaced by a poly T tag and the stop codon was lost.
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M A S N R V I E I H A H Y D Q R Q L S Q S P N T N F L V H H P Y
M - - N R V I E I H A H Y D Q R Q L S Q S P N T N F L V H H P Y
T L I P K F L L G A L I V Y A P Y S F A E M E L A I S G H K Q G
T L I P K F L L G A L I V Y A P Y S F A E M E L A I S G H K Q G
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G F G A G V F S E S S I E F T D L R K L V A F G S E S T G G I F
G F G A G V F S E S S I E F T D L R K L V A F G S E S T G G I F
A K E D I S F K N N H H I A F R N N I T K G N G G V I Q L Q G D
A K E D I s F K N N H H I A F R N N I T K G N G G V I Q L Q G D
K G S V S F V D Q R G A I I F T N N Q A V T S S S M K H S G R G
K G S V s F V D Q R G A I I F T N N Q A V T S S S M K H S G R G
A I S G D F A G S R I L F L N N Q Q I T F E G N S A V H G G A I
A I S G D F A G S R I L F L N N Q Q I T F E G N S A V H G G A I
N K N G L V E F L G N A G P L A F K E N T T I A N G G A I Y T S
N K N G L V E F L G N A G P L A F K E N T T I A N G G A I Y T s
F K A N Q Q T S P I L F S Q N H A N K K G G A I Y A Q Y V N L E
F K A N Q Q T S P I L F S Q N H A N K K G G A I Y A Q Y V N L E
N Q D T I R F E K N T A K E G G G A I T S S Q C S I T A H N T I
N Q D T I R F E K N T A K E G G G A I T S S Q c S I T A H N T I
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F s G N T M L H I T K K A S L D R H N s I L I K E A P Y K I Q L
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F F S P K G M I V F S G A N L L D D A R E D V A N R T S I F N Q
K
H  L  R  S  G  C
V  H  L  Y  N  G
Figure 2.16 - Sequence of C.trachomatis serovar E recombinant N-terminal Pmp A 
passenger domain following site-directed mutagenesis as in section 2.2.16. 
Recombinant Pmp A passenger domain sequence is shown in black, published serovar D 
Pmp A sequence is aligned in red. The recombinant changes are underlined.
87
M K Y L L P T A A A G L L L L A A Q P A M A M D I G I N S D P N S
M K Y L L P T A A A G L L L L A A Q P A M A M D I G I N S D P N S
S S V D P N T A N N G P Y T L K A T W T K T G Y N P G P E R V A S
S S V E S I S I L I S S M A I Y F Y I T C / R S I H R S S N H N S
L V P N S L W G S I L D I R S A H S A I Q A S V D G R S Y C R G L
M S C / M K G I C C P C L L M G / E R C L S T R D G A I S I T D I
W V S G V S N F F Y H D R D A L G Q G Y R Y I  S G G Y  S L G A N S
S R H K A I F I R M C T R T S I K L H S N R N  /  I  /  E M S A L E C
Figure 2.17 - Depicts the changes caused by frame shift mutations in putative 
pPmpG22b-C. The N-terminal region of the recombinant protein sequence expected of the 
putative pPmpG22b-C construct following ligation of digested pmpG-C into digested pET22b 
shown in black. The actual sequence after ligation is aligned in blue. The translational 
changes caused by the frameshift are underlined, resulting in the transcription of the 
incorrect Pmp G protein sequence for the entire protein domain with several stop codons. 
The frameshift occurred after the pelB sequence (bold) at the highlighted valine residue.
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M K Y L L P T A A A G L L L L A A Q P A M A M D I G I N S D P N S
- - - -
s s V D P N T A N N G P Y T L K A T W T K T G Y N P G P E R V A S
- - w D P N T A N N G P Y T L K A T W T K T G Y N P G P E R V A S
L V p N S L W G S I L D I R S A H S A I Q A S V D G R S Y C R G L
L V p N S L w G S I L D I R S A H S A I Q A S V D G R S Y C R G L
W V s G V S N F F Y H D R D A L G Q G Y R Y I s G G Y s L G A N S
W V s G V s N F F Y H D R D A L G Q G Y R Y I s G G Y s L G A N S
Y F G S S M F G L A F T E V F G R S K D Y V V c R S N H H A C I G
Y F G S S M F G L A F T E V F G R S K D Y V V c R S N H H A C I G
S V Y L S T K Q A L C G S Y L F G D A F I R A s Y G F G N Q H M K
S V Y L S T K Q A L C G S Y L F G D A F I R A s Y G F G N Q H M K
T S Y T F A E E S D V R W D N N C L V G E I G V G L P I V I T P S
T S Y T F A E E S D V R W D N N c L V G E I G V G L P I V I T P S
K L Y L N E L R P F V Q A E F S Y A D H E S F T E E G D Q A R A FK L Y L N E L R P F V Q A E F S Y A D H E s F T E E G D Q A R A F
R S G H L M N L s V P V G V K F D R C S S T H P N K Y S F M G A Y
R S G H L M N L s V P V G V K F D R C S s T H P N K Y s F M G A Y
I C D A Y R T I s G T Q T T L L S H Q E T W T T D A F H L A R H GI C D A Y R T I s G T Q T T L L S H Q E T w T T D A F H L A R H G
V I V R G S M Y A S L T S N I E V Y G H G R Y E Y R D T L E H H H
V I V R G S M Y A S L T S N I E V Y G H G R Y E Y R D T S R G Y G
H  H  H  S t o p
L S A G S K V R F
Figure 2.18 - Sequence of C.trachomatis serovar E recombinant Pmp G 
autotranslocator domain following site-directed mutagenesis aligned with published 
serovar D. The sequencing results for Pmp G autotranslocator sequence after site-directed 
mutagenesis (section 2.2.16) is shown in black. Recombinant Pmp G autotransloctor domain 
was designed to incorporate the pelB fusion petptide, published serovar D Pmp G 
autotransloctor sequence is aligned in red and does not contain a fusion pelB peptide 
(highlighted in yellow). The other recombinant changes are underlined.
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• N L I C S G N V N P L F F T G N S A T N G G A I C C I S D L N T
■ N L I C S G N V N P L F F T G N s A T N G G A I C c I S D L N T
s E K G S L S L A C N Q E T L F A s N S A K E K G G A I Y A K H M
s E K G S L S L A C N Q E T L F A s N S A K E K G G A I Y A K H M
V L R Y N G P V S F I N N S A K I G G A I A I Q S G G S L S I L AV L R Y N G P V S F I N N S A K I G G A I A I Q S G G s L S I L A
G E G S V L F Q N N S Q R T S D Q G L V R N A I Y L E K D A I L S
G E G S V L F Q N N S Q R T S D Q G L V R N A I Y L E K D A I L S
s L E A R N G D I L F F D P I V Q E S S S K E s P L P S S L Q A S
s L E A R N G D I L F F D P I V Q E S S S K E s P L P S S L Q A S
V T S P T P A T A S P L V I Q T S A N R S V I F S S E R L S E E E
V T S P T P A T A S P L V I Q T S A N R S V I F S S E R L S E E E
K T P D N L T S H Y S G Q L A A A L E H H H H H H Stop
K T P D N L T S P L Q R P H S S T T T T T T E I R L L T K P R
Figure 2.19 - Depicts the frame shift mutations caused by the loss of nucleic acids in 
putative pPmpl23b-N. The expected C-terminal sequence of the recombinant pmp I 
passenger domain following ligation of digested pmpl-N into digested pET23b is shown in 
black. The actual sequence after ligation is aligned in blue. The translational changes 
caused by the frameshift are underlined. The frameshift occurred following the highlighted 
serine residue. The hexahistine tag is replaced by a poly threonine tag and the stop codon 
was lost.
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M A S R P D H M N F C C L C A A I L S S T A V L F G Q D P L G E TM - - R P D H M N F C C L C A A I L S S T A V L F G Q D P L G E T
A L L T K N P N H V V C T F F E D C T M E S L F P A L C A H A S Q
A L L T K N P N H V V C T F F E D C T M E S L F P A L C A H A S Q
D D P L Y V L G N S Y C W F V S K L H I T D P K E A L F K E K G D
D D P L Y V L G N S Y C W F V S K L H I T D P K E A L F K E K G D
L S I Q N F R F L S F T D C S S K E S S P S I I H Q K N G Q L S L
L S I Q N F R F L S F T D C S S K E S S P S I I H Q K N G Q L S L
R N N G S M S F C R N H A E G S G G A I S A D A F s L Q H N Y L F
R N N G S M S F C R N H A E G S G G A I s A D A F S L Q H N Y L F
T A F E E N S S K G N G G A I Q A Q T F s L S R N V S P I S F A R
T A F E E N S S K G N G G A I Q A Q T F s L S R N V S P I S F A R
N R A D L N G G A I C C S N L I C S G N V N P L F F T G N s A T N
N R A D L N G G A I C C S N L I C s G N V N P L F F T G N s A T N
G G A I C C I S D L N T S E K G S L S L A C N Q E T L F A s N S A
G G A I c C I S D L N T S E K G S L S L A C N Q E T L F A s N s A
K E K G G A I Y A K H M V L R Y N G P V S F I N N S A K I G G A I
K E K G G A I Y A K H M V L R Y N G P V S F I N N S A K I G G A I
A I Q S G G S L S I L A G E G S V L F Q N N S Q R T S D Q G L V R
A I Q S G G s L S I L A G E G S V L F Q N N S Q R T S D Q G L V R
N A I Y L E K D A I L S S L E A R N G D I L F F D P I V Q E S S S
N A I Y L E K D A I L S S L E A R N G D I L F F D P I V Q E S S S
K E S P L P S S L Q A S V T S P T P A T A S P L V I Q T S A N R SK E s P L P S S L Q A S V T S P T P A T A S P L V I Q T s A N R s
V I F S S E R L S E E E K T P D N L T S P L Q R P Q L E H H H H H
V I F S s E R L S E E E K T P D N L T s Q L Q Q P I E L
H Stop
Figure 2.20 - Sequence of C.trachomatis serovar E recombinant N-terminal Pmp I 
passenger domain following site-directed mutagenesis aligned with published 
serovar D. The sequencing results for recombinant Pmp I passenger domain sequence 
after site-directed mutagenesis (section 2.2.16) is shown in black. Published Pmp I 
sequence is aligned in red. The recombinant changes are underlined.
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2.4  D iscu ss io n
Initialising studies with a large number of clones is one approach to counteract the 
high attrition rates associated with the expression of membrane proteins, a 
screening process often used in high-throughput studies (Cowieson et a!., 2005). Of 
the initial fifteen pmp  cloning targets, fourteen were successfully amplified using 
polymerase chain reaction with the exception of full length pmpG  that proved very 
difficult to amplify. To address the difficulty with pmpG-FL  two different sets of 
primers were designed incorporating alternative restriction sites and various PCR 
conditions were trialled with each combination resulting in either zero amplification 
or a high amount of non-specific amplification. This could be an indication that the 
sequence is uniquely different from that of the published serovar D pmp G on which 
the primers were designed, possibly within the N-terminal region as there were no 
difficulties in amplifying the C-terminal pmpG  autotranslocator domain. Furthermore 
Pmp G has been suggested to display a high antigenic variation where four 
subtypes have evolved in C. pneumoniae, C, caviae and C. abortus (Tan, et al. 
2006).
Of the eight full length genes that were amplified, three were successfully 
incorporated into a pET vector in a manner suitable for expression trials. These 
recombinant constructs containing pmpA-FL, pmpD-FL  and pm pl-FL  were termed 
pPmpA23b-FL, pPmpD28b-FL and pPmpl23b-FL respectively. The translated 
products of these recombinant sequences were designed to possess a C-terminal 
hexa-histidine fusion tag to allow detection and isolation of the expressed product 
via chromatographic methods. Unfortunately restriction mapping and sequencing of 
the recombinant constructs containing full length pmpB, pmpC, pmpE, pm pF  and 
pm pH  showed these to be unsuitable for expression screening. These constructs 
contained undesirable truncated sequences that had lost the native N or C terminal 
regions or were deficient in the intended fusion tag due to an alteration in the 
reading frame. The errors could have occurred during amplification as a result of 
mismatched priming, during ligation or transformation if the gene was unstable 
during replication. Many various attempts to adjust the cloning procedure were 
made. However the constructs were still unsuitable for further analysis.
By an adaptation of cloning strategies used to produce constructs for full length 
pmpA, pmpD  and pmpl, recombinant constructs were made for the predicted 
functional domains of these Pmps with the use of nested primers. Of particular 
interest was the predicted passenger domains of Pmp A and Pmp I. Out of the nine
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C. trachomatis Pmps, Pmp A is the only member with no obvious signal peptide 
sequence (Gomes et at., 2006) and is highly conserved (Stothard et al., 2003) 
therefore a putative role as a microbial virulence factor may be unique and differ 
distinctively from the other Pmps in the family. The Pmp I passenger domain was 
also of particular interest because of its variable sequence amongst the different 
serovars indicating a vital function for pathogenesis. It was therefore proposed that 
these predicted functional domains would be very attractive to study in functional 
adherence assays and structural analysis. The recombinant constructs for these 
Pmp domains were named pPmpA23b-N and pPmpl23b-N since the predicted 
passenger domains reside at the N-terminal region of the gene. The expressed 
products were also designed to contain a poly-histidine affinity tag at the C- 
terminus. Efforts to construct a recombinant clone for the Pmp H and Pmp D 
passenger domains were executed as both Pmp H and Pmp D are documented to 
be surface expressed in the bacterial cell, with Pmp D having a highly conserved 
sequence and Pmp H having a variable sequence amongst different strains 
indicative of tissue tropism (Stothard et al., 2003). However the constructs were not 
suited for expression screening as the insert within the vectors was incorrect 
although further analysis has shown an error within the reverse primer used to 
amplify the pmpD  passenger domain (primer set: pmpD-N) was responsible for a 
truncated insert. The one base error within the primer sequence resulted in the loss 
of the restriction site intended to be incorporated into the amplified sequence for 
subsequent cloning into the pET vector. A new primer with the correct base could 
easily rectify this as amplification was strong and ligation conditions were 
successful. Having identified this, successful cloning and expression of the 
passenger domain of Pmp D would be a consideration for further work.
Although the passenger domains were of interest in identifying Pmp function, the
‘autotranslocator’ C-terminal regions amongst the Pmps were of particular interest
with regards to an understanding of the structure. Current structural data exists
based solely on bioinformatic analysis that predicts Pmps to belong to the
autotransporter fam ily (Henderson and Lam 2001a, Wehrl et al., 2004). These data
suggest that the C-terminal autotranslocator regions have a p-barrel structure,
typical of other prokaryotic autotransporters (Henderson et al., 1998) but this has
not been substantiated by circular dichroism or any other biophysical technique for
any of the predicted Pmp pore-forming regions. In an attempt to confirm p-barrel
structure a recombinant construct was made to contain the predicted
autotranslocator domain of Pmp D and Pmp G. These recombinant vectors were
93
termed pPmpD28b-C and pPmpG22b-C. The expressed product of pPmpG22b-C 
was designed to contain a pelB leader sequence, an aid to help protein localisation 
to the periplasm as it was unknown at this point if the lack of the native N-terminal 
signal leader peptide would affect localisation of the expressed products. 
Additionally the recombinant cloning of PmpG autotranslocator domain had led to 
the loss of the carboxy terminal phenylalanine, an amino acid considered essential 
for localisation to the outer membrane (Struyve et al., 1991).
Site-directed mutagenesis was necessary to adjust the plasmid in some of the 
constructs. Errors in the sequence were not unexpected because the primers used 
were not completely complementary to the sequences they were intended to amplify 
and the custom design of the primers were designed using the published sequence 
of DNA of serovar D. Furthermore, the primers incorporated synthetic restriction 
sites for directional cloning which inevitably resulted in a certain amount of base 
mismatching, possibly introducing frame-shifts and point mutations.
2.5 S u m m ary
Overall, the cloning strategies developed led to the successful construction of seven 
recombinant expression plasmids containing either full length or truncated pmp  
sequences obtained from a clinical strain of a serovar E C. trachomatis, all bearing 
a poly-histidine fusion tag ready for small scale expression trials in E. coli.
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Chapter 3 - Heterologous expression of full length 
and truncated recombinant Pmps in for 
downstream analysis
95
3.1 In troduction
To date, C.trachomatis Pmps have not been expressed as recombinant proteins at 
high enough levels for biophysical and functional analyses. Several of the 
homologous Chlamydia pneumoniae  Pmps have been successfully expressed as 
recombinant protein yet structural information has not been obtained (Niessner et 
al., 2003). As discussed in se c tion  1.5.2 the Pmps are predicted to be 
autoransporters that are likely to interact with the host cell to initiate infection, for 
which little analysis has been carried out to either substantiate or reject this notion. 
In order to investigate this further it is necessary to express high quantities of pure 
recombinant proteins suitable for biophysical and protein interaction studies.
The recombinant expression system provides opportunities to include modifications 
such as fusion tags and leader peptides which can direct protein targeting, increase 
stability and facilitate detection and purification. The most commonly used vehicle to 
express both prokaryotic and eukaryotic membrane proteins is E.coli since it is well 
characterised, inexpensive and easy to handle. However the over-expression of 
membrane proteins is rarely a straightforward task and often requires extensive 
optimisation due to their insolubility in aqueous buffers and a high occurrence of 
protein misfolding into inclusion bodies is observed (Seddon et al., 2004). The 
choice of vector and host strain are therefore an important consideration because 
they have a direct effect on the level and timing of protein expression, which affects 
the location in the cell where the protein will accumulate, and whether the protein is 
biologically active (Miroux and W alker 1996). This is of particular importance when 
expressing membrane proteins, which can also be toxic to the cell, especially when 
produced at high levels. Therefore many parameters have to be met to ensure 
successful expression. However high levels of successfully expressed bacterial 
membrane proteins have been observed using E.coli, including numerous 
membrane proteins (Dutzler et al., 2002, Griffin et al., 2003, Korepanova et al., 
2009, Lee et al., 2011). Importantly, it is currently impossible to predict whether a 
recombinant membrane protein can be over-expressed. If expression is attainable it 
is not currently possible to predict if it will be over-expressed in the membrane or as 
misfolded aggregates in inclusion bodies.
This chapter investigates the use of different expression vectors and E.coli hosts for 
the expression screening of rPmp A, rPmp D and rPmp I. As an alternative strategy 
the expression of predicted Pmp functional domains as truncated rPmps was also 
examined in an effort to increase the outcome of successful expression products
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where changes in solubility and functionality of the proteins may have been 
affected. The hosts and vectors are discussed in se c tions  3.1.1 and 3.1.2, Several 
methods to overcome the common bottlenecks have been employed enabling the 
production of recombinant Pmp proteins suitable for downstream processing.
3.1.1 The pET exp ress io n  system
Of the various expression systems that exist, many are designed for different 
applications and compatible with a range of hosts. The most widely used system for 
the recombinant expression of proteins in E.coli is the pET expression system 
commercialized by Novagen for which more than 40 different plasmids are available 
(Novagen). The system consists of multiple cloning sites for a range of genetic 
background modifications such as the incorporation of fusion partners, protease 
cleavage sites and hybrid promoters (Sorensen and Mortensen 2005).
Due to its adaptability, the pET system was used throughout these studies. In 
particular, vectors pET22b, pET23b and pET28b were chosen as each offered 
different potential attributes; pET22b allows the incorporation of a pelB signal 
peptide to encourage periplasmic localisation, pET23b allows incorporation of an N- 
terminal T7 tag that can be used as an alternative detection technique and pET28b 
possess the high stringency T7lac promoter to help suppress basal expression. The 
three vectors all allow for incorporation of a C-terminal histidine tag for purification 
and detection. Furthermore, the successful expression of several membrane 
transporters including the Bacillus subtilis tetracycline efflux protein TetA and the Na 
-dependent citrate carrier of Klebsiella pneumoniae  has been achieved with the pET 
vectors (Cheng et al., 1996, Kastner et al., 2000). Moreover, the expression of a 
truncated recombinant Pmp C from C. trachomatis has been expressed using these 
strategies (Gomes et al., 2005).
The system is designed for use with several strains of ?iDE3 lysogenised E.coli 
(sec tion  3.1.2) which carry a T7 RNA polymerase gene under control of the 
Isopropyl |3-D-1-thiogalactopyranoside (IPTG) inducible lacUV5 promoter (F igu re
3.1). IPTG binds to the la d  repressor protein, preventing interaction with the lac 
operator which in turn allows for the transcription of T7 RNA polymerase encoded 
for on the E.coli chromosome (Sorensen and Mortensen 2005). This T7 RNA 
polymerase binds to the T7 promoter on the pET plasmid to begin transcription of 
the target gene. Some pET vectors such as pET28b (section  3.2.2.1) confer a more 
stringent regulatory promoter, the T7/ac promoter that offers a second lac  operator 
situated downstream of the T7 promoter (F igure 3.1) such that binding of the
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repressor molecule inhibits T7 RNA polymerase interacting at this site. This duo of 
lac operators inhibits both the binding of E.coli RNA polymerase at the lacUV5 
promoter reducing transcription of T7 RNA polymerase whilst also inhibiting the 
interaction of T7 RNA polymerase with the T7 promoter, collectively offering a 
tighter regulation over basal expression of the target gene (Novagen). The pLysS 
plasmid, compatible with many of the strains in sec tion  3.1.2 presents an even 
tighter regulation by encoding for T7 lysozyme, a natural inhibitor of T7 RNA 
polymerase thus reducing its capacity to transcribe the target gene in uninduced 
cells. The addition of IPTG is strong enough to overcome the levels of T7 lysozyme. 
Under non-stringent conditions without these regulatory mechanisms a small 
amount of transcription is permitted in the uninduced state and can be useful for the 
expression of genes that have innocuous effects on the host cell growth. However 
with membrane proteins a more stringent method is often necessary to avoid 
deleterious effects on cell growth when the expressed protein is toxic to the cell 
and/or when protein aggregation levels are high.
3.1 .2  S tra ins  fo r E .coli exp ress io n  screen in g
BL21 (DE3) is the standard strain used for protein expression and is often the initial 
choice of host for expression screening trials. Protease deficient strains such as 
BL21 (DE3) and its derivatives are lacking in the Ion protease and the om pT  outer 
membrane proteases. Strains containing lacY1 deletion mutants of BL21 (DE3) 
such as Tuner™ (DE3) cells allow adjustable levels of protein expression 
throughout all cells in culture. The lac permease (lacY1) mutation prevents active 
transport of IPTG into the cells, entry is via diffusion producing a concentration 
dependent homogenous level of induction allowing some repression by la d  see 
F igure  3.1. Controlling the expression rate this way can help with the solubility of 
the target protein by helping minimise the aggregation of protein. Furthermore, such 
protease deficient strains were chosen for this study as they offer some stability 
against protein degradation especially when downstream purification is necessary 
(Grodberg and Dunn 1988).
Strains with glutathione reductase (gor) and thioredoxin reductase (trxB ) mutations 
greatly enhance the formation of disulfide bonds in the E.coli cytoplasm (Prinz et al., 
1997). Many proteins require the formation of stable disulfide bonds to ensure 
proper folding and thus activity. Usually disulfide bonds are formed only upon export 
into the periplasmic space. W ithout disulfide bonds, the proteins may accumulate as 
mis-folded inclusion bodies or instead may be degraded. This was deemed an
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important consideration for expressing rPmps, which rich in cysteine residues may 
also fold in the periplasmic compartment (Tanzer and Hatch 2001a) and/or form 
intra-molecular disulfide bonds like other autotransporters (sec tion  1.5.2.2). This 
can be limited in E.coli due to the relatively high reducing potential in the 
cytoplasmic compartment however the Origami™ strains (Novagen) carry both the 
gor and trxB mutations to allow disulphide formation within the cytoplasm.
E.coli and other species carry their own bias in the usage of the 61 available amino 
acid codons. In each cell the tRNA population closely reflects the codon bias of the 
mRNA population (Kane 1995). When the mRNA of heterologous target genes is 
expressed in E.coli, differences in codon usage can impede translation due to the 
demand for one or more tRNAs that may be lacking in the population. In particular, 
codons for arginine (AGG, AGA, CGA), leucine (CTA), isoleucine (ATA) 
and proline (CCC) can pose problems with expression. The presence of more than 
-  8-9 of the two rarest arginine codons (AGG and AGA), particularly back-to-back 
as a tandem repeat can lead to translational stalling, early translation termination, 
translational frame-shifting and amino acid mis-incorporation. Rosetta strains 
(Novagen) are designed to enhance the expression of eukaryotic proteins by 
supplying these rare tRNAs providing a ‘universal’ translation. All the 
aforementioned were considered carefully in these studies when choosing a 
suitable host for expression and codon analysis was carried out on the Pmps 
undergoing expression trials.
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3.2 M ateria ls / M ethods
3.2.1 S u p p lie rs  used in th is  ch ap ter
Analytical grade chemicals were used throughout this study with all solutions being 
prepared using sterile water. Materials were obtained from the following suppliers.
Bio-Rad Laboratories Ltd., Hemel Hemsted, Hertfordshire, Cambridge 
Bioscience., Cambridge, GE Healthcare Ltd, Amersham, Buckinghamshire, 
Invitrogen Life Technologies., Paisley, Merck Chemicals Ltd., Beeston, 
Nottingham, New England Biolabs (UK) Ltd., Hitchin, Hertfordshire, Novagen, 
Merck Chemicals Ltd., Beeston, Nottingham, Perbio Science UK Ltd., 
Cramlington, Northumberland, Qiagen Ltd., Crawley, W est Sussex, Sigma Aldrich  
Company Ltd., Gillingham, Dorset, Starlab UK., Blakelands, Milton Keynes, 
Stratagene Ltd., Cambridge, Stratech Scientific., Newmarket, Thermo-Fisher 
Scientific UK., Loughborough, Leicestershire.
Glassware and media were sterilised by autoclaving at 121°C, 15 p.s.i. for 20 
minutes. Solutions were made from molecular biology grade reagents and sterilised 
by filtration or autoclaving before use.
3.2 .2  pET exp ress io n  vectors
Recombinant vectors were produced using pET vectors shown in section 3.2.2.1 to
3.2.2.3 and Pmp coding sequences amplified from genomic DNA as described in 
chapter 2. Plasmids pPmpA23b-FL, pPmpD28b-FL and pPmpl23b-FL contained the 
coding regions for full length Pmp A, Pmp D and Pmp I respectively. Pmp N- 
terminal signal/passenger domains of Pmp A and Pmp I and the C-terminal 
autotranslocator domains of Pmp D and Pmp G were present within plasmids 
pPmpA23b-N, pPmpl23b-N, pPmpD28b-C and pPmpG22b-C respectively.
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3.2.2.1 P lasm id  pE T 28b (+)
In the plasmid pET28b, expression via the T7/ac promoter is controlled by 
repression from the la d  gene present on the plasmid. A pET28b expression 
construct can be transformed into many host strains since it operates independently 
of the host. The plasmid allows incorporation of a hexahistidine tag both at the N- 
terminus and the C-terminus of the inserted gene to produce an affinity tag to assist 
in the detection and purification of the recombinant protein. The plasmid offers 
kanamycin resistance as a selective marker.
pET-28b(+)
(5368bp)
PshA 1(1968)
Bgl 1(2187)
Fsp 1(2205)
Psp5 11(2230)
Dra 111(5127)
X h o  1(158) 
N o t  1(166) 
Eag 1(166) 
Hind 111(173) 
Sal 1(179)
S a c  1(190) 
E c o R  1(192) 
B a m H  1(198) 
N h e  1(231) 
N d e  1(238) 
N c o  1(296) 
1(335)
Bgl 11(401)
SgrA 1(442) 
Sph 1(598)
Pvu 1(4426) 
Sg f 1(4426)
Sma 1(4300)
Eco57 1(3772)
AlwN 1(3640)
Mlu 1(1123) 
Bel 1(1137)
BstE 11(1304; 
Apa 1(1334)
11(1534) 
EcoR V(1573) 
Hpa 1(1629)
BssS 1(3397)
BspLU11 1(3224)
Sap 1(3108) 
Bst'l 107 
T th l 1
Figure 3. 2 - The expression vector map, pET28b (+) (Novagen)
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3 .2 .2 .2  P lasm id  pE T23b(+)
Unlike pET28b, the la d  gene is not present on the pET23b plasmid. A pET23b 
expression construct can also be transformed into many host strains. The plasmid 
allows incorporation of a hexahistidine tag at the C-terminus and a T7 tag at the N- 
terminus. The plasmid offers ampicillin resistance.
N g o A  IV (3525) - 
D rd  1(3429). \
D ra  111(3424) v \
, S ty  1(57)
■ B p u 1 1 0 2  l(8Q)
^  ^ 3655)
B s a H
S e a  1(2761) pET-23a(+)(3666bp)
PVU 1(2651) \ \ \\\\« 
P s t 1(2526)- A
B g l 1(2401)
A h d  1(2281)
Xho 1(15B)
Not 1(166)
Eag 1(166)
Hind 111(173)
Sal 1(179)
Hinc 11(181)
Sac 1(190)
EcoR 1(192)
B a m H  1(198)
N h e  1(231)
-  Nde 1(238)
 X b a  1(276)
B g l 11(334)
Msc 1(359)
Dsa 1(360)
Bpu10 1(494 > 
-  B b s  1(506) 
— B s g  1(548)
E C 0 4 7  111(642)
!•- P v tl  11(879)
/
/ - T t h 1 1 1  1(1133) 
/ ‘ B s t1 1 0 7  1(1159)
I s * S a p  1(1272)
A fl 111(1388) 
B s p L U 1 1  1(1368)
I-
* A lw N  1(1804)
Figure 3. 3 - The expression vector map, pET23b (+) (Novagen)
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3 .2 .2 .3  P lasm id  pE T22b(+)
The pET22b(+) vector has similar properties to pET23b (+) but differs by carrying an 
N-terminal pelB  signal sequence for potential periplasmic localisation, plus an 
optional C-terminal hexahistidine sequence. This can be potentially helpful for 
sequences that do not have a signal sequence but where periplasmic localisation of 
the target product would be advantageous.
pET-22b(+)
( 5 4 9 3 b p )
BspLU'11
Bst1107 I(2986) 
Tth111 1(2960)
Psp5 11(2221) 
B pu io  1(2321)
Dra 111(5251)
AlwN l{3631)
Bpu1102 1(80) S a l 1(179) 
S a c  1(190) 
E c o R  1(192) 
B a in H  i(l98) 
N c o  1(220)
(326)— Bgi 11(392)
ApaB 1(798)
BstE 11(1295) 
1(1323} 
1(1325)
11(1525) 
Hpa 1(1620}
PshA 1(1959)
Sea 
Pvu 1(4476) 
Pst 1(4353)
Bsa 
E3n1105 1(4108 )
Figure 3. 4 - The expression vector map, pET22b (+) (Novagen)
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3.2 .3  E. coli tran s fo rm atio n  and protein  exp ress io n
3.2.3.1 E. coli tran s fo rm atio n
A 20 pi aliquot of competent (DE3) lysogenic strain, see genotypes in section 
3.2.3.7, was transformed with plasmid DNA as in section 2.2.9 with appropriate 
antibiotic (50 p.g/ml ampicillin, 15pg/m l kanamycin and/or 34 pg/ml 
chloramphenicol). Single bacterial colonies were selected as in section 2.2.11 to 
inoculate liquid culture by placing a single colony into 50 ml LB broth with the 
appropriate antibiotic, and grown at 37°C, 200 rpm.
3.2 .3 .2  P rote in  exp ress io n
A 50 ml overnight culture of E. coli in LB (1% (w/v) NaCI, 1% (w/v) tryptone, 0.5% 
(w/v) yeast extract) with the appropriate antibiotic(s) (50 pg/ml ampicillin, 15 pg/ml 
kanamycin and/or 34 pg/ml chloramphenicol), was used to inoculate 500 ml LB. The 
culture was incubated at varying temperatures to optimise expression, from 25 0 C - 
37° C, 200 rpm until A60o = 0.6-0.8. Protein expression was induced by the addition 
of 0.5 - 1 mM IPTG or alternatively expressed without IPTG, followed by a further 
incubation with varying time periods to optimise expression. Cells were harvested 
by centrifugation at 5000g for 20 minutes and were stored at -20° C.
3.2 .3 .3  S ec inh ib ition
Azide is recognized as a potent inhibitor o f secA of the inner membrane sec 
translocon (Oliver et al., 1990). Inhibition o f the sec machinery can prevent the 
translocation and subsequent cleavage of signal peptides from pro-proteins such as 
autotransporters which are predicted to be processed via the sec pathway. 
Consequently, unprocessed pro-proteins that are restricted from sec processing 
accumulate in the cytoplasm as inclusion bodies (Gathmann et al., 2006). During 
protein expression, where sec inhibition was required, cultures were treated with 0.2 
mM, 1 mM or 2 mM sodium azide at the same time as IPTG induction.
3 .2 .3 .4  P repara tion  o f to tal cell p rote in  fo r S D S -P A G E  analys is
A 50 ml aliquot of induced culture section 3.2.3.2 was centrifuged at 5000g for 10 
minutes. The pellet was resuspended in 2 ml sonication buffer (50 mM Tris-HCI, 150 
mM NaCI, 1 mM EDTA, pH 8.0). This was incubated with 50 pi lysozyme (40 mg/ml) 
for 15 minutes at 37°C to disrupt the cell wall. Samples were passed through a 
Hamilton syringe until the viscosity was reduced followed by dilution in SDS sample 
buffer as described in section 3.2.5.1.
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3.2 .3 .5  F ractio n atio n  o f cells  u n d er non -d en atu rin g  cond itions
Fractionation of cells into soluble and insoluble components was carried out. A 
culture was induced to express protein as described in section 3.2.3.2. The cell 
pellet was freeze/thawed prior to resuspension in ice cold lysis buffer (1XPBS, 
20mM (3-ME, 3mg/ml lysozyme, DNase (50 U) and 3mM MgCI2) and incubated on 
ice for 20 mins. All handling buffers were supplemented with 1X Halt™ EDTA-free 
protease inhibitors (Thermo-scientific). The suspension was then sonicated on ice 5 
X 10 second bursts with a sonication probe (set at 30% amplitude), then incubated 
on ice for a further 30 minutes before centrifugation at 13,000g for 20 minutes at 
4°C. The supernatant was retained (soluble fraction). The pellet was resuspended 
in solubilisation buffer (1XPBS, 20mM [3-ME and 1-2% detergent (Triton X-100 or n- 
Dodecyl (3-D-maltoside, DDM)). The suspension was incubated with gentle mixing at 
4°C for 2 hours and centrifuged at 36,000g for 30 minutes at 4°C, during this step, 
membrane proteins are released into the buffer. The supernatant was retained 
(solubilised membrane fraction). The insoluble pellet was washed in solubilisation 
buffer before centrifuging again at 36,000g at 4°C to pellet inclusion bodies. All 
samples were diluted in SDS-sample buffer as in section 3.2.5.1 for analysis by 
SDS-PAGE and western blotting.
3.2 .3 .6  F ractio n atio n  o f ce lls  u n d er d enaturing  cond itions
Fractionation of cells into soluble and insoluble components was carried out. A 
culture was induced to express protein as described in section 3.2.3.2, The cell 
pellet was freeze/thawed prior to resuspension in denaturing lysis buffer (100 mM 
NaH2P 0 4 10 mM Tris-HCI 8 M urea pH8.0). The suspension was incubated with 
gentle mixing of the tube, end over end at room temperature for 1 hour and 
centrifuged at 12,000g for 30 minutes at room temperature. The supernatant was 
retained (solubilised denatured protein fraction). The insoluble pellet contained urea 
insoluble debris and proteins. All samples were diluted in SDS-sample buffer as in 
section 3.2.5.1 for analysis by SDS-PAGE and western blotting.
3 .2 .3 .7  G en otypes  o f the s tra in s  o f E sch erich ia  coli used
(C41 & C43 (DE3) +/- pLysS: F- ompT hsdSB (rB- mB-) gal dcm (DE3).
(Cambridge Bioscience)
Rosetta-gami 2 (DE3) pLysS: A(ara-leu)7697 AlacX74 AphoA Pvull phoR araD139 
ahpC galE galK rpsL (DE3) F'[lac+ laclq pro] gor522::Tn10 trxB pLysSRARE2 
(CamR, StrR, TetR) (Novagen, Merck)
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Tuner (DE3): F -  ompT hsdSB (rB - m B -) gal dcm lacY1(DE3) (Novagen, Merck)
Tuner (DE3) pLysS: F- ompT hsdSB (rB-mB-) gal dcm lacY1(DE3) pLysS (CmR) 
(Novagen, Merck)
3 .2 .4  P ro te in  P urifica tion
3.2.4.1 M etal a ffin ity  co lum n c h ro m ato g rap h y  w ith  N i-N T A  ag aro se
Crude membrane fractions from 500 ml of E. coli culture were solubilised in 5-10 ml 
buffer containing the appropriate detergent (1XPBS, 10 mM imidazole, 1-2% (v/v) 
detergent [Triton X-100 or n-dodecyl-(3-D-maltopyranoside DDM], 10Ojul HALT 
EDTA-free protease inhibitor cocktail). The suspension was incubated with gentle 
mixing of the tube, end over end at 4°C for 2 hours and centrifuged at 36,000g for 
30 minutes at 4°C. The supernatant was applied to a 2ml column containing 750pl 
of pre-washed 50% Ni-NTA agarose slurry (Qiagen). The flow through was 
collected. The column was washed with 2 ml wash buffer (1XPBS, 20 mM 
imidazole, 0.1% (v/v) detergent). Protein was eluted in steps with increasing 
concentrations of imidazole (1XPBS, 0.1% (v/v) detergent with increasing gradients, 
from 20 mM to 500 mM imidazole), using 4 X 0.5 ml fractions for each 
concentration. Aliquots of all fractions were examined by SDS-PAGE and western 
blot as in sections 3.2.5.1 and 3.2.5.2 for the presence of protein. To examine 
proteins under denaturing conditions the buffer was replaced by denaturing lysis 
buffer as section 3.2.3.6, and the same procedure was followed in the presence of 
imidazole. W here 50 ml cultures were used the protocol reagents were scaled down 
accordingly.
3.2 .5  G en era l pro te in  tech n iq u es
3.2.5.1 S D S -p o lyacry lam id e  gel e lec tro p h o res is  (S D S -P A G E )
SDS-PAGE was performed according to Laemmli (1970). The electrophoresis of 
resolving gels, 1.5 mm thick, 10-12% acrylamide (w/v), was performed using a 
Biorad vertical minigel apparatus for approximately 1 hour at 40 mA per gel. 
Samples were diluted 1:4 in SDS-sample buffer (0.2 M Tris-HCI pH 6.8, 4 mM 
EDTA, 4% (w/v) SDS, 4% (v/v) glycerol, +/- (3-ME). Gels were stained with 
Coomassie blue (0.25% (w/v) Coomassie brilliant blue in 25% (v/v) methanol/10% 
(v/v) acetic acid) and destained with 10% (v/v) acetic acid.
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3 .2 .5 .2  W estern  b lotting
Transfer to nitrocellulose was performed as described by Towbin et al. (1979). 
Following SDS-PAGE gels were rinsed in transfer buffer (25 mM Tris, 192 mM 
glycine, 20% (v/v) methanol, pH 8.3). A nitrocellulose membrane (0.45 pm pore 
size, GE Healthcare, Amersham) was cut to the same dimension as the gel and 
soaked in dH20  for 10 minutes. A Bio-rad mini-gel blotting apparatus was set up 
according to the manufacturer’s instructions, and the proteins were transferred for 1 
hour at 100V in transfer buffer. Membranes were washed Tris-buffered saline (TBS, 
20 mM Tris, 500 mM NaCI, pH 7.5) for 10 minutes prior to blocking with 1% alkali- 
soluble casein (Merck) in TBS containing 0.2% Tween-20 (TBST), for 2 hours at 
room temperature. A penta-His primary antibody (2 pg/ml) (Qiagen) in antibody 
buffer (TBST containing 1% alkali-soluble casein) was added for 2 hours at room 
temperature. Membranes were washed three times in TBST. Secondary antibody, a 
horseradish peroxidase conjugate of goat anti-mouse IgG (Stratech) was added at a 
dilution of 1:10,000 in antibody buffer for 1 hour at room temperature. Membranes 
were washed three times in TBST and peroxidase activity detected using the Pierce 
Supersignal ECL kit (Perbio Scientific UK) according to the manufacturer's 
instructions.
3 .2 .5 .3  P ro te in  precip ita tion
Protein precipitation of the media was performed using the Trichloroacetic acid 
(TCA) protein precipitation protocol (Novagen, 2005). 10ml of the media from the 
cell harvest in sec tion  3.2.3.2 was incubated with 1ml (1/10 volume) of 100% TCA 
(w/v) on ice for 15 minutes. The sample was centrifuged at 16,000g for 10 minutes 
and the supernatant discarded. The pellet was washed twice with 1ml acetone and 
centrifuged at 16,000g for 5 minutes. The acetone was removed and the pellet was 
allowed to air dry in a fume hood for 2 hours or until dry. Samples were 
resuspended in 1X PBS and SDS-sample buffer.
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3.3 R esults
3.3.1 E xp ress io n  tria ls  fo r fu ll length  rPm p A, D and I using the E.coli 
stra in s  Tuner™  (D E 3), R ose tta -g am i 2™ (D E3), O verexp ress  C41™  
(D E 3) and C43™  (D E3)
Membrane proteins that are expressed at a rapid rate have a high tendency to 
aggregate into inclusion bodies (Rudolph and Lilie 1996). As explored in section
3.1.2 the lac permease (lacY1) mutation present within the Tuner™ (DE3) cells 
prevents active transport of IPTG. Instead entry is via diffusion producing a 
concentration dependent homogenous level of induction. Controlling the expression 
rate this way can help with the solubility of the target protein and so this was the 
initial strain chosen for early expression trials.
Expression plasmids pPmpA23b-FL, pPmpD28b-FL and pPmpl23b-FL were 
transformed separately into Tuner™ (DE3) cells (section 3.2.3.1) and expression 
trials were cultured in LB (sections 3.2.3.2). The expression of rPmps was 
examined under a variety of conditions with cultures induced to express 
recombinant Pmps for between 2-16 hours, dependent upon the incubation 
temperature used; at 37 °C the induction period was between 2 and 3 hours whilst 
cultures induced at room temperature were allowed an extended growth period, 
typically overnight. IPTG concentrations used for induction were typically between 
0.5 mM and 1 mM following the recommended guidelines for the particular pET 
vector: Coding sequences inserted in to pET28b are under control of the T7/ac 
promoter. This promoter allows binding of the lac repressor thus reducing 
transcription by T7 RNA polymerase to suppress basal expression as discussed in 
section 3.1.1. This high stringency promoter requires a higher concentration of 
IPTG (1 mM) to fully induce compared to the regular T7 promoter of pET23b and 
pET22b (0.5 mM). Alongside each o f the induced cultures was an uninduced culture 
grown under the same conditions that served as a control. Following expression, 
harvested cultures were separated into total cell protein, soluble and insoluble 
fractions under both denaturing and non-denaturing conditions (sections 3.2.3.5 
and 3.2.3.6) for analysis by SDS-PAGE and Western blotting (sections 3.2.5.1 and
3.2.5.2). Any secreted proteins localised to the media were also precipitated using 
TCA (section 3.2.5.3).
Western blot analysis showed rPmp A, rPmp D and rPmp I were not detected in 
induced Tuner™ (DE3) cells under any of the variant conditions (data not shown)
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when compared to uninduced cultures and cultures expressing empty pET vectors. 
The expected sizes of rPmp A, rPmp D and rPmp I are approximately 105 kDa 160 
kDa and 95 kDa, respectively. Such bands were not detected when probed with a 
range of different anti-His primary antibodies as described in section 3.3.6. Growth 
rates were observed before and after induction with IPTG to monitor the effects of 
IPTG induction on the cells. The growth o f the induced culture slowed notably in 
relation to the uninduced culture following induction of each of the rPmp expression 
plasmids (data not shown). This was encouraging as it is likely the resources of the 
induced cells were being diverted in an effort to produce the rPmps. Induction with 
IPTG did not appear to be lethal to the cells as growth was maintained albeit at a 
slower rate (data not shown).
Rosetta strains (Novagen) are designed to enhance the expression of proteins 
carrying rare codons not recognised in E. coli by supplying the rare tRNAs (section
3.1.2). Using the Rare Codon Calculator (RaCC) (NIH MBI Laboratory for Structural 
Genomics and Protemoics) codon analysis of pmp A, pmp D and pmp I revealed a 
high number of rare codons for these pmps. pmp D contained 55, 30 of these were 
rare Arg codons with 1 tandem rare Arg codon, pmp A contained 57 rare codons, 17 
being rare Arg codons and pmp I contained 32 rare codons with only 11 as rare Arg 
codons. These were all at levels that could affect the expression of the full length 
Pmps.
Therefore following expression attempts using Tuner™ (DE3) cells, trials were 
performed using a cell line that could allow for rare tRNAs. The Rosetta-gami 2™ 
(DE3) pLysS cell line was transformed with pPmpA23b-FL and pPmpl23b-FL and 
were cultured in LB (section 3.2.3.2). Expression was induced with 0.5 mM IPTG 
for between 2 and 4hrs at both 30 °C and 37 °C alongside uninduced cultures. 
Expression was also examined for an extended period typically overnight at room 
temperature for both plasmids. The cells were harvested and prepared into total cell 
protein, soluble and insoluble fractions under both denaturing and non-denaturing 
conditions for analysis by SDS-PAGE and Western blotting. Secreted proteins 
localised to the media were also precipitated using TCA for examination. Expression 
trials for rPmp D were not carried out with this cell line because the strain is 
kanamycin sensitive and this expression plasmid carries the kanR gene.
Western blot analysis indicated that rPmp A and rPmp I were not expressed in 
Rosetta-gami 2™ (DE3) pLysS cells under any of the variant conditions (data not 
shown). Interestingly the addition of IPTG had a marked effect upon the growth of
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pPmpl23b-FL transformed Rosetta-gami 2™ (DE3) pLysS cultures. Following 
induction, the culture growth rate began to plateau and did not recover after three 
hours (shown in F igure 3.5). It is possible that the recombinant Pmp I may have 
had a deleterious effect on the growth rate. The pLysS plasmid was present to 
reduce basal expression and minimise putative toxic effects of expressed harm ful 
protein prior to induction. However up to this point pre-induction growth rates were 
comparable. The change in growth rate led to the assumption that recombinant 
protein was produced. However rPmp I was not detected via Western blotting or via 
SDS-PAGE. The addition of IPTG did not have a deleterious effect when inducing 
the expression of recombinant Pmp A in Rosetta-gami 2™ (DE3) pLysS cells (data 
not shown). However it was noted that the transformation efficiency of pPmpA23b- 
FL compared to pPmpl23b-FL was poor using this strain. This could indicate that 
the rPmpA plasmid or recombinant protein also had deleterious effects. Cultures 
were always propagated from freshly transformed E.coli, however the stability of the 
plasmid maintenance was not checked. A positive control was not available.
OverExpress™ C41 and C43 (Lucigen) strains have been developed to allow high 
level expression of a wide variety of toxic proteins proteins previously difficult or 
impossible to express in bacteria (Miroux and W alker 1996). To this end, trials were 
carried out with OverExpress™ C43 (DE3) and Overexpress C41™ (DE3) cells 
transformed separately with pPmpA23b-FL, pPmpD28b-FL and pPmpl23b-FL. 
Transformed cells were cultured in LB. Cultures were induced for between 3 and 4 
hours both at 30°C and 37°C with both 0.5 mM and 1 mM concentrations of IPTG. 
Overnight trials at room temperature were also performed. The cultures were 
prepared into total cell protein, soluble and insoluble fractions under both denaturing 
and non-denaturing conditions for analysis by SDS-PAGE and Western blotting. 
Secreted proteins localised to the media were also precipitated for analysis.
Recombinant proteins rPmpA, rPmpD and rPrnpl were not detected in induced 
OverExpress™ C43 (DE3) or Overexpress C41™ (DE3) cells under any of the 
variant conditions according to Western blot analysis and SDS-PAGE (data not 
shown). Although transformation efficiency of this cell line was good with all three 
recombinant plasmids, examination via Western blot and SDS-PAGE did not detect 
over-expressed His-tagged proteins.
Commonly a very poor yield of expression hampers detection by Western blot or 
SDS-PAGE. Ni-NTA affinity was therefore used to concentrate putative His-tagged 
proteins prior to analysis for each of the fractionated cultures expressing rPmps.
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This was performed under denaturing conditions (section  3.2.3.7) to ensure 
exposure of the fusion tag. The solubilised cellular fractions were loaded on to the 
column to collect any putative polyHis tagged protein. The washing steps were 
omitted to prevent dilution of the proteins for detection. Instead the Ni-NTA 
associated proteins were eluted from the column with 500 mM imidazole to produce 
a sample 10 times more concentrated for Western blot analysis. Western blotting 
did not detect any putative His-tagged rPmps.
Based on the theory that the protein is targeted to the Sec machinery, full length 
recombinant Pmps were expressed in the presence of a sec inhibitor, sodium azide 
to inhibit the translocation and subsequent cleavage of the full length Pmp. By 
attempting to inhibit the sec machinery using methods described by Oliver et al., 
(1990), expressed recombinant protein could be restricted to the cytoplasm. 
Although this would most likely cause the protein to aggregate into inclusion bodies 
unsuitable for this study, it was hoped that it could confirm protein expression. The 
growth rates of the cultures were monitored during expression trials in the presence 
of azide. Compared to untreated controls the growth rates slowed but were 
maintained steadily showing no lethal effect on the cells (data not shown). 
Subsequently Western blotting and SDS-PAGE did not detect any putative His-tag 
recombinant Pmps as soluble or inclusion bodies from these trials (data not shown).
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Uninduced
oo<
IPTG
0.2
8.03.0 7.00.0 1.0 2.0 4.0 5.0 6.0
Time(hrs)
Figure 3. 5 - Growth curve of induced and uninduced strain Rosetta-gami 2™ (DE3) 
pLysS transformed with plasmid pPmpl23b-FL. Cells were cultured as described in 
section 3.2.3.2 with or without induction using 0.5 mM IPTG at 30 °C. IPTG was added 
when A60o reached 0.7-0.8, as indicated. The A60o was measured every hour.
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3.3 .2  E xp ressio n  and pu rificatio n  tria ls  o f the pu ta tive  p-barrel 
a u to tra n s lo ca to r dom ain  o f Pm p D (rP m p D au to )
Expression trials were performed in order to produce a recombinant 
autotranslocator domain of Pmp D. Tuner™ (DE3) cells transformed with 
pPmpD28b-C were induced with 1.0mM IPTG for 3hrs at 30°C as in section 
3.2.3.2. Harvested cells were lysed and resuspended in 8M urea phosphate buffer, 
separated into soluble and insoluble, as in section 3.2.3.6 to denature the proteins 
and expose the C-terminal His-tag of putative expressed protein. Proteins from the 
media were concentrated using TCA precipitation to check for protein secretion.
Figure 3.6 shows the expression of the putative recombinant Pmp D 
autotranslocator domain (rPmpDauto) at approximately 27kDa observed by 
Coomassie stained SDS-PAGE and confirmed by Western blot probed with the 
penta-His primary antibody (red arrows). The penta-His antibody binds with high 
avidity to rPmpDauto domain. Expression was observed in both the induced and 
uninduced cultures with bands o f sim ilar density on the Coomassie stained SDS- 
PAGE gel. The protein was observed in the insoluble fractions. Insoluble fractions 
consist of unsolubilised cellular membrane proteins and inclusion bodies. 8M urea is 
a strong denaturant but it is not always capable of solubilising all proteins and does 
not always differentiate between inclusion body aggregates and unsolubilised 
membrane bound proteins. Therefore it was necessary to determine if the protein 
detected in the insoluble fraction was situated in the membrane or if it was in the 
form of inclusion bodies. This would require the use of detergents. There was no 
indication that rPmpDauto was secreted from the cell into the media.
Harvested cells from identical expression trials were lysed to isolate the inclusion 
bodies as in section 3.2.3.6. Visualisation on a Coomassie SDS-PAGE gel 
indicated the recombinant PmpDauto had aggregated as inclusion bodies typically 
found in high level expression shown in Figure 3.7. Importantly the high level of 
basal expression did not have detrimental effects on the E.coli growth (data not 
shown) indicating that expression of this particular rPmp was tolerated. Interestingly 
high levels of target protein expression were observed in both the induced and 
uninduced control. The expression of rPmp D autotranslocator domain was under 
the control of the T7/ac promoter, a tight regulatory promoter that should prevent 
basal expression (described in section 3.1.1) but the inhibitory effect of this 
mechanism was not observed here. Furthermore, Tuner™ (DE3) cells permit 
uniform entry of IPTG to allow control over expression levels within the cell,
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however, the expression observed in the uninduced cells was comparable to the 
expression seen in the IPTG induced cells in both Figure 3.6 and Figure 3.7 
suggesting that expression was influenced by other factors.
To test whether cyclic AMP (cAMP) levels were responsible for the high basal 
expression of rPmpDauto trials were repeated in the presence of media 
supplemented with 1% glucose, a method termed catabolite repression. Expression 
was performed at a reduced temperature of 25 °C to also reduce basal expression. 
Samples were fractionated under non-denaturing conditions and analysed by 
Coomassie stained SDS-PAGE. As it was previously noted that uninduced Tuner 
(DE3) also expressed rPmpDauto, this time cells were also transformed with the 
empty vector pET28b to serve as a negative control.
When comparing the differences between induced and uninduced inclusion bodies 
shown in Figure 3.7 with the induced and uninduced inclusion bodies shown in 
Figure 3.8, catabolite repression accompanied with a lower incubation temperature 
of 25 °C reduced basal expression of rPmpDauto prior to IPTG induction. However 
this was insufficient to prevent basal expression completely as rPmpDauto protein 
was still expressed as insoluble inclusion bodies in the uninduced culture Figure 3.8 
Further efforts were necessary to minimise protein aggregation to allow rPmpDauto 
to localise to the membranes.
Subsequently expression trials were performed using heat shock methods to 
enhance chaperones at 42 °C for 1 minute prior to IPTG induction. An alternative 
technique that is thought to elicit the same response is to add 1-2% ethanol to the 
culture prior to induction with IPTG. These methods were utilised in order to 
facilitate protein folding and thus help direct rPmpDauto to the membrane. However 
all rPmpDauto protein was found to be in inclusion bodies concluding that these 
techniques used alone or in combination were not useful in the elim ination of 
insoluble aggregates (data not shown).
To modulate basal expression observed using E.coli Tuner™ (DE3) cells, the pLysS
plasmid was used to ensure expression was regulated by IPTG levels (section
3.1.1) The pLysS encodes for T7 lysozyme that breaks down T7 RNA polymerase
necessary for expression. After an initial growth period at 30°C, expression was
induced at 25 °C and cultures were incubated overnight. The harvested cells were
lysed and fractionated under non-denaturing conditions into soluble proteins,
detergent solubilised membranes and inclusion body fractions. Figure 3.9 shows
the addition of the pLysS plasmid significantly reduced basal expression of the
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uninduced control where inclusion bodies were minimal. In a further attempt to 
regulate expression and improve localisation of rPmpDauto to the membranes, sub- 
culturing phases and the exponential growth phase of the E.coli culture were 
performed at room temperature 25 °C. This had previously been done at 30 °C or 
37 °C before lowering the incubation temperature for the induction period. Cultures 
were then incubated overnight without IPTG to modulate expression. Monomers of 
putative rPmpD autodomain at 27 kDa were detected in the detergent solubilised 
membrane fractions of F igure  3.10. Interestingly, it was noted that the majority of 
rPmpDauto expression was still in the form of inclusion bodies even under these 
tightly regulated expression rates.
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Figure 3. 6 - Coomassie stained SDS-PAGE gel (top) and Western blot (below) of rPmp 
D autotranslocator domain expression in Tuner™ (DE3) cell line. Tuner (DE3) cultures 
were induced with 1 .OmM IPTG (+) or uninduced (-) at 30°C. Molecular weights are shown in 
kDa. The E.coli lysates were separated into soluble and insoluble fractions using 8M urea 
and centrifugation. Proteins were also precipitated from the media. An equal volume of each 
fraction was loaded into each lane. Lanes are: His-tagged positive control Endol monomers 
(17 kDa) and dimers (35 kDa), precipitated media proteins, urea insoluble proteins, urea 
soluble proteins and total cell proteins, followed by a prestained protein marker (NEB 
Biolabs). The expression of rPmpDauto at approximately 27 kDa was detected in both the 
induced and uninduced cultures and is shown by the red arrow in the total cell protein 
fractions and the insoluble fractions.
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Figure 3.7 - Coomassie stained SDS-PAGE gel showing rPmp D autotranslocator 
domain expressed as inclusion bodies in Tuner™ (DE3). Tuner (DE3) cultures were 
induced with 1.0mM IPTG (+) or uninduced (-) at 30 °C. The E.coli lysates were separated 
into soluble and insoluble fractions. The insoluble fractions were suspended in 1% Triton- 
X100 to release membrane bound proteins. The remaining pellet contained the inclusion 
body aggregates. An equal volume of each fraction was loaded into each lane. Lanes are as 
labeled, the protein marker is shown in kDa. rPmpD autodomain was found as inclusion 
bodies at approximately 27kDa, shown by red arrow.
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Figure 3. 8 - Coomassie stained SDS-PAGE gel shows catabolite repression reduces 
basal expression of rPmp D autodomain. Tuner (DE3) cultures were induced with 1 .OmM 
IPTG (+) or uninduced (-) at room temperature with 1% glucose supplementation. The E.coli 
lysates were separated into soluble fractions, detergent solubilised proteins using 1% Triton 
X-100 and inclusion bodies. An equal volume of each fraction was loaded into each lane as 
labelled. E.coli transformed with empty vector pET28b were induced as a negative control. 
The prestained protein marker (NEB biolabs) depicts MW in kDa.
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Figure 3.9 - Western blot (top) and Coomassie SDS-PAGE (below) showing the 
expression of rPmp D autodomain using the pLysS plasmid to inhibit basal 
expression. Tuner™ (DE3) pLysS transformed with pPmpD28b-C were induced (+) or not 
induced (-) with 1.0mM IPTG at room temperature. The E.coli lysates were separated into 
soluble fractions, detergent solubilised proteins using 1% Triton X-100 and inclusion bodies. 
An equal volume of each fraction was loaded into each lane as labelled. The basal 
expression of rPmpD autodomain was reduced by inhibiting T7 RNA polymerase, a 
reduction in rPmpD autodomain inclusion bodies between the induced and uninduced 
cultures is shown by yellow arrow.
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Figure 3.10 - The natural unregulated expression of rPmp D autotranslocator domain 
shows expression to the E.coli membranes for solubilisation using detergent. Tuner™ 
(DE3) pLysS transformed with pPmpD28b-C expressed rPmpD autotranslocator domain 
without IPTG regulation, relying on the natural unregulated expression of the plasmids and 
E.coli. All growth phases were carried out at room temperature. The E.coli lysates were 
separated into soluble fractions, detergent solubilised membrane fractions and inclusion 
bodies. An equal volume of each fraction was loaded into each lane. A faint band was 
detected in the detergent solubilised fraction at approximately 27kDa. This was also 
detected in the inclusion body fractions. Discrepancies between the pre-stained marker 
(NEB biolabs) and the 6xHis ladder (Qiagen) between 25kDa and 30kDa bands are evident. 
rPmpDauto is observed at ~27kDa when compared against the pre-stained marker, but 
appears to be ~32kDa when compared against the 6xHis ladder. This discrepancy was seen 
on all Western blots where both markers were used.
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3.3.2.1 S m all-sca le  pu rificatio n  o f E .coli d erived  rP m p D au to  using Ni- 
N TA  ch ro m ato g rap h y
The detergent so lubilised membrane fractions o f IPTG independent express ion of 
rPmpD autotrans locator domain from Tuner™ (DE3) pLysS were bound to Ni-NTA 
agarose as described in section 3.2.4.1. To optimize the purification, numerous 
wash and elution conditions under using a range of imidazole concentrations of 
between 10 and 500 mM were trialed in the binding and washing steps. This protein 
was only partially purified using Ni-NTA chromatography. Desp ite varying the 
purification parameters it was difficult to obtain a sample w ith at least 95% 
homogene ity suitable for c ircular dichroism. Western blot analysis shows 
recomb inant PmpDauto domain eluted with 500mM imidazole under low stringency 
conditions where imidazole wash concentrations were kept below 50 mM to allow a 
sharp elution of rPmpDauto. However the Coomassie gel (Figure 3.11) shows the 
500 mM imidazole fraction containing rPmpDauto contains severa l contaminant 
proteins. A step-by-step gradient of increasing imidazole at 50 mM, 60 mM, 75 mM, 
100mM and 250mM in the e lution buffers were tested in an attempt to remove the 
contam inant prote ins but resulted in early e lution o f rPmpDauto at 50 mM imidazole 
(data not shown).
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Figure 3.11 - Western blot and Coomassie gel showing the fractions obtained during 
Ni-NTA purification of detergent solubilised rPmpD autotranslocator domain.
(Extracted from a 500 ml E.coli culture). Western blot analysis (top) indicated that 
specifically bound recombinant Pmp D autotranslocator of correct monomer size -27 kDa 
(red arrow) eluted from the column with 500 mM imidazole. Traces of rPmp D 
autotranslocator domain, were also found in the fourth 40mM wash due to a low binding 
affinity. The Coomassie stained SDS gel (below) demonstrated the level of purity where 
many other non-specific proteins were present in the sample, rPmpDauto is depicted by red 
arrow. Downstream purification steps are necessary to remove these contaminants.
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3.3.3  E xp ressio n  tria ls  o f the putative  p-barrel rPm p G a u to tra n s lo ca to r  
dom ain  (rP m p G au to ) using E .coli s tra in  Tuner™  (D E 3) + /- pLysS
Expression trials were performed in order to produce a recomb inant 
autotranslocator domain o f Pmp G. Tuner™ (DE3) pLysS cells transformed with 
pPmpG22b-C were induced with 1.0mM IPTG overn ight at 30°C as in section  
3.2.3.2, Harvested cells were freeze/thawed and lysed in buffer and fractionated into 
soluble, detergent so lubilised and inclusion bodies and exam ined on Western blot. 
Expression o f the putative recomb inant Pmp G autotranslocator domain 
(rPmpGauto) at approximate ly 40kDa was detected by Western blot (Figure 3.12) 
using the penta-H is primary antibody. Unlike the homologue in Pmp D, the 
recomb inant Pmp G autotranslocator domain was designed as a fus ion protein with 
the pelB leader sequence on the N-term inus to direct the recomb inant protein 
across the inner membrane of E.coli, where it may be incorporated into the lipid 
bilayer. This was not observed; instead insoluble aggregates of rPmpGauto 
appeared to be present in two bands, indicated by the red arrows at approximate ly 
40 kDa, in the inclusion body fraction. The sma ller band was thought to be a 
truncated fragment of rPmpGauto, possibly as a resu lt o f cleavage of the pelB 
leader peptide. The same resu lts were observed using Tuner™ (DE3) cells without 
the pLysS plasmid (data not shown).
3 .3 .4  E xpression  screen in g  o f N -term ina l rP m p A  p a ssen g er d o m ain s  
using E .coli s tra in  Tuner™  (D E 3) +/- pLysS
Expression trials were performed in order to produce a recomb inant passenger 
domain o f Pmp A (rPmpA-N). The express ion of this domain was not observed in 
E.coli Tuner™ (DE3) pLysS (data not shown), further express ion trials of rPmpA-N 
was carried out using E.coli Tuner™ (DE3) cells lacking the pLysS p lasmid to 
minimise regulation within the cells with no express ion detected. The growth o f the 
cu ltures was monitored and did not show the recomb inant express ion plasmid to 
have any de leterious effects on the cells however extensive screening trials were 
om itted using E.coli as an alternative express ion system was being exp lored that 
could express rPmpA-N (see Chapter 4).
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Figure 3.12 - Western blot showing the expression of rPmp G autotranslocator 
domain in Tuner™ (DE3) pLysS. E.coli transformed with pPmpG22b-C were induced with 
1.0mM IPTG at 30 °C. The E.coli lysates were separated into soluble fractions, detergent 
solubilised proteins using 1% w/v DDM and inclusion bodies. An equal volume of each 
fraction was loaded into each lane as labelled. Putative rPmpGauto was detected at -40 
kDa, with an additional smaller band thought to be an fragment of rPmpGauto, depicted by 
red arrows.
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3.3 .5  E xpression  screen in g  o f N -term inal rPm p I dom ain  using E .coli 
stra in  Tuner™  (D E 3) pLysS
Expression trials were performed in order to produce a recomb inant passenger 
domain of Pmp I. Tuner™ (DE3) pLysS cells transformed with pPmpl23b-N were 
induced with 0.5 mM IPTG overn ight at 30°C (section 3.2.3.2). Harvested cells 
were freeze/thawed in lysis buffer and fractionated into soluble, detergent 
so lubilised and inclusion bodies that were exam ined by Western blot. Detection 
using the penta-H is primary antibody indicated the express ion o f the putative 
recomb inant Pmp I passenger domain (rPmpl-N) at approximate ly 44kDa observed 
by Western blot (Figure 3.13). The protein was observed as inclusion bodies w ith 
some traces present in the so luble cytop lasmic fraction, the detergent so lubilised 
membrane fraction and in the cu lture media. The rPrnpl passenger domain has a 
native am ino-term inal signal peptide sequence for inner membrane sec processing. 
It was expected that this native signal leader peptide would help direct recomb inant 
protein to the E.coli membrane to be processed via sec machinery for trans location 
and possible secretion out o f the cell as described in section 1.4.6. The predicted 
size of the passenger domain o f Pmp I is approximate ly 46 kDa, recomb inant Pmp I 
passenger domain was detected in some fractions as two bands at approximate ly 
46 kDa and 40 kDa (Figure 3.13) which may have demonstrated proteo lytic 
cleavage of the native signal peptide that is predicted to be approx imate ly 6 kDa. In 
addition a third band o f approx imate ly 25 kDa was detected in the detergent 
so lubilised membrane fraction, indicated by ye llow arrow given in Figure 3.13. This 
20 kDa band was not apparent in the soluble, inclusion body or TCA precipitated 
media fractions, and so appeared to be associated with the membranes.
3.3.5.1 S od ium  azide e ffec ts  on the exp ress io n  o f the N -term in a l rPrnpl 
dom ain  w ith  and w ith o u t native  s ig nal peptide
To assess the processing o f the passenger domain o f rPrnpl (rPmpl-N) further, 
expression cultures were treated with varying concentrations o f sodium azide to 
inhibit sec processing (section 3.2.3.3). Inhibition o f the sec machinery can prevent 
the trans location and subsequent c leavage of signal peptides from pro-prote ins 
such as autotransporters which are predicted to be processed via the sec pathway. 
As a control, an expression construct lacking the signal peptide sequence was 
produced for rPmp l-N by digesting the recomb inant express ion plasmid pPmpl23b- 
FL with BamHI and Notl (section 2.2.6), Digesting at these sites removes the s ignal 
sequence and the new ly digested DNA sequence was subcloned into a new ly
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digested pET23b vector (BamHI and Notl) (section 2.2.9). In the absence of the 
signal leader peptide sequence, the recomb inant passenger domain was classed as 
a non-secretory protein using the b ioinformatic prediction programs SignalP 3.0 and 
SignalP-HMM (Expasy Tools). The sequence w ith intact signal peptide rPmp l-N is 
predicted to be a secretory protein. It was expected that the passenger domain 
lacking the signal leader peptide would be restricted to the cytop lasm and therefore 
azide would have no effect on the accumu lation o f the protein.
The inclusion bodies of expressed recomb inant Pmp I passenger domains with and 
without signal peptides were isolated for ana lysis by Western blot. In the presence 
of azide, an increase in the formation o f inclusion bodies was observed for the 
express ion o f the Pmp I passenger domain with its native signal peptide (Figure 
3.14a). Furthermore, this was in a concentration dependent manner. When the 
recomb inant passenger domain was expressed without a signal peptide the domain 
accumulated as inclusion bodies w ithout azide treatment as expected (Figure 
3.14b). The growth rates of the cu ltures were mon itored and showed that the high 
inclusion body production was not due to a higher cell density. In fact, azide slowed 
the growth rates in a concentration dependent manner, but did not appear to be 
directly lethal to the cells as growth was maintained and stable throughout all the 
cu ltures (data not shown). Trials were also performed with 2mM azide treatment but 
the growth rates and the isolated inclusion bodies were a lmost identical to the 
cu ltures treated with 1mM.
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Figure 3.13 - Western blot showing the expression of rPmp I passenger domain in 
Tuner™ (DE3) pLysS. E.coli transformed with pPmpl23b-N were induced with 0.5mM IPTG 
at 30 °C. The E.coli lysates were separated into soluble fractions, detergent solubilised 
proteins using 1% w/v DDM and inclusion bodies and TCA precipitated proteins from the 
media. An equal volume of each fraction was loaded into each lane as labelled. Putative 
rPmpl-N was detected at -44 kDa, with an additional smaller band thought to be a fragment 
of rPmpl-N, depicted by red arrows. A third band -20 kDa was detected within the detergent 
solubilised membrane fraction, depicted by yellow arrow.
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Figure 3.14 - Western blots showing sodium azide effects on the expression of rPmp I 
passenger domain with and without native signal peptide sequence, in Tuner™ (DE3) 
pLysS. The inclusion body fractions were isolated as in section 3.2.3.5. An equal volume of 
each fraction was loaded into each lane, (a) E.coli transformed with pPmpl23b-N was 
induced with 0.5mM IPTG at 30 °C and treated with sodium azide at varying concentrations 
(0.2 mM, 1.0 mM (2.0 mM not shown)), (b) E.coli transformed with pPmpl23b-N-signal 
(without signal peptide) were induced with 0.5mM IPTG at 30 °C and treated with sodium 
azide ((0.2 mM, 1.0 mM (2.0 mM not shown).
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3.3 .6  W es te rn  b lot op tim isatio n
During expression trials several commercial anti-His Abs were trialled to find a 
sensitive but spec ific antibody for use in Western blot to detect expressed 
recomb inant His-tagged protein. Initially a mouse monoclonal anti-polyHistidine 
antibody used at a 1:3000 dilution (Sigma) was used both in conjunction with a 
rabbit anti-mouse IgG-HRP (S igma) for chem iluminescence detection and a goat 
IRDye 800CW anti-mouse secondary antibody (Licor) for infrared fluorescence 
using an Odyssey Imaging System. These were tested with a positive contro l (Endol 
with an 8 residue po ly-Histidine tag, obta ined from Dr J.Hadden, Un iversity of 
Leeds) alongside the expression trial samples. The signal via these methods was 
very weak in comparison to protein load (data not shown) and therefore was 
deemed an unreliable method to detect putative expressed rPmps. At this point in 
the study it was unclear whether the absence of expressed full length rPmps in 
section 3.3.1 was due to an insensitive detection technique w ith the monoclonal 
anti-polyHistidine antibody (Sigma) or due to a lack o f expression. An authentic 
positive control (hexahistidine tagged recomb inant Pmp) was not available at that 
point. Further trials used mouse monoclonal tetra-H is and penta-H is antibodies 
(Q iagen) w ith a commercial 6xHis protein ladder (Q iagen) as a positive control. 
Subsequently, after the successfu l express ion o f a detectab le po lyHis-tagged 
truncated Pmp (rPmpDauto section 3.3.2) the penta-H is antibody was chosen for 
its high avidity and spec ificity to both the 6xH is ladder control and rPmpDauto. All 
rPmp expression trials from section 3.3.1 were re-exam ined using this optimised 
technique w ith the penta-H is antibody as described in section 3.2.5.2 and full 
length rPmps were not present.
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3.4  D iscussion
3.4.1 H etero lo g o u s  exp ress io n  o f fu ll length reco m b in an t Pm ps
The first aim o f this chapter was to express the fu ll-length rPmps in E.coli o f which 
several commerc ially adapted strains are available to optimise express ion yields. 
Being a Gram-negative bacterium and displaying native autotransport prote ins it 
was hoped that E.coli would be a su itable vehicle to express these proteins, 
possibly to the membrane for detergent so lubilisation and purification for 
downstream assays a lthough inclusion bodies were also anticipated. The trials 
carried out in an attempt to express full length rPmps are displayed in Table 3.1.
Recombinant protein 
(Expression plasmid)
E. coli strain Expression yields
rPmpA Tuner™ (DE3) Not detected
(pPmpA23b-FL) Rosetta-gam i 2™ (DE3) pLsyS Not detected
OverExpress C41™ (DE3) Not detected
OverExpress C43 ™(DE3) Not detected
rPmpD Tuner™ (DE3) Not detected
(pPmpD28b-FL) OverExpress C41™ (DE3) Not detected
OverExpress C43 ™(DE3) Not detected
rPrnpl Tuner™ (DE3) Not detected
(pPmpl23b-FL) Rosetta-gam i 2™ (DE3) pLsyS Not detected
OverExpress C41™ (DE3) Not detected
OverExpress C43 ™(DE3) Not detected
Table 3.1 - Summary of E. coli strains used in full length rPmp expression trials. Each 
construct was expressed at 37 C, 30 C and 25 C for short incubation periods (<3hrs) and 
prolonged incubation periods (<16hrs). His-tagged proteins were not detected.
Tuner™ (DE3) was the initial strain chosen to begin expression trials as this strain 
allows a high level o f transcriptional control (Novagen). To this end, variable 
concentrations of IPTG can be emp loyed to allow control over express ion rates; an 
important consideration for expressing membrane prote ins due to the ir low 
solubility. However expression o f rPmpA, rPmpD or rPrnpl was not observed using 
this strain o f E.coli under many variable conditions including expression at different 
temperatures, w ith variable amounts of IPTG and extended express ion periods.
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Interestingly the growth rates of the cu ltures undergoing express ion trials were 
indicative of a culture diverting its resources in an effort to transcribe the rPmps yet 
polyHistidine rPmps were not detected.
Although Pmps are from a Gram negative prokaryotic organism, they differ in that 
they would naturally reside encapsu lated within the eukaryotic host and within a 
Gram-negative membrane that lacks peptidoglycan so the Tuner™ (DE3) strain 
may lack the necessary resources, env ironment and machinery to construct large 
hetero logous membrane prote ins such as Pmps. It is possible that the Pmps may 
have evolved to carry eukaryotic codon sequences like other intrace llular bacteria 
that have evolved to carry eukaryotic-like coding sequences from lateral gene 
transfer such as Legionella pneumophila  (Lurie-W e inberger et al., 2010). When the 
mRNA of hetero logous target genes are expressed in E.coli, differences in codon 
usage can impede translation due to the demand for one or more tRNAs that may 
be lacking leading to translational stalling, early translation term ination, translational 
frame-shifting and amino acid mis-incorporation (Kane 1995). In view of this, codon 
analysis was performed on the full length pmp sequences and revealed severa l rare 
codons not commonly used by E. coli. One strain o f E.coli that could potentially 
overcome this difficulty was the Rosetta™ strain. This strain and its derivatives 
contain a chloramphen icol-res istant plasmid that supplies the rare tRNAs thus has 
the ability to express proteins containing rare codons. In addition the Rosetta-gam i 
2™ (pLysS) strain is adapted to allow disulfide bond formation within the cytop lasm. 
Many prote ins require the formation o f stab le disulfide bonds to ensure proper 
folding and thus activity (Prinz et al., 1997) and this can be limited in E.coli due to 
the re latively high reducing potential in the cytop lasmic compartment. Cons idering 
the Pmps are re latively rich in cysteine residues, efforts to a llow disulfide bond 
formation within the cytop lasm in an attempt to aid folding or allow rPmps to be 
chaperoned to prevent m is-folding was another reason to exam ine express ion in 
this strain. To date, the folding o f Pmps has not been explored and so it rema ins 
unclear where and what mechanisms are involved, however rPmp were not 
detected using this strain under all of the variable conditions trialled.
A further consideration for the lack o f express ion was plasmid instability through 
segregational loss o f the plasmid to daughter cells. Importantly it is known that 
several autotransporters act as toxins and although it rema ins uncerta in if Pmps 
function as toxins, it is possible that the rPmps or the rpmp  genes could have been 
tox ic to the E.coli, possibly at expression levels too low to detect by conventional
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means. Interestingly the growth curves were not suggestive of rPmps having a toxic 
effect on the Tuner™ (DE3) cells as growth was maintained upon IPTG induction, 
however there were differences in the growth rates when express ing rPmpl-FL in 
the Rosetta-gam i 2™ strain where the growth began to plateau upon the addition of 
IPTG induction. If expression was de leterious to the cell it is possible that the 
plasmid may have been lost by the Tuner™ (DE3) so the gene and its products 
could not be expressed. The presence of the pLysS plasmid within the Rosetta- 
gam i 2™ cell line works to prevent basal expression o f the target protein by 
inhibiting T7 RNA polymerase, therefore putative toxic effects should only be 
demonstrated upon IPTG induction as was observed. Although this was purely 
specu lative, choosing a strain shown to confer resistance to tox ic express ion was 
an appropriate choice to overcome such difficulties. Futhermore express ion trials 
with the plasmid pPmpl23b-FL, using an E.coli derived ce ll-free protein expression 
system that utilises nano lipoprote ins to mimic the lipid bilyer (section 4.1.1), 
produced a -8 0  kDa His-tagged protein; a size expectant of rPmp l-FL indicating 
that transcription and translation o f the gene was viable (chapter 4).
OverExpress™ C43 (DE3) and Overexpress C41 ™ (DE3) were deve loped to allow 
high level expression o f a w ide variety of tox ic prote ins prev iously difficult or 
impossible to express in bacteria. Both strains are reported to be very effective in 
express ing complex membrane prote ins from all classes of organ isms including 
viruses, bacteria, yeasts, plants, insects and mammals (Masi et al., 2003, Drory et 
al., 2004, Pos et al., 2004, Thai et al., 2009). In particular, the OverExpress™ C43 
(DE3) have been deve loped to allow high level expression o f a w ide variety of toxic 
prote ins previously difficult or impossible to express in bacteria (Miroux and W alker 
1996).The strain derived from BL21 (DE3) conta ins genetic mutations 
phenotyp ically se lected for conferring toxicity tolerance a lthough the mutation 
responsible is uncharacterised. Dumon-Se ignovert et al., (2004) showed that C43 
(DE3) presented only 4 per cent express ion-induced toxicity compared to 96 per 
cent observed in BL21 (DE3) cells so became a favourab le choice for screen ing 
trials. Yet after numerous expression trials with variable conditions, rPmps were not 
detected using this strain.
Other possible exp lanations for the lack of express ion o f full length rPmps could be 
due to the size of the expression plasmids. The recomb inant plasmids transformed 
into E.coli for expression were re latively large constructs, each over 10kb in size. 
There are corre lations between plasmid size and instability; the larger the p lasmid
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the higher the propensity for intramolecu lar recomb ination or genome integration 
(Olive ira et al., 2009). In addition such plasmids also have an increased metabo lic 
burden on the cell.
In summary, full length recomb inant Pmps were not detected when expressed in a 
variety of E.coli expression hosts. Early indications implied that induced express ion 
o f certain rPmps may have had a lethal effect on certain E.coli hosts however there 
is no published data to support this and perform ing trials in a strain that confers high 
tolerance to tox ic prote ins did not substantiate this, nor did it improve detectab le 
expression. A major drawback throughout these early trials was the re liability o f the 
detection technique. Until a suitable sensitive and specific primary antibody was 
determ ined, re-exam ination o f the expression samples obta ined from the full length 
Pmp expression trials with an optimised detection technique revealed no 
discrepanc ies from the original findings. Using the assumption that Pmps were 
expressed in poor yields below detectab le levels, methods to concentrate the 
protein using IMAC were explored and putative rPmp-FL remained undected. A 
further consideration was that Pmps, may have undergone proteo lytic cleavage 
during expression into the ir functional autotransporter domains before, during and/or 
after inner membrane translocation. If this had occurred it may have hindered 
detection o f the protein since the C-term inus o f the rPmps boast a hexahistine tag, 
both necessary for N i-NTA chromatography and penta-H is probing. Method to inhib 
processing using sodium azide did not resu lt in the accumu lation o f rPmps. F inally it 
was concluded that the over-express ion of such large comp lex membrane prote ins 
was beyond the scope of E.coli’s capab ilities and an alternative approach to 
produce rPmps was necessary.
3.4 .2  H etero logous exp ressio n  o f tru n cated  P m ps
As full length rPmp expression was unsuccessfu l in E.coli, focus on express ing the 
sma ller functional domains o f these prote ins was considered. As autotransporters 
are large proteins made up of three distinct domains described in section 1.4.6 
(Henderson et al., 1998) other autotransporter prote ins have been studied this way 
with success. In particular the IgAP protease from Neisseria gonorrhoeae, an 
organ ism that also infects the genital ep ithe lial cells has had its autotranslocator 
domain structure determ ined by expressing the C-term inal functional region (Ve iga 
et al., 2002) where the 25-30kDa C-term inal region builds the trans location unit 
needed to export the passenger domain. In addition the N-term inal passenger 
domain o f the Hia autotransporter from Haemophilus influenza has been expressed
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for use in adherence assays (Laarmann et al., 2002). Expression screen ing trials to 
produce such regions o f C.trachomatis Pmps in this study have led to the 
successfu l express ion o f several truncated rPmp functional domains in E.coli (Table 
3.2).
Recombinant protein 
(Expression plasmid)
E. coli strain Expression yields
rPmpA-N Tuner™ (DE3) Not detected
(pPmpA23b-N) Tuner™ (DE3) pLysS Not detected
rPmpDauto Tuner™ (DE3) Inclusion bodies
(pPmpD28b-C) Tuner™ (DE3) pLysS Mainly inclusion bodies w ith 
some targeted to 
membranes after 
optim isation to reduce 
expression rates 
s ignificantly (section 3.3.2)
rPmpGauto Tuner™ (DE3) Inclusion bodies
(pPmpG22b-C) Tuner™ (DE3) pLysS Inclusion bodies
rPmpl-N
(pPmp l23b-N)
Tuner™ (DE3) pLysS Inclusion bodies and 
putative so luble cleaved 
products
Table 3.2 - Summary of outcome for the expression trials of recombinant truncated 
Pmps. The autotranslocator domain of rPmpDauto was the first to be expressed and be 
positively identified. Extensive efforts were made to optimise the expression to target protein 
to the membranes. Due to the difficulties, the other rPmp domains were not followed up with 
optimisation trials.
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However express ion o f truncated rPmps was mostly in the form of inclusion bodies, 
a common problem when expressing membrane proteins. Inclusion bodies are 
dense particles of m is-folded prote ins (Lilie et al., 1998) formed intracellularly, 
although the mechanisms behind the aggregation are not fully understood, it is 
believed they form as part of a stress response when recomb inant prote in is 
expressed at a high rate. Because inclusion bodies are often res istant to proteo lysis 
and contain a high percentage of over-expressed protein they can sometimes be 
exploited for purification and are often used in favour of prote ins that are unstable, 
tox ic or easy to refold (Baneyx and Mujacic, 2004). Still, in order to achieve this they 
must first be so lubilised in strong denaturants to disrupt aggregation. In order to 
study the structure and function o f the protein it is then necessary to refold by 
renaturing the prote ins via a titration method (Vallejo and Rinas, 2004). 8M urea has 
already been shown incapable of denaturing rPmpDauto inclusion bodies in this 
study, therefore a stronger a lternative would be needed such as 6M guanidine 
hydrochloride (GuHCI). However, refolding can lead to conformational changes 
different from the native structure particularly where disulfide bonds are present 
therefore denaturation and refolding is not a re liable method for production of 
functionally active protein. Optimisation o f such a method also requ ires a contro l 
assay to demonstrate function which is not possible in this study. Therefore a more 
su itable approach to produce a homogenous, native ly folded, active prote in suitable 
for structura l and functional analysis was to prevent target protein aggregation to 
such a level that allows target protein to localise to the membranes. D isruption o f 
the membranes w ith detergents would allow for so lubilisation of the rPmp domain, in 
a correctly folded and active state, into detergent m ice lles for purification. The 
optim isation trials in this study were time consum ing and focused on rPmpDauto.
Early trials to express the rPmp D autotrans locator domain in this study were under
the control o f the T7/ac promoter only, a tight regu latory promoter that should have
prevented basal expression (section 3.1.1) however the inhibitory effect of this
mechanism was not observed during the express ion and the propens ity to form
inclusion bodies was extreme ly high. Furthermore, Tuner™ (DE3) ce lls perm it
uniform entry of IPTG into the cell to allow control over expression levels however,
the expression observed in the uninduced cells was comparable to the express ion
seen in the IPTG induced cells and indicated express ion was affected by other
factors. cAMP can directly affect the level o f transcription (Grossman et al., 1998).
cAMP forms comp lexes w ith the cAMP receptor protein (CRP) and this cAMP/CRP
complex binds upstream of the lacUV5 promoter, directly stimulating transcription of
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T7 RNA polymerase. Such levels are strong ly influenced by the carbon source 
available to the cells and one approach to counteract this and increase protein 
solubility is to perform express ion trials in media supplemented with glucose. When 
g lucose is absent, the cell is forced to use an a lternative carbon source, such as 
glycerol that causes cAMP levels to rise. The addition o f g lucose acts as an 
a lternative carbon source, keep ing cAMP levels low within the cell which in turn 
inhibits the production o f T7 RNA po lymerase and expression of the target gene 
until IPTG is added, a term referred to as catabolite repression (Zhang et al., 2003). 
Subsequently the addition o f g lucose w ithin cultures reduced the basal expression 
thus reducing the amount of inclusion bodies, but did not avert them.
Often mo lecu lar chaperones are necessary to assist with the fo lding, espec ially of 
large mu ltidomain and over-expressed prote ins (Baneyx and Mujacic, 2004). In 
E.coli, where transcription and translation are tightly coupled, one po lypeptide chain 
is released from the ribosome every 35 seconds (Lorimer, 1996), which can lead to 
the saturation of the ce llular chaperones and the trans location machineries. 
Consequently fa ilure to interact w ith folding modulators has two possible 
consequences, e ither degradation or deposition into inclusion bodies (M idde lberg, 
2002). Chen et al., (2002) described a simple method for enhancing soluble protein 
yie lds using heat shock prior to inducing protein expression. By exposing the cu lture 
to a temperature of 42 °C for 1 m inute prior to induction increased the so lubility of 
the target protein significantly with no de leterious effects upon yield. Although the 
mechanism o f increased solubility is not fu lly understood, the likelihood is heat- 
shock proteins aid correct folding. Previous studies have shown that co-express ion 
of heat-shock prote ins with target prote ins can enhance proper protein fo lding, since 
heat-shock proteins, such as GroEL, GroES and DnaK, function as molecu lar 
chaperones to prevent m isfo lding (Gragerov et al., 1992; Goenka and Rao, 2001). 
In view of this expression trials for rPmpDauto were performed using heat shock 
methods to enhance folding modulators. However rPmpDauto remained in the form 
of inclusion bodies.
Efforts to decrease inclusion body formation in conjunction with increas ing 
expression at the membrane can be extreme ly cumbersome if little is known about 
how the membrane protein is targeted or the mechanisms involved in fo lding. Yet it 
is largely accepted that lowering expression temperatures decreases aggregation 
and this was fundamenta l to the expression o f truncated rPmp domains in these 
trials. Previous studies have explored this, Ami et al., (2005) investigated the fo lding
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k inetics o f Pseudomonas fragi lipase, a co ld-adapted enzyme susceptible to 
aggregation when expressed even at moderate temperatures and found that 
express ion into inclusion bodies was decreased with a lower expression 
temperature and subsequent so luble protein levels were increased compared to 
express ion at 37 °C. Further support in the form of a kinetic model proposed by 
(Kiefhaber et al., 1991) showed that the yield o f native protein depends only on the 
rate of folding, the rate of aggregation and the rate of synthesis. Therefore the yield 
o f native protein increases, and inclusion body formation decreases, w ith a lowered 
rate of protein expression. This corre lates w ith other studies that have explored 
expression under reduced growth conditions including decreased growth 
temperature, using spec ific culture media and limiting the induction to produce 
increased yields of native, so luble protein (Schein and Noteborn, 1988; Kopetzki et 
al., 1989). Although these studies were largely based on soluble proteins, 
implementing these adaptable parameters were considered to target the rPmpDauto 
domain to the membranes of the host, possibly by limiting the inclusion body 
formation.
Consequently the pLysS p lasmid was employed, the pLysS encodes for T7
lysozyme that breaks down T7 RNA polymerase necessary for expression.
Lowering expression temperatures w ith the addition o f the pLysS plasmid
significantly reduced basal express ion and prevented early formation o f inclusion
bodies however upon induction the inclusion bodies were formed. Unsurprising
when under control of the strong pET promoters, induction o f recomb inant protein
can exceed 50% o f the total ce llular protein leading to the titration o f other
endogenous proteins (Lorimer, 1996). Because IPTG induction prev iously resu lted
in a high level o f unfavourab le inclusion body formation IPTG independent
expression was trialled with success. The expression o f membrane-localised
rPmpDauto appeared to be fac ilitated by slow (overn ight), IPTG independent
expression under the tight control o f the pLysS p lasmid at low incubation
temperatures (25 °C) a term that could be referred to as ‘restra ined express ion’. In
theory, one would expect to observe an absence of recomb inant rPmpDauto with
these restrictions in place but these conditions appeared to provide an optimal
env ironment for incorporation o f the recomb inant membrane protein into the
membrane probab ly due to the fo lding rate kinetics o f the protein, avoiding both
chaperone and membrane saturation. This would support Kiefhaber’s et al., (1991)
kinetic model where the native protein yield depends upon the rate of fo lding, the
rate of aggregation and the rate of synthesis. It is likely that rPmpDauto domain
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produced in these conditions is in a native thus active conformation suitable for 
purification and downstream b iophysical studies, although the yield o f native protein 
was very low. Further support from a recent study that showed the om ission o f IPTG 
induction led to higher yie lds o f tox ic membrane prote ins (Narayanan et al., 2011). 
The absence of the inducer IPTG, led to improved express ion levels of 
cation/Ca2+ exchangers as the express ion levels did not have a de leterious effect on 
the cells. The low level express ion occurs due to the regu latory mechanism 
whereby the equ ilibrium between free and bound states of the lac operator and lac 
repressor control the expression.
Even when express ion o f rPmpDauto was directed to the membrane, challenges 
remained. Membrane prote ins embedded within a complex and dynamic lipid bilyer, 
have to be isolated as the use of many biophysical techniques is limited (Seddon et 
al., 2004). Therefore fo llowing successfu l membrane protein expression, a suitable 
detergent had to be found that simultaneous ly extracts the protein from the 
membrane while retaining the native fold and function. Detergents can provide the 
protein with a favourab le env ironment as the hydrophobic portions o f the detergent 
mo lecules adsorb onto the apo lar surface of the protein, form ing a prote in-detergent 
comp lex that is soluble in aqueous so lvents (Gordon et al., 2008). However this 
prote in-detergent comp lex is often heterogeneous itse lf creating numerous 
problems w ith purification and downstream functional assays (Savage et al., 2009). 
Furthermore poor stab ility fac ilitating solubilisation is common and complicated the 
handling and purification o f rPmpDauto. Subsequently the purification o f rPmpDauto 
by nickel chelate affinity chromatography faced new challenges. It was difficult due 
to the low binding affinity to the N i-NTA column, the poor yield from express ion, the 
heterogene ity of the samp le and the tendency to precipitate during handling in 
detergents. A lternative strateg ies to fac ilitate purification by batch binding and 
altering the buffer conditions did not improve the outcome. It is possible that 
rPmpDauto may not have had the po lyHistidine tag exposed for binding but 
denaturing the protein to unfold the H is-tag fu lly was not feas ible as a b iologically 
active protein sample was necessary for downstream ana lysis methods. 
Consequently the partial purification that was achieved was unsuitable for c ircular 
dichroism so secondary structural analysis could not be carried out.
Several further downstream purification methods could have been carried out to 
improve the purity, such as ion exchange chromatography, however, as rPmpDauto 
was only present in a low concentrations beyond the reliable limits o f detection, this
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was deemed unfeasible due to the substantial losses that would be associated with 
further purification methods. A further problem was that the purified rPmpDauto 
would precipitate out of so lution during storage and samples did not recover well 
from storage at 4 °C, -20 °C or -80 °C, meaning that each purification trial had to be 
carried out from freshly expressed and processed samples, a long process when 
express ion was carried out slowly. Additional purification steps would prolong the 
handling time and require buffer-exchange, which would likely exacerbate 
precipitation and the loss o f so luble protein. This problem in combination with poor 
starting yie lds that were a lready difficult to detect, made further handling of the 
protein very prob lematic and further purification could not be considered. However 
trials continued exploring the express ion o f other truncated Pmp domains in this 
way. The expression, targeting, recovery and purification o f rPmpDauto was a very 
time consum ing process and is an examp le of the high attrition rates associated 
with producing recomb inant membrane proteins.
The autotrans locator domain from Pmp G was expressed as a fusion with a pelB 
leader peptide signal sequence to aid localisation to the inner membrane of E.coli, 
an approach also used to express the autotrans locator domain of IgAP by Veiga et 
al., (2002). Although express ion was successfu l with two His-tagged fragments 
detected, indicating possible proteo lytic cleavage of the signal peptide, this was also 
in the form of inclusion bodies. Due to prob lems encountered in trying to produce a 
purified rPmpDauto domain, it was deemed an uneconom ical use of time to pursue 
the expression o f rPmpGauto in the same way.
In addition to expressing the C-term inal autotranslocator domains o f the Pmps, 
expression o f the functional N-term inal passenger domains was also exp lored, in 
particular those of Pmp A and Pmp I. The N-term inal region contains the signal 
peptide leader sequence that targets the protein to the Sec apparatus in the inner 
membrane (Desvaux et al., 2004a). This peptide is cleaved by components of the 
Sec machinery to release the pro-prote in into the periplasm. Adjacent to the 'signal' 
domain is the functional 'passenger' domain. This region offers the most sequence 
divers ity among the proteins as this performs the extrace llular function. This 
passenger domain may remain intact but exposed from the cell surface or may be 
cleaved into the extrace llular milieu to carry out its function.
Interestingly the expression o f the recomb inant passenger domain o f Pmp I in E.coli 
was detected in the so luble and insoluble fractions including the cytop lasm, the 
media and solubilised from the membranes. Passenger domains of autotransporters
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are often presented externa lly o f the cell surface as well as within the membrane so 
it was anticipated that these domains may be less hydrophobic in nature compared 
to the ir C-term inal membrane-bound counterparts. Purification trials were not 
attempted with the passenger domains as a novel ce ll-free express ion system was 
being explored (chapter 4) w ith a more efficient handling time to express and purify 
these domains.
However, as the express ion o f the Pmp l-N passenger domain showed possible 
proteo lytic cleavage cons istent w ith cleaved autotransporters, these putative 
proteo lytic cleavage events were investigated further in an attempt to exam ine the 
processing of the domain where three H is-tagged bands had been cons istently 
detected upon the expression o f rPmp l-N. These bands may imply sec processing 
of the signal peptide and further c leavage w ithin the functional region o f the 
passenger domain of Pmp I was occurring. Autotransporter prote ins can undergo 
proteo lytic cleavage w ithin the passenger domain upon localisation to the 
membrane or external milieu (Henderson et al., 2004). A lthough the mechanisms 
behind this cleavage event are not fu lly understood, interactions with components of 
the outer membrane b ilayer or the extrace llular milieu are thought to trigger this and 
so the sma llest band detected in the membrane fraction was suggestive of further 
processing of the rPmp I passenger domain.
Inhibition o f the Sec machinery can prevent this translocation and subsequent 
cleavage of signal peptides from autotransporters and other pro-prote ins. 
Consequently, unprocessed pro-prote ins that are restricted from Sec processing 
accumulate in the cytop lasm as inclusion bodies. Studies to inhibit the Sec 
apparatus w ith sodium azide, a known inhibitor o f SecA (O liver et al., 1990) resulted 
in an increase of inclusion body formation o f the Pmp I passenger domain within the 
cell. In a similar study Gathmann et al., (2006) found that express ion of 
p lastocyanine (a so luble pre-apo-prote in with an N-term inal signal sequence 
targeted to the thykaloid lumen and periplasm o f Cyanobacterium), also formed 
highly enriched inclusion bodies when expressed in the presence of azide. 
Expressing the same domain without a native signal peptide also serves to inhibit 
targeting to the Sec machinery and also led to the aggregation o f this domain as 
inclusion bodies.
Azide has the same effect as removal of the leader/signal sequence and so these 
data would indicate that the sec trans locon is necessary for the processing o f 
rPrnpl, under direction o f the signal peptide. However to demonstrate this
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conc lusive ly would need considerab le further study beyond the scope of this project. 
One particular consideration is that azide is not specific only to secA but also affects 
many other proteins and pathways within the cell. To rule out other azide disrupted 
ce llular processes as the cause for increased inclusion body formation, rPmpl-N 
would have to be expressed in an azide res istant (DE3) lysogen. Consequently this 
could help e lucidate the theory that Pmps are in fact autotransporters as 
b ioinformatic studies predict. The passenger domain o f Pmp A, which differs by not 
possessing a native signal peptide compared to other Pmps w ithin the fam ily, was 
not expressed in E.coli.
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3.5 S u m m ary
E. coli were not able to express the large mu ltidomain full length Pmps or at least 
not at levels that could be detected. W here successfu l expression was observed, for 
three truncated rPmp domains, the express ion was very ‘leaky’ and conditions 
implemented to modulate this, in particular to minimise basal express ion and 
prevent inclusion body formation were met w ith some success. The host cells were 
successfu l in that the formation o f inclusion bodies could be reduced to allow some 
protein targeting to the membranes however the downstream purification that 
followed was difficult due the heterogene ity o f the express ion sample and the poor 
yield o f recomb inant protein solubilised from the membranes which became 
increas ingly difficult to detect fo llowing each downstream app lication. This was 
further hampered by the necess ity to express fresh recomb inant prote ins for each 
individual optimisation step as the protein became insoluble in detergents.
However this was a positive outcome as it rema ins impossible to predict whether a 
recomb inant membrane protein can be expressed in useful quantities, if express ion 
is possible it is not known if it will be targeted to the membrane or as m isfo lded 
aggregates in inclusion bodies. It rema ins unsurprising that over-express ion of 
membrane prote ins is challeng ing. Unlike so luble cytop lasmic proteins, membrane 
prote ins do not meet favourab le conditions upon displacement from the ribosome 
unless the protein is targeted and inserted within a lipid env ironment where 
secretory machinery and/or chaperones are necessary in order to achieve this 
correct folding and targeting. Determ ining the most su itable conditions for 
expression of membrane prote ins can be a laborious task. Currently there is no 
ideal over-express ion system that exists for the production o f such prote ins and so 
the parameters for each target protein have to be met individually as the express ion 
o f a lmost identical proteins can vary significantly. Therefore, hetero logous over­
expression o f membrane prote ins in E. coli is largely accepted as a matter of ‘trial 
and error’ often time consum ing and futile. As well as inclusion body formation, the 
production o f membrane proteins can often resu lt in low protein yield, insufficient for 
purification. These challenges were observed with the express ion o f recomb inant 
full length Pmps and truncated Pmps and E. coli as a host had many deficiencies.
A lternative ly homology screening can be a powerfu l approach, and is the centre of 
many structura l genom ics initiatives. Homo logues provide natural variation that may 
be less toxic, better expressed and more stab le (Mancia and Love 2010). However 
Pmps are unique to Chlamydia so this was not an option.
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A change of express ion host was considered but ultimately in view of the time 
involved in estab lishing these techniques, deve loping new cloning strateg ies and 
repeating the time-consum ing express ion trials already carried out in E. coli for each 
rPmp and its respective domains, this approach was thought to be an uneconom ical 
use of time. A reasonable a lternative to designing and constructing new expression 
systems was to change the express ion host to one also compatible w ith the T7- 
based expression system. As cloning strateg ies had already led to the successfu l 
expression o f several smaller rPmps domains in E. coli, an E. coli based ce ll-free 
expression system w ith a composition less comp lex than viable E.coli was chosen 
for its rapid screening ability, toxicity tolerance, and ease of handling (chapter 4). 
The fact that successfu l express ion was observed for three Pmp domains meant 
that such methods could be improved upon to obtain purified rPmps using a novel 
ce ll-free express ion system.
160
Chapter 4 - Expression of C.
Recombinant Pmps in a Cell-free Expression System
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4.1 In troduction
The hetero logous express ion o f recomb inant Pmps and Pmp domains was 
problematic using E. coli as an expression host (chapter 3). To overcome some of 
the difficulties, an a lternative, ce ll-free (CF) protein expression system was 
considered.
In vitro protein express ion systems emerged based on the early demonstration that 
cell integrity is not a requ irement for protein synthesis, such that translation can be 
accomp lished using a crude lysates conta ining the trans lational machinery, 
enzymes and tRNAs in a coupled or uncoupled system (Katzen et al., 2005). The in 
vitro ‘coup led’ transcription/translation system transcribes a DNA temp late in situ, as 
opposed to an ‘uncoupled’ system that requires RNA temp late to be added for 
translation. The most popu lar CF protein express ion systems are derived from E. 
coli lysates a lthough alternative systems originate from wheat germ extracts and 
rabbit reticulocytes. In theory, any organ ism could potentially be used as a source 
for the preparation o f a CF expression system. Typ ically E. coli based systems are 
better for bacterial genes and provide higher y ie lds at milligram levels o f protein per 
m illilitre of reaction, are more homogenous, and have been directly used for 
structura l analysis o f the product (Kigawa et al., 1999).
Since protein expression processes are not dependent on cell viability, ce ll-free 
translation systems have become increas ingly recogn ised as viable a lternatives to 
overcome the obstac les observed during in vivo over-express ion. This method has 
proved particularly useful for expressing prote ins that are cytotox ic or impossible to 
express w ithin a hetero logous ce llular env ironment, for example the Cyto lethal 
Distending Toxin (CTD) of Helicobacter hepaticus was expressed as recomb inant 
protein in vitro, where previous efforts to exam ine the activity o f the toxin were 
limited due the difficulties in producing sufficient quantities using in vivo express ion 
systems (Avenaud et al., 2004).
Moreover, membrane proteins which are notoriously difficult to express and can 
also pose a lethal effect on the cell have also been produced at high levels using 
E.coli derived ce ll-free expression systems (K lammt et al., 2004). Studies by 
Savage et al, (2009), found the in vitro CF system to be more robust than the E.coli 
in vivo system in over-expressing over one hundred E. coli membrane proteins. 
Upon comparison, 63% o f the target MPs were expressed in vitro compared to 44% 
expressed in vivo. This was interesting considering the CF system has similarities to 
in vivo mechanisms, having the same transcriptional, translational and presumab ly
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trans locational components. Unsurprisingly over the past decade, due to the open 
nature of the system in that it offers flex ibility to manipulate the reaction conditions, 
the field has expanded greatly resulting in significant improvements to the yield and 
solubility o f membrane protein expressed this way. These man ipulations come in 
the form of accessory reagents that can be directly added to a CF expression 
reaction, including lipids, folding catalysts and other amphiphilic molecu les 
potentially useful in providing a more favourab le env ironment for membrane protein 
expression (Katzen et al., 2005). Such advances in this area have led to the 
pub lication o f the first crystal structure of a membrane protein, EmrE a small 
multidrug transporter expressed using an E.co//'-derived ce ll-free express ion system 
Chen et al, (2007). It was found that the in vitro expressed EmrE, displayed 
essentially identical biochem ical behaviour to in vivo expressed EmrE. One 
commerc ially available ce ll-free expression kit has been deve loped by Invitrogen 
and has shown a high success rate for producing tens or hundreds o f m illigrams of 
active recomb inant membrane proteins, this system is termed the MembraneMax™ 
ce ll-free expression system (Katzen et al., 2008).
4.1.1 M em braneM ax™
MembraneMax™ is an in vitro coupled ce ll-free express ion system deve loped by 
Invitrogen Life Technologies, that utilises nano lipoprote in particles (NLPs) or 
nanodiscs as a vessel for membrane protein insertion (F igure 4.1). Nanodiscs are 
se lf-assemb led, soluble and stable comp lexes comprised of lipids encircled by an 
amphipathic ‘sca ffo ld’ protein belt to produce a discoidal planar lipid bilayer (Borch 
et al., 2008). In general, the scaffold prote ins o f nanodiscs are expressed by 
synthetic genes designed from a truncated form of the natura lly occurring protein 
Apolipoprote in A-l and the length of the scaffo ld dictates the diameter of the disc. 
NLPs have an approx imate average height o f 5 nm w ith diameters varying between 
10-60 nm (Cappuccio et al., 2008). The NLPs used in the MembraneMax™ system 
are approx imate ly 10 nm in diameter. The deve lopment of the MembraneMax™ 
system stemmed from several studies (Bayburt et al., 2002a, Bayburt and Sligar 
2002b, Civjan et al., 2003, Leitz et al., 2006, Bayburt et al., 2007, Bayburt and Sligar 
2009, Bayburt and Sligar 2010) that showed successfu l incorporation of integral 
membrane proteins into NLPs as an alternative tool to using liposomes or detergent 
m ice lles to ‘so lubilise’ and aid the handling o f membrane proteins. Katzen et al., 
(2008) reported that NLPs present w ithin the ce ll-free reaction dramatically 
increased the so lubility of a mu ltitude of b iologically important membrane proteins,
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suggestive that nanodiscs provide a su itable artificial membrane lipid bilayer to 
m imic the ce llular environment. Importantly, analysis on a subset of these 
membrane prote ins indicated that the prote ins were b iologically active, correctly 
folded and were embedded within the NLPs.
S ince E.coli proved to be a prob lematic host for the express ion o f serovar E full 
length recomb inant Pmps, with no expression detected and with some suggestions 
that certain expression plasmids could induce de leterious effect on some of the 
E.coli strains, a ce ll-free approach appeared to be an optimal choice for overcom ing 
these challenges. Furthermore, the ce ll-free system offers major benefits in 
overcom ing the challenges in downstream purification by reducing both the 
heterogene ity o f the samp les and the handling time, as recomb inant protein can be 
achieved in less than two hours without the need for storage between processes. 
However these ce ll-free expression systems are very expensive compared to more 
cost-effective methods such as E. coli.
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Protein
ATP energy renewal system
Ribosomes
T7RNAPolymerase
Target DNA- recombinant vector
Empty NLPs
Membrane protein inserted into NLPs
Figure 4.1 - Diagram depicting the MembraneMax™ cell-free protein expression 
reaction. The vector containing the gene of interest is added with the MembraneMax™ 
Nanolipoprotein (NLP) discs to a reaction containing E.coli lysate, an ATP energy 
regeneration buffer and T7 RNA polymerase. The E.coli lysate provides the transcriptional 
and translational machinery necessary to produce the protein of interest which can be 
localised into the NLP discs to produce high yields of soluble membrane proteins, using a 
simple and scalable method. Adapted from Invitrogen Flier (2008) lnvitrogen.com.
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4.2 M ateria ls /M eth o d s
Ana lytical grade chem icals were used throughout this study with all solutions being 
prepared using sterile water. Materials were obtained from the following suppliers.
Bio-Rad Laboratories Ltd., Hemel Hemsted, Hertfordshire, GE Healthcare Ltd,
Amersham, Buckinghamshire, Generon., Maidenhead, Berkshire, Invitrogen Life 
Technologies., Paisley, New England Biolabs (UK) Ltd., H itchin, Hertfordshire, 
Novagen, Merck Chemicals Ltd., Beeston, Nottingham, , Qiagen Ltd., Crawley, 
West Sussex, Sigma Aldrich Company Ltd., G illingham, Dorset, Starlab UK., 
B lakelands, Milton Keynes, Thermo-Fisher Scientific UK., Loughborough, 
Leicestershire,
4.2.1 P rote in  exp ress io n , M em b ran eM ax™  E xpression  k it (In v itro g en )
100 pi reaction samples were set up according to the manufacturer’s instructions 
(Table 4.1) with the appropriate express ion plasmid. A negative contro l reaction 
was set up using the corresponding empty pET vector. The reactions were 
incubated at 37 °C, 250rpm in an orbital shaker for 2 hours. ATP stocks were 
rep len ished after a 30 m inute interval with feed buffer (Table 4.2). Samp les were 
placed on ice and separated into soluble supernatant (conta ining NLPS) and 
insoluble pellet fractions (containing aggregated prote ins) by centrifugation at 
17,000g at 4 °C for 15 m inutes according to the manufacturer’s instructions, in the 
presence of protease inhibitors (1X HALT™ EDTA-free cocktail, Thermo-sc ientific). 
Soluble and insoluble fractions were resuspended in SDS-buffer for ana lysis by 
SDS-PAGE (section 3.2.5.1) and Western blot (section 3.2.5.2). Insoluble prote ins 
were not used in any downstream assays. These reactions were sca led up where 
necessary.
4 .2 .2  D e te rg en t so lu b ilisa tio n  o f reco m b in an t pro te ins  from  N LP s fo r  
purification  tria ls
The so luble fractions containing NLP-recomb inant protein complexes from ce ll-free 
expression reactions were resuspended in 2X binding buffer (section 4.2.3) w ith 
gentle agitation, end over end for one hour with 1% (v/v) detergent (Triton-X100, 
Octyl glucoside or Dodecyl maltoside) to re lease the recomb inant Pmp from the 
NLP disc. Samples were fractionated into detergent so lubilised (supernatant) and 
detergent insoluble pellet fractions by centrifugation at 40,000g for 20 m inutes at 4 
°C. Detergent so lubilised samples were passed through a 0.22 pM filter (M illipore)
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to remove any precipitated protein before undergoing purification as section 4.2.3 
or section 4.2.4.
Reagent Protein Synthesis 
Reaction
E. coli Extract 20 pi
2.5X IVPS Reaction Buffer 20 pi
50 mM Amino acids (-Met) 1.25 pi
75 mM Methionine 1 pi
MembraneMax™ NLPs 2 pi
T7 Enzyme Mix 1 pi
DNA Template
DNase/RNase-Free W ater To final volume 50 pi
Table 4.1 - MembraneMax™ cell-free expression set-up conditions. Reactions were set 
up for protein expression with expression plasmids or empty pET plasmids.
Reagent Protein Synthesis 
Reaction
2.5X IVPS Feed Buffer 25 pi
50 mM Amino acids (-Met) 1.25 pi
75 mM Methionine 1 pi
DNase/RNase-Free W ater To final volume 50 pi
Table 4.2 - MembraneMax™ cell-free expression buffer feed set-up conditions. The
feed buffer was added to the reaction in Table 4.2, 30 minutes into the reaction to replenish 
ATP and amino acid stocks to make a total reaction of 100 pi.
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4.2 .3  A ffin ity  co lum n c h ro m ato g rap h y  o f reco m b in an t pro te in  w ith  Ni- 
N TA  ag aro se
Soluble fractions containing NLPs (from 200 pi of ce ll-free express ion reactions) 
were resuspended in 2X binding buffer to make a final concentration o f (1XPBS, 10 
mM imidazole, 1X HALT EDTA-free protease inhibitor cocktail) with or w ithout 1% 
(v/v) detergent (Triton-X100 or DDM). Where detergent extraction was used, the 
samp le was fractionated again into ‘detergent so lubilised’ to re lease rPmps from 
NLPs and ‘detergent insoluble’ fractions as in section 4.2.2. The material that was 
not solubilised by detergents was exam ined but was not used in purification as this 
contained aggregated material. Soluble and detergent so lubilised samples were 
passed through a 0.22 pM filter (M illipore) to remove any precipitated protein before 
being applied to a 2 ml column containing 250 pi o f pre-washed 50% Ni-NTA 
agarose s lurry (Qiagen). The flow through was collected and reapplied 3 times 
(before reserving as unbound fraction). The co lumn was washed with 200 pi wash 
buffer tw ice (1XPBS, 20 mM imidazole, 0.1% detergent). Protein was eluted sharply 
with imidazole (typ ically 250 mM), using a 200 pi volume to m inimise dilution o f the 
eluted protein. Aliquots of all fractions were exam ined by SDS-PAGE and western 
blot for the presence of protein. Where batch-binding methods were used the 
so luble and/or detergent so lubilised fraction was incubated with 250 pi pre-washed 
50% Ni-NTA agarose slurry by gentle m ixing o f the tube, end over end at 4 °C for 1 
hour prior to loading on a 2 ml column and collecting the unbound fraction. Larger 
express ion reactions were scaled up accordingly.
4 .2 .4  S m all S cale  Ion E xchange C h ro m ato g rap h y
Prior to chromatographic analysis, soluble fractions (containing NLP-rPmp
expression from section 4.2.1) or N i-NTA purified samples from section 4.2.2 were
buffer-exchanged into a buffer of appropriate pH and ionic strength (typically 50 mM
NaCI) by washing in a Vivaspin 500, 10 MWCO concentrator (Generon). Due to
samp le precipitation this step was later replaced with dialysis overn ight at 4 °C
using GeBAflex dialysis tubes (Generon). For anion exchange chromatography
using Q sepharose (Amersham Biosciences), a 2X buffer to make a final
concentration of 50 mM Tris, 50 mM NaCI, 0.1% (w/v) dodecyl maltoside (DDM), pH
8.0 was initially used. pH 8.0 was chosen to promote the formation of a s ignificant
number of negatively charged regions on the protein, allowing it to interact w ith the
pos itive ly charged Q sepharose. S imilarly a 2X MES buffer to make a final
concentration of 25 mM MES, 50 mM NaCI, 0.1% (w/v) DDM, pH 6.0 was se lected
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for cation exchange chromatography using SP sepharose (Amersham Biosciences). 
This promotes the formation o f positively charged reg ions on the protein, thus 
allowing interaction with the negatively charged SP sepharose.
Small columns (150 pi) of Q and SP sepharose were prepared by pre-equ ilibrating 
the packing with e ither the Tris buffer (Q sepharose) or MES buffer (SP sepharose) 
deta iled above. The protein sample was applied to the column, which was then 
washed with four column volumes of the Tris or MES buffer to remove non bound 
proteins. Bound proteins were eluted in 200 pi volumes w ith increasing 
concentrations of NaCI (in Tris or MES buffer) of; 100 mM, 250 mM, 500 mM and 
1M. All fractions were exam ined by SDS-PAGE and Western blotting for the 
presence of protein. Larger expression reactions were scaled up accordingly.
4 .2 .5  E stim ation  o f protein  co n cen tra tio n  (B rad ford  m ethod)
Protein concentrations were determ ined with the Bradford assay (Biorad) according 
to the manufacturer’s instructions using Bovine Serum A lbumin as a standard.
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4 .3  R esults
4.3.1 E xpression  o f fu ll length rPm p A, rP m p D and rP m p I using  the  
M em braneM ax™  P rote in  E xpression  S ystem
M icrograms of recomb inant expression plasmids pPmpA23b-FL, pPmpD28b-FL and 
pPmpl23b-FL were produced using the PureL ink™ HiPure Maxiprep kit (Invitrogen) 
as in section 2.2.13. The MembraneMax™ express ion trials were set up as in 
section 4.2.1. Aliquots o f each expression reaction were resuspended in SDS 
buffer to exam ine the total ce ll-free prote ins and the rema inder of each reaction was 
separated into soluble supernatant (conta ining NLPs) and insoluble material via 
centrifugation as in section 4.2.1.
Analysis by Western Blot with the penta-H is antibody (section 3.3.5.2) and SDS- 
PAGE showed the express ion of full length putative rPmp I detected in the region o f 
90 kDa, shown in the insoluble fraction therefore not associated with soluble NLPs, 
Figure 4.2. The predicted molecu lar mass o f Pmp I is -9 5  kDa. The two larger 
bands detected were also recogn ised by the antibody as bearing a histidine tag so 
are likely to be dimers and trimers of rPmp I, a lthough the sizes could not be 
determ ined using the scale of 6xH is ladder on the Western blot. The band for full 
length rPrnpl was not clearly visible in the total ce ll-free protein (TCP) as this 
sample was more dilute. Insoluble prote ins pellet upon centrifugation to produce 
more concentrated samples. The antibody did not recogn ise any protein in the lanes 
conta ining expression products o f rPmp A or rPmp D.
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rPmpA rPrnpl rPmpD
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Figure 4.2 - Western blot showing the expression of full length rPmp A, rPmp D and 
rPmp I using a cell-free expression system, MembraneMax™. The proteins were 
expressed in 100 pi reactions for 2 hours at 37 °C as described in section 4.2.1. The total 
cell-free protein (TCP) was examined, alongside the soluble and insoluble fractions. Putative 
monomers of -90 kDa with possible dimers and trimers of rPmp I were detected on the 
Western blot (top) in the total cell protein and insoluble fraction indicated by the red arrows. 
There was no detection showing the expression of rPmp A or rPmp D.
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4 .3 .2  E xpression  and pu rificatio n  o f the pu tative  P-barrel Pm p D 
au to ta n s lo ca to r dom ain  (rP m p D au to ) in M em braneM ax™
M icrograms o f recomb inant express ion plasmid pPmpD28b-C were produced using 
the PureLink™ HiPure Maxiprep kit (Invitrogen) as in section 2.2.13. Ce ll-free 
express ion reactions were set up as in section 4.2.1 and were fed after a 30 m inute 
interval. As rPmpDauto was under the control o f the lac repressor gene via the 
T7/ac promoter (discussed in section 3.1.1), trials to estab lish if IPTG was 
necessary to induce the promoter were carried out with and without IPTG.
Western blotting and SDS-PAGE confirmed the successfu l express ion o f the His- 
tagged autotranslocator domain o f recomb inant Pmp D. The bands detected in 
Figure 4.3a show that the E.coli derived transcriptional/translational machinery 
readily expresses the rPmpDauto domain without the need for IPTG. Protein was of 
the expected molecu lar we ight o f this domain at approx 27kDa and is the same 
mo lecu lar we ight as prev iously detected expressing rPmpDauto in E.coli (chapter 
3). Discrepancies between the pre-stained marker and the 6XH is ladder between 25 
kDa and 30 kDa bands remain (section 3.3.2).
Fractionation of the expression products as in section 4.2.1 to separate so luble 
(NLP fractions) and insoluble products showed a small proportion was detected in 
the so luble fraction presumab ly incorporated into NLPs Figure 4.3b (Katzen et al., 
2008). rPmpDauto was also expressed as insoluble protein and more easily 
detected as this was concentrated into a pellet upon fractionation. The amount in 
the so luble fraction was within the limits o f detection from a 100 pi ce ll-free 
expression reaction and could be scaled up. Since downstream app lications were 
dependent upon Western blotting and Coomassie SDS-PAGE it was important that 
the expressed protein was within detectab le limits. This method o f express ion could 
have allowed for downstream processing to be mon itored more eas ily in comparison 
to detergent so lubilised rPmpDauto from 0.5 L of E.coli cu lture (chapter 3) where 
difficulties in the detection hampered purification trials. Variations to the incubation 
set-up conditions, including lowering the incubation to 30 °C in an effort to increase 
the levels o f expression and the yield o f so luble rPmpDauto did not have any 
beneficial effects and showed that the ce ll-free system and vector were most like ly 
expressing at the ir maximal rates (data not shown).
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4.3.2 .1  S m all-sca le  purification  o f rP m p D au to -N L P s  co m p lexes  using Ni- 
N TA  ch ro m ato g rap h y
To gain a better insight into the nature of the Pmps, purified protein would be 
required for the future ana lyses such as circular dichroism. rPmpDauto was to be 
purified by affinity column chromatography using Ni-NTA agarose (Q iagen) to bind 
the C-term inal histidine tag. As the NLPs were understood to offer a stable 
env ironment for recomb inant prote ins (Katzen et al., 2009), the purification was first 
performed using the so luble fraction containing rPmpDauto in NLPs, from a 200 pi 
MembraneMax™ ce ll-free express ion diluted in 2X binding buffer w ithout detergents 
as in section 4.2.3.
rPmpDauto in NLPs remained in the co lumn flow-through as unbound prote ins and 
therefore the binding efficiency to N i-NTA agarose was poor (data not shown). 
Additionally, rPmpDauto began to elute from the column with a re lative ly low 
concentration o f imidazole (20 mM), showing that the protein had weak b inding to 
the N i-NTA agarose. Weak binding efficiency could have been due to the 
hexahistidine tag being only partially accessible. In such circumstances, it can bind 
as long as more than two histidines are available to interact w ith the nickel ions, but 
genera lly, the sma ller the number of access ible histidines, the weaker the binding 
will be (Q iagen, 1997). Extending the association time between rPmpDauto and Ni- 
NTA by batch-binding the so luble fraction with Ni-NTA as in section 4.2.3 did not 
improve the binding efficiency (data not shown).
To test the possibility that the NLPs surrounding rPmpDauto, were not obstructing 
the access ibility o f the His tag. rPmpDauto was re leased from the NLPs using 
detergent. Detergents are necessary reagents in membrane protein biochem istry as 
they serve to disrupt lipid bilyers and solubilise membrane prote ins into mice lles. A 
m icelle is a thermodynamically stable co lloidal aggregate of detergent monomers in 
which the hydrophillic polar heads are directed outward in contact with the water and 
the nonpo lar tails are clustered inward, avoiding exposure to water thus act to 
stabilise membrane prote ins providing hydrophobic surfaces for exposed amino 
acids normally within the b ilayer (Seddon et al., 2004). Using this method, detergent 
m ice lles could replace the NLPs as the NLPs would themse lves be unsu itable for 
structura l analysis by circular dichroism and ultimate ly would have to be removed 
during purification.
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Many prokaryotic membrane transporters are soluble in Triton-X100, dodecy l-p-D- 
maltoside (DDM) or octyl-(3-D-glucoside (OG) (persona l communication, Dr D. 
Hadden). Octyl glucoside and dodecyl maltoside are s im ilar in structure, based on 
alkyl chains with a carbohydrate moiety, and both are chem ically well defined. One 
advantage of octyl glucoside is it has a high critical micelle concentration (CMC), 
which enab les the detergent to be easily removed from so lution by dialysis. Triton- 
X100 is an inexpensive non-ionic detergent, common ly used in the laboratory for 
many app lications and is well suited for membrane protein extraction, it contains 
impurities but is useful as a cost effective method for use during optim isation trials.
Solubilisation trials were therefore initiated using Triton-X100, OG and DDM at a 
concentration range of 1% (w/v). Soluble expression fractions containing rPmpDauto 
with NLPs were incubated for one hour, with gentle agitation, end over end in 1% 
(w/v) detergent as detailed in section 4.2.2. Precipitated prote ins were pelleted into 
the detergent insoluble fraction by centrifugation at 4 °C, 40,000g for 20 m inutes and 
the supernatant was passed through a 0.22 pm filter (M illipore). The pellet and 
supernatant samp les were analysed by Western blot.
Western blots showing the results of detergent extraction are shown in Figure 4.4. 
rPmpDauto was not recovered into detergent m ice lles using OG as all the protein 
was detected in the detergent insoluble pellet as precipitate. Triton-X100 and DDM 
were able to partially extract rPmpDauto shown by ye llow arrows and therefore were 
se lected as the detergent of choice to begin purifying rPmpDauto extracted from 
NLPs.
4 .3 .2 .2  S m all-sca le  purification  o f d e te rg en t ex trac ted  rP m p D au to  w ith  
T rito n -X 100  or DDM , using N i-N T A  ch ro m ato g rap h y
Initial attempts to purify rPmpDauto by N i-NTA chelation revealed ce ll-free 
expressed rPmpDauto in NLP complexes had a very low affinity for the N i-NTA 
(section 4.3.2.1). On the basis o f the detergent so lubilisation trials it was decided 
the purification of rPmpDauto would be attempted using Triton-X100 and DDM 
extracted protein. The purification was performed on a small scale using the so luble 
fraction from a 200 jul reaction that had undergone incubation with 1% (w/v) 
detergent to extract the rPmpDauto from the NLPs. rPmpDauto in detergent was 
applied to 250 pi Ni-NTA 50% agarose s lurry and the purification carried out as 
described in section 4.2.3. Fractions were analysed by SDS-PAGE and Western 
blot.
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The Western blots and Coomassie SDS-gels showing the purification o f rPmpDauto 
in both Triton-X100 and DDM are shown in Figure 4.5 and Figure 4.6 respective ly. 
Triton-X100 extracted rPmpDauto bound to the N i-NTA and was eluted with 250 mM 
imidazole. However the binding efficiency was poor as this protein also eluted with 
the 20 mM imidazole wash. A similar outcome was obta ined using DDM however the 
bands remained very fa int and difficult to identify desp ite efforts to load more protein 
on to the blotting membrane. Severa l methodologies to improve the binding 
efficiency included batch binding as in section 4.2.3 at both 22 °C and 4 °C, were 
attempted but did not improve the outcome.
Coomassie SDS-PAGE ana lysis o f the same fractions showed few protein bands 
within the second 20 mM and within the 250 mM imidazole eluted fractions (lanes 
‘Wash 2 ’ and ‘Eluate’ in Figure 4.6 bottom).This indicated that the overall presence 
of contam inants was low and the stringency of the wash conditions (20 mM 
imidazole) was adequate. Because of the low quantity of proteins, it was difficult to 
assess whether rPmpDauto was present as a pure protein in the 250 mM fraction. 
To exam ine these fractions more closely, TCA/acetone precipitation was used to 
concentrate the purified 250 mM fraction from Figure 4.6. Coomassie SDS-PAGE 
revealed the presence of rPmpDauto (red arrow) with few larger unidentified 
contaminant bands (green arrows) that co-purified with rPmpDauto given in Figure 
4.7 and confirmed by Western blot.
E fforts to separate the contam inant prote ins from the samp le w ith an extra higher 
stringency wash at both 40 mM and 75 mM imdazole did not separate the prote ins 
(data not shown). Additional purification methods such as ion exchange 
chromatography or size exclusion chromatography could not be implemented to 
remove the larger contam inant prote ins as the yield o f rPmpDauto was a lready at the 
limit o f reliable detection following Ni-NTA purification, further losses as a resu lt of 
buffer exchange and purification steps made this an impractical step.
C ircular dichroism requires a 200 jliI samp le of at least 0.5 mg/m l and 95% 
homogene ity. It was difficult to estimate the protein concentration o f the partially 
purified rPmpDauto fraction because it was so low. The Bradford (section 4.2.5) 
protein estimation method was used and revealed the tota l protein in the 200 pi 
fraction to be very low at approximate ly 20 pg/ml, a level far below the concentration 
required for CD analysis. Although CD analysis could not be carried out for 
rPmpDauto, efforts to express and purify other rPmp domains were attempted in the 
hope that these homologues would display a higher affinity for N i-NTA purification.
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Figure 4.4 - Western blots showing the detergent solubilisation (extraction) of 
rPmpDauto from NLPs with Triton-X100, OG and DDM to release rPmpDauto from the 
MembraneMax™ NLP scaffolds. The soluble fraction from the cell-free expression reaction 
of rPmpDauto in NLPs was resuspended in 1XPBS with 1% detergent to disrupt the NLPs 
and release rPmpDauto into detergent micelles. After detergent extraction, the samples were 
centrifuged to remove the detergent insoluble proteins i.e. aggregated proteins displaced 
from the NLPs that did not encounter detergent micelles. Triton-X100 and DDM offered some 
detergent extracted protein recovery with faint bands detected via Western blot (yellow 
arrows). There was no recovery into the detergent using OG. Triton-X100 and DDM offered 
the best recovery from NLPs out of these trials.
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Figure 4.5 - Western blot showing the initial trials to purify rPmpDauto expressed 
using MembraneMax™ protein expression system, released from NLPs using 1% 
Triton-X100. The soluble rPmpDauto expressed in NLPs (soluble fraction) was extracted 
from the NLPs using 1% Triton-X100 to produce detergent solubilised rPmpDauto and 
detergent insoluble rPmpDauto as indicated above. Subsequently the detergent solubilised 
sample was applied to Ni-NTA for binding 3 times. A large proportion of rPmpDauto 
remained in the unbound fraction after application onto a Ni-NTA column. A small amount of 
rPmpDauto was eluted with 20 mM (Wash 1) and 250mM imidazole (Eluate 1). The presence 
of rPmpDauto within these fractions was not visible on a Coomassie SDS-PAGE.
178
Figure 4.6 - Western blot (top) and Coomassie gel (below) showing the purification of 
rPmpDauto expressed using MembraneMax™ released from NLPs using 1% DDM. The
soluble rPmpDauto expressed in NLPs (soluble fraction) was extracted from the NLPs using 
1% DDM to produce detergent solubilised rPmpDauto and detergent insoluble rPmpDauto as 
indicated above. Subsequently the detergent solubilised sample was applied to Ni-NTA for 
binding 3 times. Although very faint the majority of rPmpDauto applied to the resin remained 
in the unbound fraction and the first wash. A very faint trace of rPmpDauto was detected in 
250mM imidazole eluate fraction via Western blot. However these bands were not visible on 
the Coomassie SDS-PAGE. The insoluble rPmpDauto (black arrows) was used as a guide to 
determine putative rPmpDauto in the eluted fractions.
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Figure 4.7 - Western Blot (left) and Coomassie gel (right) of the X10 concentrated 
fractions of purified rPmpDauto. The unbound, Wash 1 and 2 and Eluate 1 fractions from 
the purification trials using DMM in Figure 4.6 were concentrated X10 using TCA/acetone 
precipitation to pellet the proteins. The pellets were resuspended in SDS loading buffer and 
examined via Western blot and Coomassie SDS-PAGE. Concentrating the proteins showed 
the presence of rPmpDauto (red arrow), at levels previously beyond detection in addition to 
co-purified protein bands at approximately 58 kDa and 80 kDa that were not recognised by 
the penta-His antibody (green arrow).
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4.3 .3  M em b ran eM ax™  ce ll-free  exp ressio n  o f the  p red ic ted  p-barrel 
dom ain  o f rP m p G au to
M icrograms o f recomb inant expression plasmid pPmpG22b-C were produced using 
the PureL ink™ HiPure Maxiprep kit (Invitrogen) as in section 2.2.13, Ce ll-free 
expression reactions were set up as in section 4.2.1 and were fed a fter a 30 m inute 
interval. A fter express ion the comp lete reaction was separated into soluble proteins 
and insoluble aggregates by centrifugation prior to exam ination by SDS-PAGE and 
by Western blot using a penta-H is primary antibody (section 3.2.5.2).
Western blotting shows the successfu l expression o f putative rPmpGauto as both 
soluble and insoluble protein in Figure 4.8a. The protein was detected as two bands 
in the so luble fraction at approximate ly 40 kDa and 34 kDa and insoluble rPmpGauto 
was v isualised on the Coomass ie SDS-PAGE gel. These mo lecu lar we ights were as 
predicted for the Pmp G autotrans locator domain and were comparative to the sizes 
observed when expressing rPmpGauto in E.coli (chapter 3). The two bands were an 
indication that proteo lysis was taking place, possibly o f the pelB fus ion peptide.
4.3.3 .1  S m all-sca le  pu rificatio n  o f M em braneM ax™  derived  rP m p G au to  
using N i-N T A  ch ro m ato g rap h y
Attempts to purify rPmpGauto were by affinity column chromatography using Ni-NTA 
agarose (Q iagen) to bind the histidine tag. The purification was performed on a small 
scale using rPmpGauto expressed in the NLP-so luble fraction from a 200 pi reaction, 
later extracted from the NLPs in 1% (w/v) DDM using similar methods emp loyed to 
purify rPmpDauto (section 4.3.2.2). The detergent so lubilised rPmpGauto was 
applied to 250 pi Ni-NTA 50% agarose s lurry and the purification carried out as 
described in section 4.2.3. Fractions were analysed by SDS-PAGE and Western 
blot with the penta-H is antibody.
The Western blot showed very fa int putative rPmpGauto bands of approx imate ly 40 
kDa present in the detergent so lubilised fraction the majority of rPmpGauto was lost 
in the detergent insoluble pellet (Figure 4.8b). However the detergent extracted 
rPmpGauto was applied to a Ni-NTA column and the domain appeared to bind to the 
N i-NTA agarose as it was not detected in the unbound flow-through fraction or any o f 
the wash and e luate fractions. The N i-NTA resin was probed showing rPmpGauto 
had not remained bound however as the amount of protein loaded on to the N i-NTA 
column from the detergent so luble fraction was already very difficult to detect this 
hampered efforts to locate rPmpGauto throughout the fractions desp ite efforts to
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load more protein onto the gel for immunoblotting. Concentration o f these fractions 
using TCA to precipitate the prote ins did not improve the Western blot detection of 
rPmpGauto and did not show that the protein was wide ly distributed throughout the 
fractions (data not shown). Purification trials were repeated using Triton-X100 to 
extract rPmpGauto from the NLPs to improve the yield o f detergent so lubilised 
protein yet the outcome was s im ilar and rPmpGauto could not be detected (data not 
shown).
4 .3 .4  M em braneM ax™  ce ll-free  exp ressio n  o f the p red icted  p assen g er  
dom ain  o f P m p A  (rP m p A -N )
Micrograms o f recomb inant express ion plasmids pPmpA23b-N were produced using 
the PureLink™ HiPure Maxiprep kit (Invitrogen) as in section 2.2.13. Ce ll-free 
expression reactions were set up as in section 4.2.1 and were fed after a 30 m inute 
interval. The expression reaction was fractionated into soluble and non-soluble 
samples. The separated fractions were ana lysed by Western blotting and SDS- 
PAGE as in sections 2.2.5.
The Western blot revealed the successfu l expression o f putative rPmpA-N at the 
expected molecu lar we ight of 56 kDa (Figure 4.9) however this was as insoluble 
aggregates not associated with NLPs. Efforts to produce some so luble rPmpA-N in 
NLPs by lowering the incubation temperature, reducing the aeration to slow 
expression were met w ithout success (data not shown).
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Figure 4.8 - Coomassie SDS-PAGE and Western blots showing the expression and 
purification trials of rPmp G autotranslocator domain (rPmpGauto). (a) The truncated 
rPmpGauto was expressed for 2 hours at 37 °C in 100 pi MembraneMax™ cell-free reaction. 
The sample was fractionated into soluble (containing NLPs) and insoluble fractions. 
rPmpGauto is shown by the black arrows at approximately 34 kDa with a larger 40 kDa band 
detected in the soluble NLP fraction (right), (b) The rPmpGauto expressed in NLPs (the 
soluble fraction from above (a)) was extracted from the NLPs using 1% DDM to produce 
detergent solubilised rPmpGauto and detergent insoluble rPmpGauto (yellow arrow). The 
detergent solubilised sample was applied to Ni-NTA for binding 3 times. rPmpGauto was not 
detected in the remainder of the fractions.
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kDa
Figure 4.9 - The expression of rPmp A passenger domain (rPmpA-N) using a cell-free 
expression system MembraneMax™. The truncated protein domain was expressed for 2 
hours at 37 °C in 100 pi reaction and was fractionated into soluble and insoluble fractions as 
described in section 4.2.1. rPmpA-N was detected as insoluble aggregates, shown by the 
yellow arrow at approximately 56 kDa. The protein markers are shown in kDa.
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4 .3 .5  M em braneM ax™  ce ll-free  expression  o f the p red icted  p assen g er  
dom ain  o f Pm pl (rP m pl-N )
M icrograms of recomb inant express ion plasmids pPmpl23b-N were produced using 
the PureL ink™ HiPure Maxiprep kit (Invitrogen) as in section 2.2.13. Ce ll-free 
express ion reactions were set up as in section 4.2.1 and were fed after a 30 m inute 
interval. The expression reaction was fractionated into soluble and non-soluble 
samp les.
Probing with a penta-H is primary antibody shows the successfu l express ion of 
putative rPmp l-N as both soluble (w ith NLPs) and insoluble aggregates confirmed by 
Western blot and Comassie stained SDS-PAGE (Figure 4.10a). The w ide band was 
due to abundant detection by the penta-H is antibody. At approximate ly 44 kDa the 
mo lecu lar size was as expected for this domain and corresponded with the size of 
the rPmp l-N domain expressed in E.coli (Chapter 3).
4.3 .5 .1  S m all-sca le  pu rificatio n  o f M em braneM ax™  derived  rP m pl-N  
using N i-N T A  ch ro m ato g rap h y
As this passenger domain was intended to undergo secondary structural analysis it 
was necessary to purify the protein and remove the NLPs. Considering the NLPs 
construction is based around a scaffold protein co-purification o f NLP scaffo lds 
would have interfered with CD structural analysis o f rPmp l-N. This exchange from 
NLPs into detergent m ice lles was done prior to purification as opposed to during 
purification when the protein is bound to the column. Disrupting the NLPs whilst 
bound to the column was not favoured as protein precipitation occured when adding 
detergents (observed previously when adding detergents to re lease rPmpDauto and 
rPmpGauto) that ultimately could have led to the loss of protein conformation. The 
purified fractions would then have become contam inated with misfo lded rPmpl-N 
unsuitable for structura l and functional analysis. Based on the detergent extraction 
trials of rPmpDauto, where Triton-X100 and DDM were capab le of recovering some 
the Pmp domain from the NLPs, DDM was chosen to extract the passenger domain 
of Pmp I since Triton X-100 contains aromatic rings that absorb at 260-280 nm and 
is genera lly known to contain impurities such as peroxides as contam inants 
unsuitable for CD ana lysis (Ke lly et al., 2005). Therefore the NLPs were disrupted 
using 1.0% (w/v) DDM to release the proteins (section 4.2.3) and detergent 
so lubilised recovery of rPmp l-N was observed in Figure 4.10b.
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Subsequently rPmpl-N was purified by affinity column chromatography using Ni-NTA 
agarose (Q iagen). The purification was performed using the detergent extracted 
rPmpl-N from the so luble fraction o f a 200 |ul MembraneMax™ ce ll-free expression 
reaction. Protein was eluted in steps w ith increasing concentrations of imidazole (10 
mM, 40 mM, 75 mM and 250 mM imidazole), using 200 pi volumes for each 
concentration. Aliquots o f each fraction were exam ined by SDS-PAGE and Western 
blotting. Using this method, rPmpl-N was partially purified, and putative rPmp l-N 
bands were detected on the Western blot at 38 kDa and 44 kDa (blue arrows) in the 
75 mM and 250 mM imidazole eluted fractions (Figure 4.11a). These bands were 
also observed when express ing rPmpl-N in E.coli possibly an indication o f cleavage 
of the predicted native signal leader peptide as the sma ller 38 kDa band becomes 
more prom inent during downstream processing. The predicted molecu lar we ight of 
the passenger domain of Pmp I is approximate ly 44 kDa with a predicted 6 kDa 
signal peptide. However a third band seen prev iously in E.coli express ion trials of 
rPmp l-N was not detected here. A Coomassie stained SDS-PAGE gel showing the 
purification profile of rPmp l-N using Ni-NTA agarose (Figure 4.11a) could not 
determ ine the presence of rPmp l-N in any o f the fractions as the yield of rPmp l-N 
was too low to detect w ith this staining technique.
To investigate the purity o f the fraction containing rPmpl-N, TCA/acetone 
precipitation o f the 250 mM imidazole fraction to produce a samp le ten times more 
concentrated verified the presence of rPmp l-N at approximate ly 38 kDa (red arrow) 
and two larger contam inant proteins (green arrows) that would render the samp le 
unsu itable for c ircular dichroism analysis Figure 4.11b. Although rPmpl-N was not 
fu lly purified, attempts to remove the co-purified contaminant prote ins could be made 
using additional purification methods such as ion exchange as the yield o f purified 
rPmpl-N by Ni-NTA chelation was still within the limits o f detection by Western blot 
(section 4.3.5.2).
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Figure 4.10 - Coomassie SDS-PAGE gel and Western blots showing the expression of 
rPmp I passenger domain (rPmpl-N) and detergent solubilisation recovery from 
MembraneMax™ NLPs. (a) The truncated protein domain was expressed for 2 hours at 37 
°C in 100 pi MembraneMax™ cell-free expression reaction and was fractionated into soluble 
and insoluble fractions. rPmpl-N was present as both soluble and insoluble aggregates, 
visualised on a Coomassie stained SDS-PAGE gel (left) shown by the red arrow and 
detected with via Western blotting (right) at approximately 44 kDa. NLPs are shown by 
orange arrow. The protein markers are shown in kDa. (b) The soluble fraction from the cell- 
free expression reaction of rPmpl-N (from part (a)) was resuspended in 1% DDM to disrupt 
the NLPs and release rPmpl-N into detergent micelles. Precipitated protein was separated 
into the ‘detergent insoluble’ fraction by centrifugation and was not used further.
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Figure 4.11 - Western blots and Coomassie gels showing the partially purified rPmpl-N 
expressed using MembraneMax™ by Ni-NTA affinity chromatography, (a) Western blot 
(top) shows the Ni-NTA purification of the two fragments of the Pmp I passenger domain. The 
detergent extracted rPmpl-N protein prior to application on to the Ni-NTA column is shown in 
the pre-column load lane. The sample was applied to the column 3 times and the unbound 
proteins were retained. The bound proteins were washed with 10 mM, 40 mM, 75 mM and 
250 mM imidazole concentrations. rPmpl-N started to elute with 75 mM imidazole. And was 
detected in the 250 mM imidazolefraction (blue arrows). No protein was detected by 
Coomassie stained SDS-PAGE gel (below), (b) Concentration of the eluate (250 mM fraction) 
shows the purity of the fraction and rPmpl-N can be visualised on the Coomassie gel (left) 
indicated by the red arrow with two larger unidentified proteins at -58 kDa and -80 kDa 
(green arrows) previously seen when purifying rPmpDauto (Figure 4.7) rPmpl-N is confirmed 
by Western blot (right).
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4 .3 .5 .2  S m all-sca le  purification  o f M em braneM ax™  d erived  rP m pl-N  
using N i-N T A  c h ro m ato g rap h y  and ion exch an g e  c h ro m ato g rap h y
To improve the purity of rPmp l-N produced using nickel affinity chromatography, ion 
exchange chromatography was employed. Ion exchange chromatography separates 
mo lecu les based on differences in the ir accessible surface charges. The partially 
purified reaction (section 4.3.5.1) was divided into two aliquots. In order to lower the 
ionic strength and alter the pH, the a liquots were buffer exchanged by applying the 
fractions to a concentrator (V ivaspin 500, 10 MWCO, Generon) and washing through 
with e ither 50 mM Tris, 25 mM NaCI, 0.1% DDM, pH 8.0, or 25 mM MES, 25 mM 
NaCI, 0.1% (w/v) DDM, pH 6.0. Samples in the a lkaline buffer were applied to an 
anion exchanger, Q sepharose (Amersham Biosciences), and samples in the ac idic 
buffer applied to a cation exchanger SP sepharose (Amersham Biosciences). Ion 
exchange chromatography was performed as described in section 4.2.4.
The described method failed to produce any visible bands on a Coomassie stained 
SDS-PAGE gel and rPmpl-N was not detected via Western blot a fter the buffers 
were exchange in the concentrators (data not shown). The v ivaspin 500 
concentrators were chosen for the ir hydrophilic polyethersu lfone (PES) membrane 
that reduces samp le binding however the rapid changes to the pH and ionic strength 
o f the buffer using this method may have caused rPmpl-N to prec ipitate and bind to 
the PES membrane. A gentler method to exchange the buffer and minimise protein 
precipitation was done by dialysing rPmpl-N overn ight at 4 °C as in section 4.2.4 
after which the samp le was passed through a 0.22 pM Millipore filter to remove any 
precipitated proteins before app lication on to the equ ilibrated anion/cation exchanger 
as in section 4.2.4,
A Western blot showing the results o f the purification using SP sepharose is shown 
in Figure 4.12. At pH 6.0, the rPmp l-N bound to SP sepharose tightly and did not 
elute until the column was washed with 1 M NaCI, where three H is-tagged bands 
were detected on a Western blot (Figure 4.12a). Because of the weak detection of 
the protein, these were not v isible on a Coomassie SDS-PAGE gel (data not shown) 
and so it was necessary to concentrate the 1M fraction to assess the purity o f the 
fraction. Examining this concentrated fraction on a Coomassie stained gel (Figure 
4.12b) confirmed the larger contam inant proteins that co-purified with rPmpl-N 
following Ni-NTA purification (Figure 4.11b dep icted by green arrows) were not 
present on the Coomassie gel in Figure 4.12b. Presumab ly, these prote ins did not 
bind to the sepharose, or were eluted from the column at a lower NaCI
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concentration. However a sma ller contam inant band was detected on the Coomassie 
gel at -1 5  kDa that was not recogn ised by the penta-H is when probing the same 
fraction. Additonally although Western blotting detected rPmpl-N in the 1M fraction, 
the y ie lds were too low to be identified clearly by Coomassie SDS-PAGE even after 
concentration with TCA (F igure 4.12b). Furthermore it was difficult to estimate the 
protein concentration within this fraction as this was beyond the re liable lower limits 
of protein estimation by Bradford assay. Consequently two purification steps 
produced a protein unsuitable for CD ana lysis due to poor yields. Purification using 
Q sepharose was unsuccessfu l as rPmpl-N could not be detected in any o f the 
fractions after column loading (data not shown) this could be due to dilution o f rPrnp l- 
N where the protein elutes in a wide range of NaCI concentrations at pH 8.0. If the 
protein had eluted sharply in few fractions, detection o f the protein by Western 
blotting may have been easier.
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Figure 4.12 - Western blot and Coomassie gel showing purification of Ni-NTA purified 
rPmpl-N by ion exchange chromatography, (a) Western blot shows the second step of 
rPmpl-N purification using ion exchange chromatography. The detergent solubilised rPmpl-N 
(Pre-purified) was partially purified by Ni-NTA as in section 4.3.5.1 (Ni-NTA purified). This 
partially purified rPmpl-N was dialysed into the MES buffer and remained soluble (post­
dialysis). This dialysed rPmpl-N was applied to the SP sepharose column and the unbound 
proteins were retained (unbound). The column was washed with 50 mM, 100 mM, 250 mM, 
500 mM and 1 M NaCI. The rPmpl-N protein was eluted at 1M NaCI as three His-tagged 
bands at approximately 44 kDa, 38 kDa and 20 kDa. (b) The 1M fraction was concentrated 
X10 to show the purity of the fraction on a Coomassie SDS-PAGE gel. rPmpl-N could not be 
clearly identified on the Coomassie gel.
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4 .3 .5 .3  Sm all sca le  p urification  o f M em braneM ax™  d erived  rPm pl-N  
using ion exch an g e  c h ro m ato g rap h y  a lone
Based on the finding that recomb inant Pmp I passenger domain had a strong binding 
a ffinity for SP sepharose (section 4.3.5.2), purification was carried out using cation 
exchange alone. By om itting the N i-NTA purification, the losses in yield could be 
m inimised. 200 \x\ of so luble express ion of rPmp l-N was resuspended in 25 mM MES 
buffer conta ining 1% DDM to disrupt the NLPs and extract rPmp l-N into micelles. 
The detergent so lubilised fraction was applied to the cation exchanger and 
subsequent fractions eluted in MES buffer w ith 0.1% DDM with increasing 
concentrations of NaCI as in section 4.2.4.
A Western blot shows the majority o f rPmp l-N eluted within the 700 mM NaCI 
fraction (Figure 4.13 (W7)), where the levels were too low for detection on the 
comp lementary Coomassie SDS-PAGE. This fraction was concentrated using TCA 
precipitation to check the purity. rPmpl-N was identified on the Coomass ie SDS- 
PAGE and confirmed by Western blot (Figure 4.14 red arrows). Severa l smaller 
contam inant proteins had co-purified and were more prom inent. These contam inant 
prote ins were tightly bound to the sepharose, eluting at and above 600 mM NaCI and 
were still ev ident in the 1M NaCI fraction (see W 9 fraction on Coomassie gel, Figure 
4.13). It would be very difficult to separate them from rPmp l-N using this technique. 
Additionally the yield o f rPmp l-N was low making further purification o f this eluted 
fraction impractical.
Following ion exchange chromatography the rPrnpl passenger domain was detected 
as three peptides that were spec ifically identified by the penta-H is antibody indicating 
the presence of His-tag. These sizes were -3 8  kDa, -4 4  kDa as prev iously 
observed in Figure 4.11 with a third additional band present at -2 2  kDa Figure 4.14. 
These bands are cons istent w ith the peptides observed a fter express ion o f rPmp l-N 
in E.coli (chapter 3) where it was specu lated the protein underwent auto-proteo lysis. 
This 22 kDa band was not observed prior to ion exchange chromatography. 
Furthermore the Coomassie SDS-PAGE gel in Figure 4.12b shows the 
accumu lation o f a prom inent non-H is tagged peptide at approx imate ly 12 kDa within 
the purified 1M NaCI rPmpl-N fraction that is not detected on the corresponding 
Western blot. This peptide was not seen previously in the Figure 4.11b where 
rPmp l-N was purified by Ni-NTA affinity chromatography. This peptide could be a by­
product o f rPmp l-N as a result of protein cleavage. This was consistently found 
following ion exchange chromotography purification trials, all in the presence of
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protease inhibitors. Despite numerous efforts to produce a pure samp le of the 
passenger domain o f Pmp I, the co-e lution o f contam inant prote ins rema ined a 
consistent problem and deemed the samp les unsu itable for CD analysis.
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Figure 4.13 - Coomassie gel (top) and Western blot (below) showing purification 
rPmpl-N by ion exchange chromatography. The Western blot shows the rPmpl-N domain 
extracted from NLPs by detergents before binding to the column (solubilised rPmpl-N). This 
sample was applied to the SP sepharose three times prior to collecting the unbound fraction. 
The column was washed with increasing concentrations of NaCI as shown (W1-W9) rPmpl-N 
eluted at 700 mM NaCI (W7) as two faint His-tagged bands. rPmpl-N could not be clearly 
identified on the Coomassie gel above so fractions were concentrated (shown in Figure 4.14).
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Figure 4.14 - Western blot (left) and Coomassie SDS-PAGE (right) of the eluted fraction 
W7 from ion exchange chromatography X10 concentrated. rPmpl-N eluted with 700 mM 
NaCI during ion exchange chromatography (Figure 4.13 lane W7) was concentrated X10 
using TCA/acetone precipitation to visualise the bands on a Coomassie gel. rPmpl-N is 
shown as three His-tagged peptides at approximately 44 kDa, 38 kDa (red arrows) and a 
third 22 kDa on the Western blot. The 44 kDa and 38 kDa bands can be seen as very faint 
bands on the Coomassie gel, shown by the red arrows. The smaller band at -20 kDa is not 
clearly identifiable on the Coomassie gel. Several other proteins also eluted with 700 mM 
Nacl.
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4 .4  D iscuss ion
The aim o f this section o f work was to express recomb inant Pmps or rPmp domains 
in a manner su itable for downstream processes including purification for structura l 
and functional analyses. Problems w ith the yield, handling and purification were 
prob lematic using E.coli as an expression host and so hampered progress at this 
stage. It was hoped that the novel MembraneMax™ ce ll-free express ion system 
would overcome some of the challenges prev iously met.
The MembraneMax™ ce ll-free system appeared to express one of the full length 
Pmps, recomb inant Pmp I in an insoluble form. It was hoped that these prote ins 
would be incorporated into the nano lipoprote in discs (NLPs) in the so luble fraction 
however it is possible that the full length rPrnpl was too large at approx imate ly 95 
kDa, and also the system may not provide an env ironment su itable for full length 
Pmp protein folding. The MembraneMax™ ce ll-free system has displayed the 
expression o f membrane prote ins up to 100 kDa in previous studies however 
membrane prote ins over 100 kDa have not been expressed or are expressed as 
truncated products (Katzen et al., 2008), A lthough rPmp I was in an aggregated 
form, this was an improvement on the express ion trials previous using E.coli where 
the express ion o f full length rPmps was not observed.
The autotrans locator domain of Pmp D, that embeds and acts as a pore w ithin the 
membrane b ilayer was expressed in a soluble state using the novel ce ll-free 
expression system that utilises nano lipoprote in scaffo lds to mimic the lipid bilyer. 
Purification o f the recomb inant Pmp D autotranslocator (rPmpDauto) domain from 
this ce ll-free expression using Ni-NTA agarose was partially successfu l. It was 
separated from the majority of the E. coli endogenous prote ins present w ithin the 
ce ll-free system. However, rPmpDauto did not bind tightly to the N i-NTA column, and 
therefore began to elute w ith a low concentration o f imidazole (20 mM), which limited 
the purification efficiency. This was unexpected as rPmpDauto produced in E.coli 
bound with a useful efficiency to N i-NTA during purification (chapter 3). It was 
considered that the NLPs surrounding the ce ll-free expressed rPmpDauto, being 
large prote ins themse lves, could have been obstructing the access ibility o f the His 
tag reducing its affinity to interact w ith the nickel ions. Disrupting the nano lipoprote in 
discs to re lease rPmpDauto into detergent m ice lles did not improve the b inding of 
rPmpDauto to the nickel ions. It is possible that the use of denaturing conditions to 
fully expose the H is-tag would have provided some success in binding efficiency but 
this would not be appropriate since the protein was required for secondary structure
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analysis. Alternative ly, additional histidines could be incorporated into the expression 
vector to lengthen the hexahistidine tag where in some cases the use of longer 
po lyhistidine tags has resulted in increased purity due to the ab ility to use more 
stringent washing steps (Bornhorst and Falke 2000). However increasing the length 
of the H istidine tag up to 10 residues has been shown to decrease the purification 
yield o f H istidine tagged membrane prote ins by both metal a ffinity chromatography 
and by ion exchange possibly due to overall changes in ionic behaviour in pH 
solutions, also the position o f the tag (N- or C-term inus) has been shown to have 
little effect upon purification yield (Mohanty and W iener 2004). It is advised to use 
the sma llest number of histidine residues as required for efficient purification to 
minimise changes to the protein that could affect protein function. In genera l, a six 
histidine tag as used in these studies is wide ly accepted as an appropriate choice 
(Bornhorst and Falke 2000). Furthermore, a longer po lyHistidine tag may on ly be 
useful when the tag is located and accessible on the outer surface of the prote in. As 
rPmpDauto was predicted to form an autotransporter pore region, o f (3-barrel 
structure, there were uncerta inties over the protein confirmation and tag location. In 
addition, express ing an alternative autotrans locator domain Pmp G for purification 
via the H istidine affinity tag resulted in a similar outcome. On the basis that 
purification was re liant upon detection by Western blot and early purification trials led 
to undetectable levels o f the autotrans locator domain of Pmp G (rPmpGauto) the 
production o f a homogenous sample, sufficient for CD ana lysis was not rea listic for 
this domain. The cost of pursuing the purification o f these domains only had 
implications on the rest of the study. In order to pursue the express ion and structural 
analysis o f Pmp passenger domains, the purification o f Pmp D and Pmp G 
autotranslocator domains were not explored further.
The passenger domain o f Pmp I (rPmp l-N) was successfu lly expressed in a soluble 
state using nanolipoprote in scaffolds. Using Nickel a ffinity chromatography, rPmpl-N 
was partially purified with relative ease and was eluted sharply into a single fraction 
with very few contam inants that could be identified on a Coomassie SDS-PAGE gel. 
However for secondary structural analysis by CD a useful sample requ ires at least 
95% homogene ity (Ke lly et al., 2005) making it necessary to purify further. A two 
step purification with Ni-NTA agarose and the cation exchanger SP sepharose was 
implemented with some success and the rPmp l-N domain was separated firstly from 
the majority o f the endogenous prote ins by Ni-NTA and those that co-purified during 
Ni-NTA affinity chromatography were removed by ion exchange chromatography.
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Unfortunate ly, the yield in the final sample following two purification steps was poor 
rendering the samp le unsu itable for CD analysis.
As rPmpl-N had a strong affinity for the cation exchanger SP sepharose, pre lim inary 
nickel purification was omitted to minimise the loss o f protein that resulted from using 
a two step purification technique. However, when purifying such a heterogeneous 
samp le directly using this method, contaminants that would have been e liminated 
previously by Ni-NTA methods, became bound to the ion exchange co lumn and co­
eluted with rPmpl-N therefore purification using this method alone was also 
unsuccessful.
Interestingly aside from the problems in obtaining sufficient quantities of purified 
protein, the ce ll-free express ion and purification trials for rPmp l-N resu lted in the 
detection o f three bands o f H is-tagged proteins at -4 4  kDa, -3 8  kDa and -2 2  kDa. 
Similar products were obta ined following the expression o f rPmp l-N in E.coli. The 
size of these fragments may have indicated proteo lytic cleavage of the predicted 
native signal peptide producing a fragment -6  kDa sma ller than the expected and 
observed -4 4  kDa band. Additionally the third fragment of -2 2  kDa was detected 
after ion exchange chromatography when rPmp l-N was introduced into higher ionic 
concentrations. Some autotransporters have a c leavage site w ithin the passenger 
domain and undergo proteo lytic cleavage upon certain env ironmenta l triggers 
(Henderson et al., 2004, Desvaux et al., 2004a, Desvaux et a i, 2009). It is possible 
that autoproteo lysis o f the Pmp I passenger domain may have been displayed here. 
One exp lanation is that Pmp I functions as a secretory autotransporter in which the 
passenger domain is cleaved upon exposure to the external milieu during host 
infection as described in section 1.4.6. To investigate this further the fragments 
would need to be purified at levels high enough for proteom ic analysis or for N- 
term inal sequencing o f the fragments so that the c leavage sites could be identified. 
Following identification o f these sites, mutagenes is could be carried out to 
investigate this notion. However this was hampered by the low yie lds that rema ined 
after purification and such methods rely on the ab ility to identify the bands on a 
Coomassie SDS-PAGE gel.
The recomb inant passenger domain o f Pmp A was also produced however this was 
only present as insoluble aggregates and not incorporated into the so luble NLPs. 
B ioinformatic data suggest this protein does not contain an N-term inal signal peptide 
(Gomes et al., 2006), which may indicate that the protein is targeted to the 
membrane by other mechanisms. Possibly hydrophobic regions within the C-term inal
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autotrans loctor domain o f this Pmp target this protein to the membrane. It is possible 
that the truncated Pmp A passenger domain cannot be targeted to the membranes, 
or in this case the NLPs, when lacking its hydrophobic C-term inal autotranslocator 
domain. However the mechanisms o f targeting to the NLPs may differ from native 
env ironments and are not yet fu lly understood.
The purification o f the recomb inant Pmp domains was fraught with difficulties making 
structural analysis by circular dichroism unrealistic. Although soluble protein was 
expressed, the losses in yield that resulted from the purification steps resu lted in 
protein levels below the detection limits o f Coomassie SDS-PAGE and Western 
blotting making it very difficult to locate and isolate the protein o f interest. W hile low 
yie lds or dilute samp les of prote ins can be concentrated using a variety of methods, 
the levels necessary for CD ana lysis would require costly scale up. In addition the 
optim isation steps are time consum ing. Furthermore for each optimisation step, a 
fresh expression sample had to be obtained as the rPmps were highly susceptible to 
precipitation therefore storing the protein between downstream processes (at 4 °C, - 
20 °C and -80 °C) was not suitable. W ith the extreme ly high costs involved in 
expressing proteins using a ce ll-free system, lim itations in expressing, optimising 
purification and scaling up the samp les had to be considered.
Furthermore, a common problem w ith relying on the use of polyHistidine affinity tags 
which was observed in this study was nonspec ific binding o f untagged proteins. 
Although histidine occurs re latively infrequently (2% o f all protein res idues are 
histidine) (Schmitt et al., 1993), some ce llular prote ins contain two or more adjacent 
histidine residues and so also display an affinity for the N i-NTA matrix, co-e luting 
with the protein o f interest, resulting in contamination of the final product. This 
problem is genera lly more pronounced in systems other than E.coli. Mammalian 
cells, for example, have a higher natural abundance of prote ins containing 
consecutive histidine residues (Crowe et al., 1994). An a lternative method metal 
affinity purification using Co2+-carboxylmethylaspartate (Co2+-CMA) matrix (Talon™ 
resin) which displays a lower affinity for po lyHistidine affinity tags than the N i-NTA 
resin, resulting in elution o f the tagged prote ins under m ilder conditions (Chaga et 
al., 1999a, Chaga et al., 1999b). It has been reported to exhibit less nonspec ific 
protein binding than the N i-NTA resin, resu lting in higher elution product purity and 
so may have overcome some of the problems associated with NiNTA purification in 
these studies.
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4 .5  S u m m ary
Practically the expression o f rPmp domains was re latively simple using a ce ll-free 
expression method specialised for the expression o f membrane proteins. Although 
downstream purification resu lted in yields insufficient to allow structural analysis, 
compared to the express ion E.coli, the ce ll-free system provided a sample that was 
eas ier to handle w ith less heterogene ity and rapid results. This proved an 
advantageous method for the expression for rPmp domains where extended 
handling times cause protein precipitation. Most importantly, as soluble protein was 
produced for two Pmp autotrans locator domains and one Pmp passenger domain, 
indicating insertion into nanolipoprote in discs (Bayburt and Sligar, 2010). It is 
assumed that the domains would be in a native conformation ideal for functional 
studies (Katzen et al., 2008, Katzen et al., 2009) where purification was not 
necessary. Therefore it rema ins important that these domains can be expressed as 
soluble protein with the aid o f NLPs. As NLPs m im ic the lipid bilyer (Katzen et al., 
2009, Yang et al., 2011), the investigation o f Pmp domains can be explored further 
to investigate if and how they interact w ith host cells and host cell membranes.
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Chapter 5 - In vitro investigations of recombinant 
truncated Pmps in interaction assays with HeLa and
HeclB cells
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5.1 In troduction
Chlamydiae appear to have various mechanisms in which attachment to host cells is 
estab lished; thus far, the comp lex ity o f these mechanisms have not been fu lly 
e lucidated and several theories remain with regards to which particular ligands and 
receptors are involved. To date, several ligands belonging to Chlamydia have been 
implicated in attachment to the host including heparan su lfate-like g lyosaminoglycan 
(GAG), the major outer membrane protein (MOMP), OmcB, heat shock protein 70 
(Hsp70) and the high-mannose o ligosaccharide g lycan moiety on such prote ins 
(Campbe ll and Kuo 2006). In view of this, studies have focused on determ ining the 
type of ligand - host cell receptor comb inations involved and found that Chlamydia 
may use several different receptors and that dependence was upon host cell type 
(Mou lder 1991, Kuo et al., 2002). Multiple studies have shown the importance of 
heparan su lfate GAGs in attachment of Chlamydia. GAGs bind extrace llular matrix 
components including fibronectin, collagen and laminin (Bernfield et al., 1999). 
Neisseria gonorrhoeae, Leishmania donovani and varice lla zoster virus amongst 
other pathogens have all been shown to use heparan su lfate on the host cell as a 
receptor (Butcher et al., 1992, Zhu et al., 1995, Fre issler et al., 2000, Van Putten et 
al., 2002). However studies w ith C.trachomatis have been inconclusive in 
determ ining if the GAG is displayed on the organ ism or on the host cell to initiate 
attachment. MOMP, also implicated in attachment through heparan su lfate on 
epithe lial cells has been shown to interact through hydrophobic interactions and 
through possessing glycan moieties (Campbell and Kuo, 2006). These g lycan 
moieties cons ist of mannose and mannose-6-phosphate residues and studies have 
hypothesised that Chlamydiae also use the mannose receptor and the mannose-6- 
phosphate receptors for attachment (Swanson and Kuo 1994, Kuo et al., 1996, Kuo 
et al., 2002, Kuo et al., 2004). In addition, the oestrogen receptor on human 
endometrial cells has been revealed as an important receptor for the attachment of 
C.trachomatis serovars B and E (Davis et al., 2002). Earlier studies had discovered 
e lectrostatic interactions were important for the binding o f Chlamydia to host ce lls 
and demonstrated that positive ly charged polycations such poly-L-lysine, divalent 
cations such as Ca2+, Mg2+and Mn2+ and monovalant cations of Na+ all increased the 
binding of different Chlamydia species to cells, whilst the addition o f negative ly 
charged heparan su lfate inhibited the attachment and entry aga in indicating its 
importance (Kuo et al., 1973, Hatch et al., 1981, Sneddon and Wenman 1985). 
Collectively, this information deta ils a complex array of adherence mechanisms 
displayed by Chlamydiae.
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B ioinformatic studies have revealed characteristics about the Pmps that would 
suggest these prote ins also act as potential adhesion molecu les involved in host cell 
attachment espec ially since the Pmp prote ins contain repeated signature motifs 
GGAI and FXXN. These s ignature motifs have been implicated in adhesion for other 
m icrobial virulence factors such as OmpA o f Rickettsia spp. (Grimwood and 
Stephens, 1999). Furthermore, Pmps have been implicated in tissue spec ific tropism 
(Stothard et al., 2003, Gomes et al., 2006), adding we ight to the adhesion theory 
such that Pmps function to target spec ific host tissue types. Additionally, truncated 
portions o f Pmp D were expressed as inclusion bodies and identified as a stimulatory 
antigen, recogn ised by CD4+ cells (Goodall et al., 2001) and Pmp F was predicted to 
possess T-ce ll epitopes that bind human leukocyte antigen (Carlson et al., 2005), 
both indicating surface interactions with human cells.
Since these discoveries, few studies have proceeded to demonstrate attachment of 
Pmps in vitro. The studies that have explored this notion have shown that the N- 
term inal passenger domain o f the Pmp D homologue, Pmp21 from C.pneumoniae 
trans locates to the outer membrane and antibodies raised against this, have blocked 
chlamydial infectivity (Wehrl et al., 2004). More recently, Pmp G and Pmp D 
homologues, Pmp6 and Pmp21 respectively, from C.pneumoniae, were shown to 
adhere to human ep ithe lial cells whilst using truncated Pmp domains on yeast cells 
and latex beads (Molleken et al., 2010a). Flowever these studies only exam ined the 
central passenger domain o f the prote ins and so lacked data associated with 
adherence of the C-term inal autotranslocator domains or the signal leader peptides 
(a lthough it is expected this would not be displayed on mature Pmps). These studies 
are by no means conclusive, and little attention has been paid to any o f the nine 
Pmps (A-l) of C.trachomatis w ith regards to adherence and interaction with 
mammalian cell surfaces.
In this study, with the use of nanodiscs to mimic the lipid bilayer, truncated rPmps 
were expressed for use in protein interaction assays with cervical (HeLa) and 
endometrial (F lec lB ) cells o f the female urogen ital tract to screen for putative ligand- 
receptor interactions. Several techniques were explored including cross-binding 
assays using chem ical cross-linkers after incubating rPmp domains with whole cells, 
immunofluorescence to exam ine the possibility o f rPmp domains in localisation to the 
host cell surfaces and finally biophysical techniques using surface p lasmon 
resonance (SPR) and e llipsometry as a ligand fishing approach utilising lysed 
mammalian cells as potential orphan receptors.
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The particular rPmps domains used in these screening trials were the (N-term) 
passenger domain o f Pmp I and the (C-term) autotrans locator domains o f Pmp D 
and Pmp G. These truncated rPmps were expressed as soluble prote ins with the aid 
of NLP nanodiscs (chapter 4). However, as purification o f the rPmp domains was 
challeng ing, producing only partially pure protein, which resulted in low protein yields 
and increased handling time esca lating the chances of degradation and precipitation, 
these rPmp domains were not isolated from other MembraneMax™ endogenous 
proteins. Instead, as a control the empty vector was applied to the MembraneMax™ 
express ion system and was used in control assays to e liminate potential fa lse 
positives. The N-term inal passenger domains of Pmp D and Pmp G have a lready 
been suggested to carry adherent mechanisms in the homologue C.pneumoniae 
(Mo lleken et al., 2010a).
5.1.1 C hem ica l c ro ss -lin k in g
Chem ical cross-linking is a process whereby two prote ins or protein reg ions are fixed 
through covalent bonds formed at the end reaction groups present on the cross­
linker w ith functional groups on the prote ins (Tang and Bruce 2009). Cross-linkers 
are used for identification o f close ly associated protein re lationships and ligand- 
receptor interactions. The cross-linkers used to identify surface receptors to the ir 
ligands often require a cross-linker w ith a longer space arm compared to a zero or 
short spacer arm used to fix subunits within a protein. The most common reactive 
groups on cross-linkers are A/-hydroxysulfosuccinimide (NHS) esters, ma lema ides 
(su lfhydryl-reactive) and non-spec ific photo-reactive groups.
5.1 .2  Im m u n o cyto ch em istry
Immunocytochem istry (ICC) can be a useful tool to investigate the spatial distribution
of prote ins within cultured ce lls using antibodies directed against the prote in of
interest. Immuofluorescence is dependent upon the coupling o f fluorophores to
antibodies, which when bound to the antigen of interest and excited by a light
source, such as UV light, em it light that is visible under a fluorescent m icroscope to
a llow identification o f antigen/prote in localisation. Prior to antibody application the
ce lls are fixed to retain ce llular and subce llular structures, interactions and to fix the
distributions of proteins. Permeab ilisation o f the ce llular membranes is necessary to
a llow entry of the antibody and can be accomp lished by using an organic solvent
such as acetone which also fixes the cells. A blocking step is implemented with a
non-spec ific protein such as bovine serum albumin (BSA) or using serum to which
the antibody is raised in order to reduce non-spec ific binding to endogenous Fc
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receptors (FcR) present on the surface of some cells (Buchwalow et al., 2011) . The 
cells are washed between each step to ensure unbound proteins, antibodies and 
other reagents are removed. Determ ination o f a su itable staining method is essential 
for successfu l amplification and identification o f prote in-ce ll and prote in-prote in 
interactions.
Two types of immunofluorescence exist: direct and indirect, the method o f choice is 
often determ ined upon the necess ity to amplify the target signal where the target 
antigen/prote in may be present in low concentrations or where the epitope may be 
obstructed. A direct method o f immunofluorescence utilises a primary antibody 
conjugated with a fluorochrome, this conjugate is directed to the antigen of interest 
and the method overall involves fewer steps. However, the technique is limited as 
only a certain amount o f primary antibodies can access the antigen of interest before 
saturation is met. Using an indirect method, a secondary antibody that targets the 
primary antibody is used to amplify this signal. This secondary antibody is 
conjugated to a fluorophore and is directed against the species of immunoglobulin 
(Ig) that the primary antibody was raised. For the purposes of this study, as the 
recomb inant protein was o f unknown concentration in a heterogeneous m ix and the 
amount necessary to estab lish an interaction with the cells was unknown an indirect 
method is the preferred method, using two antibodies to v isualise the prote in/antigen 
and so an indirect method was chosen to ensure that if such an interaction or 
localisation had taken place, this would increase the likelihood o f this being detected.
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5.1.3 S urface  P lasm on R eso n an ce
Over recent years surface p lasmon resonance (SPR) b iosensors have become an 
estab lished method of measuring molecu lar interactions. SPR-based instruments 
use an optical method to measure the refractive index near a sensor surface to 
which a ligand is immobilised and the interaction with analytes, passing over in 
solution are monitored (Cooper, 2002). Binding o f mo lecules in solution to surface- 
immobilised receptors a lters the refractive index of the medium near the surface 
(Cooper, 2002). S ince the deve lopment of the first biosensors in the late 1980s, the 
use of optical biosensors in research and deve lopment has expanded. These include 
ligand fishing (Zhukov et al., 2004, Ravanat et al., 2009), epitope mapping (Jokiranta 
et al., 2000, Fagerstam et al., 2004), and cell adhesion (Nielsen et al., 2000) 
amongst many others.
Using Biacore SPR analysis, the ligand is immobilised to a sensor chip surface, the 
surface is comprised of a 50 nm layer of gold sandwiched between a g lass layer and 
the m icro-fluidic cartridge, in which the samp le ana lyte so lution flows through and 
passes over the ligand (Figure 5.2). A polarised laser light directed through a prism 
with a high refractive index, focused on the back of the sensor chip, is reflected back 
to a diode array detector unit that monitors the intens ity o f reflected light (Besen icar 
et al., 2006). At a critical angle of incident light, surface p lasmons are generated at 
the surface of the gold layer. This absorbs the light and is visible as a decrease in 
the intensity of reflected light. When a change in mass occurs near the sensor chip 
surface, as a resu lt o f a binding event or a change in solution/bu ffer in the m icro- 
flu idic system, the angle of light at which the SPR occurs shifts due to a change in 
the refractive index near the sensor chip surface (Jason-Moller., et al 2006). This is 
measured in rea l-time and plotted on a sensorgram w ith response measure in 
resonance units (RU). Each RU is equal to a critical angle angle shift of 10'4 degrees 
w ith a linear re lationship between the mass of the components at the surface of the 
chip and the RU such that 1 RU is equal to 1 pg/mm2 (Stenberg et al., 1991).
One of the most w ide ly used SPR systems is the B iacore, produced by BIAcore AB 
(B iomolecu lar Interaction Analysis), (GE Hea lthcare). B iacore instruments are 
capab le of characterising binding interactions in rea l-time w ithout the need for a 
labelled analyte (R ich and Myszka 2000). Identification of binding interactions has 
been achieved with a variety of samp les ranging from proteins, nucleic acids, small 
molecules to more comp lex samp le m ixtures including lipid vesicles, v iruses, 
bacteria and eukaryotic cells (Jason-Moller., et al 2006).
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5.1.3.1 B iacore X  ap p ara tu s
B iacore X, used in these studies is a highly sensitive, sem i-automated system suited 
for low-sample throughput. To understand and deve lop optimised methods, a 
working knowledge of the internal micro-fluidic set up was necessary. Briefly, the 
sensor chip surface forms the floor o f the small flow cell which an aqueous solution 
(running buffer) passes under continuous flow. As described in section 5.1.3 to test 
for an interaction the ligand is fixed to the surface and the ana lyte is flushed over in 
sample buffer under continuous flow. A change in mass as a resu lt of a binding 
event increases the refractive index to form a response curve/peak. Importantly, a 
background response will also be generated if there is a change in the running and 
sample buffers and so this change in refractive indices must be subtracted by using 
a reference flow cell (Figure 5.3). The integrated fluidic cartridge in the B iacore X 
instrument conta ins only two flow cells allowing the immobilisation o f two mo lecu les 
on one chip or set-up w ith one flow cell used as a reference and the other 
immobilised with a ligand of interest (Figure 5.4). The system has a dual-channe l 
detection o f the SPR signal such that simultaneous monitoring o f both flow cells can 
be used and the instrument software allows in-line reference subtraction o f the 
control surface signal from the samp le injection (Biacore, 2002). One advantage of 
investigating interactions by this method, due to the high sensitivity, was that only 
small amounts o f samp le were needed and where strong interactions take place, 
only nanomolar concentrations may be necessary.
B iacore have a range of sensor chips suited to different app lications, all are coated 
with a thin uniform layer of gold, gold is amenab le to cova lent attachment of surface 
matrix layers and in physiological buffers it is mostly inert and so is well suited for 
SPR app lications. The original and most wide ly used due to its versatility is the CM5 
chip coated with a carboxymethylated dextran layer for the coup ling o f ligands to the 
surface by cova lent attachment via amino, thiol, aldehyde or carboxyl groups 
(Besen icar et al., 2006). Molecules bound to the dextran matrix are able to behave 
s imilarly as in solution due to the high flex ibility o f the matrix (Day et al., 2009).
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Reference surface Active surface
Referencesubtraction
Figure 5.3 - Schematic diagram to depict the bulk subtraction of reference control from 
a binding event. The sensorgram from the reference surface shows a bulk contribution from 
the sample buffer while the active surface shows association of ligand/analyte with the 
surface and an increase in baseline as a consequence of binding. This surface also includes 
the bulk contribution shown on the reference surface, when the reference bulk is subtracted 
from the active surface, only the binding response is shown. (Biacore X getting started 
manual, 2002).
Sensor surface 
.
G lass slide
IFC channels IFC
Pnsrn V '
I
F lo w  c e l ls ,  fo r m e d  b y  c o n t a c t  o f  t h e  IF C  
o n  t h e  s e n s o r  s u r fa c e
)
Figure 5.4 - Schematic diagram depicts the flow cells over the sensor chip surface in 
Biacore instruments. Flow cells are formed when the microfluidic cartridge is pressed 
against a sensor surface. All sample solutions, running buffers, analytes etc. are delivered 
through each flow cell to the surface of the sensor chip by the integrated micro-fluidics 
cartridges IFC. The diagram shows 4 flow cells, the Biacore X used in this study contains 
only 2 flow cells. (www.biacore.com/lifesciences/technology/introduction/Flow_cells/index)
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5.1.4 Ellipsometry
E llipsometry is an optical biosensor technique used to investigate and characterise 
film thickness of single layers or comp lex mu lti-layers of material by use of polarised 
light similar to conventional SPR (Nabok et al., 2011). A change in polarised light 
reflected o ff a samp le yields information about the layers w ith measurements 
sensitive to detect changes ranging from a few angstroms to several micrometers 
w ith exce llent accuracy. Total Internal Reflection Ellipsometry (TIRE) comb ines the 
highly sensitive spectroscop ic e llipsometry w ith the experimenta l conven iences of 
SPR. Where conventional SPR monitors the intensity of reflected polarised light, 
TIRE detects two parameters, the amp litude ratio qj and the phase shift A of p- and 
s-components of reflected light shown in F igure 5.5. The method o f total internal 
reflection e llipsometry has shown to be more accurate and sensitive when compared 
to SPR (Nabok et al., 2005).
Figure 5.5 - Principals of TIRE reflected light. (1) The incident light is linear with both p- 
and s- components prior to meeting sample material (2). The reflected light has undergone 
amplitude and phase changes for both p- and s- polarised light (3), and ellipsometry 
measures these changes, (http://www.jawoollam.com/tutorial_4.html).
1. Known input 
polarization
c  p - p b i n o
^  J.A. wociiom  Co.. inc.
X Measure output 
polarization
p-ptene
plcit« gf incidence
2. Reflect off sample.
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5.2 M ateria ls /m eth o d s
5.2.1 L ab o rato ry  reagents  and equ ipm ent:
Ana lytical grade chem icals were used throughout this study with all solutions being 
prepared using sterile water. Materials were obta ined from the following suppliers.
Abeam, Cambridge; Bio-Rad Laboratories Ltd., Hemel Hemsted, Hertfordshire; 
GE Healthcare Ltd, Amersham, Buckinghamshire; Generon., Ma idenhead, 
Berkshire; Invitrogen Life Technologies., Paisley; New England Biolabs (UK) 
Ltd., Hitchin, Hertfordshire; Novagen, Merck Chemicals Ltd., Beeston, Nottingham; 
Qiagen Ltd., Crawley, W est Sussex; Sigma Aldrich Company Ltd., G illingham, 
Dorset; Starlab UK., B lakelands, Milton Keynes; Thermo-Fisher Scientific UK., 
Loughborough, Leicestershire; Protein expression; Vector Laboratories Ltd., Orton 
Southgate, Peterborough
5.2.2 P rote in  E xpression
Recomb inant Pmp domains (rPmpl-N, rPmpDauto and rPmpGauto) were expressed 
in the ce ll-free expression system in 100 p.1 volumes as in section 4.2.1. Insoluble 
fractions were discarded. HALT protease inhibitors (Thermo Sc ientific) were applied 
to the so luble protein fractions prior to interaction assays. Recomb inant Pmp 
domains were not subject to purification for interaction studies.
5.2 .3  M am m alian  cell cu ltu re  m ethods
All cell culture reagents, medium and supplements were obta ined from G ibco™, 
Invitrogen UK unless otherw ise stated. All cell culture methods were carried out 
under sterile conditions in a class II laminar flow cabinet. HeLa cervical 
adenocarc inoma cells and H ec lB  endometrial adenocarc inoma cells were both 
obtained as passage 2 stocks, as a g ift from Dr Adrian Eley (Un ivers ity o f Sheffie ld).
5.2.3.1 Cell line s tocks and recovery
HeLa and H ec lB  cells were stored long-term in cryovials immersed in liquid nitrogen
until required for experimenta l work. Cells were preserved in 1 ml o f Fetal Bovine
Serum conta ining 10% dimethyl sulphoxide (DMSO) at a dens ity o f 1 x 106 cells
per/m l. Upon recovery, cells were placed in 37 °C incubator to thaw for 2 m inutes.
Upon thawing the cells were transferred into 25 cm2 filter-cap (T25) flasks containing
9 ml of the appropriate pre-warmed, complete cell culture medium and allowed to
adhere to the bottom of the flasks overn ight at 37 °C in a humidified incubator
containing 95% air and 5% C 0 2. Media was changed twice week ly and upon 80%
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confluence, cells were transferred into 75 cm2 filter-cap (T75) flasks to maintain 
stocks for experimenta l assays.
5.2 .3 .2  Cell harvesting  and seria l p assage o f cells
Thawed stocks o f adherent HeLa cervical adenocarc inoma cells and H e c lB  
endometrial adenocarc inoma cells were routine ly grown in a humidified incubator at 
37 °C with 5% C 0 2 in 75 cm2 flasks immersed in specified media with supplements 
as in Table 3.1. When cell monolayers were determ ined near-confluent at -80% , 
cells were passaged into new T75 flasks by trypsinisation. Briefly, the cu lture 
medium was removed and the cell monolayer was washed with 10 ml Dulbecco’s 
phosphate buffered saline (DPBS) w ithout calcium or magnesium to remove 
remaining media. Cells were detached from the flask using 5 ml Trypsin/EDTA 
solution (0.5% trypsin, 0.2% EDTA) and incubating at 37 °C for 5 m inutes fo llowed 
by gentle tapp ing of the flask. The enzymatic action o f the trypsin was quenched by 
the addition o f 5 ml o f comp lete media to the cell suspension and gentle p ipetting 
before transfer to a sterile Falcon tube where the cell pellet was co llected by 
centrifugation at 650 x g for 5 m inutes. The supernatant was discarded and the 
collected cells were washed in DPBS, pelleted as before and resuspended in a 
known volume of culture media for e ither cell counting (section 5.2.3.4) for 
experimenta l assays, or were seeded at 1:6 ratio for further propagation o f cells.
5 .2 .3 .3  P repara tion  o f H eLa cell lysates  fo r B iacore  and E llip so m etry
HeLa cells suspended in ice cold PBS with protease inhibitors were lysed by 
sonication with a Sonics Vibra Cell probe son icator (probe tip diameter 3 mm) on ice 
w ith five 10 second pulses at 30% amp litude. Centrifugation at 2900 xg for 20 
m inutes removed unbroken cells and nuclei (Millipore protein extraction protocols). 
Supernatant containing cell membranes and cytosol was diluted 1 in 10 in running 
buffers for app lication in Biacore SPR and e llipsometry. All cell preparations for 
these app lications were performed fresh and were used immediately.
5 .2 .3 .4  Cell counting
Cell counting was carried out using a haemocytometer. Briefly, 10 \x\ o f cell 
suspension from section 5.2.3.2 was m ixed thoroughly with the same vo lume of 
0.4% Trypan Blue. This viable/non-v iable cell staining method is based on the 
principle that certain cells i.e. w ith compromised membranes, a llow entry of the 
trypan blue dye to a llow calculation of the percentage viability o f the cells. Counting 
the number of cells in 5 o f the large outer squares (outer 4 corners and centra l
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square) and multiplying by 50,000 gave the number of cells per ml. To calculate the 
percentage of viable cells the following equation was used [1.00 -  (number of blue 
cells ^ number of total cells)] *  100. To seed cells for experimenta l assays only the 
viable cell count was used to calculate the dilution factor of the cell suspens ion to 
obtain the desired density.
HeLa Cervical
adenocarc inoma
Human Dr. A. Eley,
Medical
School,
University of 
Sheffield,
UK
500 ml Dulbecco’s 
modified eag le’s 
medium (DMEM), 
high-glucose w ith 
GlutaMAX™
10% (v/v) Heat 
inactivated foeta l 
bovine serum (H l- 
FBS)
1% (v/v)
Pen icillin/streptomyc in 
(100 U/ml/50|ag/ml)
H eclB  Endometrial
adenocarc inoma
Human Dr. A. Eley,
Medical
School,
University of 
Sheffield,
UK
500 ml McCoy’s 5A 
medium
10% (v/v) Heat 
inactivated foeta l 
bovine serum (H l- 
FBS)
1% (v/v)
Pen icillin/streptomyc in 
(100 U/ml/50p.g/ml)
1% (v/v) L-Glutamine 
(2mM)
Table 5.1 - Summary of mammalian cell lines and growth culture requirements.
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5.2 .4  C hem ica l c ro ss -lin k in g
5.2.4.1 R eco m b in an t prote in  tre a tm en t o f cells  fo r ch em ical c ro ss - 
link ing  assays
Cross-linking can be performed on cells in suspens ion or on adherent cells in culture 
plates. In the latter, adherent cells have less exposed cell surface area, limiting 
potential cross-linking therefore assays were carried out with cells in suspens ion. 
H ec lB  and HeLa cells were seeded into 15 ml falcon tubes at a dens ity o f 25 x 106 
cells per ml in 1XPBS, pH 8.0, this calculation had to take into account the amount of 
protein suspension that would be added to ensure a final volume of 0.5 ml was not 
exceeded to prevent dilution o f the recomb inant Pmp protein which limits 
downstream detection o f H is-tagged proteins and conjugates. A high concentration 
of cells was preferred to maximise the chances of identifying an interaction with 
recomb inant protein. Briefly, the medium was removed and the cells were washed 
three times w ith DBPS to remove am ine conta ining components that would quench 
the cross-linking reaction. The total soluble protein fractions from the ce ll-free protein 
expression were incubated with the mamma lian cells for one hour with gentle 
agitation. Initially this was done using 200 jul o f ce ll-free expression o f rPmp domain 
(section  4.2.1) (300 jug total protein), for each assay so that His-tagged rPmp 
domains were detectab le via Western blot. This interaction was carried out at 37 °C 
to mimic in vivo C.trachomatis attachment (Soderlund and Kihlstrom, 1983; 
Soderlund and Kihlstrom, 1988; Fadel and Eley, 2008). Finally any interactions were 
cross-linked as in sec tion  5.2.4.2, Adaptations to optimise these methods were 
subsequently made and the rema inder of the incubation assays were performed at 
4 °C to reduce recomb inant protein precipitation.
5 .2 .4 .2  C hem ical c ro ss-lin k in g  w ith  BS3
BS3 (Sulfo-DSS) is a homobifunctional amine-am ine NHS ester w ith an 8-carbon 
spacer arm as seen in F igure 5.6 (Thermo Scientific). Generally, prote ins have 
several lysine residues rich in amines exposed via side chains in addition to the N- 
term inus of each polypeptide making ample targets for NHS ester cross-linking. With 
appropriate controls, cross-linking experiments can a llow unambiguous identification 
of protein interactions when used together w ith a variety of techniques including 
Western blotting, immunoprecipitation and mass spectrometry (MS). In this case, the 
target prote ins carried a polyHistidine tag which could be probed using the 
estab lished Western blotting technique using the penta-H is antibody which has been
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used to identify rPmps (section 5.2.6.1). BS3 was chosen because it is membrane 
impermeab le making it ideal for ce ll-surface interactions, and most importantly it is 
soluble in water and can be used in a range of common buffers where the use of 
organ ic solvents may disturb protein structure and activity. The cells were seeded as 
in section 5.2.3.2 to a dens ity o f -2 5  x 106 ce lls/ml in PBS (pH 8.0) fo llowing the 
gu ide lines set out by Thermo Scientific. Cross-linking with homobifunctional linkers is 
a shotgun approach for capturing an interaction and according to the manufacturer's 
recommendations high quantities of cross-linker and targets are often necessary to 
increase the capture of such an interaction. W ithout authentic positive contro ls and 
following the manufacturer’s instructions BS3 is effective when used at a final 
concentration o f between 1 and 5 mM (Thermo Fisher). The higher end o f this 
concentration was used throughout the cross-linking studies to ensure that all 
interactions were captured. This final concentration o f 5 mM BS3 was added to the 
end of the prote in/cell incubation, from a freshly made 100 mM stock dissolved in 
PBS pH 8.0. Stocks were used immediate ly as BS3 is rapidly hydrolysed. The 
reaction was cross-linked for 30 m inutes at 4 °C fo llowed by quenching with a final 
concentration o f 20 mM Tris for 15 m inutes at room temperature. The cross-linked 
samples were prepared for ana lysis as in section 5.2.4.4.
Na+0 0io = s Q-Na+n i
0 S=Qn
0
a
BS3
Bisfsuffosuccimmidyl) suberaie
MW 572.43 
Spacer Arm U .4 A
Figure 5.6 - Chem ical structure of BS3. From http://www.piercenet.com
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5 .2 .4 .3  C hem ica l c ro ss-lin k in g  w ith  fo rm a ld eh yd e
Forma ldehyde is membrane permeab le therefore cross-linking occurs both 
intrace llularly and extrace llularly. Formaldehyde was used to fix interactions at a final 
concentration o f 1% for 1 hour at room temperature. The reaction was quenched 
with 300 mM glycine for 30 m inutes at room temperature. An a liquot o f the crude 
assay was added to SDS loading buffer for SDS-PAGE and Western b lotting and the 
supernatant and cell pellets were co llected as in section 5.2.4.4,
5 .2 .4 .4  F ractio n atio n  o f c ro ss -lin ked  assays
Cells were pelleted for 5 m inutes at 500 x g at room temperature. The supernatant 
was retained as the unbound fraction and an aliquot was added to SDS loading 
buffer. The cell pellets were lysed directly by 5 brief pulses w ith a Jencons Son ics 
Vibra Cell probe son icator (probe tip diameter 3 mm) in SDS loading buffer and 
passed several times through an Hamilton syringe to reduce viscosity. These 
fractions were analysed via Western blot.
5.2 .5  Im m u n o cyto ch em istry
5.2.5.1 R eco m b in an t protein  tre a tm en t o f ce lls  fo r im m u n o c yto ch e m is try  
(IC C )
For immunocytochem istry analysis, H ec lB  and HeLa cells were seeded into 8-well 
chamber slides in 400 jlxI volumes at a dens ity o f 1 x 105 cells per ml in appropriate 
comp lete media (section 5.2.3.2) and allowed to adhere to the slides for 24 hours at 
37 °C in a humidified incubator prior to treatment w ith recomb inant protein samples. 
Following this, the media was removed and the cells were washed three times w ith 
DPBS. The total soluble protein fractions from a 100 pi ce ll-free MembraneMax™ 
protein expression sample (section 4.2.1) were diluted in serum-free media and 
incubated with the mamma lian cells for one hour at 37 °C with 5% C 0 2to mimic in 
vivo attachment conditions (Soderlund and Kihlstrom 1983, Soderlund and Kihlstrom 
1988, Fadel and Eley 2008). A range of protein dilutions were used during 
optimisation to ensure the recomb inant protein was detectab le. A 100 pi o f diluted 
expression sample was added to each well. The recomb inant protein samples were 
aspirated and cells washed prior to ICC staining as in section 5.2.5.3.
5 .2 .5 .2  Sudan b lack  B sta in ing
Sudan black B (SBB) is a fat-so luble dye common ly used to reduce
autofluorescence of tissues and cells caused by high levels of lipofusc in, a
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fluorescent p igment which accumulates w ith age in the cytop lasm o f cells, which 
because of its broad exc itation and em ission spectra, it often interferes w ith 
fluorescent m icroscopy (Viegas et al., 2009). Using 0.3% SBB has prev iously been 
shown to be sufficient to quench lipofuscin autofluorescence (Schne ll et al., 1999). 
0.3% SBB stock is prepared in 70% ethanol, stirred for 2 hours at RT, fo llowed by 
filtering with Whatman paper and stored wrapped in foil at 4 °C. This was applied to 
cells for 10 m inutes at RT prior to mounting the slides during ICC.
5 .2 .5 .3  In d irec t im m u n o flu o rescen ce
In order to determ ine if recomb inant truncated Pmps interact w ith the cell surface of 
endometrial and cervical cells, immunocytochem istry (ICC) was carried out after 
incubating truncated Pmps with H ec lB  and HeLa cells. Following incubation the 
cells were washed three times in PBS for 5 m inutes to remove non-interacting and 
non-spec ifically bound proteins. The cells were fixed with ice cold acetone for 5 
m inutes and left to a ir dry for 15 m inutes at room temperature The ce lls were 
blocked with 1XPBS, 25% goat serum, 1% BSA for 45 m inutes at RT. The ce lls were 
stained for polyhistidine tagged proteins using rabbit polyclonal 6X His-tag antibody 
(Abeam) and/or mouse monoclonal Penta-H is antibody (Qiagen) as in Table 5.2. 
Pre liminary experiments were performed to determ ine the optimum concentration of 
Ab for ICC, w ith each antibody diluted within a range recommended by the supp lier. 
Primary antibodies diluted in DPBS, 1% BSA, were applied to each well and 
incubated for one hour at RT before three 5 m inute washing steps to remove 
unbound antibody. To detect bound primary antibodies, secondary antibodies of 
fluoresce in isothiocyanate (FITC) conjugated to goat anti-rabbit IgG (for rabbit 
polyclonal His-tag antibody) and goat anti-mouse IgG (for mouse monoc lonal Penta- 
His antibody) were applied diluted in PBS and incubated for 45 m inutes at RT in the 
dark. Cells were washed three times to remove unbound secondary antibody prior to 
staining with Sudan black B to reduce autofluorescence in HeLa cells (Figure 5.7). 
Antibody controls were also performed with untreated cells using primary and 
secondary antibodies independently to check for non-spec ific background signal, 
(Figure 5.7 and Figure 5.8). Slides were then mounted using Vectashie ld™ hard-set 
mounting medium with 4 ’, 6-diamidino-2-pheny lindole (DAPI) (Vector laboratories, 
UK), which stains the cell nuclei blue. The edges were sealed with clear varn ish and 
slides stored in the dark at 4 °C until analysed.
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5 .2 .5 .4  L ight and flu o re sc e n t m icro sco p y
ICC images were captured with equal exposure times using an upright Olympus 
BX60 fluorescent m icroscope equ ipped with a cool-snap pro (Cybernetics) digital 
camera to acqu ire images into Labworks™ where they were saved without 
manipulation.
Immunogen Species C lonality Dilution Source
6X His-tag 
-HHHHHH-
Rabbit Polyclonal 1:50,1:100,1:250,
1:500,1:750,1:100,
1:2000,1:5000,
Abeam, UK
Penta-H is
-HHHHH-
Mouse Monoclonal 1:50, 1:100, 1:250, 
1:500
Qiagen, UK
Immunogen Species F luorochrome D ilution Source
Rabbit IgG 
Mouse IgG
Goat FITC 1:250, 1:350 Abeam, UK
Goat FITC 1:250, 1:350, 
1:500
Invitrogen, UK
Table 5. 2 - Summary table of antibodies used for immunocytochemistry. Details of 
primary and secondary antibodies used for immunocytochemical detection of recombinant 
His-tagged Pmp domains in interactions with HeclB and HeLa cells. The antibodies used for 
the final immunocytochemistry assays are highlighted in bold.
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5.2 .6  Im m u n o b lo ttin g
5.2.6.1 W estern  b lo tting  w ith  m ouse m o n o c lo n al p en ta -H is  and HRP  
co n ju g ated  seco n d ary  an tib o d y
The technique for Western blotting using penta-H is primary with HRP secondary is 
described previously in se c tion  3.2.5.2.
5 .2 .6 .2  D ot b lo tting
10 pi o f each sample for ana lysis was applied directly on to a nitroce llulose 
membrane, allowed to dry for 5 m ins before the antibody staining protocol in sec tion
3.2.5.2 omitting the SDS-PAGE and methanol transfer was used to probe the 
samp les using the penta-H is antibody and HRP conjugated secondary.
5 .2 .6 .3  W estern  b lotting  w ith  rab b it po lyc lona l 6X H is  an tib o d y  and a n ti­
rab b it F ITC  seco n d ary  W es te rn  b lo tting
Transfer to n itrocellulose was performed as described by (Towbin et al., 1979). 
Following SDS-PAGE gels were rinsed in transfer buffer (25 mM Tris, 192 mM 
glycine, 20% (v/v) methanol, pH 8.3). A nitrocellulose membrane (0.45 pm pore size, 
GE Healthcare, Amersham) was cut to the same dimension as the gel and soaked in 
dH 20  for 10 m inutes. A B io-rad mini-gel blotting apparatus was set up according to 
the manufacturer’s instructions, and the prote ins were transferred for 1 hour at 100V 
in transfer buffer. Membranes were washed Tris-buffered saline (TBS, 20 mM Tris, 
500 mM NaCI, pH 7.5) for 10 m inutes prior to blocking with 1% alkali-soluble casein 
(Merck) in TBS containing 0.2% Tween-20 (TBST), for 2 hours at room temperature. 
A 6XH is primary antibody (1 pg/ml) (Abeam) in antibody buffer (TBST conta ining 1% 
alkali-soluble case in) was added for 2 hours at room temperature. Membranes were 
washed three times in TBST. Secondary antibody, a FITC conjugate of goat anti­
rabbit IgG (Abeam) was added at a dilution o f 1:10,000 in antibody buffer for 1 hour 
at room temperature. Membranes were washed three times in TBST and the 
fluorescent signal was detected using the Odyssey Infrared Imaging System (L l- 
COR Biosciences, UK).
5.2 .7  S urface  p lasm on resonance
5.2.7.1 D ocking  sen so r ch ips and m a in ten an ce
Before ana lysis using Biacore apparatus, all reagents and sensor chips must be 
equ ilibrated to room temperature. All buffers were filtered (0.22 pm) using a Millipore
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filter and degassed under vacuum filtration. The B iacore m icro-fluidic system was 
primed with running buffer after each docking o f a sensor chip. There are variations 
in the reflectance characteristics of the gold dextran surface both between chips and 
between the same chip at different temperatures. To norma lise the signal response 
between docking sensor chips, the norma lise ma intenance procedure was routine ly 
carried out using 100 pi 70% BIAnormalising solution (70% glycerol), (Biacore). All 
assays were carried out at room temperature (22 ±1 °C).
5.2 .7 .2  S am ple  loading
Sample loading is a critical step in producing unambiguous sensorgrams, as a sem i­
automated method the sample injection is by manual load and a ‘double a ir bubble’ 
technique, displayed in F igure 5.9 is necessary to prevent samp le dispersa l at the 
beg inning and after injection, in particular it is useful for v iscous samples that tend to 
drag in the samp le loop walls during injection.
5 .2 .7 .3  A m ine cou p lin g  o f penta-H is  an tib o d y  to  C M 5 s en s o r ch ip
Firstly, prior to preparing the sensor chip surface for am ine coup ling, the intended 
ligand (penta-H is Ab) for immobilisation was checked for sufficient e lectrostatic 
interactions with the carboxymethylated dextran in just one flow cell. This pH 
scouting is normally carried out at a range of pH in sodium acetate buffers. An 
a liquot o f the penta-H is antibody was subjected to a short-term dialysis for 1 hour at 
4 °C into 10 mM sodium acetate buffer pH 5.0 where it has prev iously been reported 
to associate and couple to the dextran surface (Nordin et a l,  2005). Upon 
dissociation o f the penta-H is using the running buffer (10mM Hepes, 0.15 M NaCI, 
0.0005% P20, pH 7.4) the dextran surface was activated using the B iacore am ine 
coup ling kit (GE Hea lthcare) w ith a freshly made 1:1 m ixture of 0.1 M N- 
Hydroxysuccinimide (NHS) and 0.4 M 1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiim ide hydrochloride (EDC) at 30 jul/min to reach 180-250 RU, to give reactive 
succinide esters. 30pg/m l o f penta-H is antibody diluted in 10 mM sodium acetate (pH
5.0) was injected,at 20 pl/min and reapplied until the response units were resolute. 
The remaining activated groups were blocked with 60 j l l I  1 M Ethanolamine 
hydrochloride-NaOH pH 8.5, to quench unreacted esters and remove unbound 
antibody. The immobilised sensor chip was ready for binding His-tagged proteins. 
Activation and deactivation was also carried out on the sensor chip surface in the 
second flow cell to produce a reference surface for subtraction of non-spec ific 
protein interactions with the dextran surface.
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5 .2 .7 .4  C ap ture  o f analy te  using a p en ta -H is  im m o b ilised  s en s o r su rface
The unpurified soluble fraction of the ce ll-free expressed recomb inant His-tagged 
truncated Pmps or purified Endo1-8-His control were injected over the active and 
reference surfaces for capture by the immobilised penta-H is antibody on the CM5 
sensor chip. These samp les were e ither directly applied as concentrated prote ins or 
were diluted in running buffer (10mM Hepes, 0.15 M NaCI, 0.0005% P20, pH 7.4) to 
m inimise the changes in refractive indices caused by the change in sample buffer 
and running buffer. The changes in response units were measured and the reference 
surface was subtracted from the active surface (BIAeva luation software version 3.2).
5.2 .7 .5  R eg enera tion  o f pen ta -H is  im m o b ilised  su rfaces
Regeneration buffer (G lycine-HCI pH 2.5) was injected at 7 pl/min for 10 m inutes. 
The base line was mon itored after regeneration, where the baseline was not restored, 
further efforts to regenerate were carried out with harsher regeneration buffers 
(0.05% SDS in appropriate running buffer).
5 .2 .7 .6  N TA  s en s o r ch ip  activation
Based on the optimised activation method by (Nieba et a i, 1997) 500 mM N iCI2 was 
injected at a flow rate of 7 pl/min for 1 - 4 m inutes. NiCI2 was made up using the 
re levant running buffer used for the experimenta l analyses a lthough activation has 
been shown to be stable aga inst variations in pH, NaCI concentration and contact 
time (N ieba et al., 1997).
5.2.7.7 B ind ing  o f ligand to  N TA  sen s o r ch ip  su rface
The protein samples as in Table 5.3 were injected over the active and reference 
surfaces for binding o f the H is-tag to the immobilised Ni-NTA surface. As a H is- 
tagged control to check N iNTA binding specificity, Endo1-8-His was used, and a non 
His-tagged control, 1 mg/ml BSA was emp loyed to test for non-spec ific interactions. 
These samp les were e ither directly applied as concentrated prote ins from direct cell- 
free expression reactions or were diluted in running buffer 1 (10mM Hepes, 0.15 M 
NaCI, 0.0005% P20, pH 7.4) to m inimise the changes in refractive indices caused by 
the differences in sample buffer and running buffer. Buffer 1 was later rep laced by 
running buffer 2 (PBS, 300 mM NaCI, Halt EDTA-free protease inhibitor cocktail, pH
8.0) to minimise e lectrostatic interactions. In addition the use of detergents was 
avoided to prevent the disruption o f the nanodiscs in the expressed rPmp samples. 
Changes in response units were measured and the reference surface was 
subtracted from the active surface (BIAeva luation software version 3.2).
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5.2 .7 .8  R egenration  o f N TA  s en s o r su rface
Im idazole, norma lly used to elute proteins during chromatography has been shown 
to disassociate H istidine-tagged proteins at 50 mM (Nieba et a!., 1997) whilst not 
removing the nickel ions from activated sensor chips. Regeneration o f NTA surfaces 
carried out with imidazole was unsu itable for the removal of H istidine-tagged prote ins 
in this study. This step was replaced with 350 mM EDTA, pH 8.3 at a flow rate of 7 
jLxl/min for at least 3 m inutes. EDTA also removes the nickel ions from the NTA 
surface and so reactivation of surfaces was necessary following each regeneration 
step.
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sample
7 sample 5jil
IFC
sample air sample air
5pJ
buffer
Pipette
Figure 5.9 - Air bubble technique for loading sample into the integrated micro-fluidic 
cartridge. Shows the sample pipette technique (left) and the sample loop (right). Adapted 
from Biacore X Getting Started Handbook, 2002
rPmpl-N (C-term inal 6 His-tag) 30 pg/ml
Expressed empty pET23b control (no His-tagged 30 pg/ml
prote ins)
Endo1-8-His (C-term inal 8 His-tag) 2 pg/ml, 20 jug/ml, 200 pg/ml
BSA (no His-tag) 1 mg/ml
Table 5.3 - Ligands used to test specificity of binding to activated and non-activated 
NTA sensor surfaces.
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5.2 .8  E llip so m etry
5.2 .9  Im m o b iliza tio n  o f H eLa cell ‘orphan  re ce p to rs ’ on so lid  su rfaces
The substrates for TIRE study were prepared by therma l evaporation of gold onto 
microscopic glass slides (kindly provided by Dr Anna Tsargorodskaya, MERI, 
Sheffie ld Hallam University) The typical thickness of gold layer was 25-27  nm. The 
go ld-coated glass slides had an enhanced negative surface charge from prior 
treatment overn ight in 0.1 M solution o f mercapto-ethylsulfonate sodium salt SH- 
(CH2) 2-S0 3“ Na+ in methanol. The immobilization of proteins on the gold surface 
was achieved by positive ly charging the surface w ith polyallylamine hydrochloride 
(PAH, 2 mg/m l). An incubation time of 15 m in was sufficient to achieve saturation of 
PAH adsorption. The samp le was then rinsed by purging the cell with 10-times the 
cell volumes of deionised water. After that, the surface is ready for e lectrostatic 
adsorption of proteins, which are typ ically negative ly charged in slightly alkaline (pH
8.0) Tris-HCI buffer solution (Nabok et a!., 2005).
5.2 .10 T IR E  exp erim en ts
The TIRE experimenta l set-up in built on the basis o f an automatic spectroscop ic 
J. A. Woollam e llipsometer M2000 operating in the 370 -  1000 nm spectra l range 
and exploiting the rotating compensator principle was used for e llipsometry 
experiments (Nabok and Tsargorodskaya, 2008), (Nabok et at., 2011) 
and (Kriechbaumer et al., 2011).. The light is coupled to a thin gold film depos ited on 
the g lass slide via a 68° trapezo idal prism at the conditions close to total interna l 
reflection (F igure 5.10). A 0.2 ml cell is attached to the gold film via rubber O-ring; 
the inlet and outlet tubes enable injection o f required solutions into the cell to perform 
mo lecu lar adsorption and different b iochem ical reactions on the gold surface. Briefly, 
the adsorption steps used were 1), PAH (po lyallylamine, 2 mg/m l aqueous so lution), 
2), crude HeLa cell prote ins and membranes (in 1X PBS with protease inhibitors, pH
8.0), and 3), 100 pi unpurified soluble rPmp domains (rPmp domains with nanodiscs 
and endogenous proteins at approximate ly 300 pg/ml in 1X PBS with protease 
inhibitors, pH 8.0) with 10-15 min incubation times. R insing the cell was carried out 
after every deposition step using 10 times the cell volume w ith 100 mM Tris-HCI, pH 
8.0. The parameters of the adsorbed layers such as thickness and refractive index 
were evaluated by fitting the TIRE spectra to the model system by Dr Anna 
Tsargorodskaya, MERI, Sheffield Hallam University) using the J.A. W oo llam 
software (Nabok et al., 2005).
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Figure 5.10 - Schematic diagram of TIRE experimental set-up. The orphan’ receptor 
(crude mix of HeLa cell proteins and membranes) are layered onto the PAH/gold surface by 
electrostatic interactions, the recombinant protein samples (rPmp domains expressed using 
MembraneMax™ cell-free expression kit) are passed over in solution, the reflected light is 
monitored as ip and A as described in section 5.1.4. Adapted from (Mustafa et al., 2010).
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5.3 R esults
5.3.1 R eco m b in an t P m p do m ain s  in cell su rface  c ro ss -lin k in g  b ind ing  
stu d ies  w ith  H e c lB  a n d /o r H eLa cells
To screen for potential binding o f Pmps to the cell surface of urogen ital cells, rPmp 
domains were incubated with H ec lB  and HeLa cells as in section 5.2.4.1. 
Interactions were then fixed permanently with chem ical cross-linkers. Western blots 
using the penta-H is primary antibody as in section 5.2.6.1 were used throughout the 
cross-linking assays to detect a shift in molecu lar we ight indicative of prote in-prote in 
interactions. Trials to investigate putative interactions between truncated Pmp 
prote ins and the human cells were first performed using rPmpl-N since this truncated 
His-tagged recomb inant protein provided the best signal for detection via western 
blot. Subsequently when a su itable method with controls was estab lished, these 
trials were repeated to investigate interactions o f the autotrans locator domains of 
Pmp D and Pmp G with H ec lB  and HeLa cells.
Formaldehyde is commonly used for cross-linking protein interactions, with one of 
the shortest space arms available (2 .3-2.7  A) it has been used for a long time in 
histology and pathology to fix the native state of tissues and cells (Sutherland et al., 
2008). Therefore one disadvantage of using forma ldehyde is that only close ly 
associated prote ins can be cross-linked due to the small chem ical structure yet 
forma ldehyde is fast acting at the right concentration and so can fix potentially 
transient interactions (Klockenbusch and Kast 2010). Formaldehyde penetrates the 
cell membrane and so fixes both extrace llular and intrace llular protein interactions. 
As forma ldehyde was readily available at a fraction o f the cost of other cross-linkers, 
pre liminary trials utilised this cross-linker. The majority o f rPmp l-N was detected as 
non-interacting monomers showing no putative interactions with the ce lls (data not 
shown).
BS3 a non-cleavab le, membrane-impermeab le, water-so luble cross-linking agent 
was used to fix potential cell surface interactions. For all assays recomb inant 
truncated Pmp domains were expressed using MembraneMax™ ce ll-free express ion 
system as fresh stocks for each cross-linking assay. The rPmp domains were not 
purified. To control against binding of other MembraneMax™ endogenous prote ins 
present w ithin the samp les the total soluble protein from the expression o f the empty 
pET vectors were used in chem ical cross-linking assays. As the contro l express ion 
reaction harbours the expression plasmid without the rPmp domain encoding 
sequence, the two samp les differed only by the expression o f the recomb inant rPmp 
domain.
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Early trials to investigate the interaction of rPmp l-N to urogen ital epithe lial cells were 
carried out at 37 °C to mimic the in vivo temperature in which Chlamydia trachomatis 
estab lishes infection (Su et al., 1996). An aliquot o f the whole cell assay (containing 
cells, recomb inant express ion proteins and cross-linker) and the supernatant 
conta ining rPmpl-N not bound to cells and mammalian cell secretory prote ins were 
exam ined.
Western blot in Figure 5.11 revealed a large smear of over 250 kDa, detected in the 
whole assay fraction containing cross-linked rPmpl-N and H e c lB  cells indicating an 
interaction had occurred (blue arrow). The large cross-linked conjugate rema ined at 
the interface of the resolving and stacking gel with monomers detected in the 
supernatant unbound fraction (green arrow). From this assay alone it could not be 
determ ined if the conjugate was as a result of; 1) rPmp l-N fixed to the H ec lB  cells 
or, 2) multimers of rPmp l-N cross-linked to nanodiscs or, 3) rPmpl-N cross-linked as 
aggregates of itse lf or indeed, 4) a mix of all these outcomes. Further contro ls were 
used to help rule out endogenous H ec lB  prote ins and help determ ine where the 
conjugated rPmp domains were located. Subsequently assays were set up w ith 
rPmpl-N with both H e c lB  cells and HeLa cells with further controls:
assay 1) cells + recomb inant proteins + cross-linker,
assay 2) cells + protein,
assay 3) recomb inant protein + cross-linker,
assay 4) cells + empty expression vector prote ins + cross-linker,
These contro ls were implemented in Figure 5.12 and Figure 5.13. The ce lls were 
co llected to exam ine if the cross-linked complex was directly associated with the 
cells. The supernatant conta ining unbound rPmpl-N, ce ll-free express ion prote ins 
and HeLa secretory prote ins was retained. The described samples were exam ined to 
show that rPmpl-N was not detected at the HeLa cell surface (Figure 5.12b) on ly a 
fa int band was observed in the assay 1 pellet. This band was an endogenous HeLa 
protein. The rPmp l-N protein was detected in the supernatant fractions as both 
monomers in Figure 5.12a (red arrow) and large conjuages greater than 175 kDa in 
assay 2 that did not contain cross-linker. This was only useful in showing that rPmpl- 
N was not interacting directly and permanently binding with the HeLa cells in the 
absence of cross-linker as would be expected. Where permanent interactions had 
been fixed, rPmpl-N could not be detected as strongly.
A similar outcome was observed for H ec lB  cells incubated with rPmpl-N. Monomers 
and higher mass conjugates conta ining rPmpl-N were detected in the supernatant
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fraction where reactions were not permanently fixed with BS3, (Figure 5.13a red 
arrow) however a fa int band in the region o f 40 kDa, a size indicative of rPmpl-N, 
was detected in the H ec lB  cell pellet, yet cross-linker had not been applied to this 
assay (highlighted by the ye llow arrow Figure 5.13b). However since interactions in 
this assay were not cross-linked, monomers rather than higher mo lecu lar we ight 
conjugates would be expected if rPmp l-N was interacting with cell surface prote ins 
as this interaction would most like ly be disrupted by SDS.
Most apparent was that the s ignal o f rPmp l-N in these cross-b inding assays was 
weaker in all the fractions fixed where BS3 cross-linker (assays 1 and 3, assay 4 did 
not contain rPmpl-N so no His-tag signal was detected) (Figure 5.12 and Figure 
5.13) compared to the assays w ithout cross-linker (assays 2) (Figure 5.12 and 
Figure 5.13) indicating that BS3 was responsible for this effect. In addition traces of 
H is-tagged protein were found in the stacking gel wells o f all these assays where 
prote ins had not entered the po lyacrylamide gels. The samp les were run on an 8% 
resolving SDS-PAGE without a stacking gel for Western blotting, this did not perm it 
the conjugates to be separated for ana lysis and conjugates were restricted to the 
we lls o f the gel (data not shown).
5.3.1.1 D ot b lo t analys is
It was unclear whether the BS3 cross-linking had affected the access ibility o f the His- 
tag epitope of rPmp l-N conjugates to the penta-H is antibody. The samp les from 
Figure 5.13 were re-exam ined using dot blot analysis, which confirmed the H is-tag 
ep itopes were not affected by cross-linking with BS3. Figure 5.14 shows the anti-His 
signal o f rPmp l-N was strong in assays with and without cross-linker confirming that 
the reason for the weaker s ignals via Western blotting was due to the size of the 
cross-linked rPmpl-N conjugates. The dot blots in Figure 5.14 also confirmed that 
whilst the majority o f rPmp l-N was detected in the supernatant, a weak signal was 
observed in the H ec lB  cell pellets incubated with rPmpl-N. Penta-H is mAb has 
prev iously shown some cross-reactivity with H e c lB  cell yet the signal was not 
observed in the negative control cell pellets w ith pET23b vector proteins. rPmpl-N 
does appear to have an interaction with H e c lB  cells that suggests binding may 
occur.
231
rPmpl-N pET23b
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—  100
— 75
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— 30
Figure 5.11 - Western blot showing large smeared conjugate of rPmpl-N indicates 
interaction of rPmpl-N with HeclB using cell surface cross-linker BS3. Hec lB cells were 
incubated with rPmpl-N (the recombinant passenger domain of Pmp I) and expressed 
products of empty pET23b for 1 hour before fixing all cell surface interactions with BS3. An 
aliquot of the whole cell assay includes all the components within the reaction. Following 
centrifugation the supernatant (SN) was collected and examined for unbound rPmpl-N 
(unbound fractions) where monomers of rPmpl-N were detected at -42 kDa (green arrow). 
Antibody interactions with endogenous HeclB proteins are shown by pink arrows. His-tagged 
protein marker (Qiagen) is shown in kDa.
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4
Assay 1 Assay 2 Assay 3 Assay 4
rPmpl-N + + + Empty pET
HeclB cells + + - +
BS3 (5 mM) + - + +
Unbound 
prote ins (SN)
H ec lB  cell 
prote ins (pellet)
Figure 5.14 - Dot blot shows BS3 cross-linker does not affect the epitope of cross- 
linked rPmpl-N. Dot blot analysis of the samples shown in Figure 5.13 was carried out to 
examine the accessibility of the His-tag epitope after cross-linking with BS3. Assays 1 to 4 
were carried out using the components indicated as controls.
• I I
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5.3 .1 .2  R eco m b in an t Pm p I p assen g er dom ain  in cell su rface  c ro ss - 
linking  b ind ing  s tu d ies  a t 4 °C
It was difficult to determ ine whether the large comp lexes formed during cross­
binding studies w ith rPmpl-N were genu ine prote in-prote in interactions with large 
putative receptor prote ins/molecu les or if the rPmp l-N that could not migrate through 
polyacrylamide gels was as a resu lt of aggregation. As previous studies have shown 
that adherence of C.trachomatis is not inhibited at 4 °C (Zaretzky et al., 1995, Davis 
and Wyrick 1997) further assays were carried out with a lower incubation 
temperature at 4 °C to protect the integrity o f rPmp l-N that is susceptible to 
precipitating out of so lution into insoluble aggregates, espec ially at higher 
temperatures (chapter 4).
W ith H ec lB  cells rPmpl-N was detected as monomers in the unbound fraction as 
expected in assay 2 (without cross-linker) indicated by the blue arrow (Figure 5.15) 
but it was not detected in the other fractions, with the exception o f a fa int band over 
250 kDa in the cross-linked assay 1. The cross-linking assays for HeLa cells 
resulted in a similar outcome w ith monomers of rPmp l-N detected in the unbound 
fractions of the assay 2 (Figure 5.16, assay 2, blue arrows). In contrast to the 
results for H ec lB  cells at 4 °C, the large comp lexes retained in the stacking gel 
were found in assay 2 without cross-linker and in assay 4 that contained cross- 
linked rPmpl-N only (no HeLa ce lls) and a very fa int band in assay 1 containing all 
components. This possibly indicates large cross-linked oligomers or aggregates of 
rPmp l-N. To conclude, exam ination o f the cell pellets in Figure 5.15 and Figure 
5.16 do not provide any solid ev idence that rPmp-N interacts directly with the cell 
surfaces of H ec lB  or HeLa cells at 4 °C. However, earlier assays at 37 °C observed 
a fa int band associated with the cell pellets, which was confirmed by dot blot 
analysis therefore if interactions occurring they may have been too weak to detect.
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Assay 1 Assay 2 Assay 3 Assay4 Assay 5
rPmpl-N + + - + EmptypET
HeclB  cells + + + - +
BS3 (5 mM) + - + + +
M SN P SN P SN P SN SN P
kDa
175_
Stacking
Resolving
Figure 5.15 - Western blot showing chemical cross-linking of rPmpl-N with HeclB 
cells at 4 °C. HeclB cells were incubated with rPmpl-N with controls (incubated without 
rproteins and with the expressed products of empty pET23b) at 4 °C before fixing cell 
surface interactions with BS3 . Assay 2 was not cross-linked. The HeclB cells were 
collected (P) and the supernatant (SN) containing the MembraneMax™ expression proteins 
and HeclB secretory proteins were examined with the exception of control assay 4 that did 
not contain HeclB cells. Endogenous HeclB proteins were identified from control assay 3 
that was not treated with heterologous proteins, indicated by pink arrows. Monomers of 
rPmpl-N are shown by blue arrows. Pre-stained protein marker (New England Biolabs) is 
shown in kDa.
237
Assay 1 Assay 2 Assa3 Assay4 Assay 5
rPmpl-N + + -  - + EmptypET
HeLa cells + + + - +
BS3 (5 mM) + - + + +
M SN P SN P SN P SN SN P
kDa
80 —
a— Stacking
Resolving
Figure 5.16 - Western blot shows the chemical cross-linking of rPmpl-N with HeLa 
cells at 4 °C. HeLa cells were incubated with rPmpl-N with controls (incubated without 
proteins and with expressed empty pET23b) at 4 °C before fixing cell surface interactions 
with BS3. Assay 2 was not cross-linked. The HeLa cells were collected (P) and the 
supernatant (SN) containing the MembraneMax™ expression proteins and HeLa secretory 
proteins were examined with the exception of control assay 4 that did not contain HeLa cells. 
Monomers of rPmpl-N are shown by blue arrows. Endogenous HeLa proteins were identified 
from control assay 3 that was not treated with heterologous proteins, indicated by pink 
arrows. Monomers of rPmpl-N are shown by blue arrows. Pre-stained protein marker (M) 
(New England Biolabs) is shown in kDa.
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5 .3 .1 .3  R e co m b in an t Pm p D and Pm p G a u to tran s lo ca to r dom ain  in cell 
su rface  c ro ss -lin k in g  b ind ing  s tu d ies  a t 4 °C
Assays were repeated with rPmpGauto and rPmpDauto with H e c lB  and HeLa cells 
incubated at 4 °C. rPmpGauto was not detected in the cross-linked reactions whilst 
as expected, monomers were observed in unfixed assays (Figure 5.17 and Figure 
5.18). In addition a very fa int band o f rPmpGauto was detected in the H ec lB  cell 
pellets in assay 4 without cross-linking (Figure 5.17) rPmpDauto was below the 
limits o f detection by Western b lot during assays after incubation with HeLa cells 
and so was not repeated with H e c lB  cells (data not shown). In view of the data 
generated from cross-linking assays, alternative methods to investigate these 
putative interactions were considered.
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Assay 1 Ass­ay 2 Assay 3 Assay 4 Assay 5
rPmpGauto Empty
pET + - + +
H eclB  cells + - + + +
BS3 (5 mM) + - + - +
P SN SN P SN P SN P SN M
' 1 1  s . ■ kDa
Resolving
> m#m m
Figure 5.17 - Western blot showing chemical cross-linking of rPmpGauto with HeclB 
cells at 4 °C. Hec1 B cells were incubated with rPmpGauto with controls as above incubated 
without proteins and with expressed empty pET22b at 4 °C before fixing cell surface 
interactions with BS3. The HeclB cells were collected (P) and the supernatant (SN) 
containing the MembraneMax™ expression proteins and HeclB secretory proteins were 
examined with the exception of control assay 2 that did not contain Hec lB cells. Monomers 
of rPmpGauto are indicated by the blue arrow with a very faint band in the cell pellet of the 
same assay (yellow arrow). The two bands detected in the cell pellets are endogenous 
HeclB cell proteins (pink arrows). Pre-stained protein marker (New England Biolabs) is 
shown in kDa.
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Assay ^ ssay 5Assay 1 Assay 2 Assay 3
rPmpGauto Empty
pET
HeLa cells
BS3 (5 mM)
SNkDa
Stacking
175
Resolving
Figure 5.18 - Western blot of chemical cross-linking of rPmpGauto with HeLa cells at 4
°C. HeLa cells were incubated with rPmpGauto with controls incubated without proteins and 
with expressed empty pET22b at 4 °C before fixing cell surface interactions with BS3. The 
HeLa cells were collected (P) and the supernatant (SN) containing the MembraneMax™ 
expression proteins and HeLa secretory proteins were examined with the exception of 
control assay 4 that did not contain HeLa cells. rPmpGauto is detected as monomers in the 
unbound fraction in the unfixed assay 2, indicated by the red arrow. The three bands 
detected in the cell pellets are endogenous HeLa cell proteins (pink arrows). Pre-stained 
protein marker (New England Biolabs) is shown in kDa.
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5.3 .2  M ethods to in ves tig a te  reco m b in an t Pm p dom ains in in te rac tio n s  
w ith  H e c lB  cell and H eLa cells  using im m u n o cyto ch em istry  (IC C )
Methods relying on the cross-b inding o f truncated rPmp domains with both H ec lB  
and HeLa cells with chem ical cross-linkers were hampered by the dependence upon 
Western blotting to detect conjugates which were often too large to m igrate into an 
SDS-PAGE gel or were below the limits of detection once diluted in cell 
suspensions. An alternative method using ICC was proposed to overcome these 
problems using an indirect probing method. ICC can be a useful tool to probe for the 
localisation o f prote ins within cultured cells using antibodies directed against the 
protein o f interest. Determ ination o f a su itable staining method is crucial for 
successfu l intensification and identification of prote in-ce ll and prote in-prote in 
interactions. Using the penta-H is Ab to probe for the localisation o f H is-tagged rPmp 
domains upon incubation with mammalian cells was deemed an appropriate staining 
technique since the penta-H is Ab had been shown to identify all the H is-tagged 
rPmp domains. Using an indirect method the signal can be amp lified with a suitable 
fluorescently labelled secondary antibody to reveal whether rPmp domains interact 
directly with the cells, intrace llularly or at the cell surface.
Truncated rPmp domains were expressed using the MembraneMax™ ce ll-free 
expression system and were applied to the cells prior to antibody staining as in 
sec tion  5.2.5. As a control to compare the levels o f background fluorescence and 
observe differences in localisation, the same MembraneMax™ prote in sample 
m inus the rPmp domain was added to cells by express ion o f the empty pET vector. 
During ICC optimisation trials cells were also cross-linked with BS3 prior to staining 
to deve lop a suitable ICC method. However as BS3 is a cell surface cross-linker and 
does not permeab ilise the cells, for early ICC trials it was considered necessary to 
a llow the antibodies access w ithin the cell as it was unknown if truncated Pmps 
would enter the cells. Triton X-100 is the most popu lar detergent for improving the 
penetration of the antibody. However, it is not appropriate for the use of membrane- 
associated antigens since it destroys membranes and therefore was avoided. Fixing 
of the cells in these studies was therefore carried out with acetone.
5.3.2.1 ICC o f rP m p dom ain  in teractio n s  using p en ta -H is  prim ary  
a n tib o d y  and an ti-m o u se  FITC  seco n d ary
Numerous attempts of ICC were carried out using the penta-H is primary antibody 
(Qiagen, UK) that had proved useful throughout Western blotting methods in chapter 
3 and used for detection o f cross-linked recomb inant proteins in section 5.3.1. The 
antibody was used in combination with the FITC conjugated secondary antibody as 
shown in Table 5.2. This indirect antibody method was carried out using a range of 
concentrations but this technique displayed high levels o f back-ground signal that 
could not discrim inate between cells that had been treated or untreated with rPmp 
domains (data not shown). Some cross-reactivity had been observed in the Western 
blots in section 5.3.1, where H ec lB  and HeLa protein bands were detected by the 
penta-H is Ab. Titration o f the primary antibody to very low concentrations was 
avoided as low concentrations may not have detected low levels o f recomb inant His- 
tagged protein localisation. An alternative primary antibody was chosen.
5 .3 .2 .2  W estern  b lo t o f rP m p d o m ain s  using 6XH is prim ary
The spec ificity o f the rabbit polyclonal primary 6XHis tag antibody (Abeam, UK) to 
H is-tagged recomb inant prote ins showed that this antibody had strong avidity for the 
rPmp domains with no obvious cross-reactivity with HeLa and H e c lB  ce lls or 
endogenous MembraneMax™ prote ins and so was considered suitable for ICC trials 
(Figure 5.19).
5 .3 .2 .3  ICC o f rP m pl-N , rP m p D au to  and rP m p G au to  dom ain  in te rac tio n s  
w ith  H eLa cells
A series of dilutions of rPmp l-N (1 in 2, 1 in 5, 1 in 10 and 1 in 20) and a range of 
antibody concentrations (Table 5.2) were carried out to try and optim ise ICC 
methods with the 6XH is primary and anti-rabbit FITC secondary (data not shown). 
These ICC trials were performed on cervical cells (HeLa) incubated with soluble 
rPmp l-N. In the pre liminary assays the cells were not washed after remova l o f 
rPmpN-l in order to confirm the level o f recomb inant protein added to the ce lls was 
in the detection range of the titrated 6XHis-tag primary antibody. In comparison to 
the untreated cells in Figure 5.20 (g/h), a 1 in 5 dilution o f rPmp l-N was detected 
with strong staining in the unwashed assay (images a/b, c/d and e/f). Demonstrated 
within Figure 5.20 was localisation to some of the cell surfaces (a/b), the cell nuclei 
of other cells (c/d), with a meshwork o f non-interacting rPmpl-N in other areas (e/f). 
Co llective ly these showed a diverse range of results as these images were all
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captured from the same assay. However the ‘meshwork’ of recomb inant protein 
observed in (e and f) provided a high background signal that would possibly interfere 
w ith the identification o f putative prote in-ce ll interactions and so a washing step was 
included in the experimenta l assays to remove the excess non-interacting rPmp 
samples.
Consequently ICC assays with rPmpl-N (1 in 5 dilution) and HeLa cells were 
repeated with the washing step to remove unbound rPmpl-N after the incubation 
period in which localisation to the cell surface was not observed (Figure 5.21). Cell 
nuclei were stained brightly (Figure 5.21a) and this was comparable to the negative 
contro l incubated with the expressed products o f empty pET23b (Figure 5.21b). 
This staining was brighter than the staining o f untreated cells (Figure 5.20g) where 
moderate cross reactivity/non-spec ific binding with the HeLa cells was observed.
ICC was also performed on HeLa cells to identify possible cell surface interactions 
with recomb inant Pmp autotranslocator domains of Pmp G and Pmp D. Assays 
were carried out with a more concentrated application (1 in 2 dilution) o f expressed 
rPmpGauto or rPmpDauto as the expression yield appeared less than the rPmp l-N 
domain (chapter 3) and the cells were washed to remove unbound protein. Negative 
contro ls using the so luble ce ll-free express ion of the empty pET vectors 
demonstrated a similar staining profile to cells treated with rPmpGauto (Figure 5.22) 
and rPmpDauto (Figure 5.23) and so localisation could not be determ ined.
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P o
Figure 5.19 - Rabbit polyclonal 6xHis tag antibody shows avidity for His tagged 
recombinant Pmp domains. Western blot carried out using method in section 5.2.6.3.
Antibody combination shows no cross-reactivity with HeclB or HeLa cells. Detection of 
rPmpl-N monomers, (+/- signal peptide) at -42 kDa, -36 kDa with high molecular weight 
multimers, rPmpDauto monomers -27 kDa and rPmpGauto monomers -  40 kDa are shown 
by blue arrows.
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HeLa + rPmpl-N HeLa + rPmp l-N
> /
a
HeLa + rPmpl-N //
HeLa + rPm.pl-N I
HeLa + rPmpl-N
e
HeLa + rPmpl-N
f
HeLa untreated
g
HeLa untreated
h
Figure 5.20 - Immunocytochemistry shows putative rPmpl-N localisation to HeLa cells 
when the cells are unwashed after incubation with rPmpl-N. FITC (left) and DAPI 
staining overlay (right). Images a-f were all captured from the same interaction assay of 
HeLa cells incubated with rPmpN-l and stained as in section 5.2.5.3 with 6XHis antibody 
and ant-rabbit FITC to show the variation in staining and localisation, (a/b and c/d) show 
varying degrees of rPmpl-N localisation to HeLa cell surface (blue arrows), (e/f) shows no 
interaction and (g/h) negative cells were treated with PBS only. Scale bar is 5 0 / im
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HeLa + rPmpl-N
a
HeLa + empty
pET23b
HeLa + rPmpl-N
C
HeLa + empty pET23b
Figure 5.21 - Immunocytochemistry of HeLa cells post-treatment with rPmpl-N. FITC 
(top) DAPI staining overlay (bottom), (a/c) HeLa cells after treatment with rPmpl-N (b/d) 
HeLa cells after treatment with pET23b proteins. Scale bar is 50 /jm
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HeLa + empty
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HeLa + rPmpGauto HeLa + empty pET22b
Figure 5.22 - Immunocytochemistry of HeLa cells post-treatment with rPmpGauto. 
FITC (top) DAPI staining overlay (bottom), (a/c) HeLa cells after treatment with 
rPmpGauto, (b/d) HeLa cells after treatment with pET22b proteins. Scale bar is 50 /urn.
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rPmpDauto
HeLa + empty
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HeLa + rPmpDauto HeLa + empty pET28b
Figure 5.23 - Immunocytochemistry of HeLa cells post-treatment with rPmpDauto. 
FITC (top) DAPI staining overlay (bottom), (a/c) HeLa cells after treatment with 
rPmpDauto, (b/d) HeLa cells after treatment with pET28b proteins. Scale bar is 50 jum.
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5 .3 .2 .4  ICC o f rP m pl-N , rP m p D au to  and rP m p G au to  dom ain  in teractio n s  
w ith  H e c lB  cells
ICC was performed on H e c lB  cells to identify possible cell surface or intrace llular 
interactions with recomb inant Pmps. Assays were carried out with a 1 in 5 dilution of 
expressed soluble rPmp l-N and a more concentrated 1 in 2 dilution of expressed 
rPmpGauto or rPmpDauto applied to the cells (section 5.2.5.1). The unbound 
prote ins were washed o ff prior to fixing the cells with acetone. Negative contro ls 
were incubated with the ce ll-free expressed products of empty pET vectors for 
comparative analysis.
Differences in staining profiles were observed between cells incubated with 
truncated rPmps and the cells incubated with the control proteins. In particular 
rPmpGauto treated cells (Figure 5.24a) did not display the granu lar staining 
observed in the control cells (Figure 5.24b). Cells that had been incubated with 
rPmpGauto appeared to be stained at the cell surface. Putative cell surface staining 
was also demonstrated for H e c lB  cells after treatment w ith rPmpDauto shown in 
Figure 5.25a when compared to negative contro ls shown in Figure 5.25b. Finally, 
differences were also observed in the staining o f H ec lB  cells a fter incubation with 
rPmpl-N where the negative contro ls had granular staining o f the nuclei (Figure 
5.26 a and b). In this case it was difficult to determ ine if this staining was localisation 
to the cell surface or if it was intrace llular staining of the nuc lear membranes.
In summary, the ICC of H e c lB  cells incubated with rPmp domains (rPmpDauto, 
rPmdGauto and rPmpl-N) all displayed some staining at the cell surface that was 
indicative of these H is-tagged domains interacting with the cells. This signal was 
stronger and more localised than the signal displayed by the control cells treated 
with the empty vector expression products.
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Hec1B +
rPmpGauto
HeclB  +
empty pET22b
Figure 5.24 - Immunocytochemistry shows putative rPmpGauto localisation to HeclB 
cells. FITC staining (top) DAPI staining overlay (bottom), (a/c) Hec lB cells after 
treatment with rPmpGauto, (b/d) HeclB cells after treatment with pET22b proteins. Scale bar 
is 50 jum.
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rPmpDauto
HeclB  +
empty pET28b
HeclB + rPmpDauto HeclB + empty pET28b
Figure 5.25 - Immunocytochemistry shows putative rPmpDauto localisation to HeclB 
cells. FITC staining (top) DAPI staining overlay (bottom), (a/c) HeclB cells after 
treatment with rPmpDauto (b/d) HeclB cells after treatment with pET28b proteins. Scale bar 
is 50 jum.
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Figure 5.26 - Immunocytochemistry shows putative rPmpl-N localisation to HeclB 
cells. FITC staining (top) DAPI staining overlay (bottom), (a/c) HeclB cells after 
treatment with rPmpl-N (b/d) HeclB cells after treatment with pET23b proteins. Scale bar is 
50 /urn.
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5.3 .3  M ethods  to  in vestig ate  reco m b in an t Pm p do m ain s  in in teractio n s  
w ith  H eLa and H e c lB  cells  using  su rface  p lasm on resonance
To screen for potential interactions between Pmps w ith endometrial and/or cervical 
cells, analysis by surface p lasmon resonance was performed with truncated 
recomb inant Pmps expressed in nanodiscs (chapter 4). A variety of biacore sensor 
surfaces are available, giving a wide range of experimenta l approaches. For this 
study the deve lopment of a su itable strategy was based on the indirect 
immobilisation technique. As the prev iously used penta-H is antibody was readily 
available and showed a high avidity for recomb inant His-tagged prote ins within 
MembraneMax™ reactions, this antibody was chosen as the ligand to be 
immobilised on a CM5 sensor surface. Following successfu l immobilisation, the 
antibody was used to capture recomb inant His-tagged Pmp domains. Upon capture 
of rPmp domains, whole or lysed HeLa and H ec lB  cells were passed over the 
captured ligand (rPmp domain) to screen for prote in-protein, prote in-membrane 
interactions in a ‘ligand fishing’ technique. The advantage of using this method was 
that purified samples were not a requirement, instead a suitable reference surface 
was used and subtracted from the active surface sensorgram.
5.3.3.1 B iacore  -  C M 5 in d irec t im m o b ilisatio n  tech n iq u e  w ith  p en ta -H is  
an tib o d y  to  cap ture  reco m b in an t H is -tagged  prote ins
To e liminate capture of any non-spec ific prote ins present w ithin the samp les, empty 
express ion vector was used as a reference to a llow for the subtraction o f non­
spec ific binding to the penta-H is antibody. Given that rPmpl-N produces the 
strongest signal when probed with penta-H is antibody on a Western blot, this 
truncated Pmp was used in the first screening trials with SPR.
Electrostatic interactions between the carboxymethylated dextran surface and the 
penta-H is antibody were observed using 10 mM sodium acetate buffer at pH 5.0 
(Figure 5.27). Subsequently the active surface (flow cell 2) was activated and 
-2000  RU o f penta-H is antibody were immobilised to the dextran surface over 5 
app lications where saturation was reached (Figure 5.28).
Initial attempts to capture H is-tagged rPmpl-N saw no binding to the active surface 
or the reference surface. The peaks in Figure 5.29 show slight association with 
rapid dissociation back to baseline for both injections o f proteins. Subtraction o f the 
reference chip (Fc 2- Fc 1) shows that the immobilised chip did not capture H is- 
tagged rPmpl-N but were refractive bulk indices due to the change in sample buffer
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from the running buffer. Subsequently the rPmp l-N sample was diluted with running 
buffer 1 which lowered the bulk effect and an association curve was seen in the 
second peaks of Fc 1 and Fc 2 but did not result in any prote in binding as the 
base line returned to original for both the reference and active surfaces.
A decrease in flow rate from 30 pl/min to 7 pl/min to increase the assoc iation time 
between the antibody and the diluted rPmpl-N protein sample did not resu lt in the 
capture of proteins. Association curves on the injection peak were not recorded with 
e ither sensor surface, only the bulk refractive index is seen (Figure 5.30), 
subtraction o f the reference chip (Fc 2- Fc 1) confirmed the penta-H is mAb chip had 
not captured any His-tagged rPmpl-N.
A highly concentrated purified recomb inant 8 residue histidine-tagged protein, 
Endol (termed Endo1-8-His in this study for clarity o f H istidine tag (supplied by Dr J. 
Hadden)) was used to test the immobilised penta-H is binding capability. Initially, 
sensorgrams showed binding o f Endol-8-H is (diluted in running buffer 1 to 2 |ug/ml) 
with an increase of approx imate ly 850 RU to the active surface, 7 m inutes after the 
injection the protein was still disassociating indicating a strong affinity. However 
binding was not spec ific to the Ab coupled surface as approx imate ly 1100 RU of 
Endol-8-H is also bound to the reference surface, again with a slow dissociation 
rate. Both surfaces required regeneration to disassociate the Endo l-8-H is (Figure 
5.31). Regeneration with glycine-HCI regeneration buffer pH 2.5 (B iacore Am ine 
Coupling Kit, GE Hea lthcare) was too mild to regenerate the reference surface, but 
was too harsh for the active surface where the baseline went into negative RU. The 
E ndol-8-H is was reapplied to test for a reduction in the binding potential on the 
active surface. Less binding was seen w ith this application as the RU increased by 
approximate ly 600 RU indicating removal or denaturation o f some of the penta-H is 
antibody as a resu lt o f the regeneration procedure. W ith this second application, a 
higher association was observed with the reference surface than the active surface 
possibly showing Endol-8-H is binds non-spec ifically to the dextran surface as well 
as the penta-H is. Further app lications, with a change in buffer from Hepes to PBS 
w ith increased ionic strength (running buffer 2), to reduce e lectrostatic interactions 
between Endol-8-H is and the dextran matrix surfaces, led to an unstable base line 
w ith high and low drifts (data not shown). 0.05% SDS a strong regeneration buffer, 
was also insufficient in removing the Endol-8-H is from the reference surface 
(Figure 5.31). Inevitably, this had led to an accumulation o f bulk on the reference 
surface that would result in ambiguous results and irreversible damage to the active
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surface. Without a suitable positive control, the ability to determine the ligand activity 
was compromised therefore trials to capture rPmp domains were not pursued using 
this approach.
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Figure 5.27 - Sensogram shows the mouse monoclonal Penta-His antibody associates 
with dextran matrix at pH 5.0. 30pg/ml of antibody was injected over flow cell 2 in 10mM 
sodium acetate to test for association with the unactivated carboxymethylated dextran (CM5) 
sensor chip. Time is in seconds (s) and response is response units (RU).
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Figure 5.28 - Immobilisation of the mouse monoclonal penta-His antibody to CM5 
sensor chip using amine coupling. The chip was activated using 1:1 EDC and NHS
activation buffer prior to the coupling of 30pg/ml of antibody over 5 injections (flow cell 2) in 
10mM sodium acetate, with a flow rate of 20pl/min. Approximately 2000 RU of penta-His Ab 
was coupled to the sensor chip surface. The uncoupled reactive groups were quenched with 
ethanolamine during the deactivation phase.Time is in seconds (s) and response is response 
units (RU).
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Figure 5.29 - Capture of concentrated recombinant Pmp I passenger domain on penta- 
His CM5 chip. An aliquot of the soluble fraction of the undiluted cell-free expression of 
rPmpl-N was injected at a flow rate of 30pl/min over both the immobilised penta-His CM5 
chip (Fc 2) and the blank reference chip (Fc 1). A second application of rPmpl-N was 
injected, diluted x2 in running buffer. Sharp spikes in the reference-subtracted sensorgram 
derive from the small time difference between flow cells 1 and 2. Time is in seconds (s) and 
response is response units (RU).
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Figure 5.30 - Capture of diluted recombinant Pmp I passenger domain on penta-His 
CM5 chip using a slower flow rate to increase capture association. An aliquot of the 
soluble fraction of a cell-free expression of rPmpl-N (x2 dilution factor) was injected at a flow 
rate of 7pl/min over both the immobilised penta-His CM5 chip (Fc 2) and the blank reference 
chip (Fc 1). Time is in seconds (s) and response is response units (RU).
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Figure 5.31 - Capture of purified Endo1-8-His control on penta-His CM5 chip. Endo1-8- 
His (2pg/ml) was injected at a flow rate of 7|il/min over both the immobilised penta-His CM5 
chip (Fc 2) and the blank reference chip (Fc 1). Association is observed with both chips (pink 
shading), the dissociation rate was not calculated (blue shading). Regeneration with 
glycine/HCI did not remove all Endol-8-His from the reference chip (Fc 1), and regenerated 
the active chip (Fc 2) stripping protein below the baseline. Endol-8-His was reapplied and 
regenerated, baseline was not recovered. Fc 1 was further regenerated with 0.05% SDS, 
baseline was not reached and Endol-8-His remained bound to the reference chip. Time is in 
seconds (s) and response is response units (RU).
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5 .3 .3 .2  B iacore -  N TA  in d irec t m ethod  to cap ture  re co m b in a n t H is- 
tagged  pro te ins  fo r in teraction  analys is
H igh levels of non-spec ific binding were prob lematic using the CM5 chip immobilised 
with penta-H is antibody. In addition, the regeneration of the surface w ith mild 
regeneration buffers appeared to cause irreversible damage to the expens ive 
immobilised surface. Therefore an a lternative strategy to capture the recomb inant 
Pmp domains was by use of a NTA sensor chip where NTA is pre-immobilised to the 
dextran matrix. The chip was activated with NiCI2 to capture H istidine-tagged 
prote ins by metal che lation affinity. Consequently, an NTA method was used to 
capture histidine-tagged Pmp domains with the empty vector express ion products as 
a control on the reference surface to e liminate non-spec ific interactions. Upon 
capture of rPmp domain, interactions with cervical cells were exam ined in a ligand 
fishing approach to screen for putative Pmp targets.
Endol-8-H is was readily available and less expensive to use than express ing fresh 
samples of recomb inant Pmp domains for pre liminary trials to test the binding 
specificity o f the nickel activated chip (Figure 5.32). Endol-8-H is had bound non- 
spec ifically to the carboxymethylated dextran of the CM5 sensor chip in previous 
trials but had not been tested on carboxymethylayed-NTA sensor chips. Upon 
exposure to both active and reference surfaces the Endo l-8-H is protein (2|ig/m l 
diluted in running buffer 1) had a higher binding response to the reference surface 
(w ithout nickel ions) with 1350 RU compared to 970 RU (Figure 5.33). Mild 
regeneration conditions to remove the ligand from the nickel by competitive b inding 
using 50 mM imidazole further increased the RU on the active surface by 150 RU 
indicating that Ni2+ ions on the NTA surface were still available for binding of 
imidazole, instead of competing and removing bound Endol-8-H is. A harsher 
regeneration with EDTA, which strips the nickel ions from the NTA surface, resu lted 
in incomplete regeneration; almost 700 RU units remained bound to the sensor 
surfaces indicating that the protein was non-spec ifically associated with exposed 
NTA-dextran matrix as opposed to spec ific interactions with the nickel ions. To test 
this theory, a non-specific, non Histidine-tagged protein, BSA (diluted running buffer 
1) was applied to the non activated surface and was found to interact directly with 
the NTA-dextran surface w ith an increase in 1921 RU (Figure 5.34).
Since PBS is a compatible buffer w ith NiNTA metal affinity chromatography (Qiagen 
Expressionist, 2003) and Ni-NTA purification trials with truncated rPmps were carried 
out in phosphate buffers w ith some success (chapter 4), the samp le and running
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buffers were changed to PBS (running buffer 2), w ith increased ionic strength, 300 
mM NaCI and higher pH 8.0 to reduce non-spec ific e lectrostatic interactions. F igure 
5.35 shows the change in buffer conditions prevented non-spec ific interaction o f BSA 
w ith the reference surface. Low concentrations o f Endol-8-H is in higher ionic 
strength buffer also did not bind to reference surface, indicating that the non-spec ific 
interactions with the NTA chip were most likely through undesirable e lectrostatic 
interactions. Since non-spec ific interactions with the reference surface had been 
reduced significantly, the activated surface was tested again for spec ificity with 
varying concentrations o f Endol-8-H is. Subtraction from the reference surface 
showed the binding o f the H is-tagged protein was spec ific to the nickel activated 
surface w ith a difference of 3211 RU bound to the activated surface, a lthough high 
concentrations o f Endo l-8-H is (200 jig/m l) resulted in some bulk binding to the 
reference surface (F igure 5.35). Furthermore, regeneration with EDTA was sufficient 
to remove all bound ligands from the surfaces and base line was restored. Therefore 
investigations with rPmps and HeLa/Hec1B cells could begin.
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Figure 5.32 - Nickel activation of pre-immobilised NTA chip, 500 mM NiCI2 was injected 
at a flow rate of 7 pl/min, followed by washing with running buffer to remove unbound 
nickel ions. The injection produced 629 RU of active surface. Time displayed in seconds.
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Figure continued on next page...
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Figure 5.33 - Endo1-8-His binds non-specifically to NTA dextran surfaces. Endo1-8-His 
protein (2|ug/ml diluted in running buffer 1, pH 7.4) had a higher binding response to the Fc 1 
reference surface (previous page) with 1350 RU compared to 970 RU with FC 2 nickel 
actived surface (above). Fc 2- Fc 1 (below) shows the negative response difference upon 
binding with Endol-8-His. Mild regeneration conditions to remove the ligand from the nickel 
by competitive binding using 50 mM imidazole further increased the RU on the Fc 2 active 
surface by 150 RU. Regeneration with EDTA to remove the nickel ions from the NTA surface, 
resulted in incomplete regeneration; almost 700 RU units remained bound to the sensor 
surfaces. Time is in seconds (s) and response is response units (RU).
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Figure 5.34 - Non-specific binding of BSA to NTA dextran surface. Non-Histidine tagged 
protein (BSA, 1 mg/ml) binds to unactivated reference NTA dextran surface in low ionic 
running buffer 1. BSA was injected at 7 pl/min and bound with 1921 RU. Regeneration with 
350 mM EDTA restored the baseline. Time is in seconds (s) and response is response units 
(RU).
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Figure 5.35 - Sensorgrams show Ni-NTA specific binding of His-tagged Endo1-8-His. 
Fc 2 was activated with 2 applications of Ni2+(yellow shading). Non-specific protein BSA 
(1 mg/ml) was injected over both active and reference flow cells (blue shading). Increasing 
concentrations of Endol-8-His were injected over both cells (pink shading) and the 2 step 
regeneration by 350 mM EDTA is shown in green. Flow rate used was 7 pl/min. Time is 
shown in seconds.
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5.3 .3 .3  Id en tifica tio n  o f rP m pl-N  prote in  in teractions  w ith  H eLa cells
The empty vector pET23b was expressed as in section 4.2.1. The binding affinity 
was tested with the reference and active surface to check for non-spec ific 
interactions with the NTA dextran surface and nickel activated surfaces. The prote ins 
present w ithin the ce ll-free expression samples bind with the NTA surface (Figure 
5.36) but could be used as a control for the subtraction o f endogenous binding 
interactions o f the MembraneMax™ prote ins present w ithin the rPmp l-N domain cell- 
free expressed sample.
Prote ins from expression o f the empty pET vector (30 jag/ml) and the expressed 
rPrnpl passenger domain (rPmpl-N) (30 pg/ml) were dialysed into running buffer 2 
and each applied to nickel activated surfaces in Figure 5.37 and Figure 5.38. The 
results displayed in Table 5.4 summarise the data showing that the rPmp l-N sample 
binds to the active surface w ith a higher response compared to the control sample, 
indicating putative capture of H is-tagged rPmpl-N. At the end o f the injection phase 
of the control sample, the sensorgram showed no binding of the contro l sample to 
the surface which was promising except after a lapse of time the response units 
increased to form a b iphasic curve (Figure 5.38). The HeLa cell crude lysate was 
applied to both the control and test flow cell. The response units were subtracted and 
show the HeLa cell prote ins had a stronger response for the contro l surface over the 
ligand surface bound with rPmpl-N. The sensorgram shows the b inding curves in 
Figure 5.37 and Figure 5.38 and the response units are in Table 5.4. The large 
highlighted peaks in Figure 5.38 are typical o f an accumu lation o f a ir bubbles in the 
integrated fluidic cartridge of the flow cells, this happened regu larly desp ite using 
freshly made and degassed buffers throughout.
The data generated from these studies did not show any significant binding events 
that would indicate rPmp l-N interacts w ith HeLa cells or HeLa cell components as 
the s im ilar levels of interaction were observed with the control surfaces. Overa ll the 
methods were not working with reproducibility or re liability and therefore studies 
were not extended to include the other rPmp domains or H ec lB  cells.
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Figure 5.36 - Sensorgram shows that endogenous proteins in the MembraneMax™ 
cell-free expression system bind to the active NiNTA surface. The empty pET23b vector 
was expressed in the MembraneMax™ system as in section, diluted to 30 pg/ml in running 
buffer 2 and applied to the activated surface. The surface was activated with nickel ions and 
the RU was increased from the baseline. Binding can be seen with a further change in RU 
from the activated surface RU (red dotted line). Time is in seconds (s) and response is 
response units (RU).
Activation 526 RU 400 RU -126 RU
Ligand bound 672 RU 817 RU 145 RU
Analyte (HeLa) 6950 RU 4694 RU - 2256 RU
Table 5.4 - Summary of response units after activation, binding of the ligand and the 
analyte, lysed HeLa cells. The difference in response units show the HeLa cells have a 
higher binding to the control surface (pET23b). The ligand injection containing rPmpl-N 
produced a higher response than the control upon association with the nickel activated 
surfaces.
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5.3 .4 . M ethods to  in ves tig a te  reco m b in an t P m p dom ains  in in teractio n s  
w ith  H eLa cells  using  e llip s o m etry
E llipsometry was used to detect potential prote in-protein and prote in-membrane 
interactions whereby HeLa cell lysate (w ith potential orphan receptors) was 
deposited on the gold surface and recomb inant Pmp domains were incubated with 
the immobilised lysate as in section 5.2.9. The rPmp domains were expressed 
using MembraneMax™ ce ll-free system and remained unpurified for the assays. 
Variations in the incidence of reflected light would be indicative of changes to the 
layers of the thin film surface representative of putative binding events w ith the 
lysate.
The spectra in Figure 5.40 to Figure 5.43 illustrate the changes in amplitude ratio 
(ip) and phase shift (A) of reflected light from the buffer and the PAH depos ition 
followed by the addition o f HeLa lysate and rPmp domains (rPmpl-N, rPmpDauto 
and rPmpGauto). The HeLa lysate deposition produced a layering o f approx imate ly 
30-34 nm at the gold surface (Figure 5.40 to Figure 5.43) The addition o f each o f 
the rPmp domains with endogenous MembraneMax™ system prote ins did not lead 
to an increase in layering in association with the HeLa lysate, instead a small shift 
backwards was observed showing that no protein interacted with the HeLa cell 
crude lysate.
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Figure 5.40 - The amplitude ratio \|/ spectra (top) and phase shift A spectra (below) 
from TIRE measurement of the recombinant Pmp I passenger domain (rPmpl-N) in 
interaction studies with HeLa cell proteins and membranes. The change in effective 
layering is shown by the shift upon addition of membranes/lysate to the PAH layer.
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Figure 5.41 - The phase shift A spectra up close showing the layering of rPmpl-N with 
HeLa cell lysate. The addition of each application is shown as a difference in layering at the 
surface in nm, the rPmpl-N domain did not associate with the layer of bound lysed HeLa 
cells, shown as negative values.
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Figure 5.42 - The amplitude ratio \\t spectra (top) and phase shift A spectra (below) 
from TIRE measurement of recombinant Pmp D and Pmp G autotranslocator domains 
(rPmpDauto and rPmpGauto) in interaction studies with HeLa cell proteins and 
membranes. The change in effective layering is shown by the shift upon addition of 
membranes/lysate to the PAH layer
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Figure 5.43 - The phase shift A spectra up close showing the layering of rPmpDauto 
and rPmpGauto with HeLa cell lysate. The addition of each application is shown as a 
difference in layering at the surface in nm, the rPmpl-N domain did not associate with the 
layer of bound lysed HeLa cells, shown as negative values.
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5.4  D iscuss ion
5.4.1 C ro ss -b in d in g  assays using ch em ica l c ross-link ing
In vitro cross-b inding assays were unable to determ ine conc lusive ly that rPmp 
domains had binding affinity with cervical and/or endometrial cells. A lthough cross- 
linking o f truncated rPmps was obversed, identifying the components of these cross- 
linked conjugates was difficult.
Initially, assays investigating interactions between the recomb inant Pmp I passenger 
domain (rPmpl-N) and endometrial cell line (H e c lB ) using the cell surface cross­
linker BS3 found high mass conjugates difficult to separate by SDS-PAGE. These 
high molecu lar we ight conjugates detected by Western blotting were retained within 
the stacking gel and resolving gel interface of the SDS-PAGE gel producing a smear 
when detected by anti-His antibody. This is typical of protein complexes that are too 
large to m igrate into the SDS polyacrylamide resolving gel using e lectrophores is. A 
possible exp lanation for this is that Pmps may interact w ith host ce lls via a group of 
known cell surface mo lecules called heparan su lfate g lycosaminoglycans (HSGAGs) 
(Kobayashi et a!., 2011)(Chen and Stephens, 1997). Due to the large size and the 
glycan moieties, such proteog lycans often m igrate between the stack ing and 
running gel interface during SDS-PAGE to also produce the characteristic smears, 
one examp le is Agrin, involved in the deve lopment of the neuromuscu lar 
junction during embryogenesis, (Tsen et al., 1995, Groffen et al., 1998). The large 
‘smearing’ conjugates in this study were in the supernatant fractions (a fter co llecting 
to cells via centrifugation), extrace llular domains o f proteog lycans can commonly be 
shed from the cell surface, generating soluble heparan su lfate proteog lycans 
(Bernfield et al., 1999). However, rPmp l-N was not applied to the ce lls as a 
homogenous protein and therefore it would be premature to specu late cross-linking 
with endometrial cell proteins had definite ly occurred. It is a possibility that these 
high molecu lar we ight conjugates also involved endogenous E.coli prote ins (from 
the MembraneMax™ ce ll-free E.coli extract), nanodiscs and/or 
oligomers/aggregates of rPmpl-N.
In an effort to optimise the conditions of the cross-b inding assays to reduce putative 
rPmp l-N aggregation, assays were performed at 4 °C and reduced the high 
molecu lar we ight conjugates, suggesting that the higher temperature of 37 °C forced 
rPmpl-N to precipitate out of solution into the insoluble comp lexes that were too 
large to resolve. Therefore assays w ith rPmpl-N, rPmpDauto and rPmpGauto were
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carried out under these a ltered conditions but did not reveal any convincing 
ev idence of putative interactions with H e c lB  or HeLa cells. In particular, leve ls of 
rPmpDauto were so low that detection was difficult desp ite efforts to incubate the 
cells with higher levels o f protein. It could be disputed that at 4 °C, putative 
interactions between Pmps and receptors would not take place, it is quite like ly that 
low temperatures were not conducive to binding studies however studies have 
shown that Chlamydia attachment can still occur at these low temperatures in some 
circumstances (Zaretzky et al., 1995, Davis and Wyrick 1997).
Using the cross-linker BS3 is a shotgun approach to capturing interaction 
complexes; as a high efficiency NHS ester linker, BS3 will cross-link any and all 
interacting molecu les whose respective lysine residues come w ithin the 11.4 A 
spacer arm of the linker (Sinz, 2010). Because lysine residues are norma lly in 
plentiful supply on most proteins the formation o f conjugates cons isting o f several 
components is sometimes an inevitable outcome. Paradoxically, in assays with 
rPmpl-N and Hec1B/HeLa cells these conjugates were also found when cross-linker 
was not used. Additionally, the same high mass conjugates were a lso detected in 
assays where H e c lB  and HeLa cells were om itted to test the cross-linking o f rPmp l- 
N under the same buffer and incubation conditions and led to the conc lusion that 
these conjugates were cross-linked aggregates or o ligomers of rPmp l-N. It has been 
reported that Pmp D forms flower-like o ligomer structures (Swanson et al., 2009) 
and so it is possible that other Pmps could also form oligomers, a lthough this theory 
would need further investigation.
An alternative approach was to use a cross-linker w ith higher specificity. W ith the 
exception o f zero-length cross-linkers, forma ldehyde has the shortest cross-linking 
span (~2-3 A) o f any cross-linking reagent (Sinz, 2010). Cross-linking with 
forma ldehyde did not show any traces of size shifts suggestive of interactions of 
rPmp l-N with H ec lB  cell proteins. However, having such a short arm span 
forma ldehyde requires the reactive groups of interacting proteins to be in very close 
association and so is only ideal for fixing spec ific prote in-prote in interactions.
Heterob ifunctional cross-linkers which possess two different reactive groups as 
opposed to the identical reactive group present on homobifunctional cross-linkers 
were considered as an alternative approach. Heterob ifunctional cross-linkers a llow 
for a two-step conjugation method that can minimise unwanted se lf-conjugation. In 
sequential procedures, heterobifunctional reagents are app lied to the target prote in
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first where one reactive group reacts w ith the target protein. In this case, the 
modified rPmp domain could have then been app lied to the uro-gential cell lines 
where reaction through the second reactive group of the cross linker wou ld occur 
where interaction took place. However, this would not be as stra ightforward for 
these studies as the rPmp domains were not purified samples therefore other 
endogenous prote ins in the MembraneMax™ system would also become modified 
with the ab ility to cross-link leading to fa lse positives. Furthermore, modification by 
addition o f cross-linker directly on the protein may affect the functionality o f the 
rPmp domain and without feas ible tests for activity would not be conclusive. 
Purifying the rPmp domains to reduce the heterogene ity prior to cross-binding 
assays may have m inimised non-spec ific binding events however, the leve ls would 
have been beyond the limits o f detection so this was not an option.
In summary one of the major problems throughout these assays was the inability to 
exam ine the cross-linked samples thoroughly. The signal from rPmp l-N was 
weakened significantly when cell surface cross-linking with BS3 was carried out 
which indicated three possible events; i) degradation/loss of rPmp l-N had occurred 
upon cross-linking, ii) His-tag epitopes were inaccessible after cross-linking or iii) the 
majority o f the protein was cross-linked into conjugates too large to m igrate into the 
SDS-PAGE gel. Since dot blot analysis found that that the epitope of cross-linked 
recomb inant Pmpl-N protein was not affected and the strong signal in all the assays 
did not indicate s ignificant loss of protein, it was considered that the main problem 
was the size of cross-linked conjugates and the transfer of these onto n itroce llulose 
membranes. Using dot blot analysis to overcome these problems was not a so lution 
as successfu l cross-binding identification relied upon identifying a size shift from 
monomers to higher mass conjugates. These studies did infer that cross-linking was 
taking place between rPmp l-N and H ec lB  cells, however in other trials high 
molecu lar we ight complexes were found in the supernatant separated from the cells, 
with similar bands detected when cross-linking rPmps without cells. Therefore in 
some c ircumstances it was concluded that the rPmps had se lf-conjugated or to 
extrace llular domains of proteoglycans.
5.4 .2  Im m u n o flu o rescen ce
This technique was used to overcome the problems experienced with aggregated 
protein that produced ambiguous results in the cross-b inding assays as this method 
does not rely on SDS-PAGE techniques to separate prote ins prior to
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immunoprobing. Instead, aggregated non-spec ifically bound protein is removed 
during washing of the cells to allow fixing of only bound truncated rPmps.
This is the first study of its kind to incubate recomb inant truncated Pmp domains 
with endometrial and cervical cells for immunostaining methods. This method was 
chosen as a pre liminary screening assay to detect fluorescent s ignals that could 
indicate localisation o f potential rPmp binding to the cell surface. ICC may not be a 
fitting model to test recomb inant prote ins in adherence. Instead express ing the 
rPmps to the membranes of E.coli and applying recomb inant E.coli to interact w ith 
the cells is a more practiced method. However, expressing the truncated rPmps to 
the membranes was very challeng ing due to the high amounts of inclusion bodies 
formed during the express ion trials and the expression levels o f truncated rPmps 
were low in E. coli.
Staining using anti-His antibodies directed against the H is-tagged recomb inant 
trunctated Pmps indicated possible localisation o f the rPmp domains to the cell 
surface of H e c lB  cells. Such putative interactions were observed between each 
rPmpGauto, rPmpDauto and rPmpl-N with the endometrial H e c lB  cell line but not 
w ith the HeLa (cervical) cell line. This could support the theory that Pmps function 
as adhesins with distinctive organotrop isms for different tissue sites (Gomes et al., 
2006) to the extent that certain Pmps o f serovar E C.trachomatis target the 
endothe lium and not the cervix. There is as yet no published data to support this or 
to illustrate which, if any, Pmps target definite tissue types. However studies w ith 
human H ec lB  endometrial cells have shown that serovar E is close ly associated 
with the protein disulfide isomerase (PDI), a component of the oestrogen receptor 
comp lex (Davis et al., 2002). This is further supported by earlier studies which 
showed Chlamydia attachment is dramatically enhanced in oestrogen dominant 
primary human endothe lial H e c lB  epithe lial cells, (Maslow et al., 1988). The data 
from cross-b inding truncated rPmps with H e c lB  cells in this study were inconclusive 
and so although it was tempting to suggest such a hypothesis, this was highly 
specu lative and requires further study as immunocytochem istry in this context was 
not a very spec ific or reliable technique.
In some instances desp ite efforts to optim ise the amount of antibody used, a strong 
fluorescent signal was noted in the negative control assays that were untreated with 
His-tagged protein. Although the staining patterns between the H e c lB  cells treated 
with rPmp domains displayed obvious spatial differences compared to the sta ining
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of the control assays treated with prote ins from the same empty express ion vector, 
this could have been as a resu lt o f problems w ith the antibody spec ificity which was 
a concern throughout these experiments. Even a trivial event such as insufficient 
permeab ilisation o f the cells prior to antibody staining could have prevented access 
of the antibody to within the cell, resulting in accumulation of the antibody to the cell- 
surface by hydrophobic or e lectrostatic interactions.
Therefore one of the prob lems throughout optimisation o f the ICC investigations was 
the apparent cross-reactivity o f the anti-His antibodies w ith the HeLa cells and the 
H ec lB  cells and efforts were made to m inimise these background signals. Initially 
the penta-H is primary antibody was used in combination with a fluorescently tagged 
secondary, anti-rabbit conjugated FITC, however this combination displayed high 
cross-reactivity with both HeLa and Hec1 B endogenous prote ins in spite of titration 
to low concentrations, this cross-reactivity was also ev ident during the Western blot 
analyses of the cross-b inding assays. An alternative approach was to use an anti- 
His primary that was spec ific to a 6XHis epitope as opposed to a 5XHis ep itope 
(penta-H is) to minimise cross-reactivity that can resu lt from the presence of histidine 
rich prote ins residing within the HeLa and H ec lB  cells. Concerted efforts were made 
to titrate the antibodies for each staining method, however the risk with using 
antibodies at very dilute concentrations was a consideration as this may have 
comprom ised the detection o f the rPmp domain. The 6XH is antibody displayed no 
cross-reactivity with HeLa or H ec lB  cells when tested on a Western blot, on the 
basis o f this it was considered suitable for ICC however a high background 
fluorescent signal was still ev ident in ICC experiments particularly with the HeLa 
cells. This high background was mainly demonstrated as granular staining within the 
nuclei. Interestingly in a previous study, upon fractionation o f HeLa cytop lasmic or 
nuclear extracts on NTA co lumns, enrichment of a ce llular protein was observed 
from HeLa nuclear extracts (Schmitt et al., 1993). This protein bound was identified 
as Oct-6 a transcriptional factor, previously believed to be expressed only in 
undifferentiated cells (Suzuki et al., 1990) but has since been found in other cell 
types including fibroblasts and macrophages (Hofmann et al., 2010). In agreement 
w ith its function as a transcriptional regu lator during neurogenes is and mye lination, 
Oct-6 is predominantly found in the nucleus, in addition Oct-6 is thought to shuttle 
constantly between nucleus and cytoplasm by use of a nuc lear export signal 
(Baranek et al., 2005). Interestingly Oct-6 contains a naturally occurring stretch o f 6 
histidines near the C-term inus (amino acids 436-441) as well as another His rich
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sequence (am ino acids 208-216) (Suzuki et al., 1990). These histidine enriched 
sites were thought to mediate the high affinity binding o f Oct-6 to the NTA matrix in 
the studies by Schmitt et al., (1993) . The granu lar staining within the nuclei o f the 
HeLa and H ec lB  cells in the ICC assays and the H istidine bands detected in the 
cross-linking assay Western blots could have been anti-His binding to the 
6Xhistidine stretches present w ithin Oct-6 transcriptional factor and so using an anti- 
His antibody may not have been an appropriate antibody for these trials. However, 
anti-His antibodies are common ly used in ICC to identify eukaryotic cells express ing 
Histidine-tagged recomb inant prote ins (Hao et al., 2006).
Addtionally, autofluorescence of mamma lian cells is often a common problem during 
immunofluorescent techniques therefore Sudan black B that quenches lipofuscin 
autofluorescence was used throughout the assays to m inimise background signal 
(Schne ll et al., 1999). However, many other ce llular metabo lites exhibit 
autofluorescence, including flavins and NADPH whilst generally, prote ins rich in 
tryptophan, tyrosine and phenylalanine show some level o f autofluorescence 
(B illinton and Knight 2001) Interestingly, a study was able to quantify E.coli and 
other bacterial cells dependent upon the autofluorescence of bacterial cell lysate 
(Bao et al., 2008) and so high background signals may have resulted from the 
natural fluorescence em itted from the MembraneMax™ prote ins derived from E.coli 
lysate rather than non-spec ific binding o f the antibodies.
A lthough localisation was observed with h ec lB  cells, similar findings were not
observed with HeLa cells. ICC methods that involve washing away excess prote ins
from adhered cells could serve to disrupt ‘weak’ non-cova lent interactions.
Interestingly, during a pre lim inary optimisation trial, localisation may have been
demonstrated in assays where the washing step was om itted, this procedure was
only intended to verify that the concentration of rPmp l-N applied to the cells was
within the detection range of the antibody dilution used but the findings were diverse
in showing localisation o f staining for rPmp l-N. Notably macromolecu lar interactions
can often be of unexpectedly low affinity even when they are of c lear physiological
importance. Studies investigating the affinity and kinetics o f such interactions using
a technique based on surface plasmon resonance have shown that ce llular
adhesion molecule interactions that mediate trans ient cell adhes ion have
surprisingly low affinities and extreme ly fast dissociation rate constants (Anton van
der Merwe, P. and Neil Barclay 1994). Other examp les of low a ffinity complexes are
those formed transiently by prote ins involved in e lectron transfer (Pe lletier and Kraut
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1992), and weak ly bound multi-enzyme comp lexes, such as those formed by 
enzymes of the tricarboxylic acid cycle (Srere et al., 1997). The low stability of these 
non-cova lent assoc iations is such that, in vitro, the comp lexes usua lly dissociate, 
making non-covalent interactions challeng ing to study. However to investigate the 
putative interactions observed using chem ical cross-linking and antibody staining 
which displayed some prom ising results, surface plasmon resonance was applied.
5.4 .3  L igand fish in g  fo r  potentia l b ind ing  in terac tio n s  betw een  
p assen g er dom ain  o f rP m p I and cerv ica l cell lines in v itro  using  
S u rface  P lasm on resonance
SPR was used to investigate putative interactions between truncated rPmp domains 
observed with crossbinding and ICC that could potentially be weak and transient 
interactions difficult to confirm within those detection limits, for examp le rPmp l-N 
binding weak ly to HeLa cells where interactions may have been observed when the 
protein was not displaced by washing. Two indirect capture methodologies were 
trialled during these studies as this was a novel method for Pmps and deve loping an 
appropriate procedure and suitable conditions was a priority based on the properties 
of the ligand to be immobilised, including factors such as purity and availability o f 
affinity tags. These indirect methods were based on the capture of the H is-tag on 
the C-term inus o f the rPmp prote ins by e ither immobilised anti-His antibodies or 
nickel activated NTA surfaces. Lysed mammalian cells were then passed over 
immobilised truncated rPmps in an effort to capture a binding event. To e lim inate 
non-spec ific binding o f MembraneMax™ expression prote ins within the rPmp l-N 
sample, the empty expression vector products were expressed and captured on a 
reference surface. Using the indirect penta-H is capture techniques was prob lematic 
due to non-spec ific binding to the penta-H is antibody. Studies using the indirect Ni- 
NTA immobilisation methods for SPR were only tested for the recomb inant Pmp I 
passenger domain (rPmpl-N) with HeLa cell lines and were inconclusive. A lthough 
interactions occurred between the un-purified recomb inant Pmpl-N domain and the 
HeLa cells for this method, interactions of a higher response occurred with the 
negative contro ls containing the same un-purified prote ins minus the rPmp l-N 
domain.
Initially, as the avidity o f the penta-H is Ab was good for detecting rPmp domains 
within MembraneMax™ ce ll-free heterogeneous samples, this indirect technique 
based on the capture of the recomb inant His-tagged was intended for SPR studies.
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However, upon coupling o f the penta-H is antibody to the sensor surface, un-purified 
rPmpl-N was not captured by the antibody. Subsequently function and spec ificity of 
the coup led penta-H is was tested using a purified His-tagged control protein E nd o l- 
8-His. Binding was not spec ific to the penta-H is surface. Furthermore, mild 
regeneration buffers were sufficient to cause irreversible damage to the coupled 
surface by stripping or denaturing the penta-H is Ab, yet harsh conditions with SDS 
did not remove Endo1-8-His from the control surface (lacking antibody), indicating 
an undes irably strong binding a ffinity to carboxymethylated dextran. Increased pH 
and ionic strength o f the samp les did not reduce the non-spec ific associations. 
Consequently sensor chip surfaces were unsuitable for experimenta l assays and 
optimisation of these conditions were not pursued as such methods are extreme ly 
time consum ing and expensive w ith the use of multiple sensor chips and milligram 
quantities of antibody. However, other studies have successfu lly used penta-H is as 
a capture molecule in biacore studies (G iannetti and Bjorkman 2004, Nordin et al., 
2005, Gluck et al., 2011).
Instead an alternative indirect capture method was used emp loying a NTA surface 
based on Nickel metal a ffinity capture. An advantage of using NTA chips is that 
generic regeneration conditions can be emp loyed by stripping the nickel ions from 
the surface to remove bound analyte thus minimise assay deve lopment. Importantly, 
the surfaces can be reactivated with nickel ions between app lications unlike the 
CM5 chips that once regeneration has taken place under conditions too harsh, a 
new sensor chip is necessary. Before prote in-protein interactions could be tested, 
further assay deve lopment was carried out using control ligands (His-tagged and 
non His-tagged prote ins) in an attempt to produce optimal binding conditions as 
Endo1-8-His, an 8 His-tagged purified protein was found to bind strongly with both 
nickel activated and non-activated surfaces, displaying little to no spec ificity for the 
nickel ions. This non-spec ific binding was also confirmed with a non His-tagged 
protein bovine serum albumin (BSA). This non-spec ific binding was most like ly 
attributed to e lectrostatic interactions with the highly negative ly charged dextran 
surface. A change in buffer to PBS w ith increased pH and ionic strength resu lted 
then in the capture of Endo1-8-His whilst preventing the binding o f BSA. This also 
significantly reduced the binding o f Endo1-8-His to the reference surface (m inus 
nickel ions).
The revised buffer conditions were used for all subsequent experiments. The rPmp l-
N domain was applied to the nickel activated surface a longside the empty
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expression vector products lacking rPmpl-N to provide a contro l as similar as 
possible for reference subtraction. Subsequently, the rPmp l-N sample was shown to 
give a higher binding response than the control that would indicate the capture of 
H is-tagged rPmpl-N from the sample. This was observed on each occasion where 
the control surface binding interactions were subtracted, indicating a higher 
spec ificity for H is-tagged proteins. However, some endogenous protein binding 
(from the MembraneMax™ express ion system) was expected since several 
endogenous prote ins were seen to bind to the N i-NTA agarose during the 
purification o f rPmp domains (chapter 4). Since the MembraneMax™ expression 
system is derived from E.coli lysate, Tween 20 or urea can be used as additives to 
reduce E,coli components adsorbing non-spec ifically onto sensor surfaces 
(Oshannessy et al., 1995), however these were considered unsuitable for use in 
rPmp binding assays as urea is a denaturant and detergents may disrupt the lipid 
based components of the NLP nanodiscs and the ana lyte (HeLa) cell membranes 
possibly compromising potential binding sites. Therefore w ith such a sensitive 
method and close ly matched controls it was proposed that subtraction o f the binding 
response would be sufficient to indicate spec ific capture of rPmp l-N. Furthermore, 
other studies have used this methodology to capture and purify affinity-tagged 
prote ins using Biacore sensor chips, including the cytop lasmic C-term inal domain of 
the receptor of the Xenopus ca lcium channel, IP3, (inositol 1,4,5-trisphosphate) 
using E.coli lysate as a reference blank (Natsume et al., 2002). A lthough the 
experimenta l design appeared to be working between active surface and capture of 
rPmp l-N, the app lication o f the HeLa cell lysate did not bind with a higher affinity to 
the experimenta l surface conta ining rPmpl-N. Instead, the components of the HeLa 
lysate produced a higher binding response w ith the control surface conta ining the 
expressed empty vector products. It was likely that the high occurrence of non­
spec ific binding was observed due to the heterogenous ligand and analyte samp les 
and ultimately, flaws in the experimenta l design o f these assays were prom inent and 
could not provide any convincing data.
Some of the difficulties w ith background signal using the N i-NTA capture method 
were as a resu lt of using complex, heterogenous samp les. This can be overcome by 
using a direct immobilisation technique in which the ligand (rPmpl-N domain) is 
directly coupled to the CM5 sensor chip surface and the ana lyte (HeLa ce lls) is 
passed over in solution omitting the use of antibodies and other capture techniques. 
However purified ligand is usually necessary when using this approach. In this study
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this mechanism was not utilised due to several limitations. Firstly, rPmpl-N could be 
only partially purified, therefore contam inants that are not removed during 
purification would also be directly coupled to the surface limiting the qua lity o f the 
procedure. Furthermore, ligands that are directly coupled to the surface can display 
a random orientation and so potential binding sites w ithin the protein may become 
inaccessible. This was observed in studies by W ear et al., (2005) where the surface 
charge potential o f CypA a recomb inant cyclophilin, a potential drug target for a 
several diseases including HIV and malaria infection, was altered in low pH 
immobilisation buffers. D irectly immobilising CypA to the sensor chip surface 
resulted in the mo lecule being orientated with its binding surface downward toward 
the activated chip surface. A further consideration using this approach is the 
regeneration step necessary to remove bound analyte from the ligand in order to 
perform further app lications, critical for successfu l assays. Regeneration conditions 
are dictated by the stab ility and nature of the ligand, often harsh regeneration 
conditions cause irreversible damage to the bound ligand, yet mild conditions can 
allow analytes to accumu late on the surface decreasing the available binding sites. 
As the rPmps have displayed a tendency to precipitate during buffer exchange even 
in physiological buffers, it was like ly that these prote ins would not withstand even 
mild regeneration when bound to a sensor chip surface. In fact it is quite like ly that 
the process of am ine coupling the rPmp to the chip surface wou ld denature the 
protein in the first instance. Moreover, immobilised ligands by indirect capture 
methods, such as the N i-NTA method used, are reported to exhibit higher binding 
activity often as a result o f a homogenous arrangement of the ligand and 
access ibility o f the binding sites and so can be advantageous over direct 
immobilisation (Baumann et al., 1998).
Alternative approaches for B iacore ana lysis would be by immobilisation o f the 
orphan receptors (HeLa cell lysate or membranes) to the surface of a hydrophobic 
sensor surface such as the HPA chip, this fac ilitates adsorption o f lipid monolayers 
for ana lysis of interactions involving lipid components. However, this was considered 
unsuitable as in similar procedures, the use of detergents is recommended to 
prevent aggregation within the m icrofluidic flow system. The poss ibility that even 
small concentrations (0.01%) o f detergent would e ither re lease potential receptors 
from ce llular membranes or shield targets/ligands in mice lles or disrupt the 
nanodiscs were considered. Ellipsometry, an a lternative optical biosensor technique,
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lacking a microfluidic system thus allowing the immobilisation o f comp lex materials, 
was used instead.
Finally, according to an extensive rev iew by (R ich and Myszka 2008) the vast 
majority o f b iosensor data published is o f poor quality, displaying poor experimenta l 
design with over interpreted results and application of comp lex models to fit data 
sets. Despite this the data are accepted by peer reviewers. The data obtained from 
the B iacore study indicated binding events but the sensorgrams produced were 
sometimes presented with spikes, jumps and drifts, occurrences ma inly caused by 
instrument artifacts and sample aggregation. Biphasic binding curves were also 
observed when app lying the contro l analyte to the surface which are often described 
as rapid and slow interaction o f mo lecu les w ith the surface yet this is difficult to 
substantiate w ith confidence as such curves detail more comp lex responses than an 
exponential binding curve. Additionally, binding responses are not a lways applicable 
to true binding events, m ismatched sample and running buffers, non specific 
binding, analyte aggregation/prec ipitations as well as poor instrument performance 
are often m isinterpreted as interacting molecu lar events (R ich and Myszka 2008). 
However in this study, alterations in conditions and repetition o f experiments were 
undertaken to m inimise artefacts
5 .4 .4  E lip so m e try -T IR E  to  m easu re  tru n cated  rPm p in te rac tio n s  w ith  
H eLa cells
Total internal reflection e llipsometry measures the thickness of surface layers or the 
stacking o f materials on a surface by reflected light, similar to SPR analysis but 
measures two components of the oscillating reflected light as opposed to the 
change in intensity and therefore has been described as being more accurate and 
sensitive than conventional SPR (Nabok et al., 2005). Recently several publications 
have emerged validating this technique for the measurement of prote in-prote in 
interactions (Nabok et al., 2007, Kriechbaumer et al., 2011, Kriechbaumer et al., 
2012a, Kriechbaumer et al., 2012b) where protein interactions with membranes and 
putative membrane receptors have been explored with positive results. This 
technique has been used to measure quantitative interactions between the novel 
plastidial chaperone receptor OEP61 and isoforms of the chaperones Hsp70 and 
Hsp90 (Kriechbaumer et al., 2011). In addition the behaviour o f such membrane 
protein receptors in the ir native membrane env ironment was explored 
(Kriechbaumer et al., 2012a). G-prote in-coupled receptors (GPCRs) have since
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been used in e llipsometry to quantify spec ific interactions o f receptors w ithin native 
mamma lian cell membranes, where the GPCR-ligand CXCL12a and its receptor 
CXCR4 were used. Human-derived Ishikawa cells were deposited onto gold coated 
slides and interactions between the receptor CXCR4 on these cells and its ligand 
CXCL12a were detected. This interaction was inhibited by application o f the 
CXCR4-b inding drugs (Kriechbaumer et al., 2012b).
A lthough this is a re latively new approach for studying membrane protein 
interactions, the published data shows it to be a reliable method in overcom ing 
some of the challenges associated with studying membrane protein interactions in a 
lipid environment. Based on the pub lisehed methods by (Kriechbaumer et al., 
2012a), experiments were carried out using HeLa cell lysates as orphan receptors 
on to the gold surface and the unpurified soluble rPmp domains ( in nanodiscs) were 
laid over the orphan receptors using the TIRE method to monitor any changes in 
molecu lar layering that was indicative of ligand-receptor binding. This method found 
no interaction between truncated rPmps and HeLa cell proteins. Ne ither was non­
spec ific binding observed desp ite the use of two heterogeous samp les. A difficulty in 
this study was screening for interactions between two potentially membrane bound 
proteins, the rPmp domain and putative urogen ital cell surface receptors. On 
reflection, the experimenta l conditions, such as insufficient incubation time or buffer 
conditions may not have been suitable. (Kriechbaumer et al., 2012a) demonstrated 
that native membrane protein activity was retained after deposition onto gold film, 
the divers ity of these macromo lecu les means that conditions favoured by one 
species may not extend to another. In addition, this method would not detect 
interactions with secreted or cell surface shedding molecules that would possibly 
have been lost during preparation o f the lysates, such as the interactions seen in the 
crossb inding assays. Immobilising whole cells using the Langmu ir-Schaefer 
deposition technique (Kriechbaumer et al., 2012b) may have improved the 
experimenta l design however, these methods were not ava ilable at the time. 
Endometrial H ec lB  cells were not tested due to limited access to the equ ipment but 
it would be very useful to carry out these methods using the cells and truncated 
rPmps to confirm interactions found with ICC. Also a consideration for further work 
would be test all the truncated rPmps with both cell lines using whole cells to 
investigate interactions with native membranes now these methods are estab lished.
288
5.5 S u m m ary
In summary chem ical cross-linking, immunocytochem istry, surface plasmon 
resonance and e llipsometry were all tested to some degree to screen or ‘fish ’ for 
potential binding event using rPmp domains as ligands and urogenital cells as 
‘orphan receptors’. From the data generated from these studies it cannot be 
determ ined with confidence that rPmpl-N, rPmpDauto and rPmpGauto act as 
adhesins to host cells, ne ither can the data reject this theory. Interestingly, some 
binding interactions were observed between H e c lB  and rPmp domains in ICC 
studies and for the cross linking assays. These findings were not tested further w ith 
other methods. Similar interactions were not observed when testing HeLa cells 
using chem ical cross-linking, ICC, SPR and e llipsometry. However, this was difficult 
to conclude as the methods applied in this study were not always working efficiently 
and the ICC data for the HeLa cells displayed a high background signal. Overall the 
methodologies were challeng ing due the heterogeneous nature of both the 
recomb inant prote ins and the putative receptors, which resulted in high background 
and non-spec ific binding events. Therefore w ithin these heterogeneous binding 
interactions, the signal from one binding event may have been obstructed by the 
large non-spec ific interactions observed such as for the SPR study. Although 
Biacore was implemented as a very sens itive method to detect even small levels o f 
binding interactions, it does not differentiate between spec ific and non-spec ific 
interactions (Nede lkov and Nelson, 2001). Consequently, relying exc lusive ly on the 
subtraction o f contro ls to e liminate background signals resulted in ambiguous 
interaction data. Furthermore, the NLP nanodiscs used in this study may have 
prohibited interactions if the rPmp binding sites were not accessible. However the 
incorporation o f membrane prote ins within nanodiscs is growing and has been 
successfu lly implemented in protein binding interactions, in particular for SPR 
ana lysis exam ining the binding o f so luble prote ins to immobilised membrane 
receptors in nanodisc complexes (Shaw et al., 2007, Borch et al., 2008) and for 
detection o f drug binding to an enzyme reconstituted in immobilised nanodiscs (Das 
et al., 2009). Ultimate ly as this was the first study o f its kind in exp loring the use of 
predicted functional rPmp domains as adhes ins with the potential to interact w ith 
several putative receptors.
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6.1 P o lym o rp h ic  m em b ran e  pro te ins  (P m p s) from  c lin ica l s tra in s  o f 
sero var E C .trach o m atis  are ch a llen g in g  to  exp ress  as fu ll length  
reco m b in an t pro te ins
To date, C.trachomatis Pmps have not been expressed as recomb inant prote ins at 
high enough levels for structura l and functional investigations. The Pmps are 
predicted to be autoransporters composed o f three major domains, the N-term inal 
signal peptide, the passenger domain and the C-term inal autotranslocator domain. 
The am ino signal peptide region o f autotransporters in many other species conta in a 
consensus signal peptidase recogn ition site, SPase l (c-domain) that is cleaved by 
components of the Sec machinery to re lease the pro-prote in into the periplasm 
(Henderson et al., 2004; Desvaux et al., 2004a; Desvaux et al., 2004c). The 
Chlamydial Pmps are thought to be processed this way but this is yet to be 
confirmed. Adjacent to the putative 's ignal' domain is the functional 'passenger' 
domain. This region offers the most sequence divers ity among autotransporter 
prote ins as this performs the extrace llular function. This passenger domain may 
remain intact in association with the cell surface or may be cleaved into the 
extrace llular milieu to carry out its function (Henderson et al., 2004, Desvaux et al., 
2004b). The p-barrel C-term inal domain forms the trans locator pore embedded with 
the membrane to transport the functional passenger domain to externa l membrane 
surface. In addition to the specu lative data that shows Pmps to be autotransport 
prote ins with a p-barrel membrane domain, studies have suggested Pmps interact 
w ith the host cell to initiate infection, although little ana lysis has been carried out to 
determ ine which, if any Pmps function in this way with the exception o f Pmp D 
(Wehrl et al., 2004p; Crane et al., 2006).
In order to investigate the function o f the C. trachomatis Pmps it was necessary to
express high quantities of pure recomb inant proteins. Thus far, very few studies
have expressed rPmps, instead the focus has been largely based on purifying native
Pmps from e lementary bodies isolated from infected mammalian cells yet these
have not been used for structura l or functional studies, probab ly due to the low
abundance of these proteins within the membranes (Swanson et al., 2009b). E. coli
was the first choice as an expression host as it is a Gram-negative prokaryote like
Chlamydia and was considered suitable due the presence of both inner and outer
membranes. However, hetero logous recomb inant express ion of membrane prote ins
poses unique challenges for several reasons. First, the ir over-express ion can often
be de leterious to the membrane and consequently toxic to the host organism
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(M iroux and Walker, 1996). Second, correct folding o f prote ins within the membrane 
is rate-limiting for any expression system (Loll, 2003) and if this capacity is 
exceeded; inclusion bodies are likely to accumulate w ithin the cell which was a 
common problem in this study. Finally, many membrane proteins, particularly 
eukaryotic proteins, undergo functionally important posttranslational modifications 
that cannot be replicated in hetero logous express ion systems and so can affect 
protein function (Sarramegna et al., 2003). As anticipated the express ion of 
recomb inant Pmps was extreme ly challeng ing using E. coli as a hetero logous 
expression host. O f the expression vectors constructed containing rpmp genes, full 
length rPmps were not expressed, yet a variety of E. coli stra ins and a range of 
optim isation techniques were employed.
It is possible that E.coli is insufficiently equ ipped to express full length Pmps due to 
the ir large size and complexity. The lack of published data that has exp lored the use 
of recomb inant Pmps would support this theory. W here recomb inant Pmps have 
been produced, they have been expressed in the form of inclusion bodies for the 
production o f Pmp specific antibodies ma inly raised against C.pneumoniae 
truncated rPmps or peptide sequences (Vandahl et al., 2002; Niessner et al., 2003; 
Pedersen et al., 2006; Molleken et al., 2010a). A study that was successfu l in the 
production of C.trachomatis rPmps in E.coli, expressed them as inclusion bodies for 
the use of antibody generation. Crane et al., 2006 were able to produce rPmps but 
only in truncated form and lacking a signal peptide (Figure 6.1). Previous to this, a 
study had expressed a recomb inant Pmp C as a fusion again without the 
hydrophobic amino-term inal signal leader sequence However, express ion o f rPmps 
w ithout signal peptides were not attempted in this study as the signal peptide was 
considered important for targeting Pmps to the E.coli membranes where express ion 
was desired for the extraction of native rPmps. It was thought that express ion would 
most like ly result in inclusion bodies w ithout the signal peptide as seen in these 
published studies and was unsuitable for the purposes of structura l and functional 
investigations.
Although not reported, collectively the difficulties in express ing full length rPmps
compared to the success of expression of rPmps lacking signal peptides in other
studies (Gomes et al., 2005; Crane et al., 2006) (a lthough as inclusion bodies) may
suggest that the Pmp am ino-term inal signal peptides have a detrimenta l role upon
the production of these proteins in E.coli. Genera lly signal peptides cons ist o f a
short, positively charged N-term inal region (n-reg ion), a 7-15 residue hydrophobic
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core (/7-region), and a polar 3-7 residue C-term inal region (c-reg ion) leading up to 
the signal peptidase cleavage site between the signal peptide and the mature 
protein (von Heijne and Abrahmsen 1989; C laros et al., 1997). As demonstrated in 
early studies, there are defined differences between signal peptides between some 
species. D ifferences in c-reg ions may be as a resu lt o f different signal peptidase 
specificities and differences in the n- and /7-regions could be due to differences in 
the lipid composition o f membranes between species. For examp le E. coli 
membranes contain more of the zw itterionic phosphatidylethanolamine and less of 
the negatively charged cardiolipin than Bacillus and Streptomyces however (von 
Heijne and Abrahmsen, 1989). Therefore in the early part o f this study it was 
thought the native Pmp signal peptides may be spec ific for expressing and targeting 
Pmps to constituents of the Chlamydiae membranes only and so could possess 
unrecognised codons resulting in early term ination during transcription or 
translation. However, later findings in this study reject this notion as E.coli was used 
to express the am ino-term inal passenger domain o f Pmp I w ith native s ignal peptide 
and putative cleavage of the signal peptide was observed.
In some species autotransporter prote ins function as toxins containing a toxic 
passenger domain. It is possible that some of the C.trachomatis Pmps may also 
serve this function such that the N-term inal transcriptional and/or translational 
products may have de leterious effects on E.coli leading to early term ination of 
transcriptional machinery. This was a possibilty as the expression o f C-term inal 
autotranslocator domains o f Pmp D and Pmp G were successfu l. A sim ilar 
observation was not reported by Crane et al., (2006) during the express ion o f C. 
trachomatis rPmps.
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Recombinant
Pmp (length)
Residues expressed N-sig Passenger Translocator
rPmpA(975) 47-979
rPmpB(1751) 949-1747
rPmpC(1770) 994-1766
rP m pD I, rPmpD2,
rPmpD3 (1531)
921-1528,45-1079,
45-1528
rPmpE(964) 27-962
rPmpF (1034) 28-449
rPmpG(1013) 139-502
rPmpH (1016)
rPmpl(876)
337-1009
30-879
Figure 6.1 - Schematic diagram showing the recombinant Pmp regions derived from 
C.trachomatis expressed as inclusion bodies in other studies. Arrows depict the regions 
expressed by Crane et al., 2006. All constructs were truncated and lacked the N-term inal 
signal peptide
Another consideration for the lack o f Pmp-FL expression could resu lt from
discrepanc ies w ithin the trans lation initiation regions of the recomb inant express ion
vectors. Initiation of protein synthesis in E.coli requires several features of the
mRNA to form a ribosome binding site (RBS) and direct ribosomes to the correct
trans lational start site (Sprengart et al., 1996). The e lements of the RBS include the
initiation codon (usually AUG or GUG) and upstream of this the Shine-Da lgarno
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(SD) region (GAAGGAGA provided by the pET vector). The SD sequence is 
complementary to the 3' end of 16S rRNA and so the distance between the start 
codon and the SD is vital to allow interaction with the ribosome (Kozak 1999). The 
distance between a functional SD sequence and the start codon usually varies 
between three and 12 nucleotides, w ith an optimal spacing o f 7-9 nucleotides 
(R ingquist et al., 1992). The distance between the initiation codon o f the inserted full 
length pmp  genes and the SD of the pET vector were all within this range so it is 
unlikely ribosomal binding was affected. Furthermore trials using a ce ll-free 
express ion host later expressed full length Pmp I showing that ribosome binding 
activity was functional for this expression construct.
Finally, there is evidence to suggest that the folding o f autotransporters is both an 
autonomous process and/or requires chaperones. BrkA is a Bordetella 
pertussis  virulence factor that is one of many B. pertussis adhesins. BrkA and is 
expressed as a preproprotein o f 103 kDa that is subsequently processed into an N- 
term inal signal peptide, passenger domain and C-term inal autotranslocator domain 
(Oliver et al., 2003a). Studies have shown a region in the C-term inus o f the BrkA 
passenger domain is required for folding of this same domain by acting as a 
intramolecu lar chaperone (O liver et al., 2003b). This region is conserved in a large 
group of autotransporters signifying that it serves a key function but thus far has not 
been identified in the Pmp proteins. In contrast, periplasmic chaperones such as 
DsbA and FkpA were shown to influence the folding o f hetero logous N-term inal 
passenger domains used in a study to test the tolerance of the C-term inal pore of 
the autotransporter lgA1 protease (IgAP) from Neisseria gonorrhoeae  (Ve iga et al., 
2004). Here it was demonstrated that passenger domains are transported through 
the C-term inal pore in a pre-folded state. However the passengers domains were 
made of single or multiple folded Ig domains as opposed to the natural IgAP N- 
term inal secretory protease and therefore may not be representative of all 
autotransporter periplasmic folding mechanisms. Overall, studies are contradictory 
with regards to autotransporter folding mechanisms and it seems one rule does not 
app ly to all and this area of protein folding needs further investigation. Essentially 
the folding mechanisms o f Pmps remain unclear, it is possible that e ither 
cytop lasmic and/or periplasmic chaperones have important roles during the 
synthesis and fo lding of these prote ins in vivo. The co-express ion o f full length 
rPmps with chaperones in E. coli may have been necessary in order to produce full
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length Pmps, however there rema ins no published data to support which, if any 
chaperones are involved.
One recent study has determ ined the first ever crystal structure of a comp lete 
autotransporter expressed in E. coli, the esterase EstA from the opportun istic 
human pathogen Pseudomonas aeruginosa (van den Berg 2010). This is 
remarkable as there has been a void o f information prior to this highlighting the 
difficulties assoc iated with producing such large comp lex proteins. With such 
information emerg ing, successfu l expression o f full length Pmps could pave the way 
for successfu l structural and functional Pmp studies.
6.2 T ru n cated  P o lym o rp h ic  m em b ran e  pro te ins  (P m p s) from  clin ical 
stra ins  o f s ero var E C .trach o m atis  are less ch a llen g in g  to  exp ress  
using a novel ce ll-free  exp ress io n  system  w ith  n an o lip o p ro te in  d iscs
A lthough not reported, collective ly the lack o f full length rPmp express ion in these 
investigations and ev idently the lack o f native rPmp expression in prev ious studies 
(Gomes et al., 2005; Crane et al., 2006) would suggest that E.coli is an unsuitable 
host for the production o f C.trachomatis full length Pmps possibly due to a 
comb ination o f factors prev iously discussed. Alternative methods were therefore 
considered to express Pmps for secondary and functional analysis.
As it is wide ly accepted that Pmps are autotransporters, made up of three distinct 
domains, express ion o f these sma ller functional domains o f some of the 
C.trachomatis Pmps was explored. Other autotransporter prote ins have been 
studied this way with success; in particular the IgAP protease from Neisseria 
gonorrhoeae, an organ ism that also infects the gen ital epithe lial cells has had its 
autotranslocator domain structure determ ined by expressing the C-term inal 
functional region to the outer membranes of E.coli (Veiga et al., 2002). Oomen et al., 
(2004) also presented the crystal structure of the trans locator domain o f the 
autotransporter NalP from Ne isseria men ingitidis, again from over-express ion in 
E.coli. In addition the N-term inal passenger domain o f the Hia autotransporter from 
Haemophilus influenza has been expressed for the use in adherence assays 
(Laarmann et al., 2002). Furthermore, previous studies have expressed truncated 
rPmps.
In this study, expression trials to produce such reg ions of C.trachomatis Pmps led to
the successfu l express ion o f several truncated rPmp functional domains in E.coli
although mostly in the form of inclusion bodies. This is unsurprising as inclusion
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bodies are a common occurrence when expressing proteins which are hydrophobic 
or membrane bound (W agner et al., 2006). Inclusion bodies can be purified with 
relative ease for in-vitro refolding but can lead to conformational changes different 
from the native structure. This is espec ially problematic where disulfide bonds are 
present and since Pmps are reported to be rich in cysteine residues (Swanson et al., 
2009; Liu et al., 2010) this was deemed impractical. Furthermore, refolding often 
requires extensive optim isation with the use of a contro l assay to demonstrate that 
the folded protein is functional, which was not possible in this study. Instead an 
alternative approach pursued the expression o f native ly folded, active protein 
suitable for structura l and functional analysis by reducing protein aggregation to 
such a level that allowed truncated rPmp to localise to the membranes.
By reducing the express ion rates s ignificantly (Sorensen and Mortensen, 2005), a 
reduction in aggregation of the rPmp domains, in particular the trans locator domain 
of Pmp D (rPmpDauto) were met w ith some success. T ight regu lation using the 
pLysS plasmid, (that encodes T7 lysozyme), IPTG independent express ion and low 
incubation temperature a llowed small amounts o f rPmpD autotrans locator domain to 
localise to the membranes of E.coli for detergent so lubilisation. However the 
purification o f this domain by nickel chelate affinity chromatography was met w ith 
great difficulty due to the low binding to the column, a poor yield o f express ion and a 
high tendency for the protein to precipitate and aggregate during handling and 
storage. It is possible that the C-term inal polyhistidine tag was not fu lly exposed for 
binding (Bornhorst and Falke, 2000) but denaturing the protein to unfold the H is-tag 
fu lly was not viable as a b iologically active protein sample was necessary. 
Co llective ly the purity, yield and tendency to aggregate made this protein domain 
unsuitable for structura l studies. However this is the first study of its kind to express 
the C.trachomatis Pmp D trans locator domain both as inclusion bodies and as 
membrane localised protein with a 6XHistidine affinity tag.
Other methods described to aid localisation to the membrane were by express ing
target protein as a fusion with a protein known to localise to the membranes for
example the ma ltose-binding protein (Fox et al., 2008) or as a fus ion with an N-
term inal signal peptide leader sequence. This was considered a useful exerc ise as
the autotrans locator domains o f the Pmps lack a native signal peptide as this is
normally located upstream at the am ino-term inal so is lost in these truncated C-
term inal Pmp constructs. Pmp G was expressed as a fusion with a pelB leader
peptide to aid localisation to the inner membrane of E.coli, an approach also used to
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express the C-term inal autotranslocator domain o f IgAP (Veiga et al., 2002b). 
Although express ion was successfu l this was not localised to the membranes and 
was in the form of inclusion bodies.
In addition to the production o f the C-term inal autotranslocator domains o f the Pmp 
D and Pmp G, express ion o f the functional N-term inal passenger domains was also 
explored, in particular those of Pmp A and Pmp I. The N-term inal region o f Pmp I 
conta ins a native s ignal peptide leader sequence predicted to target prote ins to the 
Sec apparatus in the inner membrane for processing (Desvaux et al., 2004a). The 
expression o f the recomb inant passenger domain o f Pmp I in E.coli was detected as 
both soluble and insoluble protein. This fits with other data that have observed non 
membrane bound passenger domains o f autotransporters (leva and Bernste in 
2009). Some passenger domains, including that o f Pmp D (K ise lev et al., 2007), are 
often presented externa lly of the cell surface possibly necess itating less 
hydrophobic reg ions compared to the ir C-term inal membrane-bound counterparts. 
At present there are no repeated studies that comment on the process ing and 
localisation o f Pmp I or the Pmp I passenger domain to corroborate the finding that 
the N-term of this protein is soluble in nature. Interestingly, the passenger domain of 
Pmp A, which differs from the other Pmps by absence of a native signal peptide 
(Gomes et al., 2006), was not expressed by E.coli. This protein has prev iously been 
expressed as inclusion bodies in E.coli by Crane et al., (2006) however the ir 
recomb inant construct lacked the first 46 residues of the am ino term inus which may 
be a s ignificant deletion to ensure successfu l expression.
In summary, the express ion o f recomb inant full length Pmps and truncated Pmps in
E.coli was extreme ly challeng ing. E.coli could not be used to express the large
mu ltidomain full length Pmps and where expression was observed, for the truncated
domains, the express ion was very ‘leaky’ resu lting in inclusion bodies. Conditions
implemented to modulate this, in particular to minimise basal express ion and
prevent inclusion body formation were met w ith varying degrees of success. They
were successfu l in that the formation of inclusion bodies could be reduced to allow
some protein targeting to the membranes where potentially, fo lding could take place.
However, this process of optim isation was very time consum ing and so only
extended to the expression o f Pmp D autotrans locator domain (rPmpDauto). The
downstream purification that followed was difficult due the heterogene ity o f the
samp le and a low affinity between the H istidine-tag and purification media. Moreover
the poor yield o f recomb inant protein solubilised from the membranes was
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increas ingly difficult to detect fo llowing each downstream app lication. This was 
further hampered by the necess ity to express fresh recomb inant prote ins in large 
cu lture vo lumes for each individual optimisation step as the rPmpDauto aggregated 
upon storage.
While pmp genes are prokaryotic, Chlamydiae do reside w ithin a eukaryotic host so 
it was considered that mammalian expression systems may be su itable to overcome 
the problems associated with expression o f rPmps in E.coli. Furthermore, 
prokaryotic cells are not equ ipped to carry out posttranslational modification where 
eukaryotic systems can. This is particularly important for prote ins that are 
g lycosylated as this can a ffect protein activity or stability. Although there is no 
evidence to suggest C.trachomatis Pmps are g lycosylated, studies have shown Pmp 
homologues of C.abortus are g lycosylated (Vretou et al., 2001). Few studies have 
used yeast as a host for the express ion o f Pmps. One study that did, expressed 
passenger domains o f some of the C.pnuemoniae Pmps as fusion prote ins to the 
yeast surface protein Aga2p to direct the Pmp domain to the surface for use in 
adherence assays and showed the passenger domains o f Pmp D, B/C and G 
homologues act as adhesins (Molleken et al., 2010a) yet this study did not express 
full length Pmps. Ultimate ly considering the time involved in estab lishing these 
techniques, deve loping new cloning strateg ies and repeating the time-consum ing 
expression trials already carried out in E.coli for seven Pmp targets, c loning fo r an 
alternative expression system was considered to be an uneconom ical use of time. A 
reasonable a lternative to designing and constructing new express ion systems was 
to change the expression host to one also compatible w ith the T7-based express ion 
system. As cloning strateg ies had already led to the successfu l express ion o f 
several smaller rPmps domains in E.coli, an E.coli based ce ll-free express ion 
system w ith a composition less comp lex than viable E.coli was chosen for its rapid 
screening ability, toxicity tolerance, and ease of handling.
The autotrans locator domains of Pmp D and Pmp G (rPmpDauto, rPmpGauto) plus
the passenger domain o f Pmp I (rPmp l-N) were successfu lly expressed as soluble
protein using nanolipoprote in scaffo lds (NLPs or nanodiscs) as part of a novel cell-
free expression system (MembraneMax™, Invitrogen). Whilst the production o f
recomb inant protein was consistent using this method, purification was difficult as
the yield o f recomb inant protein was low and not sufficient for any b iophysical
analysis. Moreover this was a very expensive protein expression technique where
aga in the proteins were highly susceptible to aggregation during handling and so
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required new ly expressed prote ins for every optim isation step. This was possibly 
due to the use of detergents necessary during purification. Although nanodiscs are 
reputed to offer a more stab le env ironment than detergent m icelles (Nath et al., 
2007) the original aim o f this study was to obtain biophysical data by circular 
dichroism and the scaffold protein o f the nanodiscs would have interfered with this 
analysis. Interestingly the rPmp A passenger domain, the only Pmp reputed to lack 
a native signal peptide sequence was expressed in the ce ll-free system but not in E. 
coli. However this passenger domain was not incorporated into NLPs and was only 
present as insoluble aggregates, a possible indication that Pmp A is targeted to the 
membrane by another mechanism, possibly by use of a C-term inal anchor region, 
also suggested by Gomes et al., (2006) which was not present in this express ion 
construct as it lacked the C-term inus region.
The ce ll-free system was also shown to express one of the full length Pmps, 
recomb inant Pmp I (rPmpl-FL), in an insoluble form. It is likely that rPmpl-FL is too 
large at approx imate ly 95 kDa, to be incorporated in to the nano lipoprote ins (NLPs) 
(according to the manufacturer). It is like ly that the system may not provide an 
env ironment su itable for full length Pmp protein folding, for examp le if chaperones 
are essential. The MembraneMax™ ce ll-free system used has been used 
successfu lly for membrane prote ins up to 100 kDa. Very large membrane prote ins 
over 100 kDa have not been reported, or have been expressed as truncated 
products, for example the human potassium voltage-gated channel ERG prote in 
(-155  kDa) could not be expressed as a full length protein (Katzen et al., 2008). 
A lthough full length rPmp I was insoluble, this was an improvement on the 
expression trials previous using E.coli where the expression o f full length rPmps was 
not observed, and was also an indication that the express ion vector conta ining full 
length pmp I was indeed functional. The larger rPmps (rPmpA-FL and rPmpD-FL) 
that are over 100 kDa at 105 kDa and 156 kDa were not expressed by the ce ll-free 
system concurring with previous findings. This is the first study to exp lore the 
expression o f rPmps and predicted rPmp domains using nanodiscs and a ce ll-free 
expression system. Importantly, this is the first study to report the express ion o f 
so luble rPmps.
In summary, it is wide ly accepted that expression o f recomb inant membrane 
prote ins is a difficult process. Even in the most successfu l cases, the over­
expression and/or purification protocols are often unique for each target, being both
technically challeng ing and extreme ly expens ive (Dobrovetsky et al., 2005).
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Furthermore, few recomb inant membrane prote ins are expressed in native, fu ll- 
length and this is reflected in the number of membrane prote ins that have had the ir 
structure determ ined successfu lly compared to the ir soluble counterparts. S im ilar 
difficulties were observed in this study which set out to express recomb inant Pmps 
for structura l and functional purposes and are an example of the high attrition rates 
common w ith membrane prote in expression and purification. This is summarised in 
Figure 6.2, where fourteen expression constructs resulted in only five expressed 
prote ins and was narrowed down further to just three prote ins suitable for 
purification. At this final stage, the purified products were then not suited to a basic 
biophysical analysis such as circular dichroism, therefore secondary structure of 
these Pmp domains could not be obta ined. High attrition rates are ev ident in other 
studies. Dobrovetsky et al., (2005) investigated the expression and purification of 
numerous membrane prote ins from E.coli and T. Maritime, a thermophilic 
eubacterium, o f the total number of genes cloned, only -8%  (n 17/203) and ~6% (n 
5/77) respectively, o f the represented prote ins were obta ined in quantities sufficient 
for structura l studies.
A lthough expensive, the ce ll-free system proved to be an advantageous method 
over E.coli for the express ion for rPmp domains. Firstly, handling times were 
reduced significantly; an important factor where protein precipitation is a problem, 
expression was achieved within two hours and solubilised protein was acquired with 
the use of nano lipoprote in discs. Although structural analysis was unattainable for 
the recomb inant Pmps domains due to low yie lds after purification, functional 
screening assays where purified protein is not a requ irement were still exp lored. 
Most importantly, as soluble protein was produced for two Pmp autotrans locator 
domains (Pmp D and Pmp G) and one Pmp passenger domain (Pmp I), it was 
considered that the domains would be in a native confirmation ideal for prote in 
interaction studies (Katzen, et al. 2008; Bayburt and Sligar, 2010), therefore 
investigation o f these Pmp domains with the use of nanodisc technology was 
explored further to screen for interactions with host cells and host cell membranes.
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6.3 C -term in a l a u to tran s lo ca to r do m ain s  o f Pm p D, P m p G and the N- 
te rm in a l p assen g er dom ain  o f Pm p I as adhes ins  fo r C h lam yd ia  
trach o m atis  in fection
The importance of studying membrane prote ins is highlighted by the fact that almost 
half of the major pharmaceutical drug targets are designed to target membrane 
receptors (Cooper, 2004). However, mon itoring protein interactions in lipid 
env ironments is also technically challeng ing. Existing biochem ical and biophysical 
methods to study membrane protein interactions require e ither sufficient native 
protein or recomb inant protein into a lipid or detergent env ironment to ma intain 
biological activity. In one study, recomb inant OmcB from C. trachomatis was 
expressed and targeted to the membranes of E. coli and E.coli displaying the 
protein on its surface were used in adherence assays and showed Chlamydial 
OmcB acts as an adhesin (Fadel and Eley, 2008). However, as demonstrated for 
the expression o f rPmpD autotrans locator domain in this study, directing the 
expression o f membrane proteins to a hetero logous membrane is not always a 
straightforward process, especially where a high tendency to form 
thermodynamically stable inclusion bodies is also favourab le (Fo it et al., 2009). 
Other methods require the membrane protein to be reconstituted into detergent 
m ice lles or liposomes yet these techniques are not always suitable as liposomes 
are large, unstable and difficult to prepare at a contro lled size and stoichiometry and 
detergents can decrease protein stability and interfere w ith assays. Hence few 
techniques are available to study spec ific membrane protein interactions in situ.
Over the past decade, reconstituted high-dens ity lipoprote in particles (rHDL) have 
emerged for the incorporation of membrane prote ins in a native-like membrane 
environment, allowing solubilisation and de livery of hydrophobic drugs (Civjan et al., 
2003; Leitz et al., 2006; Whorton et al., 2007; Mi et al., 2008; Bayburt and Sligar, 
2009). In this system, membrane prote ins in detergent m ice lles are reconstituted 
into lipid bilayers of apo lipoprote in particles. These particles are homogenous and 
monodispersed with membrane prote ins incorporated in monomeric form. This 
system has been tested in studies w ith membrane prote ins such as 
bacteriorhodopsin (Bayburt and Sligar, 2009), cholera toxin and receptor b inding 
(Borch et al., 2008) the pore of the anthrax toxin (Katayama et al., 2010) amongst 
many other app lications making nanodiscs, sim ilar to those used in this study 
(MembraneMax™ NLPs) su itable to investigate potential receptor-ligand
interactions between rPmps and urogen ital cells.
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Prom inent tra its of the Pmps shared among the spec ies are the mu ltiple sequence 
repeats GGAI and FXXN (Stephens et al., 1998), s im ilar motifs are found in several 
prote ins believed to be involved in attachment w ith eukaryotic cells including OmpA 
of Rickettsia spp. (Grimwood and Stephens, 1999) and uncharacterised surface 
prote ins o f Trichomonas Vaginalis, another bacterium associated with infection of 
the urogen ital system (H irt et al., 2007). Chlamydiae have been shown to 
demonstrate various mechanisms in which attachment to host cells is estab lished 
but so far the comp lex ity o f these mechanisms have not been fu lly e lucidated 
however the Pmps have been identified as a possible ligand, functioning as an 
adhesin to bind and interact w ith host cells for this purpose (Wehrl et al., 2004; 
Molleken et al., 2010b). The possibility that Pmps act as adhes ins were tested in 
this study with the use of recomb inant truncated Pmps: Pmp I passenger domain 
(rPmpl-N), Pmp D and Pmp G autotranslocator domains (rPmpDauto and 
rPmpGauto), expressed using a novel ce ll-free express ion system w ith nanodiscs.
Truncated rPmp prote in-ce ll interaction assays were prob lematic and encountered 
several difficulties due to the heterogene ity o f the both the truncated rPmp samples 
and the orphan receptors (whole or lysed urogen ital cells). It is possible that rPmp 
interactions have been shrouded by some of the high background signals observed 
using the experimenta l designs applied in this study. However several techniques 
were emp loyed to try and overcome such problems w ith methodologies including 
cross-linking assays, immunocytochem istry, surface plasmon resonance and 
e llipsometry to screen for interactions with HeLa cervical and H ec lB  endometrial 
cell lines, the assays and findings are summarised in F igure 6.3 and F igure 6.4.
Co llective ly the observed protein interactions were often contradictory between
methods but a concerted effort was made to try and rule out fa lse positive resu lts
from background signals. Cross-linking rPmpl-N with HeLa or H e c lB  ce lls resu lted
in high mass conjugates conta ining rPmpl-N suggestive of protein interactions, yet
these were too large to be exam ined by Western b lotting techniques and would not
migrate into a polyacrylamide gel making it difficult to determ ine the size or identify
the components of the interaction where methods such as mass spectrometry could
have been applied. Additionally small traces of rPmp l-N were assoc iated with the
cell surface of H ec lB  cells, potentially this interaction could have involved large
mo lecules such as heparan su lphate, also a target of Chlamydial MOMP attachment
(Su et al., 1996), Heparan su lphate can also be shed from the cell surface (Bernfie ld
et al., 1999) large conjugates that could not be characterised but were separated
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from the urogen ital cells, could have contained such secretory/shedding molecules. 
However studies have shown that serovar E attachment is not affected by heparin 
or heparan su lphate (GAGs) and so this may not be involved in the attachment 
mechanisms o f this particular serovar, instead these GAGs dramatically reduced the 
attachment of more invasive serovar L2 (Davis and Wyrick, 1997, Vretou et al., 
2001). There was little evidence to show rPmpD and rPmpG autotranslocator 
domains had interacted with the HeLa or H ec lB  cell surfaces, however if interaction 
had occurred these levels may have been below the limits o f detection by Western 
blot as rPmpGauto and rPmpDauto were difficult due to the low express ion levels o f 
these domains.
An alternative method to ‘fix ’ and detect cell surface interactions was carried out 
using immunocytochem istry (ICC). ICC methods showed putative localisation o f the 
passenger domain o f rPrnpl to the HeLa cell surfaces when washing steps to 
remove unbound rPmpl-N were om itted, however localisation was not observed for 
any of the rPmp domains when the HeLa cells were washed indicating possible 
weak interactions and so more sensitive methods to capture weak, trans ient 
interactions were employed. SPR detected binding events between rPmp l-N and 
lysed HeLa cells, but this could not distinguish between spec ific binding o f the 
rPmp l-N domain and non-spec ific binding where endogenous prote ins within the 
express ion sample also bound to HeLa cell lysate and so was not extended to test 
rPmpDauto and rPmpGauto. Finally, Ellipsometry, a method that monitors changes 
in molecu lar thickness caused by binding events was used to capture potential 
weak interactions (Kriechbaumer et al., 2012b) yet this technique revealed no 
association between lysed HeLa cells and e ither rPmp l-N, rPmpDauto or 
rPmpGauto domains.
Differences between the standard protocols for methodologies may have resu lted in
the contradictory findings. For example the cross-linking and ICC methods were
carried out using whole HeLa cells, at 37 °C to mimic in vivo chlamydial attachment
(Soderlund and Kihlstrom, 1983; Soderlund and Kihlstrom, 1988; Su et al., 1996; Su
et al., 1996; Fadel and Eley 2008), w ith an incubation time of at least one hour. In
contrast, SPR and e llipsometry methods required lower incubation temperatures at
25 °C, lysed HeLa cells and shorter incubation times of around ten m inutes which
may not have been optimal conditions to allow interactions to take p lace.lt is
reported that temperatures as low as 4 °C have not prevented adherence of
C.trachomatis in previous studies (Zaretzky et al., 1995; Davis and Wyrick, 1997)
305
and so it could be argued that lower temperatures should not have prevented 
interactions,. The passenger domains o f Pmp D and Pmp G homologues from 
C.pneumoniae have been suggested to carry adherent mechanisms (Molleken et 
al., 2010a) at 4 °C and 37 °C, although these were presented at the surface of yeast 
ce lls or latex beads and the study did not exam ine interactions o f the C-term inal 
autotranslocator reg ions o f these Pmps.
Interestingly, immunocytochem istry indicated cell surface localisation for all three 
rPmp domains when incubated with H ec lB  endometrial cells. Furthermore, traces 
of rPmp l-N were also found associated with the H e c lB  cells in the cross-linking 
assays. These results were prom ising to indicate C.trachomatis serovar E Pmps 
may have a role in tissue tropism, having a higher affinity for endometrial cells. 
Converse ly, previous studies have shown that the b inding o f serovar E 
C.trachomatis e lementary bodies (EBs) was comparab le among H e c lB  and HeLa 
cells (Davis and Wyrick, 1997). Yet those studies were not exam ining the particular 
binding partners responsible and so using EBs with an array o f outer membrane 
proteins, could have resulted in binding from Pmps and other outer membrane 
prote ins present on the EB surface such as MOMP and OmcB, also involved in 
attachment (Campbell and Kuo, 2006; Fadel and Eley, 2008; Moe lleken and 
Hegemann, 2008). Furthermore, this may also show that the autotrans locator 
domains (rPmpDauto and rPmpGauto) may not only function as translocator 
prote ins but could also interact directly with host cells.
6.3.1 P m ps as c leaved  au to tran sp o rt p rote ins
The methodology and experimenta l designs in this study were based around the 
notion that Pmps function with an autotransporter mechanism, however any study is 
yet to confirm Pmps are in fact autotransporters. Severa l o f the pmp  a lle les encode 
a lipoprote in signal sequence which is not compatible w ith autotransport yet it 
rema ins unclear whether the lipoprotein sequences are ever functional (Henderson 
and Lam, 2001a). The findings in this study may suggest the predicted signal 
peptide of Pmp I is functionally active and the putative Pmp I passenger domain 
undergoes post-translational processing when expressed in E. coli. Similar 
investigations have shown the c leavage of the signal peptide of autotransporter 
adhesion: BrkA, a Bordetella pertussis virulence factor which is expressed as a 
preproprotein (Oliver et al., 2003a). Recomb inant express ion o f the predicted amino 
passenger domain o f Pmp I w ith its native signal peptide observed putative
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c leavage events w ithin the passenger region. Autotransporter passenger reg ions 
are directed to the membrane under direction of the signal peptide where they can 
remain surface exposed or undergo proteo lytic cleavage to re lease peptide 
fragments into the extrace llular environment, via cell surface proteases or 
autoproteo lysis (Henderson et al., 1998; Henderson et al., 2004; Desvaux et al., 
2004a). Three H is-tagged peptides were detected during express ion o f the am ino- 
passenger domain o f Pmp I in E.coli that were suggestive of protein processing 
possibly upon interaction with sec machinery. The sizes of these fragments were 
indicative of this passenger domain with and without the N-term inal signal peptide 
and o f cleavage w ithin the passenger domain itself. Furthermore, trials inhibiting 
secA of the sec trans locon in E. coli showed an increase in the formation of 
inclusion bodies during the expression of the Pmp I passenger domain possibly 
showing restriction to within the cytop lasm. W ithout a native signal sequence so that 
rPmpl-N would not be targeted to the sec translocon, the express ion o f the 
passenger domain o f Pmp I appeared to be restricted and confined within the 
cytop lasm form ing large inclusion bodies. These studies may be an early indication 
to show the importance of the signal sequence for the targeting o f Pmp I and 
processing o f the protein to produce mature Pmp I. Expression o f the same domain 
using the E.coli derived ce ll-free expression system resulted in only two His-tagged 
peptides during expression, again sizes expected for the domain with and without 
the signal sequence. Exposing this domain to higher ionic strength buffers and 
increased pH during ion exchange purification, a third peptide of the same 
mo lecu lar we ight prev iously observed during E.coli express ion, was detected. 
Published work investigating the processing o f Pmps is substantially lacking, 
however a study by Swanson et al., (2009) also found similar results after probing 
purified native Pmp D from C.trachomatis extracts, severa l processed fragments 
derived from both the carboxy-term inal autotranslocator domain and the am ino- 
passenger domain o f Pmp D were found. Therefore it is tempting to specu late that 
the mature form of the Pmp I passenger domain (without signal peptide) undergoes 
autoproteo lytic cleavage, possibly as a result o f env ironmenta l factors or changes in 
confirmation due to surface charge.
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Figure 6.4 - Summary of findings investigating truncated rPmps (pink) in interaction 
studies with endometrial cells by immunocytochemistry and chemical cross-binding
assays. ICC, Immunocytochemistry
6 .4  Future  w o rk
Some of the major challenges in this study could possibly have been a llev iated by 
reducing the dependency upon the H istidine affinity tag. For example, capture of the 
recomb inant Pmp domains was re liant upon exposure of the H istidine tag for Ni- 
NTA purification and SPR Ni-NTA interaction studies. Additionally the express ion 
and purification, cross-binding interactions, ICC investigations and alternative SPR 
capture techniques were all dependent upon anti-His antibodies binding to the rPmp 
po lyhistidine affinity tags. Moreover, the H istidine tag could have had some affect 
upon the folding o f rPmps. As Pmps are unique to Chlamydia, the production o f 
anti-Pmp antibodies to specific rPmp peptides may have overcome some of these 
prob lems by m inimising non-spec ific binding to endogenous proteins, within the
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express ion samples and eukaryotic cells and by overcom ing problems w ith 
access ibility o f the H is-tags. Spec ific anti-Pmp Abs raised to the rPmp inclusion 
bodies could replace generic anti-His Abs used throughout these studies for 
detection o f interactions with ce lls by ICC, for immunoprec ipitation with rPmps and 
orphan receptors, flow cytometry and with direct coupling to a sensor surface for 
capture of rPmps in SPR. This is potentially an area for future work to proceed with 
the studies investigating the function and processing o f the rPmps produced in this 
study.
Investigating the processing o f Pmps to determ ine if Pmp I is processed via the 
inner membrane Sec trans locon into a mature protein from its amino-term inal signal 
peptide would offer clues as to the function o f Pmp I as a secretory molecule. If 
sufficient protein could be obta ined for e ither method, identification o f the cleavage 
site could be achieved by Edman sequencing of the mature passenger domain or 
using N-term inal peptide sequenc ing by mass spectrometry fo llowing separation o f 
c leavage products. In addition mutagenes is studies could be carried out on the 
new ly identified signal peptidase cleavage site to determ ine if the targeting o f this 
protein is under direction o f the native leader sequence. Pre liminary work using 
sodium azide, which inhibits SecA, an ATPase involved in the trans location of 
prote ins via the Sec machinery (O liver et al., 1990; O liver, 1993), has suggested 
Pmp I is directed to the Sec trans locon for N-term inal processing, however this work 
is by no means conc lusive as azide can interrupt other ce llular pathways. However, 
studies carried out express ing the passenger domain of rPrnpl w ithout its native 
peptide, resulted in increased accumulation within the cells, as expected indicating 
confinement of this expressed domain when not under directional processing. Azide 
res istant mutants have a lready been obta ined from the Coli Genetic Stock Center 
(Yale Un iversity) but are not suited to expressing target prote ins from pET 
expression vectors. However, integration of ADE3 prophage into this mutant E. 
coli host cell chromosome can be carried out, so that the azide res istant host 
containing the secA protein res istant to inhibition by azide can be used alongside an 
azide sensitive host to express rPrnpl passenger domain. The effects of azide on 
protein accumulation could be directly related to secA inhibition or not and would 
show if Pmp I is processed via Sec processing as predicted.
In addition to the putative cleavage of the signal peptide, other cleaved peptides 
were observed during the express ion o f Pmp I passenger domain, potentially from 
autoproteo lytic cleavage w ithin the passenger domain itse lf (Henderson et al., 1998,
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Henderson and Nataro 2001b, Desvaux et al,, 2004a). Confirmation o f this cleavage 
site is o f interest as it may show Pmp I is cleaved and re leased into the externa l 
milieu whilst other autotransporters remain intact at the cell surface (Henderson et 
al., 1998; Desvaux et al., 2004a; De et al., 2008; Benz and Schmidt, 2011). 
Problems in identifying these cleaved products on a Coomassie SDS gel were as a 
resu lt o f low yie lds a fter purification and hampered efforts to proceed with peptide 
sequencing. Future work to improve these yie lds could possibly be achieved by 
using cobalt ions in metal a ffinity chromatography. The Co2+" 
carboxy lmethylaspartate (Co2+-CMA) matrix (Talon™ resin) has been reported to 
exhibit less nonspec ific protein binding than the N i-NTA resin, resulting in higher 
e lution product purity and so may have overcome some of the prob lems associated 
with contaminants difficult to remove via Ni-NTA and ion exchange purification 
(Chaga et al., 1999a; Chaga et al., 1999b). Subsequently, these peptides could be 
gel excised for N-term inal peptide sequenc ing by mass spectrometry to identify the 
putative c leavage sites and mutagesis studies on these sites could be carried out.
To corroborate the ICC findings with H e c lB  cells and rPmpl-N, rPmpDauto and 
rPmpGauto, where putative localisation at the cell surface was observed, indicating 
tissue tropism for endometrial cells, e llipsometry should be carried out. This 
sensitive method requires no labelling of samp les, instead changes in the reflected 
light indicate a change to the mo lecu lar layering. As the ICC showed cell surface 
staining, e llipsometry should be done using whole H e c lB  cells via Langmuir- 
Schaefer film deposition (Kriechbaumer et al., 2012b) as oppose to lysed ce lls to 
ensure the membrane outer surface is exposed for binding. Based on these 
findings, assays could be repeated with whole HeLa cells as prev iously used 
methods may have resu lted in an immobilised surface where HeLa 
membranes/membrane prote ins were unava ilable for binding.
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